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Regulation of cardiac output is mediated by intrinsic and extrinsic factors 
that modulate the rhythmic transitions between contraction (systole) and 
relaxation (diastole). At the level of cardiac myofilaments, the troponin complex 
(troponin I (TnI), troponin C (TnC), and troponin T (TnT)) is the allosteric 
regulatory unit that controls the transition between active and inactive actomyosin 
cross-bridges. This is accomplished by the C-terminal switch arm of TnI toggling 
between actin during diastole and cTnC during systole in a calcium-dependent 
manner.  
These studies elucidate new knowledge regarding the structural, 
functional, and evolutionary implications of a histidine residue in the switch arm 
of troponin I. Molecular modeling of TnI isoforms and large scale bioinformatics 
analysis of chordate phylogenies were used to study the evolution of the cardiac 
troponin complex. At the molecular level, a single histidine to alanine substitution 
in the cTnI switch arm was the most effective mechanism for decreasing the 
binding free energy at the regulatory interface of TnI and TnC. Evidence 
suggests that this single amino acid substitution increases the intrinsic relaxation 
potential of the cTn complex enhancing diastolic performance to meet 
mammalian lusitropic demands.  
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A histidine button in TnI is known to provide a therapeutic basis for pH 
responsive titratable inotropy in response to various cardiac stresses. As such, 
the physiological implications of a histidine button in mammalian cardiac TnI 
(cTnI A164H) were studied. Whole organ in vivo cardiac hemodynamic analysis 
shows that cTnI A164H Tg mice protect cardiac function from age-induced 
cardiomyopathy. Furthermore, cTnI A164H Tg hearts sustain cardiac 
performance during severe hypercapnic acidosis compared to complete pump 
failure with 100% mortality observed in control mice.  
In situ and in silico site-directed protein mutagenesis, in vitro cellular 
biophysics, and atomic resolution molecular dynamics simulations were used to 
analyze the therapeutic basis for a histidine button in cTnI. Evidence suggests 
that differential ionization of histidine mediates the titratable inotropy observed in 
myofilaments containing cTnI A164H. Under physiologic conditions, histidine 
remains deprotonated and behaves functionally and structurally like WT cTnI. 
However, acidosis induces a protonation of histidine’s imidizole group causing 
enhanced intermolecular electrostatic and hydrophobic side chain contacts at the 
interface between cTnI and cTnC in the calcium saturated state. These data 
indicate that differential histidine ionization is required for cTnI A164H to act as a 
molecular rheostat capable of therapeutically modulating sarcomere performance 









At its most fundamental level, the maintenance of cardiac output is 
required for proper communication between organ systems. This pertains to the 
earliest bilaterian organisms which have a single heart tube that lacks valves or 
chambers and does not drive unidirectional flow as well as the mammalian heart 
that is four chambered, has valves, and drives blood in a directed fashion to all 
tissues of the body1. During repetative cycles of contraction and relaxation, the 
maintainance of the heart occurs at the molecular level where a carefully 
orchestrated process of protein synthesis and degradation maintains the capacity 
for efficient performance over the lifetime of an organism2, 3.  
Variance in organ structure (chambers, valves etc) and function (heart 
rate, ejection fraction) are dependent on organismal demands. Phylogenic 
studies show a remarkable range of possibilities that meet the physiological 
requirements of different organisms. For example, fish regulate cardiac output 
primarily through modifications in stroke volume as opposed to changes heart 
rate4, 5. The flounder heart has the highest reported stroke volume of a teleost 
measured at 2.3 mL per gram of body weight6.  On the other hand, endothermic 
chordates regulate cardiac output by modulation of heart rate and, to some 
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extent, modifications in stroke volume5. The fastest heart rate ever recorded in 
any vertebrate was found in a mammal, the Etruscan shrew, with a measured 
rate in excess of 1500 bpm7.  At the level of energetics, all of the ATP stores of 
the human heart are replaced every 10 seconds8.  
During evolution, organisms have also developed important mechanisms 
of regulating heart function in response to environmental changes9-13. These 
interactions between systems of the body are designed to maintain cardiac 
output. Given the critical importance of cardiac output for maintenance of normal 
physiological health, it is no surprise that disruptions to this system (e.g. 
myocardial infarction) significantly compromise the survival capacity of an 
organism. In the human population, heart disease has come to be the leading 
cause of morbidity and mortality worldwide14. To address this public health 
concern, biomedical research into the fundamental functions of the heart as well 
as novel therapeutic approaches for treatment of heart disease are critical. This 
dissertation provides new insights into the role of the myofilament protein 
troponin I (TnI) in sarcomere function. Studies described here also outline a 
novel approach to modifying TnI in order to therapeutically modulate sarcomere 
function in response to numerous cardiac pathologies.   
  
Structure of the Sarcomere  
 
The following is a discussion of the current state of knowledge regarding proteins 
that compose the sarcomere. The major protein complexes that regulate cardiac 
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contraction and relaxation include the thick filament and the thin filament. 
Together these multi-protein based filaments are organized to form the striated 
pattern of cardiac and skeletal muscle. There are numerous structural proteins 
required for proper functioning of the myofilaments (e.g. Z disk proteins) and the 
myocyte as a whole (e.g. dystrophin) that will not be discussed. For the purposes 
of this dissertation, a major focus is placed on the members of the troponin 
complex as opposed to other proteins that regulate functions of the sarcomere or 
calcium cycling of the myocyte.  
The contractile unit of muscle is the sarcomere. Repeating units of 
sarcomeres in series are termed myofibrils. Within the sarcomere are parallel 
units of thick and thin filaments. The proteins of the thick filament are numerous, 
but the molecular motor protein of the sarcomere is myosin. The proteins of the 
thin filament that regulate myosin motor activity include actin, tropomyosin (Tm), 
and the troponin complex (Tn). Under the control of intracellular calcium fluxes 
the thin and thick filaments slide past each other resulting in sarcomere 
shortening at the molecular level and contraction of muscle at the whole organ 
level. The sliding-filament theory of muscle contraction was originally proposed 
over fifty years ago15. 
 
The Thick Filament of the Sarcomere 
 
 Since this discussion will focus mostly on the thin filament proteins with 
only the following cursory analysis of the thick filament, I refer readers to a 
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number of excellent reviews on or including in-depth analysis of the thick 
filament2, 16-22. The thick filament is primarily composed of the bipolar polymer 
myosin heavy chain (MHC) with its various associated proteins (e.g. C, H, X, M, 
and titin). Myosin, a 200 kDa protein, has four light chains. These light chains 
include two essential and two regulatory subunits of about 20 kDa each. The 
parallel two chain coiled-coil structure of myosin forms the backbone of the thick 
filament while the N-terminal globular head, subfragment 1 (S1), protrudes at 
regular intervals. The S1 domain of myosin is essential for the binding of the thick 
filament to actin on the thin filament during muscle contraction23. This globular 
domain is also the site of ATP hydrolysis, the reaction required for force 
generating movements between myosin and actin17. Different isoforms of myosin 
hydrolyze ATP at different rates. The fast motor protein, α-MHC, hydrolizes ATP 
3-7 time faster than the slow motor protein, β-MHC24-26. However, maximal force 
generation is not different between these isoforms27. Overall, myosin is a protein 
centrally involved in the actions of sarcomeric contraction and relaxation.  
 The ATPase activity of myosin has been reviewed in great deal 
elsewhere18, 28. To emphasize the principles and necessity of this process, the 
following is only a brief synopsis of the critical aspects of myosin ATPase 
activities as they occur during muscle contraction and relaxation. The S1 
subfragmant of myosin is the functional domain required for binding and 
processing of ATP and its isomers as well as the cyclical binding and release of 
actin. In the fully relaxed state when actin and myosin are not in contact, the 
myosin cross-bridges are in an energized state having hydrolyzed ATP into ADP 
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and inorganic phosphate (Pi). Thus there is a great deal of potential energy 
contained within this S1 fragment in the relaxed state of the myofilaments. Upon 
calcium activation, this energized myosin develops an initial weakly bound 
association with actin (A-M-ADP-Pi). This weak connection then isomerizes into a 
strong actomyosin interaction (AM-ADP-Pi). AM-ADP-Pi is then further 
isomerized in the force generating power stroke that releases the high free 
energy through release of ADP and Pi. During the power stroke, actin and 
myosin are tightly bound. Release from this rigor conformation is enabled by the 
allosteric effects caused by rapid binding of ATP to form actomyosin-ATP (AM-
ATP). Importantly, at this stage ATP functions exclusively as an allosteric 
modulator of actin-myosin interactions and not as an energy source. Upon 
myosin dissociation from actin to form myosin-ATP (M-ATP), myosin S1 
subsequently hydrolyzes ATP into ADP and Pi (M-ADP-Pi) resulting in the cocked 
highly energized pre-power stroke position. As long as calcium is present for 
activation of the myofilaments, crossbridge cycling will continue. Relaxation 
occurs when calcium is removed from the thin filament regulatory protein 
troponin C and actin binding sites are no longer accessible to myosin. These 
descriptions of thin myofilament changes during contraction and relaxation are 
grossly over simplified and greater detail will be provided in subsequent sections 
to elaborate on specific molecular mechanisms of myofilament contraction and 
relaxation.  
 




 The thin filament is comprised of a complex of proteins formed into an 
allosteric regulatory complex that governs calcium-mediated contraction of the 
sarcomere29. The backbone of the thin filament is composed of polymerized 
globular actin molecules (G-actin) complexed into an actin parallel pseudodouble 
helical filament (F-actin)30-32. F-actin is composed of two intertwined right-handed 
helical arrays with each repeat spanning approximately 700 Å and a pitch of 
approximately 13 monomers per turn33. Structural analysis of actin crystals has 
shown that it has four subdomains that surround a binding pocket for a divalent 
ion and nucleotide30, 31. The atomic model of F-actin derived from X-ray 
diffraction patterns of oriented actin filament gels shows that the larger 
subdomains 3 and 4 are axially located and have direct contacts with 
subdomains 3 and 4 of the second actin strand32.  The smaller subdomains 1 and 
2, located at the periphery and exposed to the solvent, contain the amino and 
carboxy terminals of actin and are the site for myosin binding.  
Located at specific regions and intervals along actin are a number of 
regulatory proteins. Tropomyosin (Tm) is an elongated protein containing hepta-
peptide repeats having the greatest number of contacts with actin along the 
length of the thin filament34, 35. Tm is a largely α-helical coiled-coil dimer about 
400 Å long that lies within the groove of the actin filament with each Tm molecule 
spanning over seven actin monomers36. A high resolution crystal structure has 
shown that the N-terminus of Tm contains a high concentration of alanine 
residues thought to be critical for the bending of the molecule and the formation 
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of the coiled coil37. Tm molecules interact in a head to tail manner through a 
single disulfide bridge forming a continuous strand along the entire length of the 
actin filament36, 38. Electrostatic interactions between actin and Tm32 allow it to 
shift positions in an azimuthal motion within the actin groove depending on the 
phase of the contraction cycle17, 18. The position of Tm is regulated by a 
heterotrimeric protein complex called troponin (Tn). Tm is the primary means of 
potentiating the regulatory actions of Tn to the rest of the sarcomere. However, 
the structural basis for this regulation of Tm by Tn remains obscure. The 
stoichiometry of Tm and Tn is 1:1 along the length of the thin filament. Together 
Tm and Tn regulate about 13 actin monomers and their interaction with myosin39-
42. Based on X-ray structural studies, it was originally hypothesized that Tm was 
the molecule primarily responsible for regulating actomyosin ATPase activity, the 
steric blocking model of muscle regulation43-45. More recent evidence, however, 
suggests that Tm facilitates the transmission of structural changes from one actin 
monomer to its neighbor along the thin filament during the transitions between 
diastole and systole46, 47. Essentially, Tm acts to amplify on actin the effects of 
upstream conformational changes caused by troponin, although the specific 
mechanism of this structural transmission is still unclear. Patchel and colleagues 
suggest that this transmission of structural changes on actin by Tm enable all 
actin molecules within a functional unit (1 Tm: 7 actin) to interact (bound or 
unbound) with myosin in concert depending on the phase of the cardiac cycle. 
Functionally upstream from these events is the troponin complex, whose 
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subunits are centrally involved in the regulation of contractile functions of the 
sarcomere.  
 
The Thin Filament of the Sarcomere: troponin  
 
Setsuro Ebashi was the first to describe the troponin complex over fifty 
years ago48 (Figure 1-1). Troponin is a heterotrimeric protein complex comprised 
of three subunits. These include the Tm binding subunit, troponin T (TnT), the 
calcium binding subunit, troponin C (TnC), and the actomyosin ATPase inhibitory 
subunit, troponin I (TnI)49, 50. The coordinated actions of the troponin complex are 
specifically designed to regulate the actions of all other members of the 
sarcomere in the transition between systole and diastole. Specifically, the 
mechanism of control by troponin involves a tight regulation of an otherwise 
highly favorable interaction between actin and myosin in the transition between 
activated and inactivated cross-bridges. Thus, the troponin complex plays a 
central role in regulating a system that is, by necessity, highly sensitive to 
stimulus. Reports of the calcium saturated crystal structures for fast skeletal 
troponin51 and cardiac troponin52 have been instrumental in helping interpret a 
great deal of functional data on the troponin regulatory complex.  
To begin, TnT is considered the structural “glue” that holds all the proteins 
of the thin filament proteins together due to its interactions with TnC, TnI, Tm and 
actin18. The various isoforms of TnT in different muscle types as well as during 










Figure 1-1. Orientation to the troponin complex. The troponin complex is situated 
on the thin filament and associates in a regulatory fashion with tropomyosin and 
actin. Schematic diagram showing structural alterations during the diastolic (left) 











calcium sensitivity, activation of actomyosin ATPase activity, and possibly 
regulate aspects of cooperativity within the thin filament during contraction53-56. 
Mild chymotryptic digestion has shown that TnT is composed of two domains, the 
extended N-terminal T1 domain (residues 1-158) and the globular C-terminal T2 
domain (residues 159-259). The N-terminal T1 domain interacts with the C-
terminal region of Tm57 while the T2 domain interacts with the C-terminal head of 
TnC and the N-terminus of TnI58. Importantly, TnT plays an essential regulatory 
role in thin filament function by connecting the activities of TnC and TnI relative to 
the positioning of Tm in the actin groove59, 60. Despite our understanding of the 
important role TnT plays in the thin filament, a great deal of ambiguity remains in 
regard to the interactions between TnT, Tm, and actin29. Of utmost importance to 
its function, however, is the observation that TnT both increases the inhibition of 
actomyosin ATPase activity in the absence of calcium and augments the 
contractile response in the presence of calcium55, 56.  
Troponin C (TnC) is a small (18 kDa) protein that is expressed in two 
isoforms, skeletal TnC (sTnC) and cardiac TnC (cTnC). Although the sequence 
of sTnC and cTnC are about 70% homologous, the major difference between 
these isoforms is their calcium binding characteristics61. The fundamental role of 
TnC is to bind calcium, the second messenger that transmits electrical 
stimulation to sarcomeric contraction. This critical function has been illustrated 
previously in skeletal muscle depleted of TnC by washing with EDTA62. These 
studies showed that the sarcomere remained permanently relaxed regardless of 
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the calcium concentration. The calcium responsiveness of the fiber was restored 
after reconstitution with TnC.  
Based on X-ray diffraction and nuclear magnetic resonance spectroscopy 
(NMR), the TnC structure has been found to be composed of two globular heads 
connected by a helical linker63-65. Based on current studies, it appears the linker 
domain (helix D and E) allows the two heads of TnC to function independently of 
each other64, 66 while keeping the N and C terminal domains within optimal 
proximity to their target sites on TnI67, 68. The contractile function of the 
sarcomere is dependent on calcium binding to the N-terminal lobe of TnC69-71. 
Together with helix 3 of TnI (residues 150-159), this region of TnC is known as 
the “regulatory head’ of the troponin complex.  
The ability for TnC to bind calcium is based on its structural composition 
which contains essential EF-hand calcium binding motifs characterized by α-helix 
loop helix structures63. TnC has eight α-helices comprising four calcium binding 
sites plus one extra helix at the N-terminus (N-helix). The N-terminal regulatory 
domain of TnC contains binding sites I and II72. In cardiac muscle only one of 
these sites is functional (site II) whereas both sites are functional in the skeletal 
isoform of TnC65, 71, 73.  This difference is due to primary amino acid sequence 
differences between the isoforms at key residues with cTnC having an insertion 
(V28) and several significant substitutions in the pentagonal bipyramidal 
coordinating site relative to sTnC (Leu29, Ala31 in cTnC compared to Asp30 and 
Asp32 in sTnC)61. The functional N-terminal EF hand motif of TnC (site II) has a 
binding  affinity for calcium calculated at a KCa of about 2x105 per mol71. Studies 
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have shown that the acid side chains in the EF hand of site II are highly 
conserved and involved in coordinating the binding of calcium to cTnC74. Site-
directed mutagenesis and experiments using fluorescence stopped flow analysis 
of calcium exchange have shown that calcium binds and releases cTnC site II 
within the physiologic range75, 76. This binding affinity is of critical importance 
because it allows calcium to bind and release from TnC in direct correlation with 
calcium cycling in the myocytes on a beat-to-beat basis. As with other calcium 
binding proteins, the calcium-TnC interaction results in a wide range of structural 
and energetic changes including exposure of a critical hydrophobic patch77-79. 
Specific details of conformational changes in TnC during calcium binding 
(systole) will be discussed later. However, in the apo state, when the intracellular 
calcium concentration is low, the calcium binding sites on NTnC form short β-
strands80 and, importantly, the hydrophobic residues involved in activation of the 
regulatory arm of TnI remain inaccessible77. This closed state is specifically 
characterized by a close association between the B-C helix and the central helix 
(D/E) where helices B and D are roughly parallel to each other.  
The D-E linker of TnC is a critical region because of its largely electrostatic 
interactions with TnI during the transitions between systole and diastole. Studies 
by Kobayashi et al have performed mutagenesis experiments and assessed 
actomyosin ATPase activity to show that acidic residues within this region of TnC 
are required for actomyosin activity. Specifically, they found that alanine 
mutagenesis of E85 and D86 retained complete inhibition of actomyosin ATPase 
activity in the presence and absence of calcium81. Whether this was due to 
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disruption of calcium binding to TnC was not clarified. Additional mutagenesis 
studies with the inhibitory region of TnI have shown the importance of the 
interaction between TnI IR and the TnC D-E linker (to be discussed) for the 
regulatory functions of Tn. 
The C-terminal domain of TnC has two corresponding EF hand motifs 
(sites III and IV), however, the function of these sites are thought to be mostly 
structural, providing an important role in anchoring TnC to the thin filament82. 
More specifically, these sites have a much higher affinity for calcium (KCa 2x107 
per mol) and for magnesium (KMg 5x103 per mol)71 and, in accordance with this, 
kinetic analysis has shown that these sites are constitutively bound with a metal 
ion under normal physiological conditions62, 83.  
Fluorescence has been used as a methodology to study TnC function in 
regard to calcium binding and dissociation kinetics by linking TnC to IAANS, an 
environment sensitive fluorophore which covalently alkylates protein sulfhydryl 
groups via its iodoacetamide functionality84. It has been shown85 that the IAANS 
fluorescence of labeled WT cTnC increases by about 60% with Ca++ binding to 
site II. This provides an effective means of measuring changes in calcium binding 
to cTnC by means of changes in fluorescence. Furthermore, studies in which 
either Cys35 or Cys84 was substituted with serine demonstrate that the IAANS 
label at Cys84 alone is responsible for this fluorescence change in isolated 
cTnC86, 87. 
Toponin I (TnI) is the Tn subunit responsible for inhibition of actomyosin 
ATPase activity88. In all vertebrate chordates, there are three genes that encode 
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three different TnI isoforms, the slow skeletal (ssTnI), fast skeletal (fsTnI), and 
cardiac (cTnI). In the heart, the slow skeletal isoform is expressed during 
embryonic development and transitions to the adult cardiac isoform around the 
time of birth2, 89. In humans this isoform transition occurs during the first year of 
life90. Details of these biochemical and functional differences in these isoforms 
will be discussed later. As proposed by Farah and colleagues33 and confirmed 
more recently in structural studies52, TnI is situated in the Tn complex such that it 
interacts in an anti-parallel orientation with TnC with the N-terminal domain of TnI 
engaging with the C-terminal domain of TnC. The fundamental function of TnI is 
to transmit calcium binding on TnC to other units of the thin filament. Essentially, 
TnI acts as a calcium dependent molecular switch of the thin filament making it a 
critical protein involved in this interdependent allosteric regulatory complex9, 91-93.  
Despite extensive biochemical studies on TnI, much remains unknown about 
certain structural characteristics of this protein and, functionally, how it interacts 
with other members of the thin filament.  
Seminal work in recent years has provided important structural information 
about troponin I52, 94-98. The first domain of TnI is the N-terminal cardiac-specific 
extension (cNTnI, residues 1-43). Syska and colleagues showed that this region 
of TnI binds to TnC99. It has subsequently been shown, using recombinant TnI 
molecules, that this interaction is independent of calcium55, 100. One of the critical 
characteristics of the N-terminus of cTnI is the presence of PKA-dependent 
serine phosphorylation sites (S23/24). Fundamentally, the phosphorylation status 
of cTnI (occurring in response to adrenergic signaling in the myocyte) has 
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significant structural and functional effects on the N-terminal lobe of TnC that 
effect the calcium sensitivity of the myofilament93, 101-104. Cross linking studies 
have shown that cTnI (residues 1-29) interacts with the N-terminus of TnC105, 106 
and phosphorylation of cTnI effects this interaction102. However, the binding of 
calcium to the N-terminus of TnC is not affected by changes in the interaction 
between TnC and cTnI mediated by phosphorylation events102. Furthermore, 
both cTnI (residues 1-29) and residues from the switch arm of TnI (residues 147-
163) can simultaneously bind TnC in the presence of calcium. The current model 
by which cTnI modulates calcium sensitivity in response to adrenergic signaling 
is by depressing the affinity of the switch arm of TnI for the calcium saturated 
hydrophobic patch of TnC102, 107. Let it be known, however, that there are 
disagreements about this which have been outlined in previous studies and 
reviews indicating the need for further investigation on this matter108, 109. 
Beyond the N-terminal extension of cTnI, the first α helix of TnI (H1, 
residues 43-79) binds the C-terminal domain of TnC through multiple polar and 
van der Waals interactions. The C-terminal region of H1 (residues 66-79), a 
flexible linker (residues 80-89) and the second α helix of TnI (residues 90-135) 
wrap around the H2 helix of TnT (residues 226-271) and interact by multiple 
hydrogen bonds and hydrophobic interactions, thus forming a hydrophobic core. 
A critical component of this domain is the coiled-coil formed by the H2 helix of 
TnI and H2 helix of TnT that form inter-chain contacts. These interactions are 
well conserved across species reinforcing the important functional and structural 
characteristics of this region52. TnC also converges with the TnI and TnT in this 
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domain making it a tripartite interaction (termed the IT arm). Crystal structure and 
solution experiments have suggested that the conformational state of the ion 
bound C-terminus of TnC opens the hydrophobic patch of TnC such that it binds 
the N-terminal amphiphilic α-helix of TnI as well as the H2 helix of TnT  thus 
anchoring TnC to the rest of the troponin complex52, 95. The IT arm is thought to 
remain unchanged as a unit regardless of the concentration of intracellular 
calcium or the physiological state of the myofilaments (contracted or relaxed)52. 
Although the IT arm is thought to be a rigid structure, recent studies by Sun and 
colleagues have found that the domain does toggle during the phases of the 
cardiac cycle based on its sensitivity to myosin head binding66. This study also 
showed that, when contraction is blocked, the position of the IT arm is only mildly 
effected by the binding of calcium and significant conformational changes of the 
N-terminal lobe of TnC. Together these findings indicate that the IT arm is 
involved in cross-bridge dependent activation and not the calcium-mediated 
response of the myofilaments. Lastly, there is no evidence to date that the IT 
domain interacts with any other thin filament proteins such as tropomyosin or 
actin52 suggesting that this region is crucial only for transfer of energy within the 
Tn molecule between phases of the cardiac cycle. Lastly, in terms of the 
inhibitory role of TnI, early biochemical studies using recombinant fragments 
showed that the N-terminal region of TnI up to residue 102 were not necessary 
for the complete inhibition of actomyosin ATPase activity55.  
Beyond the IT domain is a basic inhibitory region (IR) (residues 137-148). 
The IR region through to the C-terminus of TnI (residues 137-210) is considered 
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the regulatory domain (TnIreg) due to its central role in the allosteric functions of 
the TnI. The IR region is the first actin binding domain but is poorly defined in the 
crystal structure suggesting significant flexibility52, 110-113. These observations 
have been confirmed by cross-linking and Förster resonance energy transfer 
(FRET) experiments showing the IR region to exist in a flexible β-hairpin during 
diastole114. Interestingly, a truncated TnI molecule containing only the minimal IR 
region (residues 138-147) was found to recapitulate the actin inhibitory and Tm 
accentuating functions of the full TnI molecule illustrating the importance of this 
region in TnI function47. Proton NMR spectroscopy and cross-linking studies have 
suggested that the IR region of TnI binds the N-terminus of actin at sites also 
implicated in myosin S1 subfragment binding during cross-bridge activation115. 
More recent structural studies using peptide fragments have gone further to show 
that a significant conformational change occurs in actin upon the binding of the 
IR region of TnI during diastole that fully impedes the binding of myosin to actin46, 
47. Additionally, the three-dimensional reconstructions from electron micrographs 
fitted with the atomic model of actin show that Tn binds the N-terminus of actin 
during relaxation of the myofilaments116. As mentioned previously, these 
structural changes on the actin surface are propagated along from monomer to 
monomer within a functional actin unit (as defined by the distribution of 1 Tm 
along 7 actin monomers) by Tm. Thus, during diastole, the specific interactions 
between Tn, Tm, and actin coordinately prevent actomyosin activity with the IR 
region of TnI playing a central role in the blocked state of the myofilament. A 
recent study by Kobayashi et al using alanine scanning across the IR domain has 
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shown that residues L145-R149 are required for activation of the 
myofilaments117. In other words, when these residues are substituted for alanine, 
TnI continues to inhibit actomyosin ATPase activity even in the presence of 
calcium. This raises an important question regarding the role of these IR residues 
play in 1) actin binding for inhibition of cross bridge cycling and 2) binding of TnI 
IR to the D/E linker of TnC. These data would suggest that the IR domain (145-
149) is more involved in the electrostatic interactions with TnC as opposed to 
actin.  
The IR region of TnI is followed by a switch domain (or, mobile domain) 
that begins with the amphiphilic helix H3 (residues 150-159) and continues 
through helix 4 (residues 164-188) and the C-terminal domain (residues 192-
210). The flexibility of TnI, a hallmark of this protein, is exemplified in this mobile 
domain, aptly named because even in the absence of calcium this region 
remains highly mobile118. Rarick and colleagues have shown that two 
independent actin binding sites exist on TnI between residues 151-210119, 120. 
This TnI domain is positioned on azimuthally related actin monomers similar to 
other actin binding proteins such as caldesmon in smooth muscle thin filaments 
(which lack Tn)121, 122. During diastole, the primary function of this region is to 
provide a second actin and Tm binding site for TnI. Consistent with this, a recent 
study showed that a truncated cTnI molecule (containing residues 1-193) had 
increased actin-activated S1 ATPase activity123. By docking the switch arm of TnI 
into the cryo-electron micrograph map of the thin filament, Murakami and 
colleagues were able to visualize the atomic structure of this region to the level of 
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single amino acids124. Together with previous studies, they show that actin and 
TnI interact weakly in this region despite the formation of numerous salt bridges. 
This weak contact likely explains the observation that no conformational changes 
in the surface structure of actin occur in the interaction between TnI and actin in 
this domain. In contrast to the role of the IR region in actively inhibiting myosin-
actin interactions by alterations of the actin surface structure as discussed above, 
the binding sites between actin and the regulatory arm of TnI are distinct from the 
attachment sites of the myosin head. In fact, three-dimensional EM 
reconstructions of actin filaments decorated with myosin light chain showed that 
the interactions between these molecules occurred at the C-terminus of actin, 
exactly where the mobile domain of TnI was found to interact124, 125. Additionally, 
previous studies have shown that when peptides associated with the second 
actin binding domain of TnI are mixed with actin or actin-Tm, myosin does not 
dissociate from the actin binding sites47. As such, several hypotheses have been 
proposed regarding the function of this domain. It is thought that this region does 
not act to specifically inhibit actomyosin ATPase activity but, rather, limits the 
possible configurations of the C-terminus of TnI during diastole. Thus, the C-
terminal actin binding sites on TnI make the relaxed state more robust: a “fail-
safe molecular latch”124. Another hypothesis proposed by Kobayashi and 
colleagues is that this second actin binding site on TnI increases the local 
concentration of the TnI molecule for actin. This would facilitate the critical 
interaction between actin and the first actin binding domain of TnI in the inhibitory 
region (IR)126, 127. The interaction between Tm and the C-terminus of TnI is also a 
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key component of this thin filament regulation. Recent studies using electron 
micrograph image reconstruction on filaments saturated with a construct 
representing the C-terminal domain of TnI indicate that TnI competes with Tm for 
binding sites on actin thus shifting Tm into the blocking position122.  
Overall, it has been proposed that the Tn complex as a whole plays a 
critical role in stabilizing a more rigid conformation of the thin filament during the 
blocked state which is released during calcium activation of the myofilaments122. 
Specifically, it is thought that TnI, acting as a molecular tie, straddles the two long 
pitch strands of actin thus increasing the rigidity of this complex122, 128, 129. 
Bringing the thin filament proteins together, it seems that both steric and 
allosteric effects of multiple myofilament proteins (e.g. cTnI-actin and TnT-actin-
Tm) converge to inhibit the actomyosin binding sites on actin during diastole.  
 
Whole Organ and Cellular Transitions between Systole and Diastole 
 
Given the above detailed analysis of myofilament proteins that compose the 
sarcomere, the following discussion outlines the specific processes that are 
involved in the transition of these proteins during the systolic and diastolic 
phases of the cardiac cycle. These subcellular events, including calcium cycling 
and myofilament responses to calcium, will provide context for descriptions of 
whole organ cardiac function. Although the correlation between cellular and 
whole organ functionality is very complicated, the correlate of LV pressure is 
sarcomere tension, and that of LV volume is sarcomere length. The relationship 
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between LV pressure (tension) and volume (length) is the basis of Starling’s law 
of the heart. Consistent with this, classic experiments on the Frank-Starling 
response by Gordon and colleagues 130 illustrated that the sarcomere length-
tension relationship was based on characteristics of thin and thick filament 
overlap. Specifically, it was observed that optimum myocyte force generation was 
reached when sarcomere lengths reached a specific point that maximized thin 
and thick filament interactions. In addition to the thin and thick filaments, 
numerous other proteins (e.g. titin) are centrally involved in regulating the 
Starling response by modulating the distensibility and tension dynamics of the 
myocyte and whole heart4. 
 Several methodologies have been put to use in the studies composing this 
dissertation to experimentally investigate the process of cardiac whole organ as 
well as myocyte contraction and relaxation in the context of health and disease.  
To study whole organ cardiovascular performance in vivo, mice were 
instrumented with a 1.4 F Millar conductance micromanometry catheter. To 
understand the fundamental kinetics of calcium cycling and myocyte function, 
adult rat myocytes were isolated, exposed to adenovirus for gene transfer, and 
cultured for study using various in vitro cellular analytical techniques. The specific 
details of in vivo and in vitro study of cardiac physiology are well established by 
the Metzger laboratory as outlined extensively by studies outlined in this 
dissertation as well as previous reports (for example24, 131-133). 
To provide sufficient background for the forthcoming studies, the following 
discussions will outline the critical actions of calcium cycling followed by an 
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integration of concepts involving whole organ hemodynamics as well as the 




Cardiac excitation-contraction coupling is the mechanism by which the heart 
undergoes cyclic contraction and relaxation during each beat. Calcium mediates 
the transmission of extracellular depolarization to intracellular myofilament 
activation134. A number of excellent reviews have been written on calcium 
handling in the myocytes134-137 as only a brief overview is discussed here. Upon 
stimulation by an action potential, membrane depolarization causes an influx of 
calcium through the L-type calcium channel (LTCC). This local concentration of 
calcium causes an opening of the ryanodine receptor (RyR) in a mechanism 
termed calcium induced calcium release. The RyR is the pore through which all 
of the calcium stores of the sarcoplasmic reticulum (SR) are released into the 
myoplasmic space. This alters the cytoplasmic calcium concentration from sub-
micromolar during diastole to micromolar during systole. The primary target of 
this calcium is the thin filament protein Troponin C (TnC) which enables 
activation of the sarcomere. The events leading to this point occur during the 
systolic phase of the cardiac cycle.  
As calcium stores are reduced in the SR, the RyR is inactivated leading to 
the subsequent resequestration events during the diastolic phase of the cardiac 
cycle. Several mechanisms are involved in the removal of calcium from the 
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myoplasm. The most significant mode of calcium resequestration is through the 
Sarco(endo)plasmic reticulum calcium ATPase pump, SERCA2a. Closely 
associated with SERCA2a, phospholamban is a negative regulator of SERCA 
ATPase activity and is itself functionally responsive to β-adrenergic signaling. 
Another mechanism of calcium removal from the myoplasm is the sarcolemmal 
sodium-calcium exchanger, NCX. The relative contributions of SERCA2a and 
NCX in calcium removal are species dependent. The periodic calcium 
oscillations, mediated by these various regulatory proteins, are called calcium 
transients and fundamentally determine the systolic and diastolic phases of the 
cardiac cycle. Among various mammalian species, machanisms of calcium 
regulation via various channels is widely varying.  
 
Overview of Cardiac Contraction and Relaxation 
 
At the onset of systole, myocardial stimulation is initiated at the sinoatrial 
node of the heart and directed through the atrioventricular node and to the rest of 
the myocardium through the Purkinje fibers.  From the hemodynamic standpoint, 
this myocardial stimulation begins the stage of isovolumic contraction where the 
LV contracts against the closed aortic valve (afterload). At the level of the 
myofilaments, sarcomere tension increases but length does not change during 
this phase of the cardiac cycle. It has been proposed by Wolff and colleagues 
that Ktr (the rate constant reflecting the cross-bridge cycling kinetics) may limit 
the rate and extent of ventricular pressure development during isovolumic 
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contraction138. This is based on the observation that calcium transients are 
significantly shorter in duration than the tension development. When pressure in 
the LV exceeds that in the aortic root (usually around 120 mmHg) the valve 
opens, pressure plateaus, myofilaments contract, and LV volume decreases by 
ejection through the aorta. The transition from systole to diastole occurs 
somewhere around the point preceding aortic valve closure when pressure in the 
aortic root exceeds pressure generated by the ventricle. Hemodynamically, this 
point is characterized at the point of end systolic pressure and end systolic 
volume. The onset of relaxation requires the re-sequestration of calcium into the 
SR, however, the specific mechanisms of relaxation at the myofilament level 
remain very unclear. Although calcium removal is unequivocally required for 
relaxation, myofilament characteristics have been found to be rate limiting. 
Strong evidence of this has been shown by studies revealing the myosin 
isoforms significantly affect the rate of relaxation139. Furthermore, studies have 
demonstrated that enhanced relaxation is more closely correlated with cross-
bridge cycling kinetics than calcium dissociation from TnC140, 141. Similar to 
systole, relaxation begins with a period of isovolumic pressure decay as pressure 
in the LV exceeds that of the mitral valve. When atrial pressure rises above 
ventricular pressure (very close to 0 mmHg), LV volume rapidly increases in the 
filling phase of the cardiac cycle. From the myofilament standpoint, sarcomere 
length increases with a mild increase in tension until end diastolic volume and 
pressure are reached and the cardiac cycle begins again at the onset of systole.  
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The hemodynamic relationship between pressure and volume (or 
myofilament length and tension) as outlined by Starling’s law of the heart, can be 
analyzed in vivo by altering venous return. Briefly, Starling’s law states that within 
the physiologic range there is an inexorable correlation between pressure 
(tension) and volume (length) and the performance of the heart involves a 
constant synchronous adjustment of these parameters during any given heart 
beat depending in response to changes in preload. Experimental analysis of this 
relationship is accomplished by occlusion of the inferior vena cava which feeds 
venous blood back to the heart via the right atrium. Reducing preload directly 
impacts the function of the LV as illustrated by a sudden collapse of the PV loops 
during this manipulation. A line drawn through the end systolic pressure and 
volume during collapse of the PV loops provides insight into the load-
independent function of the heart (the end systolic pressure volume relationship). 
Specifically, hearts that are performing well and have a broad dynamic range of 
activation of the myofilaments will have a steeper slope. In contrast, hearts that 
are injured or performing poorly will have a shallower slope indicating a blunted 
range of myofilament performance.  
Although other models exist, the widely prescribed view of muscle 
regulation is grounded in a three state description of the molecular mechanism of 
myofilament function first proposed by Hill and colleagues in 1980 and 
elaborated upon since142-145. As the name suggests, this model delineates three 
different states of the myofilaments during the cardiac cycle. These states 
include the blocked state (B) reflecting full steric block of actomyosin ATPase 
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activity; a closed state (C), reflecting the formation of weakly bound cross-
bridges; and an open state (M) reflecting strongly bound actin-myosin cross-
bridges associated with sarcomeric contraction.   
In the B state (diastole), when cytoplasmic calcium concentrations are 
sub-micromolar, the regulatory site on Tn is closed and Tm is positioned at the 
outer domain of actin sterically blocking actomyosin crossbridge formation. In the 
C state, when calcium is released from the SR, conformational changes in Tn 
cause Tm to move closer to the inner domain of actin allowing for weak, non-
force generating but stereo-specific interactions to occur between myosin and 
actin. Using electron microscopy and 3-D reconstruction of the thin filament, 
Lehman et al have shown that TnI actively regulates azimuthal movements of Tm 
in the transitions between the B and C states146, 147. Kinetics of myosin S1 
binding indicate that the B and C states are not entirely distinct events. Rather, 
findings show that during relaxation of the myofilaments (diastole), about 50% of 
the cross-bridges are in the B state and 50% in the C state148. The transition from 
the C state to the M state is thought to rest entirely on the kinetics inherent in 
cross-bridges and is dependent on the load of the muscle22, 149. The M state is 
characterized by strong force generating cross-bridges forming between actin 
and myosin with subsequent sarcomeric contraction. Importantly, cooperativity 
within and among neighboring regulatory units has been found to be a central 
characteristic of myofilament function17, 18, 145. This propagated activation of the 
sarcomere seems to be of particular importance in cardiac muscle. Specifically, 
evidence has shown that small changes in strongly bound cross-bridges 
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markedly increase the calcium sensitivity of force and cross-bridge kinetics in the 
myocardium150, 151. Lastly, experimental studies suggests that active, force-
generating cross-bridges of the M state extend beyond the loss of bound 
calcium, a finding that has significant implications on the duration of cardiac 
ejection and the timing of myocardial relaxation22, 152. Even so, calcium 
dissociation from TnC is ultimately required for relaxation of the myofilaments in 
anticipation of a second contractile stimulus76, 153. The myofilament proteins (with 
a major focus on the thin filament) involved in this process as well as the specific 
structural features of the sarcomere during the phases of relaxation and 
contraction are outlined in further detail as follows.  
 
Myofilament Structural Changes During Systole 
 
As discussed in detail above, the systolic phase of the cardiac cycle is 
initiated upon depolarization of the myocyte and the subsequent flux of calcium 
ions out of the sarcoplasmic reticulum into the cytosol. The direct target of this 
calcium for activation of the myofilaments is the the N-terminal domain of TnC. 
As originally proposed by Herzberg and colleagues63, 153, calcium binding 
fundamentally changes the structure of TnC from the apo “closed” conformation, 
its thermodynamic nadir, to the calcium saturated “open” conformation. 
Interestingly, the “open” configuration of cTnC is markedly different from that of 
sTnC and appears to contribute to the wide range of isoform specific differences 
between skeletal muscle and cardiac muscle that result in fundamentally different 
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myofibrillar dynamics17, 18. The following discussion focuses on the current 
understanding of cTnC during systole. Various studies have established that 
calcium binding to site II at the N-terminus of cTnC is solely responsible for 
initiating processes involved in sarcomeric contraction71, 85. However, the calcium 
sensitivity of the regulatory domain of cTnC is highly dependent on other 
myofilament proteins. For example, a very recent study using a reconstituted thin 
filament containing an IAANS labeled cTnC and a truncated cTnI has shown that 
the C-terminal domain of TnI (193-210) is a negative regulator of calcium binding 
to TnC under normal physiologic conditions123. Furthermore, solution studies 
have shown that binding of cTnC to cTnI and cTnT increases the calcium binding 
affinity of cTnC by at least an order of magnitude primarily due to a slowing of the 
calcium dissociation rate85, 154, 155. Studies have also shown that the cooperative 
binding of calcium to TnC only occurs when the Tn complex is fully incorporated 
into the thin filament126, 156. This further suggests that feedback mechanisms 
between Tn, actin, and Tm are of critical importance proper calcium activation of 
the myofilaments. Binding of calcium to the regulatory domain of cTnC results in 
a wide range of structural and energetic changes78, 79. These changes include a 
decrease in the flexibility of the backbone of cTnC and a more rigid loop in the 
defunct calcium binding site (site I)157. The binding of calcium to site II, however, 
is considered a priming of cTnC for binding of the regulatory arm of cTnI because 
this event does not provide enough activation energy to fully open the 
hydrophobic pocket of cTnC64.  
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 With the change in the structure and biochemistry of the calcium-bound N-
terminal region of TnC, the switch arm of TnI develops an affinity for cTnC 
measured as an increase of two orders of magnitude158. Förster resonance 
energy transfer (FRET) experiments have shown that the movements of the 
regulatory arm of TnI during systole and diastole are essential for the 
transmission of the calcium signal to the rest of the myofilament proteins159, 160. 
This increased affinity causes a translocation of the entire regulatory arm of TnI 
and binds with cTnC by multiple van der Waals contacts52, 161. With this important 
role, TnI has come to be known as the molecular switch of the myofilament9. 
According to the ‘drag and release’ model for myofilament regulation of 
contraction29, calcium induces a movement of the switch domain of TnI toward 
the N-terminal lobe of TnC, dragging along the downstream actin binding domain 
and ultimately releasing the inhibition on actin. The ‘drag and release’ model 
suggests that TnC and actin compete for the binding of the regulatory arm of TnI. 
This model has also recently been supported by Xing et al using FRET analysis 
of fluorescence quenching between labeled residues on the C-terminus of actin 
(C374) relative to Cys-modifed residues on the C-terminus of cTnI162. 
Fundamentally, this translocation and the subsequent interaction between TnI 
(residues 150-166) and cTnC during systole is a requisite step in developing 
enough energy to complete the opening of the hydrophobic patch (e.g. Met45, 60, 
80, 81) on cTnC163, 164. Interestingly, Bell and colleagues recently reported that the 
calcium-dependent structural transitions of TnC also precede force 
development165. This supports the hypothesis that these initial events during 
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systole involving calcium and TnC are not the rate limiting steps of contraction. 
Studies have also shown that the rate of thin filament activation by calcium is 
independent from and thus does not impact cross-bridge cycling kinetics166. 
Specifically, studies where calcium-induced conformational changes were 
measured in conjuction with force development have shown that calcium binding 
kinetics to be much faster than cross-bridge cycling167. Other studies have 
countered this assertion. Specifically, Regnier et al have shown using photolysis 
of caged calcium that the rate of calcium induced sarcomere contraction (KCa) 
was significantly slower than the rate of force re-development (Ktr)168. These data 
suggest that there is some relationship between calcium activation of thin 
filament regulation and thick filament force development.  
Based on the crystal structure of the calcium saturated troponin complex, 
helix 4 and the C-terminus of TnI during systole are found to form a protruded 
and extended α-helix with no direct interactions with the rest of the molecule52. 
Indeed, Takeda et al found that this region of TnI (residues 164-210) did not 
crystallize well due to a high degree of flexibility. Interestingly, despite the 
continuing struggle to acquire structural information about the C-terminus of cTnI, 
Xing and colleagues have shown by FRET analysis that the C-terminus is very 
stable 162. Specifically, they analyzed the distribution of inter-site distances 
between the C-terminus of actin (C374) and sites on the C-terminus of cTnI 
(188C and 210C) as a surrogate indicator of conformational flexibility. They found 
that regardless of calcium activation and myosin S1-ADP binding, the 
conformational flexibility of the C-terminal domain of cTnI was more stable than 
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regions more N-terminal (131C, 151C, 160C, and 167C). Of further importance, 
this study also showed that the inter-site distance between C374 on actin relative 
to the most C-terminal labeled residues on cTnI (188C and 210C) did not 
translocate as far as residues in the middle of the switch domain (e.g. 167C) in 
the transition from diastole to systole (e.g. relative to C374 on actin, cTnI C210 
shifts 10.2 Å compared to 19.9 Å for 167C). It is difficult to interpret these findings 
given that numerous studies have shown that the C-terminal region of TnI is 
highly unstable9, 52. In fact, recently Hoffman and colleagues used measures of 
intrinsic disorder to show that the C-terminus is disordered in all TnI isoforms169.  
 The toggling of the switch arm during systole and diastole is thought to be 
critical in altering the conformational state of the inhibitory region (IR) of TnI, the 
domain centrally involved in regulating actomyosin ATPase activity33, 55. With the 
translocation of TnIreg this IR region transitions from a β-hairpin to an extended α-
helical structure52, 170. Correlatively, the IR region has been shown to bind to actin 
during diastole and to TnC during systole. However, the specific site of 
interaction between TnI IR and cTnC during systole is unclear at this point. 
Various studies have shown TnI IR binding to the N-terminus171, 172, the C-
terminus173, or the linker region between the domains114. Differences in 
experimental methodologies and/or peptide fragments used likely account for 
these observations. Although direct interactions have been difficult to identify, 
recent functional studies have found the D/E linker of TnC to be necessary for 
activation of the myofilaments. Specifically, several groups have found that 
mutation of various acidic amino acids in this region to neutral residues 
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completely blocked the ability for calcium to activate the myofilaments81, 174, 175. 
This indicates that these specific resides play a key role in the intermolecular 
dynamics of the troponin complex required for actomyosin ATPase activity.  
 With the switch arm of cTnI bound to the calcium saturated N-terminal 
hydrophobic patch of cTnC and the translocation of the IR domain into its α-
helical position away from Tm and actin, Tm is released from its blocked position 
leading to an azimuthal motion around the actin filament thus uncovering the 
essential myosin binding sites required for actomyosin ATPase activity and 
sarcomeric contraction23, 43, 176. Because weak ionic interactions between myosin 
and actin occur independent of calcium, the actomyosin cross-bridges are poised 
for activation just prior to systole with the products of ATP hydrolysis remaining in 
the myosin head. Upon calcium activation of the myofilaments, force generation 
by the sarcomere is mediated by a strong hydrophobic interaction between 
myosin and actin and a subsequent isomerization of the myosin head by release 
of a phosphate177. The specific biophysics of cross-bridge cycling are complex 
and have been discussed in detail elsewhere and are beyond the scope of this 
discussion16, 18, 19, 145, 178, 179. It has been proposed that the rate limiting step of 
sarcomeric contraction could be the transition from weak to strongly bound cross-
bridges as proposed by Moss and Stehle19, 180 or the process of phosphate 
release from the myosin head as proposed by Hinken22, 181. Illustrating the 
cooperative nature of thin filament activation, this azimuthal motion of cTm is 
thought to extend beyond a single stoichiometric unit of the thin filament and 
thus, may weaken the actin-cTnI interactions on neighboring units156, 182.  
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Recent studies have also shown that myosin binding to actin has a major 
reciprocal effect on calcium sensitivity of the thin filament and cooperativity of the 
sarcomere22. Evidence suggests that the binding of myosin to actin further 
displaces Tm from its blocking position which would then displace actin bound 
TnI122. By facilitating the dissociation of TnI from actin, myosin indirectly causes a 
transient increase in calcium sensitivity (approximately six fold)156, 165. However, 
the specific mechanism for this is unknown. Davis et al. and others have 
suggested that the myosin-actin interaction may cause structural changes in 
actin thus moving cTm and, subsequently, increasing the cTnC-cTnI binding 
probability122, 156. The importance of myosin binding has been further confirmed 
recently in studies showing that full activation of the thin filament requires calcium 
and rigor myosin S1183. More recent studies have also elucidated some very 
interesting dynamics between myosin and actin during myofilament activation. 
Several studies have shown that the structural states of the seven actin 
monomers in a regulatory unit are not identical145, 184, 185. These studies suggest 
that myosin preferentially binds halfway between the Tm-Tm overlap region close 
to where Tn sits on the thin filament. A functional explanation for these 
observations in the context of myofilament cooperativity was not elucidated. 
Based on the intramolecular kinetics of calcium activation in the sarcomere 
described here, contractility of the filaments is literally transmitted in a highly 
cooperative manner providing the molecular basis of the cell and whole organ 
systolic actions of the heart.  
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In looking at the kinetics of force activation, it has been observed that kACT 
(the force development following maximal calcium activation) as well as the kTR 
(rate constant reflecting the cross-bridge cycling kinetics) are not limited by the 
activation of the thin filament by calcium186, 187. Furthermore, substitution of native 
Tn with cardiac Tn or a Tn chimera containing ssTnI in rabbit psoas myofibrils 
markedly effects Ca++ sensitivity and cooperativity of force generation but does 
not affect force activation kinetics186. Together these findings provide strong 
evidence for the role of isometric cross-bridge turnover rates as limiting 
determinants of myofilament activation.  
 
Myofilament Structural Changes During Diastole 
 
Diastole begins when myoplasmic [Ca++] begins to decrease which 
initiates the dissociation of cross-bridges and the onset of force decay. Three 
different stages of diastole can be attributed to the process of sarcomeric 
relaxation including calcium decay (primarily mediated by re-sequestration into 
the SR via SERCA2a or extrusion through the sarcolemmal membrane via NCX), 
the kinetics of myofilament inactivation, and cross-bridge kinetics(reviewed in11, 
188). The interdependence of these processes and the inherent coordinated 
activities of the myofilaments has made it difficult to specifically elucidate the 
relative contributions of the component parts. Although the processes of 
contraction have been fairly well characterized, the events occurring during 
relaxation are less well understood. In all myofibril types studied to date, 
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relaxation has been observed to be biphasic with an initial, slow, linear phase 
followed by a fast, mono-exponential relaxation phase when isometric sarcomere 
conditions collapse186,187. 
Although calcium is required for relaxation of the myofilaments, the 
resequestration of calcium is not correlated functionally with relaxation of the 
sarcomere. Studies using various methodologies have shown that the fall in thin-
filament bound calcium precedes the fall in force in an isometric twitch of heart 
muscle188-190. Specifically, in studies using the stopped flow apparatus to 
measure changes in calcium dissociation from Cys84 IAANS labeled TnC or Trp 
fluorescence changes in TnCF27W found that the off rate of calcium from the 
regulatory domain of TnC were at least an order of magnitude faster than the 
mechanical relaxation of the myofilaments191-193. Essentially, force relaxation lags 
behind diminution of the calcium transient.  
These findings indicate that the rate limiting step of sarcomeric relaxation 
is myofilament inter and intra-protein structural transitions. To address this issue 
in the context of thin filament proteins, a very recent study by Xing et al used 
FRET calcium titration and FRET stopped-flow measurements to examine 
structural changes that occur between thin filament proteins induced by calcium 
dissociation194. Their results suggest a two phase transition at the interface 
between TnC, TnI, and actin. The first transition shows fast kinetics (132-147 s-1) 
correlated with the closing of the N-terminal lobe of TnC and interaction between 
the C-terminal regulatory region of TnI and actin. The second transition shows 
slow kinetics (56-69 s-1) and is correlated with movement of the TnI inhibitory 
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region (IR) from TnC to actin. It was proposed that the flexibility of the mobile 
domain of cTnI (165-210) contributes to the fast kinetics of the first phase by 
binding to actin which then facilitates the dissociation of the regulatory arm of TnI 
from the hydrophobic patch of TnC. These data would suggest that the marked 
delay in cross bridge inhibition after calcium dissociation is due, at least in part, 
to the delayed kinetics of the TnI IR release from TnC and binding to actin 
observed in the second phase of thin filament deactivation.  
Janssen et al have previously shown using phase plane analysis of 
calcium versus force at physiologic temperatures that cross-bridge cycling 
kinetics are rate limiting for cardiac relaxation195. Specifically, as opposed to 
other myofilament proteins (e.g. TnC or TnI), the critical role of activated 
actomyosin ATPase in regulating the cooperative nature of the myofilaments 
makes the dispersion of cross-bridges a major rate limiting step in myofilament 
relaxation188, 189, 196, 197.  This is supported by the recent study by Xing et al 
showing that binding of S1 to thin filament proteins markedly reduced the kinetics 
of the first and second phases of thin filament inactivation194. Maughan has 
argued that myosin release from actin at the end of the power stroke is likely the 
rate limiting step16. Consistent with this, many have argued that the rate limiting 
step of sarcomeric contraction and relaxation shifts depending on the load16, 149, 
198. Specifically, kinetic studies have shown that the greater the force developed 
during a single beat (in direct correlation with the number of strongly activated 
cross-bridges), the longer the cooperative ensemble of myofilament proteins can 
maintain force and the longer the delay in relaxation149. In support of this 
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paradigm, some forms of heart failure are characterized by slowing of the 
calcium transient such that calcium removal becomes the rate limiting step199. 
SERCA2a dysfunction and reduced protein level have been implicated in these 
findings137, 200. In these cases the proportion of cross-bridges attached would 
remain in equilibrium with the proportion of regulatory sites still bound with 
calcium thus causing calcium decay and myofilament relaxation to mirror each 
other.  
In addition to the actin-myosin interactions as rate limiting for relaxation, 
the molecular kinetics of myosin function also markedly affect the process of 
myofilament relaxation. Similar to studies on MHC isoform dependence of 
myofilament activation21, 24, it has also been found that cardiac muscle 
expressing α-MHC relax several times faster than those expressing β-MHC139, 
150.  
At the whole organ level in vivo or the working heart ex vivo, it is 
repeatedly observed that the rate of pressure decay during diastole (- dP/dt) is 
not markedly different than the positive rate of pressure development (+ dP/dt) 
during systole. In contrast, at the isolated myocyte level, calcium decay is 
observed to occur much slower than calcium release from the SR. As model 
predictions suggest123, if whole organ functional kinetics of contraction and 
relaxation were to follow calcium cycling, then isovolumic relaxation (- dP/dt) 
should occur much slower than the rate of positive pressure development (+ 
dP/dt). It has been suggested that the observed rapidity of isovolumic relaxation 
at the whole organ level favors the argument for unique sarcomere dynamics in 
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hastening the rates of cross-bridge detachment during relaxation independent of 
calcium kinetics123.  
 
Protein Kinase Modulation of Cardiac Systolic and Diastolic Performance  
 
Beyond the intrinsic biophysics of myofilament function during systole and 
diastole, there is another level of regulation at the level of the myocytes that 
modulates calcium handling and myofilament function in response to various 
stress signals. Unlike skeletal muscle, which is able to alter speed and force by 
recruiting different muscle fibers, the heart requires a coordinated interaction of 
the molecular machinery in the myocytes to alter whole organ cardiac function in 
response to external cues. Covalent modifications of specific intracellular protein 
targets by kinases are at the core of this regulation in the heart. There are 
multiple pathways known to modulate myocyte function, the most well studied of 
which include phosphorylation of protein kinase A (PKA) and protein kinase C 
(PKC).  
β-adrenergic signaling acting through PKA is a primary means by which 
the heart modulates cardiac inotropic and lusitropic function to meet whole 
animal physiological demands during stress. On the basis of numbers, the β1-
adrenergic receptor predominates in cardiac muscle201. The ligands responsible 
for mediating these responses are catecholamines, epinephrine and 
norepinephrine. At the whole organ level, adrenergic stimulation results in 
increases in contractile parameters (e.g. the rate of LV pressure development 
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(+dP/dt) and ejection fraction) heart rate, stroke volume, cardiac output, and 
relaxation parameters (e.g. -dP/dt and tau)132. At the cellular level, treatment with 
a β-adrenergic agonist such as isoproterenol has similar effects in hastening 
calcium cycling as well as augmenting myofilament activation and relaxation202. 
This response illustrates the presence of a cardiac reserve available to meet 
hemodynamic demands placed on the heart. In light of this, pharmacologic 
suppression of adrenergic drive (experimentally or therapeutically) has significant 
implications on the hemodynamic readout of cardiovascular performance203. 
Specifically, in experimental settings described here, there is a decrease in 
contractile parameters and heart rate, dilation of the ventricle, and prolongation 
of relaxation parameters. These global responses are mediated by the following 
events that are regulated at the subcellular level.  
The major response of the heart to adrenergic stimulation is activation of 
the G(s)-adenylyl cyclase-3',5'-adenosine monophosphate (cAMP)-protein kinase 
A (PKA) signaling cascade. The downstream targets of this signaling result in the 
phosphorylation of numerous proteins including the sarcolemmal L-type calcium 
channel which increases calcium influx into the cell, phospholamban which 
releases its inhibition of SERCA2a and thus increases the rate of calcium 
reuptake during diastole, troponin I which decreases myofilament calcium 
sensitivity, and the ryanodine receptor which enhances calcium release from the 
SR. Although a brief overview will be given below, adrenergic signaling has been 
reviewed in detail elsewhere204, 205. Drugs used to manipulate this response both 
clinically and experimentally (as outlined in this dissertation), include β-
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adrenergic suppression by esmolol or β-adrenergic stimulation using 
dobutamine. Esmolol specifically blocks β1 adrenergic receptors thus inhibiting 
the targeting of endogenous catecholamines. Dobutamine, in contrast, directly 
stimulates β1 adrenergic receptors resulting in a sympathomimetic effect.  
 Troponin I is one of the critical targets of PKA phosphorylation. Ser23/24 
at the N-terminus of TnI have been found to markedly regulate myofilament 
function based on alterations in their phosphorylation status206. Although 
differences have been shown (likely attributable to types or stages of heart 
failure)207, studies indicate that there is a reduction in phosphorylation at these 
sites in the failing heart208-210. In response to adrenergic stimulation, 
phosphorylation of Ser23/24 of TnI results in a weakening of the interaction 
between the N-terminal domain of cTnI and the N-terminus of TnC108, 211. This 
destabilizes the calcium bound state of TnC and results in a desensitization of 
the myofilaments to activating calcium as well as an increase in cross-bridge 
cycling kinetics123. Studies of Tg mice with cardiac expression of slow skeletal 
TnI, which lacks the N-terminal 32 amino acids present in cTnI, have shown that 
this substitution blunts the PKA-mediated response of the heart212. Due to the 
critical importance of this cTnC-cTnI interaction in contributing to hastened 
lusitropy during β-adrenergic stimulation, ssTnI Tg mice have significant diastolic 
dysfunction213. This dysfunction is evident at baseline because adrenergic drive 
is naturally very high in the resting mouse. Tg mice expressing ssTnI were also 
shown to have a blunted inotropic response which212, together with other 
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studies140, 205, 214, points to the critical role of cTnI phosphorylation in regulating 
cardiac performance.  
In an alternative approach, cardiac specific expression of cTnI with a 
Ser23/24Asp modification, which mimics constitutive phosphorylation, were 
shown to have enhanced LV inotropy and lusitropy215. Yasuda et al have also 
recently supported these findings using these cTnI S23/24D Tg mice as well as 
gene transfer strategies to show a central role for the N-terminal domain of cTnI 
in regulating cardiac lusitropic performance202. 
There is also evidence to suggest that S23/24 phosphorylation on TnI by 
PKA results in a positive inotropic effect. Studies have shown that PKA 
phosphorylation increases the cross-bridge cycling rate and shortening 
velocity140, 213, 214, 216. Several studies have tried to address the role of TnI. 
Layland and colleagues studied the adrenergic responsiveness of Tg mice 
expressing ssTnI, which lacks the N-terminal PKA phosphorylation sites. They 
found that inotropic indices were markedly attenuated in Tg mice compared to 
Ntg mice during adrenergic stimulation212. Other studies using Tg mice with 
pseudophosphorylated cTnI PKA sites exhibited markedly enhanced systolic 
performance at baseline215. Although these data are very preliminary, it suggests 
that covalent modifications of TnI enhance both lusitropic and inotropic 
myofilament performance.  
In addition to PKA modulation of myocyte function, protein kinase C (PKC) 
has also been coupled with regulation of heart performance9, 217-219. In contrast to 
a fairly well understood mechanism involving adrenergic regulation through PKA, 
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PKC signaling is not well understood205. Part of the complexity arises from the 
numerous PKC isoforms that have been reported all of which may have 
overlapping and/or specific effects9, 205. PKC is activated in response to G-protein 
coupled receptor agonists such as angiotensin II, endothelin-1, and the α-
adrenergic agonist phenylephrine. Numerous intracellular targets are 
phosphorylated by PKC including the L-type calcium channel, cTnI, cTnT, and 
MLC2220-223. Under pathophysiological conditions such as heart failure, PKC 
expression is increased224. The known targets of PKC phosphorylation on TnI 
include S23/24, S43/45, and T144222, 225. The effect of S23/24 phosphorylation 
has been discussed already in terms of PKA and shows similar effects on 
relaxation in the context of PKC phosphorylation219, 221. The effect of PKC-
mediated phosphorylation at S43/45 and T144 are not well understood. However, 
studies have suggested that S43/45 phosphorylation results in a decrease in 
maximum calcium activated force and cross bridge cycling rate226-228. Covalent 
modification of T144 has been shown to decrease myofilament sliding velocity 
and may contribute to the relaxation effects observed with S23/24 
phosphorylation221, 226. The current evidence suggests that PKC and PKA have 
somewhat opposing effects. Furthermore, the combined effects of PKA and PKC 
modulation reveal a significant level of fine-tuning required for proper 
myofilament function.  
 




In the United States, a CVD related death occurs once every thirty-five 
seconds. By 2020, the prevalence of CVD is expected to increase to three 
fourths of all deaths in the U.S. and become the leading cause of morbidity and 
mortality world-wide14, 229. Coronary artery disease is the greatest contributor to 
cardiomyopathies associated with CVD and is also the most common cause of 
heart failure230. Furthermore, heart failure is the most common discharge 
diagnosis in the U.S with greater than 1 million people suffering from this 
disease231. Despite considerable advances in medical technology and 
pharmacologic and mechanical therapeutics, the overall risk of mortality and 
sudden cardiac death related to coronary artery disease and heart failure remain 
high232, 233.  
Acute myocardial infarction, a pathology associated with coronary heart 
disease, is caused by clot formation within a ruptured atherosclerotic plaque, 
which obstructs blood flow to the region of the heart distal to the site of occlusion. 
This acutely compromises regional cardiac contractility and increases the risk for 
arrhythmias and heart failure. In severe cases, cardiac dysfunction results in 
chronic ischemic cardiomyopathy and congestive heart failure.  Pathologies 
associated with other organ systems but which have a significant effect on 
cardiac performance include sepsis234 or severe chronic pulmonary artery 
disease (COPD)235. Common to all of these conditions at the outset is the 
development of severe acidosis due to reduced plasma oxygen tension (hypoxic 
acidosis), as in cases such as myocardial ischemia230, 236, or accumulated levels 
of plasma carbon dioxide  (hypercarbia), as in cases of COPD. Despite the 
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etiological basis, it has been well established that acidosis has deleterious effects 
on the contractile function of the heart237-242. More specifically, the studies in this 
dissertation as well as others show that the myofilaments play a central role in 
the response to cardiac injury242. An understanding of the underlying dysfunction 
associated with this and other types of cardiomyopathy provides a substrate on 
which current research can investigate novel therapeutic modalities131.  
 
Effects of Acidosis on Myofilament Function 
 
Cardiac contractile dysfunction can result from a wide range of 
pathophysiological conditions ranging from acute ischemic events to chronic 
heart failure. At the molecular level, some of the central deficiencies of the heart 
that give rise to poor cardiac performance are mishandling of calcium cycling or 
an inability of the myofilaments to properly respond to calcium signals. Murphy 
and others have reported that altered phosphorylation, proteolytic degradation, or 
oxidative damage may be specific mechanisms by which myofilament and 
calcium handling proteins may be modified causing a decrease in systolic and 
diastolic performance of the heart242, 243. In any case, there is an uncoupling of 
the normal coordination required between excitation and contraction necessary 
for proper heart function. In cases such as myocardial ischemia, this uncoupling 
occurs primarily as a result of acidification due to reduced blood supply to the 
highly energetic heart tissue231. Studies have shown that the myocardial pH 
drops from 7.0 during normal function to about 6.2 during acute ischemia237. 
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Acute pump failure arises in these cases because the myofilaments have 
reduced responsiveness to normal or even heightened levels of activating 
calcium237. Although the events that give rise to cardiac pump dysfunction during 
disease are complex, it has long been argued that the myofilaments play a 
central role238, 241, 242, 244-246. Studies supporting this hypothesis have shown that 
oxidative or proteolytic modifications of myofilament proteins may contribute to 
the observed decline in cardiac function during ischemia or acidosis243, 247, 248. 
Furthermore, studies using acutely isolated adult rat myocytes have shown that 
the tension-pCa curve undergoes a marked rightward shift during acidosis133. 
Specifically, studies have shown that the pCa (-log[Ca2+]) required for 50% 
activation of myofilaments in acutely isolated adult cardiac myocytes, which 
express the adult isoform of TnI (cTnI), drops by more than 1 pCa units during 
acidification of pH (from pH 7.0 to 6.2)133. Furthermore, acidosis decreases both 
maximal Ca2+-activated tension and the Ca2+ sensitivity of tension as represented 
by a rightward shift of the calcium dependence of force development at low pH236, 
246, 249-252. Decreases in myocyte maximal sarcomere length shortening amplitude 
and shortening velocity are also found to occur during acidosis246, 253, 254. These 
experiments illustrate that myofilament Ca2+ desensitization at low pH is a 
fundamental molecular deficiency responsible for myocyte and myocardial 
dysfunction associated with myocardial acidosis242.   
 Clearly, there is a long history of experimental evidence showing that low 
pH effects myofilament function at the cellular level and pump performance at the 
whole organ level. But, beyond these gross observations what is the underlying 
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molecular deficiency that disrupts proper myofilament protein-protein 
interactions? Several key studies have provided significant insight into this 
question. Very early solution studies suggested that the calcium binding to cTnC 
could be the rate limiting step in maintaining myofilament functionality and, 
furthermore, that low pH directly effects this critical interaction255, 256. Further 
evidence for a Ca++-TnC interaction issue arose from studies showing that higher 
proton concentrations (reduced pH) decreased the reactivity of Ca++ coordinating 
oxygens within the regulatory sites of TnC257.  
 To further address this question, Parsons and colleagues238 used a 
technique in which cTnC was labeled at cysteine 84 with IAANS. They showed 
that changes in fluorescence directly paralleled the changes in force in these 
TnC-depleted cardiac fibers indicating a tight correlation between calcium binding 
to cTnC and activation of the myofilaments. When these fibers were placed 
under acidic conditions (pH 6.5), the force-pCa and fluorescence-pCa curves 
underwent a marked rightward shift thus changing the pCa50 for both curves to 
higher [Ca++]. From these studies, it can be concluded that acidosis decreases 
the Ca++ affinity for the regulatory sites on cTnC in a reconstituted cardiac muscle 
preparation. To look more specifically, the context within which TnC functions 
significantly influences the Ca++-TnC interaction. Other variables to account for 
are: TnC isoforms and their different affinities for Ca++, the influence of different 
TnI isoforms, as well as myosin cooperativity and its distant allosteric affects on 
calcium binding to TnC. Although numerous studies have addressed the pH 
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sensitivity of different TnC isoforms245, 258, 259, the following discussion will focus 
on the allosteric effects of myosin and different TnI isoforms on TnC function.  
Very early kinetic studies by Moss260 and Ebus261 showed that there is a 
pH dependence of cross bridge formation in slow-twitch, fast-twitch, and cardiac 
muscle. Consistent with prior discussions on the cooperative nature of the 
myofilaments, it is reasonable to hypothesize that decreased actin-myosin 
interactions at low pH would further exacerbate this reduction in calcium affinity 
for TnC. To specifically address the role of actin-myosin interactions on Ca++-TnC 
interations, Parsons and colleagues treated their myofibers with 2,3-butanedione 
monoxime (BDM) which specifically inhibits steady state force development by 
stabilizing weakly attached working cross-bridges262.  They found that treatment 
with BDM did not affect the force/fluorescence relationship of TnC at low pH. 
These data suggest that the primary deficiency of myofilament functionality in 
acidosis is a decreased affinity of Ca++ for TnC. As illustrated by these and other 
studies, the problem is multifaceted where low pH impacts various aspects of the 
contractile apparatus resulting in diminished sarcomeric contractile performance.  
In addition to the role of myosin on regulating the affinity of calcium for 
TnC, other avenues of investigation have focused on the role of TnI on 
modulating this Ca++ - TnC interaction. Several important reports have studied 
various isoforms of TnI (ssTnI, fsTnI, and cTnI) in the context of different TnC 
isoforms (sTnC and cTnC). This discussion will focus on the effects of different 
TnI isoforms on cTnC. Studies by Wattanapermpool and Solaro assessed the 
role of ssTnI on the binding affinity of calcium to cTnC in column chromatography 
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purified preparations of thin filament proteins263. Similar to Parsons et al, calcium 
binding was assessed using an IAANS labeled cTnC. They found that both ssTnI 
and cTnI resulted in a rightward shift in the fluorescence-pCa curve at low pH. 
However, this shift was attenuated in the ssTnI-cTnC complex. Furthermore, 
although the fluorescence-pCa titration curve shifts when cTnC is placed in the 
context of TnI or TnI-TnT-Tm, the shift in pCa50 between pH 7.0 and 6.2 does not 
change. This indicates that although TnT and Tm influence the calcium binding 
affinity to TnC, these proteins do not confer a pH dependent affect on calcium 
sensitivity of cTnC. In contrast, the TnI isoform alone contributes this pH 
dependent effect. These conclusions were more recently confirmed by Liou et al 
using porcine cardiac muscle reconstituted with N-(1-pyrene)iodoacetamide (PIA) 
labeled TnC and either ssTnI or cTnI264. 
Additional studies have gone on to analyze specific regions of the TnI 
molecule in conferring the effect of pH on the calcium sensitivity of TnC. Initially, 
Guo and Solaro265 used a truncated cTnI molecule missing 32 amino acids at the 
NH2 terminus. They found that there was no difference in the pH effects on 
calcium sensitivity between myofilaments containing WT cTnI and the amino-
truncated form of TnI. These data indicate that a region C-terminal to this domain 
is responsible for the pH dependent effect of TnI on the calcium sensitivity of 
TnC. This was corroborated by Westfall and colleagues using TnI chimeras93, 266 
(discussed later) and more recently by studies from Li and colleagues267. Similar 
to ssTnI, fsTnI confers protection of the calcium binding to cTnC at low pH. To 
address the domains of TnI involved in this effect they used the following TnI 
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chimeras: cardiac-N:Ip:fast skeletal C and fast skeletal N:Ip:cardiac C. They 
found that IAANS labeled TnC in complex with fsN:Ip:cC had the same calcium 
binding affinity as TnCIA-cTnI. In contrast the cN:Ip:fsC construct in complex with 
TnCIA attenuated the rightward shift in the ∆EC50 similar to that seen with TnCIA-
fsTnI. To further validate the importance of the C-terminal domain in conferring 
this pH-dependent effect, they measured Ca++-force relations in skinned fiber 
bundles in which cTnI was replaced with the chimeras. The ∆EC50 values for the 
Ca++-force titration curves directly reflected the ∆EC50 values for the Ca++-
fluorescence curves for TnCIA. These data provide strong evidence for the C-
terminal domain of TnI influencing the calcium binding properties of TnC at 
physiologic and low pH. However, further assays are required to define particular 
residues that may be involved in this interesting observation.  
 
Cardiac Compensation to Stress and Injury  
 
The primary response of the heart to significant injury such as myocardial 
infarction is structural compensation to maintain proper function. This process is 
regarded as myocardial remodeling. Every cardiomyopathy, regardless of its 
etiology (acquired or inherited), results in some kind of remodeling of the heart. 
The following is a brief discussion that focuses primarily on some general 
observations regarding post-infarct remodeling, although the process of acute 
and chronic myocardial remodeling can take various forms especially regarding 
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the transition into heart failure. Broader reviews on this topic have been 
published previously by Swynghedauw and others12, 242.  
In its most general sense, cardiac remodeling is seen as a process of 
rearranging normally existing structures to compensate for the emergence of 
injury or stress related dysfunction. Remodeling of the whole organ occurs 
because of adaptations developing at the level of the myocyte and the 
extracellular matrix, as well as in neurohormonal inputs which influence but are 
external to the heart. Initially, these changes help retain proper cardiac function 
by means of myocardial changes (to maintain Starling’s law and whole organ 
economy), peripheral adaptations, and increased sympathetic drive. Over time, 
global changes associated with cardiac remodeling include, for example, 
myocyte hypertrophy, ventricular fibrosis (due to ischemia, inflammation, and 
hormone affects), and cell death. In the context of myocardial infarction, akinetic 
or dyskinetic regions of the heart result in volume-overload induced hypertrophy 
of the noninfarcted myocardium. In this context, systolic dysfunction emerges 
due to the loss of contractile force and diastolic dysfunction occurs as a result of 
reduced elasticity of the myocardium limiting its relaxation performance11, 198. 
Hemodynamically, these adaptations result in increased end diastolic pressure 
and delayed tau as well as reduced positive and negative pressure derivatives 
and increased end systolic volume.  Over time, these acute changes that occur 
to maintain pump performance (such as hypertrophy) transition from a 
compensated heart to a de-compensated heart, seen as a transition into failure. 
This transition results from the cumulative effects of collagen deposition 
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throughout the heart as well as apoptosis causing dilation of the ventricle and the 
emergence of pathophysiological changes in the heart. This dysfunction at the 
level of the heart ultimately effects the function of other organ systems. One of 
the key implications of poor cardiac performance on peripheral organ systems is 
characterized by severe fluid retention (i.e. tachypnea, edema, and liver 
congestion). 
It has been well documented that many of the structural changes of the 
myocyte in response to stress are the result of alterations in gene expression 
profiles12, 268, 269. The fetal gene program is so named because of the strong 
correlation with genes attributed to cardiac development. Alterations in gene 
expression associated with this stress response program include myosin heavy 
chain isozyme shifts270, as well as up-regulation of ANF, and BNP271, 272. 
Alternatively, genes that are down-regulated include the SR calcium ATPase 
(SERCA2a)273 and its regulatory protein phospholamban273-276 as well as 
expression of the β-adrenergic receptor277. The loss of these proteins is a 
consistent finding across species and is implicated, at least in part, in the 
contractile dysfunction, impaired cardiac reserve, and propensity for arrhythmias 
during heart failure242, 278-281. Metabolically, the heart has been shown to 
transition from fatty acid oxidation to glycolysis in response to stress282-284. Lastly, 
it has been proposed that certain (unknown) genes that respond to stress signals 
of the heart regulate changes in myocyte morphometry during cardiac 
remodeling whether in terms of LV hypertrophy (building sarcomeres in parallel) 
or LV dilation (building sarcomeres in series)285. This latter process of myocyte 
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elongation occurs during cardiac development and thus it is consistent that such 
transitions occur during failure in concordance with fetal gene activation.  
One of the significant causes of pathologic cardiac decompensation is 
chronic cardiac stimulation by catecholamines. In response to an initial stress, 
this response is important for maintaining cardiac performance. However, 
evidence has shown that the cardiac response to chronic sympathetic stimulation 
is reduction of β-adrenergic receptor density as well as uncoupling of the Gs-
protein-adenylyl cyclase pathway286. More specifically, studies have shown that 
chronic β-adrenergic stimulation due to unmitigated stress switches the signaling 
cascade from the mediating effects of PKA to Ca++/calmodulin-dependent protein 
kinase II (CaMKII) which leads to apoptosis and maladaptive remodeling201, 204. 
In vitro studies by Zhu and colleagues have shown that this process occurs by 
PKA-independent influx of intracellular calcium through the L-type calcium 
channel thus activating CaMKII in cardiac myocytes287. Both aging and disease 
such as congestive heart failure are clinical settings in which there is chronic 
sympathetic activity10, 286, 288. This data supports the current hypothesis that 
constitutive activation of β-adrenergic signaling in the aging or injured heart 
contributes to the transition from compensatory remodeling to decompensated 
cardiac remodeling in the etiology of heart failure.   
  





  Based on our understanding of the pathophysiology of heart failure, it has 
been suggested that novel therapies could be directed specifically toward 
improving the Ca2+ sensitivity of the myofilament289. The consequent 
improvement in contractility that results from an increase in Ca2+ sensitivity may 
appear to counter the logic of commonly prescribed therapeutics, which calls for 
the use of beta blockers to decrease contractility, allowing for reduced oxygen 
consumption and energy expenditure. Although there is proven value in the 
diverse effects of beta blockers, we have shown, conversely, that targeted 
alteration of myofilament calcium sensitivity to increase contractile performance 
is an effective mechanism for treatment of ischemic heart disease and heart 
failure203, 242, 246, 290. Others have supported this hypothesis, recognizing that 
augmentation of myofilament responsiveness to calcium would improve the force 
generating capacity of the sarcomere and thus redress global cardiac 
dysfunction291. Altering the functionality of troponin I, the calcium-mediated 
molecular switch of the myofilament, would be an effective means of specifically 
improving calcium sensitivity.  
 Studies have shown that force development in healthy myofilaments is 
only about 20-25% of maximum which indicates that inotropic agents targeted at 
augmenting sarcomeric contraction may be an efficacious therapeutic 
approach292. Current thoughts regarding the general failure of exisiting inotropic 
therapeutics are aimed at their propensity to increase activator calcium, worsen 
arrhythmias, activate maladaptive signaling pathways, and increase energy 
utilization in the failing heart242, 293-295. Preliminary evidence, however, has 
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emerged using a new class of inotropic drugs termed calcium sensitizers291. 
These drugs are aimed at influencing the manner in which intracellular calcium is 
transduced into muscle contraction. As opposed to targeting extracellular 
receptors (e.g. β-blockers) which have diverse targets, calcium sensitizers have 
been designed to modify myofilament function by interacting with proteins 
involved in regulating force production (e.g. motor proteins or troponin).  
 One of the myofilament targets for calcium sensitizers has been the 
interaction between the N-terminal hydrophobic patch of TnC and the switch 
peptide of TnI. One such drug is bepridil which binds to TnC and induces an 
open configuration of the N-lobe similar to that caused by calcium binding296. Li 
and colleagues hypothesized that bepridil acts as a calcium sensitizer by slowing 
down both the closure of the hydrophobic patch on TnC and the dissociation of 
the TnI switch peptide upon calcium release from site II of TnC296. Other calcium 
sensitizing drugs that target alternative sites within the sarcomere include the 
pyridazinone-dinitrile derivative levosimendan and the thiadiazinone EMD-
53998289, 291, 297-302. Despite their utility as inotropic agents, these drugs also have 
off target effects including inhibiting cAMP phosphodiesterase activity or 
inhibition of ATP-sensitive potassium channels291. Even so, studies of these 
molecules support the hypothesis that calcium sensitization of the myofilaments 
may be a more advantageous strategy for ameliorating systolic dysfunction in 





Histidine Buttons as Molecular Biosensors 
 
 Regulation of molecular function through pH responsive histidine buttons 
are found throughout various physiological systems. At the level of individual 
molecules these moieties can function as a molecular switch by changing 
intermolecular or intramolecular contacts by differential ionization states that are 
pH-dependent. Through tertiary structural modifications, changes within a 
molecular micro domain can subsequently be transmitted to remote regions of 
the protein to transmit energy required to carry out important functions. The 
capacity for histidine to function in this way is a consequence of its unique 
imidazole side chain which ionizes within the physiologic range (pK≈6.0). The 
different ionization states of histidine are chemically different. Under normal pH 
(7.4) the imidazole group is largely not protonated making it hydrophobic and 
aromatic. Acidosis (pH 6.2) causes histidine to become protonated and thus 
acquire a hydrophilic and positively charged character. As a consequence of 
these two biochemical states, different ionization states of histidine enable it to 
alter its molecular interactions. Histidine buttons act as a molecular rheostat 
capable of altering protein function in response to environmental pH changes.  
 The important actions of the molecular switch behavior of histidine 
residues continue to emerge. To my knowledge, histidine buttons were first 
identified in hemoglobin nearly three decades ago303-305. In hemoglobin, a single 
histidine moiety (H146β) has been found to regulate the Bohr effect through the 
pH-dependent interaction with D94β303, 304. This event enables hemoglobin to 
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raise the fraction of oxygen carried that can be released in peripheral tissues. 
Further confirmation of the importance of this intermolecular contact has been 
shown by mutagenesis studies. Any substitution that replaces H146β or D94β 
dramatically reduces the alkaline Bohr effect303.  
The intermolecular and intramolecular contacts that mediate the switch 
function of histidine buttons markedly impact the propensity for histidine 
ionization. Studies by Perutz et al indicate that the interaction of H146β with 
D94β markedly increases the pKa of the imidizole side chain303. Furthermore, 
studies of sperm whale myoglobin have shown that most histidine buttons have a 
pKa ranging from 6.73 to 5.43303. In contrast, only one histidine residue studied 
(H36) had a pKa of 7.97 because of a key salt bridge interaction with an acidic 
residue (E60). These data provide important insights into how histidine buttons 
are modified through specific interactions in their protein micro domain.  
In addition to hemoglobin and myoglobin, numerous other proteins have 
been found to contain histidine buttons that provide important functional 
characteristics to the molecule. HLA-DR contains pH-responsive molecular 
switches that control the stability of ligand complexes306. The key interaction 
within this molecule was found to occur between H33α and V136α306. The 
channel activation of G-protein coupled inward rectification potassium channels 
(GIRK) is dependent on several pH responsive histidine residues (H64, H228, 
and H352) in the M1-H5 linker307. Similarly, a histidine (H117) in the M1-H5 linker 
in the inward rectifier potassium channel HIR was found to modulate 
conductance through this channel308.Zong and colleagues have shown that a 
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single histidine residue (H321) localized between the voltage sensing S4 helix 
and the cytoplasmic S4-S5 linker determines the pH sensitivity of the pacemaker 
channel HCN2309. Lastly, studies have shown that a pH responsive histidine 
(H98) near the pore selectivity filter regulates current in the tandem pore domain 
acid-sensitive potassium channel (TASK-3)310.     
Taken together, these studies show the critical importance of histidine 
moieties in regulating physiological functions within a wide range of proteins. By 
differential ionization of the imidazole side chain, histidine residues can interact 
with various amino acids to generate unique switch functions. As in the case of 
myoglobin described above, different types of interactions cause nuanced effects 
required for coordinated functions of a protein303. Another histidine button has 
been identified within an isoform of troponin I. The studies outlined in this 
dissertation are designed to address the basic physiology as well as therapeutic 
benefits of this residue on myofilament function.  
 
Myofilament Biosensors: a histidine moiety in cardiac troponin I 
 
In the heart of mammals and avian species two isoforms of TnI are 
expressed in a developmentally regulated manner311. The slow skeletal isoform 
(ssTnI) is expressed during embryonic development but, in the rodent, transitions 
to the adult cardiac isoform (cTnI) around the time of birth312. In other species the 
regulation of this isoform transition has been found to be different where, for 
example, in humans the transitions begins before birth and continues through the 
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first year90, 313. Although ssTnI and cTnI isoforms have 70% sequence 
homology242, they are structurally and functionally unique. There are marked 
differences in baseline function as well as in several key responses to 
physiological stress. Specifically, these include the response to adrenergic 
stimulation as well as the effect of acidosis on TnI performance.  
The functional differences between hearts expressing ssTnI or cTnI have 
been well characterized133, 213, 252, 263, 266, 267, 314-318. These functional differences 
are observed in terms of both inotropy and lusitropy. Studies looking at 
myofilament contractility have shown that ssTnI causes a dramatic increase in 
the inotropic capacity of the sarcomere compared to cTnI. The steady state 
isometric tension-Ca2+ relationship undergoes a marked leftward shift with ssTnI 
compared to cTnI133, 252. This indicates that sensitivity of the myofilaments to 
activating calcium is increased by ssTnI. Studies of intact myocytes have shown 
that sarcomere dynamics also reflect this increased inotropy as measured by a 
significant increase in the sarcomere length shortening amplitude with ssTnI 
compared to cTnI252. Furthermore, recent biochemical studies using cystine-53 
labeled IAANS on TnC in the context of ssTn or cTn provided additional evidence 
supporting the conclusion that ssTnI has higher calcium sensitivity and lowers 
the TnC calcium dissociation rate compared to cTnI156. In conjunction with 
increased contractility, myocytes expressing ssTnI show significantly delayed 
relaxation. This has been shown in isolated myocytes and in the intact heart 
where various relaxation parameters indicate diastolic dysfunction with ssTnI 
compared to cTnI213, 252.  
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In terms of adrenergic responsiveness, cTnI contains a 32 amino acid 
extension at its N-terminus that contains two key serine residues (23 and 24) 
required for phosphorylation by cyclic AMP (cAMP)-dependent protein kinase A 
(PKA) during β-adrenergic stimulation. Phosphorylation at these residues causes 
a decrease in myofilament calcium sensitivity that facilitates relaxation of the 
myofilaments104, 202, 319. This enhancement of relaxation occurs in tight 
conjunction with changes in calcium handling320-323. Specifically, phosphorylation 
of numerous calcium handling proteins, such as phospholamban, enable calcium 
cycling to occur at a faster rate. The coupling of calcium and myofilament 
dynamics are designed to meet contractile requirements of the mammalian heart 
during increases in chronotropic frequency in the heart rate322.  
Alignment of ssTnI and cTnI protein sequence shows that this critical 
extension containing the dual serine phosphorylation sites is absent in ssTnI. 
Although TnI functions in close relationship with TnT and TnC, studies have 
shown that the lack of this N-terminal extension of ssTnI in the context of cTnT 
and cTnC causes reduced responsiveness to β-adrenergic stimulation that is 
almost entirely attributed to the TnI isoform316. Functionally, the loss of PKA 
responsiveness on TnI causes E-C coupling to be inefficient because the 
myofilaments lack the capacity to relax in coordination with enhanced calcium 
cycling202.  
Another major difference between ssTnI and cTnI is their myofilament 
calcium sensitivity. Specifically, studies using adenoviral-mediated gene transfer 
into acutely isolated rat cardiac myocytes have shown a heightened calcium 
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sensitivity in response to acidosis in ssTnI transduced myocytes compared to 
those expressing cTnI133. Specifically, ssTnI expressing cardiac myocytes show 
an attenuated pCa shift during acidification of pH (from pH 7.0 to 6.2)133. These 
findings have been supported in studies using adult Tg mice expressing ssTnI 
instead of cTnI which had the capacity to protect cardiac pump function in 
response to severe acidosis and ischemia/reperfusion injury297, 318. Taken 
together, the findings of these biochemical and physiological studies clearly show 
a dominant effect of ssTnI as a pH dependent molecular rheostat capable of 
enhancing cardiac myofilament calcium sensitivity in response to acidic pH324. 
With this understanding, seminal work was carried out to identify the 
region(s) of ssTnI and cTnI responsible for the functional differences between 
these isoforms. Close analysis of the amino acids in the C-terminal domain of TnI 
showed a net positive charge difference of +3 in ssTnI compared to cTnI33. It was 
hypothesized that this difference could, at least in part, account for the difference 
in functional performance between these isoforms242. To investigate this further, 
chimeric TnI molecules were generated wherein the N-terminal region of one 
isoform was combined with the C-terminal domain of the opposite isoform266, 314, 
319. These studies revealed that a significant portion of calcium sensitivity of 
ssTnI was localized to the C-terminal domain. Additional studies have also 
mapped out the TnI inhibitory region99, 111-113 and actin binding domains of TnI91, 
119. Specific amino acids in the C-terminal domain of TnI were suggested by 
Pearlstone et al based on biochemical assays analyzing the interaction between 
TnC and various TnI peptide fragments325. The residues suggested to be critical 
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for the functionality of the cTnI C-terminus included Q157, A164, and E166 
(corresponding residues in ssTnI: R125, H132, and V134). 
To study the effects of these residues on cTnI and fsTnI function, Dargis 
et al generated mutants of these TnI isoforms and assayed their effects based on 
actomyosin S1ATPase activity249. Their results show a cTnI 
Q155R/A162H/E164V markedly decreased the acid sensitivity of cardiac Tn. 
Further assays of single and double amino acid substitutions attributed this 
resilience to changes in pH to the A162H modification. In contrast, the 
Q155R/E164V double mutant behaved like WT cTnI. The reverse mutation in a 
reconstituted fast skeletal muscle troponin system (fsTnI H130A) had a reciprocal 
effect of increasing the sensitivity to acidosis. Similar to the role of histidine 
residues in the molecular switch function of other proteins306, 326, these assays 
provided evidence for a dominant effect of a histidine button in TnI that 
modulates calcium sensitivity of troponin. However, ATPase activity may not be 
an accurate reflection of function in physiologically relevant systems such as 
intact myocytes or the whole heart where force development can be directly 
measured. More recent work described below, provides substantial evidence 
outlining the role of a histidine button in TnI based on in vitro and in vivo 
assays246, 252.    
Subsequent mechanical and functional studies showed that a histidine 
button engineered into the 164 codon of cTnI in place of alanine (cTnI A164H) 
confers the same biochemical resistance to acidosis in the adult heart246, 249. A 
seminal work by Day and colleagues used a transgenic mouse expressing cTnI 
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A164H in the heart and showed remarkable protection from various cardiac 
pathophysiological challenges246. In this study they showed that adult mice 
expressing cTnI A164H under control of the α-MHC promoter had stoichiometric 
replacement of about 80% of native cTnI in the heart. Using the Langendorff 
isolated heart preparation, cTnI A164H hearts perfused with acidic buffer 
performed markedly better than Ntg hearts. Additional Langendorff experiments 
showed that hearts expressing this histidine button had markedly improved 
systolic performance during ischemia and nearly full recovery of developed 
pressure during reperfusion. Of particular interest, these studies showed that Tg 
hearts were able to recover diastolic pressures at near baseline levels during 
reperfusion whereas Ntg hearts remained in a state of contracture. The basis of 
this protection of diastolic function, also observed in several other studies 
outlined in this dissertation, will require more data to fully understand.  In vivo 
cardiac conductance micromanometry analysis was also performed on these 
hearts to assess hemodynamic function under various stress such as hypoxia 
and acute ischemia induced by ligation of the left anterior descending coronary 
artery (LAD). During hypoxia, hearts expressing this histidine-modified cardiac 
troponin I maintained cardiac performance and survived on average threefold 
longer than Ntg counterparts. Similar findings were shown with acute ischemia 
where cTnI A164H Tg mice had elevated ejection fraction and stroke work 
compared to Ntg mice. Additional experiments showed that cTnI A164H Tg mice 
had improved cardiac contractility and reduced post-infarct remodeling in a 
model of chronic heart failure induced by LAD ligation. Lastly, failing human 
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myocytes transduced with an adenoviral vector expressing cTnI A164H showed 
improved measures of contraction and relaxation as well as enhanced force-
frequency response. Together, these seminal findings provided a strong basis to 
argue for the role of enhancing myocardial performance in the context of various 
cardiac pathologies by molecular manipulation of myofilament pH sensitivity 
through this histidine-substituted cTnI molecule.  
In cardiac troponin I, this histidine substitution (A164H) is positioned in the 
regulatory domain between the amphiphilic switch region (helix 3) and the C-
terminal actin binding domain (helix 4). Previous studies have shown that this 
region is critically involved in the interaction between TnI and TnC during systole 
through the electrostatic binding of the switch region of TnI with the calcium 
saturated N-terminal hydrophobic patch of TnC52, 96-98, 327. The potential 
implications of an ionized histidine in this position of TnI could either strengthen 
interactions with acidic residues on TnC or, alternatively, weaken interactions 
with basic residues on actin, as previously suggested246, 249. Although further 
studies are required to address the specific biophysical consequences of these 
potential interactions, the biochemical and physiological implications of this 
histidine modification have shown that cTnI A164H acts as a molecular rheostat 
maintaining systolic and diastolic pump function in models of severe acidosis246, 
249.  
In more recent studies by Westfall et al., site directed mutagenesis was 
performed to engineer single amino acid substitutions of key residues in the C-
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terminal domain of ssTnI (in isolation and in combination) to create a detailed 
functional map of the important domains involved in regulating the functionality of 
TnI under physiologic and acidic environments252. In support of findings by 
Dargis249, a key finding from these studies showed that a single amino acid 
modification from a histidine to an alanine at position 132 of ssTnI fully converted 
the ssTnI to cTnI in measures of myofilament calcium sensitivity and sarcomere 
dynamics. This was manifest by a rightward shift of the tension-pCa curve, 
reduction in the sarcomere length shortening amplitude, and enhanced 
relaxation. Furthermore, the ssTnI H132A mutant eliminated the resilience of 
myofilament contractility at pH 6.2 based on an assay measuring isometric Ca2+ - 
activated tension development250, 252. The presence of other residue substitutions 
together with H132A (e.g. ssTnI QAE) did not have an additive effect on the 
single mutant suggesting that the H132A modification has a dominant effect.  
In addition to the H132 residue, it was found that other single amino acid 
substitutions in residues in the H4 domain were involved in modulating TnI 
function under physiologic and acidic conditions (e.g. V134E and N141H). 
Assays with the ssTnI V134E mutant resulted in a shift of the pH-dependent 
calcium sensitivity of tension similar to cTnI and ssTnI H132A. In conjunction with 
this, the V134E mutant was found to decrease the sarcomere length shortening 
amplitude very similar to the cTnI control myocytes (physiologic pH). However, 
this mutant did not affect the relaxation parameters compared to ssTnI. Further c-
terminal from the V134E mutation, the ssTnI N141H mutant was found to 
decrease the pCa50 of tension at physiologic pH. In terms of sarcomere 
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dynamics, the N141H mutant did not markedly impact sarcomere shortening but 
enhanced the relaxation capacity of ssTnI closer to cTnI (physiologic pH). Taken 
together, this study provided important insights into residue effects in the c-
terminal region of ssTnI at the level of single myocytes function.  
It is interesting to note that studies of single or multiple amino acid 
substitutions in the switch domain of TnI246, 249, 252 do not always predict their 
affects within the context of different isoforms. This provides strong evidence for 
the importance of domain effects on residue function that together modulate 
troponin performance.  
Recent publication of the crystal structures for the calcium saturated 
cardiac troponin 52and fast skeletal troponin51 complexes have helped explain 
some of the functional differences between these isoforms. Molecular modeling 
analysis of the regulatory domain of troponin showed a marked alteration in the 
position of TnI helix 4 between sTnI and cTnI relative to helix A and the 
hydrophobic patch of TnC (see chapter 5). The structural alignment of these 
crystal structures indicates that cTnI Q156 and ssTnI R125 on H3 have similar 
positioning in the two complexes. At the linker and into H4, cTnI A163, E165, and 
H172 in H4 translocate away from helix A and the hydrophobic patch of TnC. In 
contrast, H132, V134, and N141 of skeletal TnI curve directly across helix A of 
TnC and come into very close proximity to the key acidic residues (E14, E15, 
E19, and D25) that decorate the hydrophobic patch of TnC. In particular the 
skeletal Tn structure indicates that the distance between H132 and E19 is close 
enough to develop a salt bridge (3.05 Å). This suggests that an electrostatic 
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interaction between histidine (H132) of sTnI and glutamate (E19) of s/c TnC, two 
oppositely charged and hydrophilic residues, is a critical feature that influences 
structure and function of sTn compared to cTn.  
The subsequent studies outlined in this dissertation provide new and 
important evidence elaborating our understanding of physiology of TnI function 
as well as the therapeutic role of a histidine button engineered into the adult cTnI 
isoform. The first study is the first phylogenetic meta-analysis of proteins 
comprising the cardiac troponin complex. This study provides evidence of 
coordinated modifications within troponin during chordate evolution of the 
mammalian cardiovascular system. The second chapter reveals a critical role for 
cTnI A164H in protecting cardiac function in a mouse model of age-induced 
cardiomyopathy290. The third study provides important insights into the role of 
cTnI A164H in protecting cardiac performance in a model of severe hypercapnic 
acidosis203. These chapters support a therapeutic role for cTnI A164H as a 
molecular biosensor of the myofilaments. The fourth study uses biochemical 















Human revertant phenotypes support an evolutionary model of coordinated 




 In cardiac muscle, the troponin complex serves as a molecular switch 
translating myocyte calcium fluxes into sarcomeric contraction and relaxation. 
Examined here is the molecular mechanism underlying changes in cardiac 
troponin (cTn) during chordate evolution of the mammalian cardiovascular 
system.  Ancestral species including fish and amphibians have myofilaments with 
heightened calcium sensitivity.  Human disease causing single nucleotide 
polymorphisms (SNPs) that cause pathologies recapitulating ancestral 
physiology, termed here as  evolutionary revertant phenotypes, were used to 
understand the mechanism of evolutionary modifications in cTn required for 
proper functioning of the mammalian cardiovascular system. Nucleotide and 
peptide sequences of all members of the ternary troponin complex were aligned 
for pairwise comparison of cTn isoforms spanning chordate evolution.  Large 
scale phylogenetic analysis, atomic resolution molecular dynamics simulations 
and modeling, and functional data support the hypothesis that a single histidine 
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to alanine substitution in the switch arm of TnI was a key evolutionary 
modification during evolution of the mammalian cTn complex. Molecular 
dynamics simulations and in silico alanine scanning of the cTn regulatory 
interaction indicate a reduction in the interface binding free energy (ΔΔG) and 
molecular untethering of cTnI switch arm during evolution of cTn into the 
mammalian lineage. In addition to the switch peptide of TnI, data indicate that 
single nucleotide substitutions in cTnC were coordinately modified during 
evolution of mammalian cTn. SNP studies of cTn show that patients with 
evolutionary revertant phenotypes have heart failure caused by heightened 
myofilament calcium sensitivity. In order to meet the requirements for refined 
mammalian lusitropic performance, it is proposed here that evolutionary 
pressures favored mutations that enhanced the relaxation properties of cardiac 




 Evolutionary pressures favor mutations that mitigate the susceptibility to 
disease, especially as it pertains to the reproductive fitness of an organism. 
Consequently, genetic diseases provide excellent reference points from which to 
understand the implications of certain changes as a retrospective view on 
evolutionary modifications. In other words, human disease causing evolutionary 
revertant phenotypes, defined as single nucleotide polymorphisms (SNPs) that 
cause pathologies recapitulating ancestral physiology, provide insight into the 
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influence of evolutionary pressures on specific residues or domains of a given 
protein to accommodate changing physiological requirements. This study 
assessed phylogenetic changes that occurred during evolution of the mammalian 
heart with a focus on troponin, the regulatory molecular switch complex of the 
myofilaments. 
Discovered by Ebashi decades ago328, troponin is a heterotrimeric protein 
complex comprised of three subunits. These include the Tm binding subunit, 
troponin T (TnT), the calcium binding subunit, troponin C (TnC), and the 
actomyosin ATPase inhibitory subunit, troponin I (TnI) (Figure 2- 1a). The 
coordinated actions of the troponin complex are specifically designed to regulate 
the functions of acto-myosin cross bridges in a calcium-dependent manner 
during the rhythmic transitions between systole and diastole18.  
During systole, myofilament activation is mediated through binding of the 
TnI switch arm to an exposed hydrophobic patch on the calcium-bound N-
terminal domain of cTnC69-71. These actions enable coordination of the azimuthal 
positioning of Tm in the actin groove by TnT and subsequent sarcomeric 
contraction mediated by actin-myosin cross bridge cycling 18, 59, 60. The 
intracellular biophysics of myofilament contraction are translated into ventricular 
inotropic performance at the whole organ level. During diastole, calcium is 
released from cTnC and sequestered into the SR allowing the regulatory arm of 
TnI to translocate into an inhibitory position on actin. This is sufficient to prevent 
actin-myosin cross bridge activation resulting in sarcomeric relaxation159, 160. 







Figure 2-1. Structure and function analysis of cardiac troponin I. Schematic 
diagram of the heterotrimeric troponin complex including troponin I (TnI), troponin 
C (TnC), and troponin T (TnT). Coloring of structural components in TnI (e.g. 
helix 1- 4) in (a) are coordinated with functional domains including the N-
terminus, the N-terminal TnC binding domain, the IT arm, the inhibitory region 
(IR), the switch arm, and the C-terminus as shown in (b). (b)  Specific amino acid 
loci of the human cardiac troponin I gene sequence with known disease causing 
single nucleotide polymorphisms (SNPs); hypertrophic cardiomyopathy (green), 
dilated cardiomyopathy, recessive (blue), dilated cardiomyopathy, autosomal 
dominant (brown), and restrictive cardiomyopathy (red). Stacked bars at a single 
locus indicate multiple known mutations at that site. SNP data were acquired 









shown that the movements of the regulatory arm of TnI during systole and 
diastole are essential for the transmission of the calcium signal to the rest of the 
myofilament proteins159, 160. Importantly, the inherent relaxation capacity of cTn is 
a major determinant of ventricular lusitropy during the filling phase of the cardiac 
cycle162, 194, 330. 
The specific amino acid composition of the cTn complex markedly affects 
its sensitivity to activating calcium which, ultimately, influences inotropic and 
lusitropic performance155, 156, 252, 331-333. Studies have shown that ancestral 
ectotherms such as fish and amphibians require heightened myofilament calcium 
sensitivity to maintain cardiac performance in the context of challenging 
environmental constraints such as cold temperatures and extended periods of 
hypoxia4, 5, 334. However, SNPs in cTn that cause increased myofilament 
sensitivity to activating calcium in mammals, termed here evolutionary revertant 
phenotypes, result in cardiomyopathy including arrhythmias, diastolic 
dysfunction, and increased susceptibility to sudden cardiac death333, 335-337. 
These clinical observations reveal an absolute requirement for enhanced 
ventricular relaxation in mammalian species. Using large scale bioinformatics 
and an array of molecular modeling techniques we propose that the intrinsic 
relaxation potential of cardiac troponin has been enhanced during chordate 









Amino acid and mRNA sequences and alignments Sequences were extracted 
by search of NCBI protein and nucleotide databases as well as the UniProt KB 
protein database. Defining the taxonomic relationship between species studied 
was accomplished by use of the NCBI taxonomy database (Figure 2-7). Table 2-
1 outlines abbreviations used to reference specific species. Table 2-2 outlines all 
relevant details on the sequences acquired from NCBI or UniProt KB databases 
used in this phylogenetic analysis. To be consistent with prior studies, all amino 
acid numbering in this study refers to the adult rat isoform sequence (cTnI, cTnC, 
and cTnT) including the starting methionine unless otherwise stated. Protein and 
nucleotide sequences were aligned by Clustal W analysis as originally described 
by Thompson et al338. Multiple alignment parameters were as follows: gap 
penalty = 15; gap length penalty = 6.66; protein weight matrix: Gonnet Series. 
Pairwise analysis of percent identity between sequences was used to define the 
relationship between proteins or within proteins across designated species.  
 
Genome scans for novel TnI genes New sequences for troponin I isoforms 
were acquired by whole genome scans of numerous species. Genome BLAST 
analysis for TnI isoforms were performed on Anolis carolinensis (lizard, USCS), 
Taeniopygia guttata (zebra finch, NCBI), Cavia porcellus (guinea pig, UCSC), 




Table 2-1. Species abbreviations
 




 Chimpanzee Ch 
 Rhesus Rh 
 Marmoset Ma 
 Bovine B 
 Horse Ho 
 Goat G 
 Sheep Sh 
 Pig P 
 Dog D 
 Cat C 
 Guinea Pig GP 
 Rabbit Rab 
 Rat R 
 Mouse M 
 Opossum O 
 Platypus Pl 
Reptile Lizard L 
Birds Chicken Ch 
 Quail Q 
 Turkey T 
 Zebra Finch ZF 




 Bullfrog BF 
 Marine Toad MT 
Fish Salmon S 




 Dinosaur eel DE 
 Arctic lamprey AL 
Invertebrates Ascidian 1 As1 
 Ascidian 2 As2 











related species were used for the genome scans. Predicted isoform for TnI 
sequences was accomplished by Clustal W analysis followed by sequence 
percent identity and phylogenetic tree analysis. The Kimura distance formula was 
used to calculate distance values, derived from the number of non-gap 
mismatches and corrected for silent substitutions. The values computed are the 
mean number of differences per site and fall between 0-1. Zero represents 
complete identity and 1 no identity. Scale of the phylogenetic tree indicates the 
number of nucleotide substitutions per 100 residues. Phylogenetic tree analysis 
was used to confirm identity of predicted TnI isoforms by sequence correlation 
with other TnI isoforms. Sequence ID and divergence values were calculated to 
define the relationship between novel TnI proteins and related TnI isoforms to 
assist in confirmation of postulated isoform designation. Divergence (i,j) is 
calculated as (100[Distance (i,j)] / Total Distance) where (i,j) is the sum of the 
branch lengths between two sequences and Total Distance is the sum of all 
branch lengths. All data regarding protein and mRNA sequences are outlined in 
Table 2-3, and Figures 2-8 (nucleotide) and 2-9 (protein). 
 
Determination of evolutionary selective pressure Phylogenetic codon models 
were used to understand the selective pressure on both the full gene sequence 
of cardiac TnI and on the switch domain. Briefly, codon-based methods (recently 
reviewed by 339, 340) make use of a continuous-time Markov process to model 
synonymous (dN) and non-synonymous substitutions (dS) along a phylogenetic 
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tree. Phylogenetic trees were estimated, using PHYML 341, independently for the 
full gene sequence and for the switch domain, since only a subset of full cTnI 
sequences were available for the mammalian taxa of interest. The switch domain 
is short (63 nucleotides), and thus some internal branches of the phylogeny had 
lengths of zero; we collapsed those branches into polytomies. It was assumed 
that synonymous and non-synonymous substitution rates at codon sites can be 
approximated using discrete distributions, the parameters of which are estimated 
by maximum likelihood. To rule out the potential confounding effect of 
recombination or gene conversion, the alignment was screened using GARD342, 
343; no evidence for recombination was detected. To identify the distribution 
which best describes synonymous and non-synonymous rate variation across all 
sites a step-wise procedure was used starting at a single rate for all sites and 
progressively adding new rate classes, each time estimating the synonymous 
and non-synonymous rates of each class and evaluating model fit using the small 
sample correction to the Akaike’s Information Criterion (AIC-c)344. The stepwise 
iteration was terminated once no further improvement in model fit was achieved. 
A Fixed Effects Likelihood (FEL) methods (implemented on 
www.datamonkey.org345) was used to estimate the synonymous to non-
synonymous substitution rate at each site independently for the switch domain. 
Briefly, evidence for either positive (dN/dS > 1) or purifying selection (dN/dS < 1) 
was identified by comparing the fit of a model in which synonymous and non-
synonymous rates are constrained to be equal, to that in which this constraint is 
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relaxed. Statistical significance was evaluated with a Likelihood Ratio Test (P < 
0.05).  
 
Molecular modeling and structural analysis All modeling was carried out 
using Maestro (Schrödinger, LLC, New York, NY; 2007). The solved X-ray 
crystallographic structures of human cardiac52 (PDB: 1J1E) and skeletal51 (PDB: 
1YTZ) troponin in complex to Ca++ bound troponin C were taken from the Protein 
Data Bank. The missing hydrogen atoms were added to both X-ray structures 
followed by energy minimization using OPLS 2005 forcefield to optimize all 
hydrogen bonding networks. Structure comparison between the cardiac and 
skeletal troponin was carried out by superpositioning the two structurally 
conserved Ca++ bound TnC. From this superpositioning, truncated hybrid and 
homotypic crystal structures were analyzed including: cTnC/cTnI, cTnC/sTnI, 
cTnC, cTnI, and sTnI. The cTnC:TnI regulatory complex was isolated by 
exclusion of all other residues in the crystal structure except: sTnI R115 – L140, 
cTnI R148 – L173, and each TnI was complexed with cTnC M1 – K90. 
Mutagenesis of sTnI was accomplished by substitution of an alanine for histidine 
at position 132 (H132A).  
 
Theoretical isoelectric point calculations Values for the theoretical isoelectric 





Theoretical pKa calculations of Tn crystal structures The sTnI:cTnC and 
cTnI:cTnC structures were analyzed for determination of the theoretical residue 
ionization titration and electrostatic atomic energy binding interaction between all 
ionizable groups. Binding energy between two ionizable groups was calculated 
as atomic energy units and converted to kcal/mol by multiplying by the 
conversion factor 332. Analysis was accomplished as previously described and 
implemented on the Virginia tech H++ server347-352.  Calculation was derived 
using the following inputs: salinity = 0.15; internal dielectric = 10; external 
dielectric = 80; structure protonation assuming pH = 7.2. Calculated by the 
Poisson Boltzmann method.  
 
Molecular Dynamics Simulation Molecular Dynamics (MD) simulations were 
performed for sTnI:cTnC; cTnI:cTnC; and sTnIH132A:cTnC using NAMD 353 
version 2.6 with CHARMM27 forcefield 354. All the X-ray structures and derived 
mutants were prepared by CHARMM version c35b1. Each of the complex was 
solvated with explicit TIP3P water model 355 using a simulation solvent box with a 
15 Å buffer region around the protein. Sodium counter ions were placed at 5 Å 
from the box boundary to neutralize the system. The solvated system was 
initialized with 5000 steps of conjugate gradient energy minimization with protein 
heavy atoms restrained at 50kcal/(mol•Å2). The system was then gradually 
heated with the same restraint from 25K to 300K at 25 K increment at 10 ps 
interval for 100 ps followed by a 100 ps equilibration with gradual removal of the 
heavy atoms restraint at 10 ps interval under NVT condition. The final 
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unrestrained equilibration was carried out for 100 ps followed by 20 ns of 
production simulation at 1 atm and 300K NPT condition. All simulations were 
carried with periodic boundary condition using Particle Mesh Ewald (PME) 356 
with SHAKE 357 method employed to constrain bond lengths involving hydrogen 
atoms. The time step in the simulations was 2 fs with coordinates saved at 1-ps 
time intervals, resulting in a total of 20,000 configurations for analysis. 
 
Interatomic distance calculations All distances are measured in angstrom over 
the 40 ns simulations for each of the simulated trajectories. For the wild type and 
H132A simulation of the sTnI:cTnC complex, the alpha carbon distance was 
evaluated between sTnI H/A132 and cTnC E19.   
 
Results and Discussion 
 
 The principle goal of this study was to assess how cardiac Tn proteins 
have been modified during evolution to accommodate the physiological 
requirements of the mammalian heart. To accomplish this, large scale 
phylogenetic analysis was performed by sequence alignment by clustal W 
analysis of 104 primary amino acid sequences of proteins including cTnT, cTnC, 
ssTnI, and cTnI from species throughout chordate evolution (Figures 2-7 through 
2-12, Tables 2-1, 2-2). Summarizing the relevant taxonomy, table 2-1 lists 





Disease causing polymorphisms in the C-terminus of cTnI recapitulate ancestral 
physiology 
 
Consistent with previous reports52, 252, the positional relationship between 
the functional domains and the secondary structural regions of TnI are outlined in 
Figure 2-1. Benign and disease causing single nucleotide polymorphisms (SNPs) 
have been identified along the full length of the human cTnI locus. Figure 2-1b 
outlines the location of known SNPs as well as their specific disease causing 
designations. Over 94% of known disease causing SNPs are located between 
the start of the IR domain and the end of the C-terminus, also referred to as the 
regulatory domain of TnI52. One of the physiological deficiencies observed in 
these cardiomyopathies is increased myofilament calcium sensitivity333, 335, 337, 358. 
The concentration of disease causing mutations within the regulatory region of 
TnI indicates that single amino acid alterations in this critical region of the 
molecule are not tolerated and have significant deleterious effects on TnI function 
that cause heart disease.  
Studies have shown that environmental demands such as cold 
temperatures and hypoxic conditions require heightened myofilament calcium 
sensitivity to maintain sufficient cardiac performance in ancestral species such as 
fish and amphibians (for further discussion see Appendix A)4, 5, 331, 334. Taken 
together, these observations indicate that heightened myofilament sensitivity to 
activating calcium is a common feature of ancestral cardiovascular function and 
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some human cTn disease causing SNPs. We conclude therefore, that some 
human disease causing cTn SNPs cause evolutionary revertant phenotypes.  
 
Phylogenetic analysis of slow skeletal and cardiac troponin I functional domains 
 
 Human evolutionary revertant phenotypes (e.g. SNPs in TnI) that cause 
pathologies recapitulating ancestral physiology can act as a retrospective view of 
evolutionary pressures providing insights into a mechanistic basis for observed 
modifications in cardiac Tn during evolution of the mammalian heart. Given the 
observed intolerance of SNPs in the C-terminus of TnI, we hypothesized that 
evolutionary pressures tightly regulated changes in these regions to modify the 
performance of Tn in accordance with the evolution of mammalian cardiovascular 
requirements. We subsequently analyzed the subdomains of TnI to understand 
the phylogenetic basis for sequence differences within these functional regions of 
the molecule between chordate species (Figure 2-2a-c).  
Different isoforms of TnI are expressed in different species through 
chordate evolution. In amphibians the cardiac TnI isoform has been found to be 
the only TnI isoform encoded at the onset of heart formation in the larva and 
continuing in the adult heart of anuran species359-361. However, in avian and 
mammalian species the slow skeletal isoform is transiently expressed during 
heart development and is replaced in the adult heart by the cardiac TnI isoform89, 
311, 362. Based on these different expression profiles, we hypothesized that 
comparative analysis of TnI isoforms expressed in the heart would provide a  
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Figure 2-2. Phylogenetic 
analysis of TnI functional 
domains. (a) Direct pairwise 
comparison by Clustal W 
analysis of sequences within 
specific functional domains 
of slow skeletal and cardiac 
TnI only from species for 
whom both isoforms have 
been sequenced; these 
include H, P, Rab, R, M, Ch, 
Q, Xl, Xt, BF, and S. * P < 
0.05 by students t-test 
comparing ssTnI to cTnI 
within a given functional 
subdomain. (c) The delta 
change in sequence percent 
identity between ssTnI and 
cTnI (as indicated in part a) 
within each given functional 
subdomain. * P < 0.05 by 
dunnet’s test comparing 
significance of all other 
functional domains to the 
switch arm. (d) Comparison 
of sequence percent identity 
between ssTnI and cTnI for 
a given species and collated 
based on class including 
mammal (H, P, Rab, R, M), 
bird (Ch, Q), or amphibian 
(Xl, Xt, BF). Differences 
between mammal, bird, and 
amphibian TnI isoforms are 
shown for both the switch 
arm and N-terminal TnC 
binding domain. P < 0.05 
based on 1 way ANOVA 





basis with which to interpret modifications in TnI during evolution of chordate 
cardiovascular systems.   
To discern evolutionary pattern differences among the functional domains 
of TnI, discrete segments of the molecule were aligned and compared across all 
species. The functional domains of TnI analyzed included the N-terminus (1-44), 
N-terminal TnC binding domain (45-65), IT arm (91-136), inhibitory region (IR) 
(138-149), switch arm (152-172) and the C-terminus (153-210). To determine if 
protein sequences within these functional domains were different between ssTnI 
and cTnI across chordate organisms, sequence alignment analysis was 
performed on species where both isoforms are known (Figure 2-2a). This 
analysis showed that, in contrast to N-terminal domains, regions within TnIreg all 
showed a significant diminution in sequence conservation within the cTnI isoform 
compared to ssTnI (P < 0.05). Furthermore, the cTnI switch arm had the greatest 
difference in sequence percent identity compared to the ssTnI switch arm (Δ 
percent ID = -20.1 ± 1.9%, P < 0.05 compared to all other domains) (Figure 2-
2b).  
To understand how this change in switch arm conservation correlates with 
specific phylogenic groupings, the ssTnI/cTnI sequence percent identity was 
analyzed in a pairwise fashion within each class (mammalian, avian, amphibian) 
(Figure 2-2c). This analysis showed that among amphibians the switch arm of 
ssTnI and cTnI isoforms are more similar than is the case for birds. The lowest 
degree of ssTnI:cTnI sequence conservation (greatest divergence) was observed 
in mammals. In contrast, other functional regions such as the N-terminal TnC 
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binding domain showed no difference in ssTnI:cTnI sequence conservation 
among the taxa studied (Figure 2-2c).  
These phylogenetic data indicate that the switch arm was a site of rapid 
ssTnI:cTnI sequence divergence within the mammalian lineage. It is well 
established that the switch arm regulates the toggling of the entire regulatory arm 
of TnI between systole and diastole (residues 138-210)18, 51, 52, 159, 160, 194. A vast 
literature supports the conclusion that the properties of the TnI switch arm can 
markedly alter the mechanism by which troponin regulates the contractile 
properties of the myofilament93, 133, 246, 251, 252, 266, 314, 363.  
 
Analysis of the amino acid composition of the TnI switch arm 
 
 We next sought to determine the specific mechanism by which the 
mammalian switch peptide was modified. To begin, the theoretical isoelectric 
point (pI) was calculated for the switch arm fragment for each class (Figure 2-
3a,i). These data show that the ssTnI switch arm pI did not change across all 
classes. In contrast, the pI for the cTnI switch arm decreased from amphibian 
(9.5 ± 0.5) and bird (8.75 ± 0.0) species to mammals (6.76 ± 0.0).  These data 
also show no significant difference between the TnI isoform (ssTnI vs. cTnI) pI for 
amphibian and avian species. Comparatively, there is a significant reduction in 
the pI for mammalian ssTnI vs. cTnI (9.99 ± 0.0 vs. 6.76 ± 0.0, P < 0.05). These 
data are supported by crystal structure analysis of pI for the avian sTnI switch 










Figure 2-3. Theoretical isoelectric point (pI) analysis and sequence analysis of 
the troponin I switch arm. (a) Analysis of theoretical pI alterations in the switch 
arm between ssTnI and cTnI for species where both sequences are available (H, 
P, Rab, R, M, Ch, Q, Xl, Xt, and BF). (a, i) Analysis of the average pI of the ssTnI 
and cTnI switch arm for amphibian, avian, and mammalian species. * P < 0.05 
vs. all other groups by 1 way ANOVA. (a, ii) Linear regression analysis showing 
the relationship of the net difference in pI and sequence percent identity between 
ssTnI and cTnI within the switch arm. Precise overlap of values within classes 
reduced the number of visible points to 5 in comparison to the 10 calculations 
made (1 for each species). (b) Alignment of troponin I protein sequences 
expressed in numerous chordate species. Analysis was performed by the Clustal 
W method. Sequences are organized by isoform and within each isoform by 
species based on taxonomic classification. The key histidine to alanine amino 
acid modification is also shown (yellow). The platypus proline is highlighted as 
the potential evolutionary intermediate residue between histidine in pre-mammals 
and alanine in all other mammals. For alignment analysis of the full TnI molecule 



















regression analysis was performed to determine if the change in sequence 
percent identity between the switch arm of ssTnI and cTnI for a given species 
was related to changes in the pI (Figure 2-3a, ii). This analysis showed that 
evolutionary pressure to modify the switch arm peptide sequence between ssTnI 
and cTnI are significantly related to alterations in the pI of the domain (r2 = 0.84, 
P = 0.0002). Evidence that the ssTnI switch arm sequence composition and pI 
are not different across classes indicates that this isoform is not being modified 
during chordate evolution. Alternatively, modifications in ionizable residues in the 
cTnI switch arm are altered during evolutionary peptide adjustments of the 
mammalian cTn complex. 
 
Sequence analysis of the troponin I switch arm 
 
 To further study the observed modification of the switch arm in cardiac TnI 
from amphibians to avian and mammalian species, predicted protein and mRNA 
cTnI sequences from numerous chordate species were collected. In addition, 
putative TnI sequences were recovered by BLAST analysis of genomes from 
Anolis carolinensis (Lizard), Taeniopygia guttata (Zebra Finch), Cavia porcellus 
(Guinea Pig), and Callithrix jacchus (Marmoset) (see Table 2-2 and Figures 2-8 
and 2-9).  
Changes in ionizable residues between ssTnI and cTnI in the switch arm 
were studied (Figure 2-3b). This analysis showed that a nonpolar hydrophobic 
moiety at position 164 in the switch arm of cTnI is 100% conserved in mammals 
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but was found to be a histidine in all other chordate species and TnI isoforms 
(with the exception of Zebra finch cTnI). Although alanine 164 was identified in all 
other mammals, a proline residue was surprisingly identified in the predicted 
platypus sequence. Taxonomically, platypus, the only egg laying mammal, is 
situated early in the mammalian lineage (Figure 2-7). This modification of an 
amino acid that is perfectly conserved through chordates prior to the 
bird/mammal divergence and subsequently altered (charged to uncharged or vice 
versa) only in mammals and thereafter perfectly conserved, was not observed at 
any other locus in the entire troponin complex (cTnI, ssTnI, cTnT, or cTnC). 
Analysis of selective pressure indicate that the mammalian cTnI switch arm is 
under significant purifying selection indicating that the current peptide 
composition has long been highly favorable for the proper regulatory functions of 
troponin in the mammalian heart (Table 2-5). Such a significant level of residue 
conservation suggests that the transition from a hydrophilic and polar amino acid 
to a hydrophobic and nonpolar moiety within the switch arm is likely a key 
modification in Tn during evolution of the mammalian heart. This is supported by 
a corpus of of literature showing the importance of this TnI histidine button on 
myofilament function203, 242, 246, 252, 290.  
Histidine has been found to be a critical moiety in regulating key 
physiological events in a number proteins including troponin I (ssTnI H132 or 
cTnI A164H)203, 246, 252, 290, hemoglobin (H146β) 303, 326, HLA-DR molecules 
(H33α) 306, the pacemaker channel HCN2 (H321) 309 and numerous other 
proteins 364, 310, 307, 308. The α-imidazole side chain of histidine is unique among 
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all of the amino acids in that it reversibly binds hydrogen ions within the 
physiologic range. Depending on the local protein environment, temperature, or 
solvent composition the pKa of histidine can markedly shift. The non-protonated 
histidine is hydrophobic and aromatic in character whereas the protonated 
histidine is hydrophilic and positively charged. Of critical importance, in the 
context of the cTn regulatory complex, the imidazole side chain of histidine 
provides a substrate for different ionization states in response to changes in pH. 
Thus, at low pH, increased hydrophilicity of a protonated histidine (H132) at this 
position would help retain intermolecular electrostatic contacts between the TnI 
regulatory domain and the acidic residues decorating the hydrophobic patch of 
cTnC (e.g. E19). As such, the ionization states of histidine enable it to perform as 
a pH responsive molecular switch by differentially regulating the biophysics of 
inter and intramolecular interactions. 
 
Crystal structure analysis of the calcium saturated troponin complex 
 
 The phylogenetic data indicate that the switch arm of amphibian cTnI is 
very similar to ssTnI from across all classes in terms of amino acid sequence and 
isoelectric point (Figure 2-3a, b). Studies have also shown that ancestral cTnI 
physiology seen in fish and amphibians is functionally recapitulated by ssTnI in 
the mammalian heart in vivo and in vitro4, 133, 267, 317, 318, 332. Importantly, what we 
know about mammalian ssTnI may therefore assist in our understanding of the 
structure/function relationship of pre-mammalian cTnI.  
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In recent years the crystal structures of the calcium saturated cardiac Tn 
complex52 and fast skeletal Tn complex51 have been reported. We assume that 
the regulatory domain of the putative ssTn complex mirrors that of the reported 
fsTn complex (for justification of this assumption and structural orientation see 
Figure 2-14). We propose that comparative molecular modeling of sTn and cTn 
through hybrid (sTnI51 with cTnC52) and homotypic (cTnI with cTnC52) atomic 
resolution crystal structures provides insight into evolutionary modifications that 
occurred in cTn to accommodate the functional requirements of the mammalian 
heart.  
We report the first structural alignment of the sTnI and cTnI crystal 
structures in complex with cTnC to accentuate the differences in the regulatory 
interaction between these protein complexes (Figure 2-4a). Comparison of the 
sTn and cTn crystal structure showed a marked alteration in the position of TnI 
helix 4 between sTnI and cTnI relative to helix A and the hydrophobic patch of 
TnC (Figure 2-4a). The structural alignment indicates that H3 has similar 
positioning in the two complexes. The structure of skeletal TnI indicates the 
unstructured helix 4 has His132 engaging helix A of TnC in very close proximity 
to a key acidic residue, Glu19, in the hydrophobic patch of TnC. This analysis 
showed that TnI H132 (protonated, pKa = 8.25) and TnC E19 (pKa = 2.51) are 
close enough to develop a salt bridge (Table 2-4, Figure 2-4a, inset). The binding 
energy of this interaction is 5.24 kcal/mol, the strongest interatomic bonding 
observed between any two ionizable groups analyzed in these crystal structures 










Figure 2-4. Molecular modeling and structural analysis. (a) Atomic level 
alignment of the crystal structures for sTnI and cTnI in complex with the cTnC 
focusing on regulatory interaction site between the switch arm of TnI and the N-
terminal lobe of cTnC. cTnC (red), sTnI (blue), cTnI (yellow). Inset image 
highlights the critical interaction between sTnI H132 and cTnC E19. (b) Atomic 
level resolution of the interaction strength (kcal/mol) between ionizable groups in 
TnI and TnC are shown for the sTnI-cTnC structure (top) and cTnI-cTnC 
structure (bottom). Interactions are organized into intramolecular interactions 
within TnI (left) and cTnC (middle) and intermolecular interactions at the interface 
between TnI and cTnC (right). The strength of interaction cTnC E19 – sTnI H132 
is indicated in red. Vertical bar = 1 kcal/mol. (c) Alanine scanning analysis of the 
change in binding free energy (ΔΔG) among all residues at the sTnI:cTnC 
regulatory interface. Important contributions to ΔΔG by cTnC E19 and sTnI H132 


















significantly influenced by the close electrostatic interaction between sTnI and 
cTnC at this locus (Figure 2-15a,b and Table 2-4). The characteristics of this key 
interaction between cTnC and sTnI (and thus its functional importance) are also 
observed in a unique histidine-aspartate interaction (H146β-D94β) in hemoglobin 
that forms a salt bridge and singularly contributes to about half of the maximal 
alkaline Bohr effect of human HbA326. 
In contrast to the sTn structure, at the H3-H4 linker and into the structured 
H4 of cTnI Ala164 translocates away from helix A and the hydrophobic patch of 
TnC (Figure 2-4a). Residue ionization titration analysis confirmed the hypothesis 
that cTnC and cTnI have limited electrostatic contact at this critical interaction 
site (Figure 2-4b, Table 2-4, Figure 2-15). Crystal structure analysis showed the 
strongest electrostatic contacts within the cTnI:cTnC complex to be over four 
times lower than E19-H132 of cTnC-sTnI.  
To gain molecular insights into the marked differences between the sTnI-
cTnC and cTnI-cTnC regulatory complexes, molecular dynamics simulation were 
carried out in nanosecond timescale to study the molecular motion of the two 
complexes in atomistic detail. These data show that the switch arm (H4 in 
particular) retains strong interface contacts between sTnI and cTnC but becomes 
highly mobile, molecularly untethered, in the cTnI-cTnC structure (Supplemental 
movies 1 (sTnI:cTnC) and 2 (cTnI:cTnC)). 
This histidine to alanine substitution in TnI at the interface with TnC 
markedly effects the performance characteristics of the troponin complex. 2D 
NMR spectroscopy analysis of amide chemical shifts during calcium titration has 
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shown that the switch peptide dissociation constant for cardiac TnI is six times 
weaker than that of skeletal TnI327. Transgenic and gene transfer studies have 
shown that myofilaments containing ssTnI have sarcomere dynamics including 
hypercontractility, delayed relaxation, and increased propensity for arrhythmias 
compared to myofilaments containing cTnI202, 252, 335. Furthermore, consistent 
with the concept of a pH-responsive histidine button, TnI proteins with a histidine 
moiety in the switch arm (ssTnI H132 or cTnI A164H) perform as a molecular 
rheostat capable of maintaining inotropy in the context of severe acidosis or other 
pathologies133, 203, 246, 249, 252, 290, 297, 317, 318. Myofilaments containing cTnI with an 
alanine in the switch arm (A164), by contrast, are highly susceptible to acidosis 
induced contractile failure. Taken together, these structural and functional data 
indicate that significant alterations in the peptide composition and, consequently, 
tertiary protein structure of the cardiac Tn regulatory interaction markedly alter 
the functional properties of Tn.  
We next sought to test the hypothesis that breaking of the His132-E19 
interaction would markedly decrease the binding affinity between sTnI and cTnC. 
To test this, computational alanine scanning was performed to calculate the 
change in the binding free energy (ΔΔG) caused by alanine substitution of all 
residues involved in the intermolecular interface contacts of the sTnI-cTnC 
structure (Figure 2-4c). In cTnC alanine substitution of E19 was found to 
contribute most to the ΔΔG (ΔΔG E19A = 0.91kcal/mol). However, the greatest 
impact on the binding free energy among all residues engaged at the cTnC:sTnI 
interface was observed with the sTnI H132A substitution (ΔΔG H132 = 2.46 
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kcal/mol). These data support the conclusion that alanine substitution of sTnI 
H132 was the most effective mechanism of reducing the binding free energy at 
the interface of the calcium saturated sTnI-cTnC structure.  
To further support this observation, interatomic distances were calculated 
between the alpha carbons of cTnC E19 and residue 132 of either WT sTnI or 
sTnI H132A across a 20 nanosecond atomic resolution molecular dynamics 
simulation (Figure 2-5a,b, Supplemental video 3 (sTnI H132A:cTnC)). These 
data show the WT sTnI:cTnC structure retains a highly stabile interface mediated 
by the high energy intermolecular interaction between His132:E19. In contrast, 
there was a marked increase in the distance between cTnC E19 and sTnI 
residue 132 in the alanine substituted structure indicating a significant time-
dependent structural interface separation (Figure 2-5b). Functional data support 
these in silico observations. A recent study by Westfall et al has shown that ssTnI 
H132A significantly reduces the calcium sensitivity of the myofilaments (pCa50) 
and enhances the relaxation performance of myocytes similar to the functional 
properties observed with myocytes expressing mammalian cTnI252.  
Given our initial assumption that sTnI recapitulates ancestral cTnI, the 
molecular modeling data indicate that there was evolutionary pressure to favor 
cTnI A164 in order to reduce the binding free energy (ΔΔG) at the interface of 
cTnI and cTnC at the mammalian juncture. This was accomplished by eliminating 
the key high energy electrostatic interaction between TnI and cTnC (H132-E19) 
making H4 and the C-terminal domain of TnI molecularly untethered. Together 






Figure 2-5. Molecular simulation modeling of interface separation caused by 
alanine substituted sTnI. (a) Structural alignment (left) of the initial X-ray crystal 
structure t = 0 ns; WT sTnI structure t = 20.789 ns; and sTnI H132A structure t = 
20.789  ns showing interface separation  only in the alanine substituted structure 
(arrow). Amino acid perspective showing separation of the alpha carbons of 
cTnC E19 from sTnI residue 132 (right). (b) Calculation of the interatomic 
distance between the alpha carbon of cTnC E19 and alpha carbon of residue 132 







data indicates that the modification in the switch arm of cTnI between amphibians 
(histidine) and mammals (alanine) significantly enhanced the relaxation potential 
of cTn in the mammalian cardiovascular system. The proline residue observed in 
platypus cTnI accentuates this point. Proline is the archetypal helix breaker and 
is also nonpolar. Thus we believe that structurally and functionally, the platypus 
proline is an excellent intermediate to enhance relaxation in large part through 
disruption of the histidine-glutamate salt bridge predicted to occur in amphibian 
cTn.  
 
Increased myofilament calcium sensitivity in pre-mammalian chordates 
 
Previous reports have shown that residues at the N-terminus of cTnC are 
required for differentially modulating the calcium binding affinity of TnC between 
endotherms and ectotherms (Figure 2-13)332. It was suggested that, in 
ectotherms, four residues (GrP sequence: N2, I28, Q29, D30) were responsible 
for decreasing the energy barrier required for conformational changes in the N-
terminus which increased calcium binding affinity at EF hand site II. In 
endotherms, these residues have been converted to D2, V28, L29, and G30 and 
markedly reduce myofilament calcium sensitivity by decreasing the calcium 
binding affinity of cTnC. In mammals, failure to modify these residues results in 
cardiomyopathy. Studies have shown that a single amino acid substitution L29Q 
in human cTnC causes a significant increase in myofilament calcium sensitivity 
that results in hypertrophic cardiomyopathy 365, 366. Other evolutionary revertant 
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phenotypes associated with increased myofilament sensitivity to activating 
calcium have been found in SNPs within other regions of cTnC as well as 
cTnT336, 358, 367-374. 
Together with modifications in the cTnI switch arm, these data provide 
evidence that the ancestral cTn phenotype of heightened myofilament 
responsiveness to activating calcium was a physiological mechanism required for 
cardiovascular function of these species4, 5, 334. The physiological demands 
placed on these species including cold temperatures and extended periods of 
hypoxia support the need for myofilament function with pH responsiveness and 
heightened sensitivity to activating calcium. In addition to residues in cTnC, this 
study provides new knowledge suggesting that a histidine moiety in the switch 
arm of cTnI also contributes to the heightened myofilament calcium sensitivity 
and reveals the likely source for this residue as responsible for pH responsive 
inotropy observed in hearts of ancestral species.  
 
Enhanced relaxation of cardiac troponin is required for mammalian heart function 
 
A significant corpus of literature has emerged in recent years providing 
comparative analysis of cardiovascular function between chordate species 1, 4, 5, 
13, 99, 334, 359-361, 375-383. These studies elucidated important details about the 
differences in physiological requirements that necessitate unique mechanisms of 
cardiovascular support. The current study contributes to this knowledge base by 
providing the first evidence for molecular evolution of the cardiac troponin 
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complex. These data show that this cTn modification enhances the relaxation 
performance of the thin filament regulatory complex and may have evolved to 
accommodate cardiovascular demands of the adult mammalian heart (Figure 2-
6).  
The expression of TnI isoforms with inherently high calcium sensitivity in 
the developing hearts of all chordate species (fish/amphibian cTnI and 
mammalian/avian ssTnI) 311, 331, 361 indicates that heightened calcium sensitivity 
and pH responsiveness of the myofilaments are characteristics required for heart 
development in all chordate species (Figure 2-6). Several studies support this 
assertion. First, the fetal heart has high lactate levels and relies on glucose 
metabolism384. Second, there is evidence that the critical cardiac developmental 
transcription factor Nkx2.5 is regulated by hypoxia-inducible factor (HIF-1α)385. 
Third, immature sarcoplasmic reticulum and calcium cycling in the developing 
heart require heightened sensitization of the myofilaments to establish sufficient 
inotropy386, 387. 
However, in the adult heart, requirements for proper regulation of cardiac 
output are markedly different between chordate species. Numerous factors 
intrinsic and extrinsic to the heart affect the efficiency of heart rate and stroke 
volume to sustain cardiac output. Sufficient ventricular filling during diastole is a 
requisite precursor to systolic ejection. In human patients, incomplete LV filling 
even in the absence of systolic dysfunction is a key symptom of heart failure388. 
This makes diastolic performance a significant point of vulnerability in the 










Figure 2-6. Proposed model for molecular evolution of cardiac troponin during 
chordate evolution. Progressive modifications in organismal cardiovascular 
requirements resulted in marked changes in heart structure and functional 
regulation to meet evolving whole animal physiologic demands. Troponin 
isoforms expressed in species identified early in chordate evolution (e.g. fish 
(cTnI) and amphibians(cTnI)) together with developmental isoforms from all 
classes (fish (cTnI), amphibian (cTnI), avian (ssTnI), and mammalian (ssTnI)) 
have a high energy histidine-glutamate interaction in the regulatory 
intermolecular interface between cTnI and cTnC. This results in myofilaments 
with heightened calcium sensitivity and reduced pH sensitivity. During evolution 
of the mammalian adult cardiovascular system (developmental isoform transition 
to cTnI), the cardiac troponin I switch arm evolved to contain a proline moiety in 
place of the histidine (as seen with the platypus) that fundamentally altered the 
critical regulatory interaction between cTnI and cTnC. Together with all other 
mammals (which have A164), this resulted in myofilaments with reduced calcium 
sensitivity (enhanced relaxation) and increased pH sensitivity. Taken together, 
this study provides seminal insight into chordate cardiovascular evolution 
providing a model of enhanced relaxation efficiency in cTn required to meet 

















At the level of single myocytes, key regulators of myocardial relaxation 
include cytoplasmic calcium re-sequestration into the sarcoplasmic reticulum 
through SERCA2a and troponin I inhibition of actomyosin ATPase activity46, 91, 103, 
119, 120, 188. Dysfunction in SR calcium uptake or cTnI inhibition of myofilament 
activation result in delayed sarcomeric relaxation137, 200, 243, 274, 333. Concerning 
cTnI function, inefficient lusitropy could either occur because of enhanced 
binding to cTnC during systole and/or incomplete inhibition of actomyosin 
crossbridge formation during diastole. In either case, the observed effect is an 
increase in myofilament calcium sensitivity66, 123, 333, 389. Cardiomyopathic SNPs 
identified in all members of the human heterotrimeric cardiac troponin complex 
have been found to cause an evolutionary revertant phenotype characterized by 
a marked increase in myofilament calcium sensitivity333, 365, 366, 390-394. Together, 
these studies show a strong correlation between evolutionary revertant 
phenotypes caused by cardiomyopathic SNPs in troponin and heart failure 
phenotypes including diastolic dysfunction, arrhythmias, and sudden cardiac 
death.  
In the context of chordate evolution, our current understanding of fish and 
amphibian physiology support the need for heightened myofilament calcium 
sensitivity with pH-responsiveness4, 5, 331, 334, 395. Similar to cTnI, other proteins 
have shown analogous adaptions in these species. For example, hemoglobin in 
many fish has an exacerbated Bohr effect known as the Root effect, an extreme 
form of pH sensitive Hb O2 binding326, 396, 397. On the part of regulating cardiac 
contractility at low pH, the N-terminal NIQD motif of cTnC and the switch arm 
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peptides of cTnI seen in fish and amphibians provide the required cardiovascular 
support to meet physiological demands of ectotherms (Figure 2-6). However, the 
observation that heart failure symptoms occur in patients with evolutionary 
revertant phenotypes including hypersensitive myofilaments indicates that 
enhanced relaxation properties at the level of the myofilaments were a necessary 
adaptation for the mammalian cardiovascular system.  
Phylogenetic alignment data show the emergence of protein kinase (PKA 
and PKC) phosphorylation sites at the N-terminus of TnI (S23, 24) at the level of 
amphibians (Figure 2-12). One of the major purposes for protein kinase 
phosphorylation of these residues is to enhance relaxation of the myofilaments in 
coordination with changes in heart rate9, 202, 205, 215. Although covalent 
modifications of TnI emerged prior to mammals, this mechanism for augmenting 
lusitropy was evidently insufficient for mammalian cardiovascular function. As a 
consequence, this study supports the hypothesis that coordinated residue 
modifications in cTn enhanced the intrinsic relaxation potential of troponin 
independent of covalent modifications.  
Structure and function data indicate that this occurred on cTnC by 
markedly decreasing the calcium binding affinity at EF hand site II332. On the part 
of TnI, this study provides important evidence that a histidine to alanine 
substitution in the switch arm disrupted a strong intermolecular electrostatic 
interaction between histidine of cTnI and glutamate of cTnC (Figure 2-6). In silico 
molecular dynamics alanine scanning simulations and functional data252 support 
the importance of this modification in enhancing myofilament relaxation by 
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making cTnI molecularly untethered from cTnC reducing the intermolecular 
interface binding free energy. These data also indicate that loss of a 
therapeutically effective pH responsive histidine button in cTnI203, 246, 290 was 
necessary to acquire proper relaxation252. This study provides the first evidence 
for the prominent role of troponin in the molecular evolution of mammalian 
diastolic performance. The model put forth by this study is that selective 
pressures during evolution of the mammalian cardiovascular system resulted in 
coordinated residue modifications in cardiac troponin enabling it to relax more 
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Phylogenetic analysis of slow/cardiac troponin C 
 
 Analysis of the cTnC sequence alignment (Figure 2-11) was also 
performed. Taken together with reported functional data332, 366, this phylogenetic 
analysis revealed important differences between ectotherms (A, As1, AL, DE, 
GP, Z, and Xl) and endotherms (Q, Ch, M, R, Rab, P, B, and H) regarding the 
role of cTnC in cardiac function between these species. The functional domains 
of cTnC analyzed include EF hand I (15-47), EF hand II (55-82), EF hand III (94-
125), and EF hand IV (134-161). Figure 2-11 shows the positional arrangement 
of the critical divalent cation binding sites, EF hand sites I-IV, relative to the 
secondary helix structures of the protein. Phylogenetic analysis of each EF hand 
site across all species showed that site II is the most highly conserved (Figure 2-
13a). This is consistent with EF hand II being the only functional calcium binding 
site in cTnC and required for Tn function65, 71, 73. Studies have shown that the 
acid side chains in the EF hand of site II are highly conserved and involved in 
coordinating the binding of calcium to cTnC74. Comparison of the conservation of 
these EF hand sites within ectotherms and endotherms showed that all regions 
of the protein are significantly more highly conserved (P < 0.05) in endotherms 
than ectotherms (Figure 2-13b). This suggests that there is a concerted pressure 
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for stabilization of this protein in order to maintain evolutionary modifications 
within the protein that are critical for cardiovascular function in endotherms.  
Functional differences within the cTnC isoform have been reported when 
comparing endothermic vs. ectothermic species4, 332, 334. Of particular interest, the 
acidic residues in the N-terminal hydrophobic patch of cTnC hypothesized to 
interact with the regulatory domain of TnI are 100% conserved across all species 
(Figure 2-13c). This indicates that functional alterations of cTnC during chordate 
evolution are not mediated through alterations in these acidic residues. However, 
previous reports have shown that residues at the N-terminus of cTnC are 
required for differentially modulating the calcium binding affinity of TnC between 
endotherms and ectotherms (Figure 2-13c)332. It was suggested that four 
residues (GrP sequence: N2, I28, Q29, D30) were responsible for this 
biophysical difference. This amino acid combination did not alter the open 
probability of the hydrophobic patch but decreased the energy barrier required for 
conformational changes in the N-terminus that affect calcium binding affinity at 
EF hand site II. When accounting for differences in temperature between the TnC 
calcium binding affinity of these ectothermic species compared to the binding 
affinity seen in endothermic TnC the calcium binding affinity was normalized. 
This indicates that these residue substitutions were required for proper 
maintenance of cardiac function during evolutionary adaptations in 
thermoregulation between these species.  
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The current analysis of an expanded number of sequences focusing on 
the cTnC isoform revealed, however, that N2 and I28 do not likely contribute 
significantly to this functional difference since these residues are not highly 
conserved within ectothermic species (e.g. instead of an asparagine, S and Xl 
have an aspartate similar to all endotherms). In contrast, Q29 and D30 are 100% 
conserved in all ectotherms and transition to L and G, respectively, in all 
endotherms with 100% conservation. This suggests that substitutions in the 
human s/cTnC L29Q and G30D would be sufficient to completely recapitulate the 
increased calcium binding affinity in the ectothermic cTnC molecule. In a recent 
report, Liang et al showed that the single amino acid substitution L29Q 
resembles the effects of the NIQD motif seen in ectotherms365. Furthermore, 
L29Q is a known TnC disease causing mutation and has been linked to a patient 
with familial hypertrophic cardiomyopathy366. Taken together, this analysis of 
cTnC protein indicates that the evolutionary pressures during the transition into 
the mammalian cardiovascular system fundamentally required a reduction in the 
calcium binding affinity of cTnC.  
 





 Fish and amphibian species are ectotherms and have many common 
features in terms of structural and functional regulation of cardiac output. Studies 
have shown that fish regulate cardiac output primarily through modifications in 
stroke volume as opposed to changes heart rate4, 5. The flounder heart has the 
highest reported stroke volume of a teleost measured at 2.3 mL per gram body 
weight6. Similarly, amphibians have the capacity to modulate cardiac output 
through changes in stroke volume but show increased regulation of heart rate 
compared to fish4, 5. An increase between 100-300% of resting stroke volume 
has been observed in exercising fish and amphibian species398, 399. Despite 
having resting sarcomere lengths similar to mammals, fish and amphibians are 
able to extend their sarcomeres beyond the optimal length of overlap and still 
develop force and thus function over a broader range of the Frank-Starling 
curve334, 400, 401. The near linear passive tension-extension properties of myocytes 
and the capacity to dramatically increase myofilament calcium sensitivity at 
longer sarcomere lengths are thought to mediate this phenotype334, 402. At the 
whole organ level, low passive tension of fish and amphibian hearts may facilitate 
decreased end systolic volume and increased end diastolic volume (ejection 
fraction near 100%398) enabling these species to regulate cardiac output by 
changes in stroke volume. Studies have shown that adrenergic-mediated 
alterations in chronotropy is less potent at lower temperatures making regulation 
of CO through modulation of HR less valuable in ectothermic species such as 
fish and amphibians403. Studies have also shown that heart rate is much lower in 
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ectotherms than endotherms making SV an optimal mechanism for regulating 
CO (Max ΔHR = 5bpm)5, 404.  
 Together with other studies332, this study provides an emerging picture of 
how the troponin complex plays an important role in cardiovascular performance 
of ectothermic species. As discussed previously, studies have shown that the 
calcium binding affinity of cTnC in ectothermic species is significantly higher than 
endothermic species. Prior evidence together with the current phylogenetic 
analysis of sequence percent identity suggests that two key amino acids 
responsible for this phenotype are Q29 and D30 (Figure 2-13). When accounting 
for physiological temperature differences, however, the calcium sensitivity of the 
myofilaments is not different between ectotherms and endotherms. Data from 
this study indicates that amphibian and fish cTnI also has properties that would 
enhance the calcium sensitivity of the myofilaments. Specifically, key amino 
acids in the switch domain have been attributed to a TnI phenotype with 
heightened contractile performance252. Furthermore, the histidine moiety has 
been shown to confer resistance to acidosis induced contractile failure133, 246. In 
species such as fish and amphibians this pH responsive regulation of inotropy is 
critical due to normal physiological conditions of hypoxia experienced by these 
species405-408. In fact, studies of perfused frog hearts have shown that 
amphibians can maintain normal cardiac function during severe hypoxia or 
ischemia408. We believe that a significant mediator of this response is the 
histidine button located in the switch domain of amphibian cTnI.  
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 The current study also shows that the dual serine phosphorylation sites 
known to be critical for cardiac adrenergic responsiveness9 are absent in fish but 
emerge with 100% conservation in amphibians through avian and mammalian 
species (Figure 2-12). This is consistent with the emergence of control of cardiac 
output through modulation of heart rate in these species. Furthermore, this 
indicates that the precise emergence of these PKA phosphorylation sites in 
species with very immature autonomic control of cardiovascular performance.  
 Taken together, regulation of cardiovascular function in fish and 
amphibians is primarily mediated through changes in stroke volume. As a 
consequence, the role of Tn in regulation of myofilament performance in these 
species is specifically designed to increase the calcium sensitivity of the 
myofilaments. This is accomplished through targeted amino acid modifications in 
the N-terminus of cTnC as well as the switch domain of cTnI.  Furthermore, cTnI 
acts as a pH responsive molecular rheostat capable of modulating myofilament 
activation in response to changes in the intracellular milieu. Placed in the context 
of whole animal physiology, these intricate functions of the troponin complex are 
necessary for healthy cardiac performance in these species. 
 





 Discussion of the impact of Tn in cardiovascular performance of avian 
species is difficult because of the limited number of cardiac studies is this 
phylogeny. As opposed to fish and amphibian species, avian and mammalian 
species show the emergence of the slow skeletal TnI isoform during early cardiac 
development with the transition to the cardiac isoform in the adult heart89, 311, 362. 
It is known that reptile and bird species regulate cardiac output through changes 
in heart rate5. In fact, some birds such as ducks and pigeons regulate cardiac 
output solely through changes in heart rate4. It is logical therefore that adrenergic 
responsiveness is a key mechanism at play in avian species. The presence of 
cTnI S23, 24 in avian species is important in modulating myofilament 
performance in response to chronotropic changes. In terms of the other major 
myofilament protein targeted by PKA, MBP-C, it is not known whether a 
threonine at site B can act as a surrogate phosphorylation site to initiate 
phosphorylation at sites A and C. Similar to mammalian species, avian species 
also have a cTnC molecule with reduced calcium binding affinity compared to 
amphibians and fish (L29, G30). In contrast to mammals, however, bird species 
have a switch domain very similar to amphibians in regard to the histidine button 
(with the exception of a proline observed in the zebra finch) and some of the 
other key residues of this domain. Overall, the functional importance of these 
characteristics of the troponin complex requires more knowledge of avian 




Adrenergic regulation of myofilament function through cardiac TnI 
 
Like bird species, mammals regulate cardiac output by modulation of heart 
rate and, to some extent, modifications in stroke volume5. Interestingly, the 
fastest heart rate ever recorded in any vertebrate was found in a mammal, the 
Etruscan shrew, with a measured rate in excess of 1500 bpm7. Due to a higher 
responsiveness to catecholamines in endothermic species5, 403, mammals meet 
whole animal metabolic demands through adrenergic and cholinergic 
adjustments in chronotropy9. Covalent modifications at sites throughout cTnI are 
known to be regulated by protein kinases to fine tune myofilament performance 
in conjuction with chronotropic changes in heart rate9, 202, 205. This phylogenetic 
analysis provides new insights into how adrenergic control of myocytes function 
emerged during chordate evolution.  
It has been shown that ssTnI diminishes the response to β-adrenergic 
stimulation9, 202, 205, 213, 409 due to the absence of a key N-terminal extension found 
in cTnI. This region in cTnI contains dual serine residues (S23,24) first identified 
by Swiderek et al410 which are known to be critical for the catecholaminergic 
response of the heart through cAMP-dependent protein kinase A (PKA) 
phosphorylation9, 107, 127, 140, 202, 205. Previous studies have shown that these 
phosphorylation sites are required for proper enhancement of relaxation during 
adrenergic stimulation202, 215. Although a great deal is unknown regarding the 
mechanism, it is generally accepted that PKA phosphorylation of S23, 24 
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facilitates faster relaxation rates by desensitizing the myofilaments to activating 
calcium158, 411. S23, 24 phosphorylation has also been shown to enhance 
inotropy at least in part by increasing the cross-bridge cycling rate214, 215, 412. 
Enhanced inotropy and lusitropy is a key mechanisms responsible for increasing 
cardiac output at higher heart rates during physiological stress9, 205, 413. The dual 
serine phosphorylation sites (S23, 24) at the N-terminus of cTnI appear at the 
level of the amphibian and are completely conserved through birds and 
mammals (Figure 2-12).  
Sequence alignment of another PKA targeted myofilament protein, cardiac 
myosin binding protein C (MBP-C), shows that the critical phosphorylation site B 
(human sequence: S284) is a glycine in amphibians and is substituted for a 
serine residue only in mammals (Figure 2-16a). Phosphorylation site B has been 
found to be required for phosphorylation of sites A and C on MBP-C 414-416. If the 
paradigm holds true for earlier vertebrates, this makes the amphibian MBP-C 
unresponsive to covalent modifications through PKA signaling. These 
observations suggest that adrenergic modulation of sarcomere function through 
PKA was initiated through targeted residues in TnI as opposed to MBP-C.  
Calcium handling is also influenced by PKA signaling321, 417. 
Phospholamban (PLN) is the regulator of calcium sequestration through the 
sarco-endoplasmic reticulum calcium ATPase (SERCA2a). Dual phosphorylation 
of PLN (S16, T17) enables faster calcium cycling to enhance diastolic 
performance of the myocytes321. Studies have shown that S16 is sufficient for the 
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full adrenergic effect on calcium handling323 and is required for phosphorylation 
of T17418. Whole genome scans were performed on Xenopus tropicalis, 
Ornithorhynchus anatinus (platypus), and Monodelphis domestica (opossum) to 
expand the number of sequences available for clustal W analysis of PLN (Figure 
2-16b). Sequence alignment showed that the key S16 residue is present in all 
chordates from amphibian to avian and mammalian species. However, the T17 is 
only present in bird species and most mammals with the exception of the 
platypus (Figure 2-16b). Taken together, this alignment data suggests that 
adrenergic control of myocyte calcium handling and myofilament function 
emerged together in amphibians through PKA-mediated covalent modification of 

















































































































Sus scrofa Mammalia NM_00109859




























































































Mus musculus Mammalia NP_001106173 NCBI 
Protein 































































































Salmo salar Teleostei NM_00114658





































































































































Name Organism Taxonomy Locus Database 
Human cTnC Homo sapiens Mammalia NP_003271 NCBI 
Protein 
Bovine cTnC Bos taurus Mammalia NP_001029523 NCBI 
Protein 
Pig cTnC Sus scrofa Mammalia NP_001123715 NCBI 
Protein 
Rabbit cTnC Oryctolagus 
cuniculus 
Mammalia P02591 NCBI 
Protein 
Rat cTnC Rattus 
norvegicus 
Mammalia NP_001029277 NCBI 
Protein 








Gallus gallus Aves NP_990781 NCBI 
Protein 
Quail cTnC Coturnix 
japonica 




Xenopus laevis Amphibia O12998 UniProtKB
Salmon 
cTnC 
Salmo salar Teleostei B5X7T1 UniProtKB
Zebrafish 
cTnC 






































Name Organism Taxonomy Locus Database 
Human cardiac 
TnT 
























































Danio rerio Teleost AAP33153 NCBI 
Protein 
Ascidian 1 TnT Halocynthia 
roretzi 




Name Organism Taxonomy Locus Database 
Human cardiac 
MBP-C 





































Name Organism Taxonomy Locus Database 
Human cardiac 
PLN 






Mammalia P61012 NCBI 
Protein 
Rat cardiac PLN Rattus 
norvegicus 
































































































































































































Details of novel troponin I (TnI) and phospholamban (PLN) genes identified in 
various species. Zebra Finch cTnI was extracted from NCBI GenBank by BLAST 
of expressed sequence tags (ESTs) in the Taeniopygia guttata genome. The 
locus identified was defined as SB02014B2A01.f1 normalized Keck-Tagu Library 
SB02 Taeniopygia guttata cDNA clone SB02014B2A01.f1 5, mRNA sequence. 
TnI isoforms identified for Lizard (Anolis carolinensis), Guinea Pig (Cavia 
porcellus), and Marmoset (Callithrix jacchus) were extracted by Blat analysis of 
the respected UCSC Genome from the bioinformatics genome site 
(http://genome.ucsc.edu/).  Predicted PLN sequences were acquired by Blat 
analysis of genomes of the platypus (Ornithorhynchus anatinus), opossum 
(Monodelphis domestica), and Xenopus (Xenopus tropicalis).  
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Table 2-4. Predicted pK titration calculations for ionizable groups in sTnI, cTnI 
and cTnC 








point 4.09  4.54  4.51  
Total 
charge at 
pH 6.5 -11  -7  -10  
        
Residue pKint pKa pKint pKa pKint pKa 
ASP-2 3.971 3.534 3.987 3.425 3.95 3.439 
ASP-3 4.202 3.921 4.205 3.907 4.2 3.919 
TYR-5 10.218 12.499 10.269 12.456 10.177 12.399
LYS-6  9.971 11.908 9.98 11.91 9.979 11.877
 GLU-10 4.581 4.332 4.588 4.335 4.576 4.325 
GLU-14 4.844 2.851 4.831 2.807 4.829 2.836 
 GLU-15  4.268 4.311 4.467 4.225 4.215 4.251 
LYS-17 10.199 12.999 10.226 13.248 10.171 13.037
GLU-19  4.656 4.768 7.365 2.512 4.591 5.197 
 LYS-21 9.657 13.188 9.681 13.282 9.641 13.214
ASP-25  5.388 2.888 5.413 2.839 5.354 2.808 
        
Structure sTnI  cTnC 
with 





point 11  4.54    
Total 
charge at 
pH 6.5 3  -7    
        
Residue pKint pKa pKint pKa   
ARG-117 7.354 7.187 7.488 7.784   
 ASP-121 3.987 2.015 4.058 1.646   
 ARG-125 12.058 12.584 12.1 13.113   
LYS-131  9.971 9.746 9.896 10.36   
HIS-132    5.451 5.072 4.733 8.253   
LYS-133 9.769 9.755 9.726 10.188   
ASP-137 4.255 3.705 4.415 3.721   
        
        
Structure cTnI  
cTnC 
with 
cTnI    
Isoelectric 
point 8.6  4.51    
Total 
charge at 
pH 6.5 1  -10    
        
Residue pKint pKa pKint pKa   
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ARG-149  7.362 7.237 7.172 7.653   
 ASP-153 3.744 3.565 3.781 3.542   
ARG-163 11.861 12.073 11.862 12.275   
LYS-165 10.41 10.879 10.562 11.14   
GLU-166 4.721 4.426 4.8 4.417   
ASP-169 4.96 4.484 5.023 4.501   
ARG-171  12.051 12.224 12.051 12.289   
HIS-173 6.602 7.09 6.612 7.098   
 
Crystal structures were analyzed for each protein individually (sTnI, cTnI, and 
cTnC) or in complex (sTnI-cTnC and cTnI-cTnC). Values for the intrinsic pK 
(pKint) and actual pK (pKa) are shown for each ionizable residue in the N-terminal 
hydrophobic patch of TnC and H3/H4 of TnI. Intrinsic pK was calculated by 
analysis of each amino acid in the peptide backbone and in the absence of any 
other interacting amino acid R groups. Actual pK was calculated by including all 
interacting R groups influencing the pH titration curve of the given moiety. The 
isoelectric point and total charge at pH 7.2 are also shown for each structure 
analyzed. For consistency throughout the manuscript, amino acid numbering has 
been modified from the original structures and is shown as the human cTnI, sTnI, 














1st Rate class 2nd Rate class  
  dN/dS P1 dN/dS P2  
       
cTnI Switch 
arm 
2 0.0 0.447 0.286 0.553  
       
 
Analysis of evolutionary pressure on the mammalian switch arm was 
accomplished using methods described by Kosakovsky Pond & Frost419. This 
methodology based on mRNA sequences uses a continuous-time Markov 
process to model synonymous (dN) and non-synonymous substitutions (dS) 
along a phylogenetic tree. In this approach, the mammalian cardiac TnI switch 
arm analysis of synonymous and non-synonymous rate classes identified the 
presence of strong purifying selection. Approximately half the sites in the cTnI 
switch arm are characterized by strong purifying selection within the mammals. 
Similarly, fixed effects likelihood (FEL) analysis only identified sites experiencing 
purifying selection, and not positive selection, in the switch arm analysis (data not 
shown). These data show that the mammalian cTnI switch arm is under 
significant purifying selection indicating that the current peptide composition has 
long been highly favorable for the proper regulatory functions of troponin in the 
mammalian heart. Rate classes, inferred using an AIC stepwise model fit 
procedure (see methods), describe the distribution of non-synonymous to 
synonymous subsitution rates (dN/dS) across all sites of an alignment, where Px 
is the proportion of sites belonging to class x. Messenger RNA sequences 
analyzed were derived from the following species: H, SO, Ch, Ma, Rh, B, Ho, P, 










Figure 2-7. Taxanomic tree showing the relationship of chordate species 




Identification of primary mRNA sequences of TnI isoforms from numerous 
species. (a) Whole genome scans were performed to isolate putative TnI genes 
from various species including Marmoset, Guinea Pig, Zebra Finch, and Lizard. 
Sequences extracted from genome scans are given. (b) Phylogenetic tree 
analysis of all TnI proteins represented in the alignment. The Kimura distance 
formula is used to calculate distance values, derived from the number of non-gap 
mismatches and corrected for silent substitutions. The values computed are the 
mean number of differences per site and fall between 0-1. Zero represents 
complete identity and 1 no identity. Scale of the tree indicates the number of 
nucleotide substitutions per 100 residues. Phylogenetic tree analysis was used to 
confirm identity of predicted TnI isoforms by sequence correlation with other TnI 
isoforms. (c) Sequence ID and divergence values were calculated to define the 
relationship between novel TnI proteins and related TnI isoforms to assist in 
confirmation of postulated isoform designation. Divergence (i,j) is calculated as 
(100[Distance (i,j)] / Total Distance) where (i,j) is the sum of the branch lengths 
between two sequences and Total Distance is the sum of all branch lengths. 























































































Figure 2-9  
Identification of primary amino acid sequences of TnI isoforms from numerous 
species. Protein sequences were generated by translation of mRNA sequences 
identified during genome analysis. (a) Clustal W alignment of novel predicted 
fragments of TnI proteins extracted from genome scans of species including 
Marmoset, Guinea Pig, Zebra Finch, and Lizard. These sequences are aligned 
with known sequences from other related species. (b) Phylogenetic tree analysis 
of all TnI proteins represented in the alignment. The Kimura distance formula is 
used to calculate distance values, derived from the number of non-gap 
mismatches and corrected for silent substitutions. The values computed are the 
mean number of differences per site and fall between 0-1. Zero represents 
complete identity and 1 no identity. Scale of the tree indicates the number of 
nucleotide substitutions per 100 residues. Phylogenetic tree analysis was used to 
confirm identity of predicted TnI isoforms by sequence correlation with other TnI 
isoforms. (c) Sequence ID and divergence values were calculated to define the 
relationship between novel TnI proteins and related TnI isoforms to assist in 
confirmation of postulated isoform designation. Divergence (i,j) is calculated as 
(100[Distance (i,j)] / Total Distance) where (i,j) is the sum of the branch lengths 
between two sequences and Total Distance is the sum of all branch lengths. 




























Alignment of cardiac troponin T protein sequences expressed in numerous 
chordate species. Analysis was performed by the Clustal W method. Sequence 
alignment consensus strength is indicated graphically above each residue. 
Residues highlighted indicate amino acids that are modified from charged to 









Alignment of cardiac troponin C protein sequences expressed in numerous 
chordate species. Analysis was performed by the Clustal W method. Sequences 
are organized species based on taxonomic classification. Sequence alignment 
consensus strength is indicated graphically above each residue. Structural 
delineations (Helix N and A-H) are indicated above residues involved in formation 
of those protein domains. The position of each EF hand motif is also indicated. 
Calcium coordinating sites for each EF hand are indicated (blue). Acidic residues 









Alignment of troponin I protein sequences expressed in numerous chordate 
species. Analysis was performed by the Clustal W method. Cardiac homologs 
and slow skeletal homologs are indicated where expression of both isoforms has 
been identified within a given species. Sequences are organized by isoform and 
within each isoform by species based on taxonomic classification. Sequence 
alignment consensus strength is indicated graphically above each residue. 
Structural delineations (Helix 1-4) are indicated above residues involved in 
formation of those protein domains. Phosphorylation targets (S23,24) are 








Justification for use of the fast skeletal troponin crystal structure. (a) Structural 
alignment of the fsTn and cTn crystal structures focusing on regulatory 
interaction site between the switch arm of TnI and the N-terminal hydrophobic 
patch of TnC. TnC (green), fsTnI (red), cTnI (orange). Critical residues of the 
switch arm are emphasized in each structure (sTnI: R, H, V, N; cTnI: Q, A, E, H).  
(b, c) Sequence alignment of the switch arm from chicken fast skeletal and slow 
skeletal TnI (b) as well as chicken fast skeletal and slow/cardiac TnC (c). Arrows 
indicate the key charged residues of the switch arm (a) and the acidic residues of 
the hydrophobic patch on TnC (c). We make the argument that the fast skeletal 
Tn crystal structure (fs TnI and fs TnC) is transposable with the slow skeletal Tn 
complex (ssTnI and cTnC) for the following reasons. Crystal structure alignment 
of the fast skeletal Tn (fs TnI and fs TnC) and cardiac Tn (cTnI and cTnC) show 
remarkable helix position similarity between TnC and TnI. At the amino acid 
level, there is a high degree of sequence similarity between fsTnI and ssTnI at 
the switch arm with only one amino acid different (as indicated in this figure). In 
terms of the cognate binding partner for TnI, it is well known that the amino acid 
sequence between fast and cTnC are markedly different, however, shown here 
are the perfectly conserved acidic residues that decorate the rim of the 
hydrophobic patch of TnC where the switch arm of TnI binds. Furthermore, the 
structural alignment of the cardiac and fast skeletal Tn complexes (Figure 7a) 
shows a perfect alignment of the N-terminus of TnC at the site where TnI binds 
suggesting that this structural interaction is highly conserved. In terms of 
function, very similar effects on sarcomere dynamics and myosin S1 ATPase 
activity are observed in fsTnI as seen with ssTnI249, 267. The skeletal and cardiac 
troponin complex have also shown similar structures in which the switch peptide 
is bound to the N-terminal hydrophobic patch of TnC between helices A and B420. 
In general, the structural agreement of cTnI, ssTnI, and fsTnI has been 
supported by numerous other reports249, 252. Consequently, we propose that 
structural data gleaned from the fsTn complex can be correlated with the ssTn 
complex. In the main text of the manuscript, sTnI refers to the skeletal TnI 
structure given that fast skeletal and slow skeletal undergo a similar folding 















Figure 2-14. Structure and function analysis of troponin C. Schematic diagram 
and analysis of subdomain sequence alignments in cardiac/slow troponin C. 
Functional domains including EF hand sites I-IV are indicated above their 
respective helical locations. Helix designations are shown over the full sequence 
of human cardiac troponin I. (a) Sequence ID comparison of all functional 
subdomains of cardiac/slow troponin C. Species include H, B, P, Rab, R, M, Ch, 
Q, Xl, Z, S, GP, DE, AL, As1, and A. (b) Direct pairwise comparison of 
sequences within specific functional domains from cardiac/slow TnC between 
ectotherms and endotherms. Ectotherm species: Xl, DE, GrP, Z, and S; 
endotherm species: H, B, P, Rab, R, M, Ch, and Q. * P < 0.05 by students t-test 
comparing ectotherms to endotherms within a given functional subdomain. (c) 
Consensus sequence after Clustal W alignment for ectotherm cTnC and 
endotherm cTnC. The position of Helix A and B as well as EF hand site I are 
indicated. Calcium coordinating sites for EF hand site I are indicated (blue). 
Acidic residues around the rim of the hydrophobic patch are also indicated 
(orange). * indicates residues shown to be responsible for the increased calcium 
binding affinity of ectotherm TnC332. The only disease causing mutation (L29Q) 


















Crystal structure analysis of electrostic interactions between TnI and TnC. (a) 
The delta pK (pKa – pKint) for each ionizable residue was calculated for the cTnI-
cTnC (blue) and sTnI-cTnC (green) crystal structures. The absolute pK shifts for 
His132 and Glu19 are shown in red. Vertical bar = 1 pK unit. (b) Decomposition 
of the residues that contribute to the pK shift for sTnI Histidine 132 and cTnC 
Glutamate 19. More than any other residue is the reciprocal effect of H132 and 
Glu19 on each others pK shift (red). Structural location for each residue in cTnC 












Alignment of cardiac myosing binding protein C (MBP-C) and phospholamband 
(PLN) sequences expressed in numerous chordate species. (a) Sequence 
alignment of MBP-C. Phosphorylation sites are highlighted and labeled A-D. It is 
known that site D is not actually phosphorylated perhaps by steric constraints 
from domain C2415. Phosphorylation at site B is required for phosphorylation to 
occur at sites A and C415. (b) Sequence alignment of PLN. Phosphorylation sites 
(S16, T17) are highlighted. All sequence information for MBP-C and PLN is 
provided in Table 3. Analysis was performed by the Clustal W method. 
Sequences are organized by species based on taxonomic classification. 

















Single histidine substituted cardiac troponin I confers protection from age-related 




Aims: Contractile dysfunction associated with myocardial ischemia is a 
significant cause of morbidity and mortality in the elderly. Strategies to protect the 
aged heart from ischemia-mediated pump failure are needed. We hypothesized 
that troponin I-mediated augmentation of myofilament calcium sensitivity would 
protect cardiac function in aged mice. Methods: To address this, we investigated 
transgenic (Tg) mice expressing a histidine-substituted form of adult cardiac 
troponin I (cTnI A164H), which increases myofilament calcium sensitivity in a pH-
dependent manner. Results: Serial echocardiography revealed that Tg hearts 
showed significantly improved systolic function at four months, which was 
sustained for two years based on EF and Vcfc. Age-related diastolic dysfunction 
was also attenuated in Tg mice as assessed by Doppler measurements of the 







contractility significantly improved in aged Tg mice made evident by increased 
SV, ESp, and + dP/dt compared to Ntg mice.  Conclusion: This is the first study 
to show that increasing myofilament function by means of a pH-responsive 
histidine button engineered into cTnI results in enhanced baseline heart function 
in Tg mice over their lifetime, and during acute hypoxia improves survival in aged 




 Cardiovascular disease (CVD) is the leading cause of morbidity and 
mortality worldwide, accounting for 16.7 million deaths globally each year14, 232, 
421. Advancing age is a major risk factor for acquiring CVD422-424. Over one-third 
of all patients with CVD are sixty-five years of age or older. Despite significant 
advances in medical therapy and technology, ischemic heart disease in the 
elderly is associated with high mortality232, 233. Myocardial ischemia results from 
inadequate regional blood flow and leads to reduced contractility, often leading to 
heart failure.  
Myocardial ischemia causes a drop in myocardial intracellular pH which 
desensitizes the myofilament to cytosolic Ca2+ fluxes, compromising myocyte 
contractility238. The pH-mediated changes in thin filament proteins, particularly 
the interaction between troponin C and troponin I, are primarily responsible for 
this reduction in myofilament calcium responsiveness and resulting decrement in 
contractile function245. Troponin I (TnI), the inhibitory subunit of the ternary 
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troponin complex, is the Ca2+ -sensitive molecular switch of the myofilament33. 
During diastole, the C-terminus of TnI interacts with actin which allows 
tropomyosin to sterically inhibit actomyosin ATPase activity. During systole, a 
conformation change in the troponin complex occurs wherein the C-terminal 
switch domain of TnI binds to the hydrophobic patch of the Ca2+ saturated N-
terminal lobe of TnC52. This releases the inhibition on actomyosin ATPase 
resulting in cross-bridge cycling and subsequent sarcomeric contraction.  
Carboxy-terminal charge differences between the neonatal and adult 
isoforms of TnI, slow skeletal TnI and cardiac TnI, respectively, are responsible 
for alterations in pH sensitivity of the myofilament249, 252. Recent studies indicate 
that a critical histidine residue underlies TnI regulation of myofilament pH 
sensitivity (Figure 3-1a)246, 249, 250, 252. When cardiac TnI is modified to contain a 
histidine at codon 164 it behaves as a titratable molecular switch regulating 
myofilament tension development in response to biochemical changes in the 
myocyte in vitro and in the whole heart in vivo246. Importantly, this engineered 
mutation increases myofilament sensitivity to activating calcium while retaining 
important PKA phosphorylation sites on the N-terminus of cTnI. PKA-mediated 
phosphorylation of TnI is a critical mediator of the β-adrenergic response in the 
adult heart9. Numerous studies have shown that increasing myofilament calcium 
sensitivity through mutations in the troponin complex results in varying forms of 






Figure 3-1. Age-dependent gene expression changes in cTnIA164H Tg mice. (a) 
Sequence alignment showing location of the single histidine substitution originally 
studied in ssTnI and subsequently introduced into cTnI (cTnI A164HFLAG). 
Expression of cDNA encoding cTnI A164H with an SV40 polyadenylation (pA) 
signal was driven by the 5.5-kb Myh6 promoter. A C-terminal Flag epitope was 
used to aid detection of cTnI A164H. (b) Immunoblot and bar graph showing 
expression of native cTnI (■) in Ntg mice as well as stoichiometric incorporation of 
cTnI A164HFLAG (□) relative to endogenous cTnI (■) in Tg mice at six months 
(n=12) and two years (n=6). Values are expressed as mean ± SEM. * P < 0.05 for 2 
year replacement vs. 6 month replacement.   
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cTnI R193H, cTnT R92Q)333, 371. In contrast, we have shown that cTnI A164H 
has cTnI R193H, cTnT R92Q)333, 371. In contrast, we have shown that cTnI 
A164H has no baseline pathology and  significantly protects cardiac function in 
response to a variety of pathophysiologic challenges including acute and chronic 
ischemia246. Adding to the evidence supporting the therapeutic role of histidine 
modified troponin I, this paper is the first to show that improvement in inotropy 
through modification of a myofilament protein attenuates cardiovascular 




Mouse model Generation and analysis of transgenic mice expressing a 
histidine-modified cardiac troponin I (cTnI A164H) with FLAG epitope was 
previously described (Figure 1a)246. The procedures used in this study are in 
agreement with the guidelines of the University of Michigan and approved by the 
University of Michigan Committee on the Use and Care of Animals. The 
University of Michigan is accredited by the American Association of Accreditation 
of Laboratory Animal Health Care, and the animal care use program conforms to 
the standards of the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (NIH Pub. No. 85-23). Aged mice were susceptible to 
complications during Millar catheterization resulting in significant loss of animals 
during the protocol. Three mice died (2 nontransgenic, 1 transgenic) during 
catheter placement and three had irreversible ventricular arrhythmias (1 
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nontransgenic, 2 transgenic) that prevented proper data acquisition either during 
baseline measurements or during the hypoxic challenge. Mice used in this study 
were exclusively from line 892, which was the highest expressing Tg mouse line 
for this model. 
 
Conductance micromanometry Measurements of in vivo cardiovascular 
hemodynamics were obtained using conductance micromanometry as previously 
performed by this laboratory246.  Mice were anesthetized and intubated via a 
tracheal cannulation and ventilated via a pressure controlled ventilator with 1% 
isoflurane. A 1.0 French Millar pressure-volume catheter (PVR-1045; Millar 
Instruments Inc., Houston, Texas, USA) was inserted into the right carotid artery 
and advanced into the left ventricle.  Pressure-volume loops were collected on 
line at 1 kHz.  Data were analyzed with PVAN 3.2 software (Millar Instruments 
Inc.). Inferior vena cava occlusions were also performed to obtain the end 
systolic and end diastolic pressure-volume relationships. After obtaining baseline 
hemodynamics (ventilated with 100% O2), mice were exposed to an acute 
hypoxic challenge (12% O2 balanced with nitrogen). Data were acquired until 
systolic failure which was defined as the point when LV pressure reached 65% of 
initial peak systolic pressure. At this point, mice were recovered using 100% O2 
in order to obtain calibration data. 
 
Echocardiography Anesthesia was induced with 3% isoflurane and then 
maintained at 1% for the duration of the procedure. Transthoracic 
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echocardiography was performed in the supine or left lateral position. Two-
dimensional, M-mode, Doppler and tissue Doppler echocardiographic images 
were recorded using a Visual Sonics’ Vevo 770 high resolution in vivo micro-
imaging system. We measured systolic and diastolic dimensions and wall 
thickness in M-mode in the parasternal short axis view at the level of the papillary 
muscles. Fractional shortening and ejection fraction were calculated from the M-
mode parasternal short axis view. We assessed diastolic function by 
conventional pulsed-wave spectral Doppler analysis of mitral valve inflow 
patterns (early [E] and late [A] filling waves). Doppler tissue imaging (DTI) was 
used to measure the early (Ea) and late (Aa) diastolic tissue velocities of the 
lateral annulus. 
 
Adult mouse myocyte isolation and analysis Adult mouse cardiac myocytes 
were isolated from 3-6 month old mice as described previously 425. Between 5 x 
105 and 1 x 106 rod-shaped cells were obtained from a single mouse heart and 
subjected to sarcomere shortening and Ca2+-transient analysis by loading with 
Fura 2AM (2 μM) as previously described426. An in vitro calibration was 
performed to convert the fluorescence ratio to [Ca2+] as described24. To 
determine the Ca2+ content of the sarcoplasmic reticulum, electrical pacing was 
discontinued and caffeine (20 mM) was rapidly applied using a capillary tube 




Immunoblot detection The stoichiometric ratio of cTnI A164HFLAG to native 
cTnI was accomplished by detection with the pan-TnI antibody MAB 1691 
(Chemicon; 1:1000). Calcium handling proteins were detected using the following 
antibodies: phospholamban (Clone A1, Upstate), SERCA2a (MA3-919, ABR), 
NCX (11-13, Swant), and calsequestrin (PA1-913, ABR). Phosphorylation status 
was performed by Western blot using antibodies directed against the serine 16 
phosphorylation site on phospholamban (07-052, Upstate) and the serine 23/24 
tandem phosphorylation sites on cardiac troponin I (4004, Cell Signaling). 
Indirect immunodetection was carried out using a fluorescently labeled 
secondary antibody (Rockland, IRDye 680 conjugated affinity purified; 1:5000). 
Western blot analysis was accomplished using the infrared imaging system, 
Odyssey (Li-Cor, Inc.) and images analyzed using Odyssey software v. 1.2. For 
protein detection, samples from young and aged Ntg and Tg mice were run on 
the same gel. After protein transfer, the gel was stained with Coomassie for use 
in quantification to account for any loading differences. 
 
Statistics All results are expressed as mean ± SEM. All two-group comparisons 
were assessed by two-tailed t-test. All multi-group comparisons were assessed 
using two way analysis of variance (ANOVA) with Tukey post-hoc test. Survival 









cTnIA164H transgene expression increases in aged murine hearts. 
 
Consistent with recent findings246, six month old mice (line 892) showed high 
levels of stoichiometric replacement of endogenous cTnI with cTnI A164H (78.6 ± 
3.5 %) (Figure 3-1b). Aging of generation F2-F3 transgenic mice to 2 years 
revealed a significant increase in cTnI A164H replacement relative to native cTnI 
(94.6 ± 3.1%; P < 0.05, Tg 6 mo vs. 24 mo expression) as determined by 
Western blotting (Figure 3-1b).  
 
cTnI A164H improves global cardiac function during aging  
 
Analysis of systolic and diastolic cardiac function at four months, one year, and 
two years of age was assessed by serial echocardiography. Comparison of 
nontransgenic (Ntg) and transgenic (Tg) mice revealed significant differences in 
contractility and chamber geometry at all ages (Figure 3-2a,b). Compared to Ntg 
mice, Tg mice had significantly higher contractility as measured by the velocity of 
circumferential fiber shortening (Vcfc) (Figure 3-2b). Ejection fraction correlated 
with the Vcfc during this time course further validating the increased inotropy of 




Figure 3-2. Age-dependent changes in baseline cardiac function by 
echocardiography and Millar catheterization. (a) Representative m-mode 
echocardiographic images along the parasternal short axis view showing 
changes in contractility of Ntg and Tg mice between four months and two years 
(scale bar = 0.1 sec). White bars delineate systole and diastole. (b) Summarized 
mean data showing age related differences in cardiac function as assessed by 
echocardiography including velocity of circumferential fiber shortening corrected 
for heart rate (Vcfc), volume at diastole (Vol d), and the ratio of the Mitral E wave 
to lateral annular E wave (E/Ela) showing changes in cardiac function in Ntg (■) 
and Tg (□) mice at four months (Ntg, n=26; Tg, n=32), one year (Ntg, n=12; Tg, 
n=13), and two years (Ntg, n=13; Tg, n=15). Values are expressed as mean ± 
SEM. 2 way ANOVA main effects: age (‡) and genotype (†): Vcfc, Vol d, E/Ela, P 
< 0.05. ANOVA interaction effects between genotype and age (§): E/Ela, * P < 
0.05 for Ntg vs. Tg at 2 yrs of age. (c) Summarized mean data showing age 
related differences in hemodynamic function including the ejection fraction (EF), 
time constant for relaxation (tau g), and heart rate of Ntg (■) and Tg (□) mice at 
four months (n=12-14) and 2 years (n=3-4) of age. Values are expressed as 
mean ± SEM. * P < 0.05 for Ntg vs Tg at 24 mo. ANOVA main effects: genotype 




volume (Vol d) compared to Ntg mice at all ages (Figure 3-2b). Although the 
aging process had similar effects on both cohorts resulting in an age-dependent 
deterioration of cardiac function and geometry, cTnI A164H Tg mice had 
sustained improvements in contractility and reduced LV cavitary dilation 
compared to Ntg mice. These conclusions were supported by ANOVA main 
effects for genotype and age with measurements of contractility (Vcfc), and 
cardiac geometry (Vol d) (P < 0.05).  
Diastolic function was also assessed by conventional Doppler of the mitral 
valve early (Ea) and late (Aa) waves as well as Doppler tissue imaging (DTI) of 
the early (Ela) and late (Ala) tissue velocities of the lateral annulus. Although no 
differences in diastolic function were observed at four months, age related 
decrements in diastolic function were observed in Ntg mice that were significantly 
attenuated in Tg mice at two years. While the lateral annular E wave (Ela), as 
measured by DTI, tended to be greater for Tg versus Ntg mice, the difference did 
not reach statistical significance (Table 1b). However, the ratio of the mitral valve 
E wave to the lateral annular E wave (E/Ela) was significantly lower in Tg mice 
compared to Ntg mice at two years of age (Ntg vs. Tg: 51.0 ± 3.8 vs. 37.8 ± 4.1; 
P < 0.05) (Figure 3-2b). Taken together, the progression of diastolic dysfunction 
that accompanies the aging process, as observed in Ntg mice, was reduced by 
cTnI A164H resulting in an attenuation of diastolic dysfunction in aged transgenic 
mice. These conclusions were supported by ANOVA main effects for genotype 










Table 3-1. Baseline Cardiac Function of Aged Mice For conductance 
micromanometry measurements n = 3-4/group. For echocardiography 
measurements n = 13-15/group. All values are from animals aged to two years. 
Echocardiography parameters: Doppler tissue imaging of the early (Ela) and 
late (Ala) tissue velocities of the  lateral annulus;  conventional Doppler imaging 
of the mitral valve early (MV E) and late (MV A) filling velocities; Ejection 
Fraction (EF). All values are expressed as mean ± s.e.m.  * P < 0.05 for Ntg vs. 





Cardiac pressure-volume analysis was assessed by implantation of a 
Millar catheter into the left ventricle for acquisition of real-time conductance 
micromanometry measurements. Continuous monitoring of cardiac function 
revealed significant differences in age dependent baseline hemodynamics 
between Ntg and Tg mice. At four months of age, measurements of systolic 
function were consistent with echocardiographic findings in that Tg mice showed 
trends toward increases in the positive derivative of pressure development (data 
not shown) and a trend toward improved ejection fraction compared to Ntg mice 
(Figure 3-2c). In terms of diastolic function, conductance micromanometry 
measurements were inconclusive based on the rate constant for isovolumic 
relaxation (Tau) which showed either an increase (Tau Glanz (Figure 3-2c)) or no 
change (Tau Weiss (Table 3-1)) during the aging process. A significant decrease 
in heart rate was also observed in two year old Tg mice compared to their Ntg 
littermates (Figure 3-2c).  
Analysis of heart weight to body weight ratio revealed significant age 
dependent changes (Table 3-2). At four months of age Tg mice had significantly 
lower body weights and heart weights compared to Ntg mice (4 month HW/BW 
ratio: 4.6 ± 0.1 vs. 4.0 ± 0.1; Ntg vs. Tg. P < 0.05). However, at two years 
HW/BW ratio was similar between Tg and Ntg mice (2 year HW/BW ratio: 5.6 ± 














Table 3-2. Heart and body weight analysis. All values are       






cTnI A164H aged mice retain cardiac hemodynamics during hypoxia  
 
 Previous studies have shown that young cTnI A164H Tg mice sustain 
cardiac function during an acute hypoxic challenge and consequently survive 
significantly longer than Ntg mice246. Similarly, to assess the physiologic and 
therapeutic role of cTnI A164H in the aged murine heart, mice were exposed to 
conditions of controlled hypoxia (12% O2) during Millar catheterization and 
assessed for global cardiac function and survival (Figures 3-3 and 3-4). After four 
minutes of hypoxia, raw traces of LV pressure (LVP), the derivatives of LV 
pressure development (dP/dt), and volume, together with their corresponding 
pressure-volume loops revealed that aged Ntg mice have significantly 
compromised cardiac hemodynamics compared to aged Tg mice (Figure 3-3a,b). 
Mean hemodynamic data taken at four minutes into the acute hypoxic challenge 
and the delta change from baseline (Table 3-1a) to hypoxia showed improved 
systolic and diastolic performance of Tg mice compared to Ntg mice (Figure 3-
3c). Specifically, compared to their Ntg littermates, LV performance was 
maintained during hypoxia in Tg mice as represented by higher stroke work 
(SW), end systolic pressure (ESP), and the positive derivative of pressure 
development (dP/dt max) (Figure 3-3c). Compared to baseline values, aged Tg 
mice showed improved contractility during hypoxia compared to a significant 
decrease in contractile function in aged Ntg mice based on measurements of 
stroke work (Δ SW), and the positive derivative of pressure development (Δ dP/dt 




Figure 3-3. In vivo hemodynamic differences between aged Ntg and Tg mice 
during an acute hypoxic challenge. (a) Two second raw data sweeps derived 
by conductance micromanometry of left ventricular pressure (LVP), LV 
pressure derivatives (dP/dt), and LV volume of two year old Ntg and Tg mice 
during an acute hypoxic challenge (12% O2). (b) Representative pressure-
volume loops in vivo of Ntg (dark gray) and Tg (black) mice during hypoxia. 
(c) Mean data showing hemodynamic function as well as the delta change 
from baseline values for cardiac output (CO), stroke volume (SV), stroke work 
(SW), end systolic pressure (ESp), and positive pressure derivatives (dP/dt 
max) derived by Millar catheterization of two year old Ntg (■;n=3) and Tg 
(□;n=3) mice. * P < 0.05. Values are expressed as mean ± SEM. Ntg, 
nontransgenic; Tg, transgenic. 
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was also maintained during an acute hypoxic challenge in transgenic mice (data 
not shown). Finally, compared to Ntg littermates, Tg mice were able to sustain 
global cardiac function during hypoxia as shown by a higher stroke volume (SV) 
and cardiac output (Δ CO), (Figure 3-3c). These data show improved cardiac 
function in response to hypoxia in Tg mice compared to their Ntg littermates 
(Figure 3-4a). Consistent with improved hemodynamic function, aged Tg mice 
survived significantly longer during an acute hypoxic challenge than Ntg mice 
(11.6 ± 1.3 vs. 3.7 ± 1.9 min, P < 0.05) (Figure 3-4b). 
 
Calcium cycling is different between Ntg and Tg mice 
 
Functional analysis of calcium handling in acutely isolated cardiac myocytes 
showed that under conditions of 1 Hz pacing, young Tg mice had a reduced 
calcium transient amplitude compared to young Ntg myocytes (Figure 3-5a and 
c), consistent with previous reports246. Furthermore, experiments were performed 
to measure SR calcium load by means of acute addition of 20 mM caffeine 
(Figure 3-5b and c). Similar to baseline calcium transients, these data show that 
SR calcium load was lower in Tg versus Ntg mice (Figure 3-5a, b, and c). This 
supports the hypothesis that increased myofilament calcium sensitivity reduces 
calcium requirements in the cell and may contribute to the protection of Tg hearts 
during aging as well as cardiomyopathic challenges such as 






Figure 3-4. In vivo hemodynamic function and survival of aged mice during an 
acute hypoxic challenge. (a) Averaged LV hemodynamic function including end 
systolic pressure (ESp), stroke volume (SV), cardiac output (CO), stroke work 
(SW), and the positive derivative of pressure development (dP/dt max) during 
the time course of an acute hypoxic challenge for Ntg (●; n=3) and Tg (○; n=3) 
mice. (b) Summarized mean survival data and survival curve showing time to 
systolic heart failure for two year old Ntg (■ and — ; n=3) and Tg (□ and – –; 











Figure 3-5. Analysis of calcium homeostasis in young mice. (a) Raw traces of 
calcium transients from FURA 2AM loaded isolated myocytes during pacing 
with 1Hz (left and middle) as well as raw calcium transient traces normalized 
to the peak amplitude (right). (b) Raw calcium transients after acute addition 
of 20 mM caffeine to release sarcoplasmic reticulum calcium. (c) Summarized 
data from calcium handling experiments (n= 20-24 myocytes per group). 
Values are expressed as mean ± SEM. * P < 0.05 for Ntg vs. Tg. Ntg, 





Calcium handling protein expression and phosphorylation levels  
 
Western blot analysis was performed to assess changes in calcium handling 
proteins between young (2-4 months) and aged (24 months) Ntg and Tg mice 
(Figure 3-6a and b). Alterations in the expression of proteins specifically involved 
in the regulation of calcium homeostasis have been established as one of the 
factors that contribute to the development of age-related cardiac dysfunction 137, 
278, 279, 427-430. These data show that calsequestrin (CSQ), the sodium calcium 
exchanger (NCX), and phospholamban (PLN) were not altered during aging by 
Two-way ANOVA. By contrast, SERCA2a was reduced in both Ntg and Tg aged 
mice based on a significant ANOVA main effect for age (P < 0.05), a finding that 
is consistent with previous reports in aging heart 200, 278. Furthermore, these data 
show that the SERCA2a/PLN ratio was not different between Ntg and Tg mice 
during the aging process (Figure 3-6b). Although the SERCA2a levels are 
elevated in Tg hearts by Western blot (based on an ANOVA main effect for 
genotype), in vitro calcium handling measurements indicate a reduced level of 
SR calcium load in Tg hearts (Figure 3-5).  
In addition, young and aged Ntg and Tg hearts were assessed for 
changes in protein phosphorylation (Figure 3-6a and b). These data showing 
serine 16 phosphorylation of phospholamban indicate that aged mice have a 
higher baseline level of phosphorylated PLN compared to young mice based on 
a significant ANOVA main effect for age. Cardiac troponin I serine 23/24 






Figure 3-6. Changes in protein 
expression and 
phosphorylation in Ntg and Tg 
mice. (a) Western blots of 
calcium handling proteins 
including the sarco-
endoplasmic reticulum ATPase 
(SERCA2a), phospholamban 
(PLN), the sodium calcium 
exchanger (NCX), serine 16 
phosphorylation of 
phospholamban (pPLN), and 
tandem serine 23/24 
phosphorylation of troponin I 
(pTnI) for young and aged Ntg 
and Tg mice. Coomassie was 
used to normalize for protein 
loading (W: Western, C: 
Coomassie). (b) Mean 
summary data for differences 
in the expression of calcium 
handling proteins including 
CSQ, NCX, PLN, SERCA2a, 
the SERCA2a/PLN ratio, 
pPLN, and pTnI. 2 way 
ANOVA main effects (P < 
0.05): age (‡), SERCA2a, and 
p-PLN; and genotype (†), PLN, 












 This study focused on the physiological impact of histidine-modified 
cardiac TnI (cTnI A164H) in aged mice. These data provide the first evidence 
that molecular manipulation of myofilament calcium sensitivity can preserve heart 
function during aging. Specifically, this study showed that age-related 
decrements in baseline cardiac systolic function were significantly attenuated in 
Tg mice compared Ntg littermates. Echocardiography studies also demonstrated 
that age-dependent diastolic dysfunction (elevated E/Ela) was attenuated in Tg 
animals. Importantly, when exposed to an acute hypoxic challenge in vivo, aged 
Tg mice maintained cardiac performance that significantly extended their survival 
compared to Ntg mice. These data support the hypothesis that myofilament-
based enhanced function by single histidine-modified cTnI provides a mechanism 
for attenuating age-related decrements in cardiac function.  
 Increasing calcium sensitivity of the myofilament consequent to alterations 
in the biochemistry of cardiac troponin I (cTnI) has been well studied9, 33, 246, 249, 
252, 431. A recent report of the crystal structure of cTnI places Ala164 at the critical 
switch domain that is key in regulating myofilament calcium activation52. Codon 
164 is situated at the interface between the amphiphilic switch region, H3, and 
the C-terminal actin binding domain, H4. Together these regions are defined as 
the regulatory segment. In the calcium saturated state, the entire regulatory 
segment of cTnI (residues 137-210) undergoes a conformational change 
concomitant with binding of the H3 domain to the conserved N-terminal 
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hydrophobic patch of TnC. In the slow skeletal isoform of TnI (ssTnI), which is 
the fetal/neonatal isoform in mammals, a unique biochemical characteristic of the 
switch region was found to confer pH-dependent increases in calcium sensitivity 
to the myofilament266, 319. In initial studies, mutagenesis experiments identified a 
critical histidine at position 132 as responsible for this pH dependent functional 
outcome246, 250. The physiological effects of this mutation in the heart directly 
reflect the unique biochemical properties of histidine’s imidazole moiety which, 
unique among all the amino acids, ionizes within the physiological range (pKR = 
6.0). Numerous studies have shown that under conditions of acidosis, ssTnI 
protects contractility of myocytes in vitro and the whole heart in vivo133, 250, 318. In 
light of these findings, we sought to introduce this pH sensitivity into the switch 
domain of cTnI. An engineered histidine modification in codon 164 of cTnI 
(A164H) takes advantage of this critical functional property of ssTnI transposed 
into the context of cTnI. This modification takes place without altering important 
physiological functions of cTnI in regulating global cardiac inotropic and lusitropic 
responses to β-adrenergic signaling246. Cardiac TnI A164H provides a titratable 
molecular switch mechanism regulating myofilament tension development in 
response to biochemical changes in the adult myocyte. One of the central 
hypotheses of this study was that increasing myofilament calcium sensitivity by 
means of cTnI A164H is a powerful molecular therapy for attenuating morbidity 




Declining cardiac function contributes to waning health in geriatric 
populations423. In many cases these age-related changes are secondary to 
coronary artery disease424. Of particular salience to this study is the propensity 
for chronic ischemia associated with vascular stenosis that prevent sufficient 
coronary blood flow, a condition typically associated with poor cardiovascular 
health of the elderly422. A portion of this study was based on an experimental 
protocol to impose a controlled state of hypoxia in aged mice through low inhaled 
oxygen. In the clinical setting, hypoxia is usually secondary to cardio-pulmonary 
pathologies frequently seen in geriatric populations. Physiologically these 
conditions are usually due to hypoventilation, vascular shunting, 
ventilation/perfusion mismatch and interstitial diffusion defects.  Clinical diseases 
of the lungs, such as COPD, pneumonia, interstitial lung disease, or pulmonary 
embolic disease are common conditions associated with hypoxia which may lead 
to secondary ischemic cardiac injury. The aged heart is particularly at risk in 
these settings because of intrinsic muscle disease and underlying coronary 
artery disease with areas of marginally perfused myocardium. These clinically 
relevant etiologies, known risk factors for cardiovascular disease, provide 
contextual relevance for the key findings of this study. These important results 
include, first, that aged cTnI A164H Tg mice have enhanced cardiac function and 
extended survival capacity during an acute hypoxic challenge compared to Ntg 
mice.  
Irrespective of etiology, systolic and diastolic dysfunction are strong 
predictors of heart failure in geriatric populations432. In this study we show that 
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cTnI A164H Tg mice have improved contractility during the aging process 
compared to Ntg mice. At four months of age, significantly larger hearts of Ntg 
mice could explain, at least in part, the corresponding decreases in contractility 
measurements compared to Tg mice. The equalization of the HW/BW ratio at two 
years of age, however, neutralizes any heart size-dependent variables that 
influence contractility measurements between groups at this time point. This 
lends credence to the conclusion that Tg mice, which retained the same relative 
increase in contractility over Ntg mice during the aging process, actually 
underwent an age-dependent and heart size-independent increase in absolute 
contractility. This could be explained in part by the increase in stoichiometric 
incorporation of cTnI A164H in old versus young Tg mice and could provide 
mechanistic basis for the observed increase in contractility at two years of age. 
Additionally, compared to Tg mice, increased LV cavitary dilation in aged Ntg 
mice may also, at least in part, contribute to the divergence of contractile 
efficiency at the two year time point. A shift toward higher sarcomere lengths, 
which occurs with dilated cardiomyopathies and may be a component of age-
related dysfunction, could reduce the efficiency of contractility based on the 
Frank-Starling principle. 
In addition to systolic dysfunction, decrements in diastolic function are also 
characteristic of the aging process. LV dilation together with stiffening of the aged 
myocardium prevents sufficient relaxation of the heart during the filling phase of 
the cardiac cycle. Unexpectedly, another key finding of this study is that cTnI 
A164H protects diastolic function during the aging process. These data indicate 
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that Ntg mice show evidence of diastolic dysfunction based on a decrease in the 
velocity of the lateral annulus during the early filling phase (Ela) of the LV as well 
as an increase in the mitral valve E wave flow velocity to lateral annular E wave 
ratio (E/Ela). This latter parameter (E/Ela) shows the ratio of the inflow velocity to 
the tissue velocity providing insight into the elastic properties of the ventricle. In 
essence, the E wave velocity controls for cardiac output, heart rate, and filling so 
that the ratio (E/Ela) correlates with left atrial pressure. Here, the E/Ela shows 
evidence of the transgene altering the typical progression of diastolic dysfunction 
based on a significant interaction effect (P < 0.05). These data indicate that cTnI 
A164H transgenic mice are able to retain improved diastolic function during the 
aging process compared to Ntg mice which experience predictable age-related 
diastolic dysfunction.  
The relationship between cTnI A164H and diastolic performance, 
however, is complex as indicated by differences in echocardiographic and 
micromanometry data at baseline. Conflicting data based on measures of 
isovolumic relaxation (Tau) provide inconclusive evidence regarding baseline 
diastolic function in Tg mice, which is consistent with previous findings246. 
However, the mechanical component of relaxation during the late (filling) phase 
of diastole, as measured non-invasively by Doppler tissue imaging indicates that 
Ntg mice have compromised viscoelastic properties of the ventricle resulting in a 
decline in diastolic function during the aging process which is significantly 
attenuated in Tg mice.   
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Taking this whole organ functional analysis into consideration, it has been 
established that, at the sub-cellular level, changes in the expression of calcium 
handling proteins contribute to the progression of pump dysfunction during 
aging188. Our study supports these findings specifically in regard to the 
observation that SERCA2a levels are diminished at 2 years of age in Ntg and Tg 
mice. Reduced expression of SERCA2a has been implicated directly in the 
progression of age-induced cardiomyopathy278 and provides a sub-cellular basis, 
at least in part, for the whole organ diastolic dysfunction observed in this study 
during aging. The lack of any genotypic differences in CSQ and NCX and the 
SERCA2a to PLN stoichiometry during aging suggests an alternative mechanism 
for improvement of cardiac function in the Tg mice during the aging process. We 
propose that this mechanism is predominantly the result of increasing inotropy by 
molecular manipulation of myofilament calcium sensitivity by means of cTnI 
A164H. 
The results of this study show that Tg hearts have reduced SR calcium 
loading. Previous reports have found that aged hearts are more susceptible to 
calcium overload than young hearts421, 433, 434. This suggests that a reduced SR 
Ca2+ load may benefit cTnI A164H hearts in aging, similar to our recent report in 
the context of myocardial injury such as ischemia/reperfusion15. We hypothesize 
that the lower SR Ca2+ load and Ca2+ transient are made possible by 
myofilament activation enhancement by cTnIA164H. We propose that there is an 
interplay between the myofilament enhancement and SR functionality that could 
account for higher SERCA2a levels in Tg hearts.  
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The cardiac functional readout of these findings at the sub-cellular level 
are seen in the whole organ serial echocardiographic analysis of Ntg and Tg 
mice during the two year aging process. The decline in cardiac contractility (e.g. 
EF), increase in LV chamber geometry, and development of diastolic dysfunction 
(e.g. increased E/Ela) particularly evident at the two year time point are likely the 
consequence, at least in part, of the changes observed in calcium handling 
proteins.  
In conclusion, ischemia-related cardiac dysfunction in aged populations 
remains a significant cause of morbidity and mortality. Therapies for ischemic 
heart disease and heart failure could be directed specifically toward improving 
the Ca2+ sensitivity of the myofilament. The consequent improvement in 
contractility that results from an increase in Ca2+ sensitivity may appear to 
counter the logic of commonly prescribed therapeutics, which calls for the use of 
beta blockers that decrease contractility acutely, allowing for reduced oxygen 
consumption and energy expenditure. Although there is proven value in the 
diverse effects of beta blockers, we have shown that targeted alteration of 
myofilament calcium sensitivity to increase contractile performance is an effective 
mechanism for treatment of ischemic heart disease and heart failure in small 
mammals246. This is in concurrence with Mann and Bristow’s view that 
augmentation of myofilament responsiveness to calcium would improve the force 
generating capacity of the sarcomere and thus redress global cardiac 
dysfunction4357. In summary, this study together with previous work246, 
strengthens the hypothesis that altering the functionality of troponin I is an 
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effective means of specifically augmenting myofilament calcium sensitivity and 
consequently enhancing cardiac contractility. Adding to the growing evidence for 
the therapeutic role of histidine-modified TnI in the heart, this study provides the 
first evidence that specific replacement of native cTnI with cTnI A164H in the 
adult heart protects cardiac function during aging. We propose that the 
progression of pathologic and age-related diminutions in cardiac function may be 
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Single histidine button in cardiac troponin I sustains heart performance in 




Intracellular acidosis is a profound negative regulator of myocardial 
performance. We hypothesized that titrating myofilament calcium sensitivity by a 
single histidine substituted cardiac troponin I (A164H) would protect the whole 
animal physiological response to acidosis in vivo. Methods/Results: To 
experimentally induce severe hypercapnic acidosis, mice were exposed to a 40% 
CO2 challenge. By echocardiography it was found that systolic function and 
ventricular geometry were maintained in cTnI A164H transgenic mice (Tg). By 
contrast, non-Tg littermates (Ntg) experienced rapid and marked cardiac 
decompensation during this same challenge. For detailed hemodymanic 
assessment, Millar pressure-conductance catheterization was performed while 







acidosis challenge. Survival and load independent measures of contractility were 
significantly greater in Tg vs. Ntg mice. This assay showed that Ntg mice had 
100% mortality within five minutes of acidosis. By contrast, baseline systolic and 
diastolic function were protected in Tg mice during acidosis and they had 100% 
survival. Conclusion: This study shows that, independent of any beta adrenergic 
compensation, myofilament-based molecular manipulation of inotropy by 
histidine-modified troponin I maintains cardiac inotropic and lusitropic 




Acute heart failure can result from myocardial acidosis.   Myocardial 
acidosis arises from reduced plasma oxygen tension (hypoxic acidosis) as in 
cases of myocardial ischemia230, 236, or accumulated levels of plasma carbon 
dioxide  (hypercapnic acidosis or hypercarbia) found with severe pulmonary 
diseases such as chronic obstructive pulmonary disease (COPD)235, or 
emphysema436. Acidosis has numerous pathophysiological implications within the 
context of many organ systems, including significant deleterious effects on the 
contractile function of the heart237-239, 241, 242. Homeostasis is tightly regulated in 
the heart, which makes this organ particularly sensitive to whole animal 
metabolic changes and the downstream influence on pH status and energy 
availability 429, 437.  
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There are numerous changes that occur in the heart under conditions of 
acidosis, including altered calcium handling240, 241, 427, 429, 431, 438.  The present 
study focused on altered sarcomeric protein function known to significantly 
reduce cardiac contractility during acute acidosis independent of altered Ca2+ 
handling238, 439, 440. A key regulator of myofibrillar contraction is the troponin 
complex, including the calcium binding subunit, troponin C (TnC), and the 
inhibitory subunit troponin I (TnI). Calcium increases the TnI-TnC interaction 
causing these subunits to act as a dynamic switch within the myofilament during 
systole and diastole.  Acidosis diminishes myofilament Ca2+ sensitivity due in part 
to reduced Ca2+ binding to troponin C238, 441, and impaired interactions between 
TnI and TnC during systole.  Thus,  this complex serves as a key regulator of 
beat-to-beat contractility in the heart33. In the whole heart this reduction in 
myofilament Ca2+ sensitivity is a key contributor to the reduction in acute 
myofilament force production and a consequent decrement in left ventricular 
developed pressure in vivo9, 246. 
Earlier biochemical studies established that neonatal myocardium is more 
resilient to low pH239, a phenotype correlated with fetal expression of the slow 
skeletal isoform of TnI. The ssTnI isoform is able to retain proper myofibrillar 
contractility even in cases of severe acidosis133, 251, 266, 314, 317-319, 324. Specifically, 
the pCa (-log[Ca2+]) required for 50% activation of myofilaments in adult cardiac 
myocytes, that express the adult isoform of TnI (cTnI), drops by more than 1 pCa 
units during acidification of pH (from pH 7.0 to 6.2). This is compared to adult 
myocytes transduced with an adenoviral construct expressing the slow skeletal 
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isoform of TnI (ssTnI), that show an attenuated pCa shift during acidification of 
pH (from pH 7.0 to 6.2)133. TnI isoform chimera structure-function studies266, 314, 
315, 319 have gone on to further demonstrate that the unique biochemistry of ssTnI 
could be reproduced by substituting a single histidine residue in ssTnI for 
alanine164 in cTnI, which is located at the interface between TnC and actin 
binding domains involved in the switch function of TnI249, 250. In recent work, this 
histidine button substitution has been engineered into the adult cardiac isoform of 
TnI (cTnI A164H) providing a biophysical basis for a functional molecular 
rheostat of intracellular pH in the adult heart242, 246. Cellular data has shown that 
myocytes expressing cTnI A164H have intact responses to isoproterinol and PKA 
by hastening relaxation kinetics and shifting the tension-pCa relationship246. 
Furthermore, calcium load is diminished in these myocytes which is manifest in a 
lower calcium transient amplitude246, 290. Studies of transgenic mice expressing 
this engineered mutant cTnI show improved cardiac inotropic function in 
response to a variety of pathophysiologic challenges, including acute and chronic 
ischemia246 as well as in a mouse model of age-induced cardiomyopathy290.  
The current study focused exclusively on the in vivo whole animal 
response to acidosis in the context of this modified cTnI using an experimental 
model of severe respiratory hypercapnia. A major aim of this study was to block 
adrenergic support in the heart and subsequently analyze cardiac function in vivo 
under baseline conditions and during exposure to acidosis. Adrenergic 
stimulation is a major regulator of cardiac function at baseline in the rodent246, 318. 
Furthermore, high sympathetic stimulation of rodent hearts at baseline has been 
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shown to compensate and mask cardiomyopathic phenotypes that are revealed 
during suppression of catecholamine signaling442. In light of this, beta blockade in 
mouse models consisting of myofilament modifications246, 333 213 is of particular 
importance for determining any functional aberrations caused by altered 
myofilament calcium responsiveness on systolic and diastolic performance.  
Furthermore, beta blockade allows for the functional readout of intrinsic inotropic 
performance of the heart in vivo which is important in determining the potential 
for cardiac contractile responsiveness to injury. These questions have not been 
addressed in the cTnI A164H Tg mouse to date.  The new findings of this study 
show that cTnI A164H preserves baseline systolic and diastolic performance 
during acidosis in vivo. This study suggests that the biochemical function of cTnI 
A164H as a molecular rheostat in the sarcomere may protect cardiac 
performance in a range of pathologies associated with acidosis.  
 
Materials and Methods 
 
Mouse Model  Generation and analysis of transgenic mice expressing a 
histidine-modified cardiac troponin I (cTnI A164H) with FLAG epitope was 
previously described246. The procedures used in this study are in agreement with 
the guidelines of the University of Michigan and approved by the University of 
Michigan Committee on the Use and Care of Animals. Veterinary care was 
provided by the University of Michigan Unit for Laboratory Animal Medicine. The 
University of Michigan is accredited by the American Association of Accreditation 
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of Laboratory Animal Health Care, and the animal care use program conforms to 
the standards of the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (NIH Pub. No. 85-23).  
 
Conductance Micromanometry  Measurements of in vivo cardiovascular 
hemodynamics were obtained using conductance micromanometry as previously 
performed by this laboratory246.  Mice were anesthetized and ventilated via a 
tracheal cannulation and ventilated via a pressure controlled ventilator with 1% 
isoflurane at a peak inspiratory pressure of 15 cm H2O and a respiratory rate of 
60 breaths/min. With aid of a dissecting microscope, the heart was exposed via a 
thoracotomy. A 1.0 French Millar pressure-volume catheter (PVR-1045; Millar 
Instruments Inc., Houston, Texas, USA) was then placed into the left ventricular 
chamber via an apical stab.  LV pressure and volume measurements were 
collected at a sampling rate of 1 kHz.  Data were analyzed with Ponemah 
software, P3 Plus (DSI International, St. Paul, MN, USA). Transient inferior vena 
cava (IVC) occlusions were also performed to obtain the end systolic and end 
diastolic pressure-volume relationships. IVC occlusions were performed at 
baseline and at five minutes of esmolol infusion (Figure 4-3a). After obtaining 
baseline hemodynamics (ventilated with isoflurane and O2), mice received a 
continuous infusion of esmolol (250 ug/kg/min) that continued until the 
completion of the assay. After five minutes of esmolol infusion mice were 
exposed to an acute hypercapnic acidosis challenge (40% CO2 balanced with 
oxygen) (for schematic diagram of protocol see Figure 4-3a). Data were acquired 
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until systolic failure which was defined as the point when peak LV systolic 
pressure dropped to 50 mmHg. At this point, esmolol infusion was stopped and 
mice were recovered using 100% O2 in order to obtain instrument calibration.   
 
Echocardiography Anesthesia was induced with 3% isoflurane and then 
maintained at 1% for the duration of the procedure. The hair was removed from 
the upper abdominal and thoracic area with depilatory cream.  ECG was 
monitored via non-invasive resting ECG electrodes. Transthoracic 
echocardiography was performed in the supine or left lateral position. Two-
dimensional, M-mode, Doppler and tissue Doppler echocardiographic images 
were recorded using a VisualSonics’ Vevo 770 high resolution in vivo micro-
imaging system (VisualSonics Inc., Toronto, Ontario, Canada). The systolic and 
diastolic dimensions and wall thickness were measured in M-mode in the 
parasternal short axis view at the level of the papillary muscles443, 444. Fractional 
shortening and ejection fraction were calculated from the M-mode parasternal 
short axis view444. Diastolic function was assessed by conventional pulsed-wave 
spectral Doppler analysis of mitral valve inflow patterns (early [E] and late [A] 
filling waves). Doppler tissue imaging (DTI) was used to measure the early (Ea) 
and late (Aa) diastolic tissue velocities of the lateral annulus. As a combined 
measure of systolic and diastolic function, the TEI index was measured as 
(LVctetrt-LVet)/LVet where LVctetrt is the total time of LV contraction, ejection 
plus relaxation and LVet is LV ejection time. After acquiring baseline 
echocardiographic data mice were exposed to a hypercapnic acidosis challenge 
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(ventilation with 40% CO2 balanced with oxygen) for ten minutes. During 
ventilation with CO2 efforts were taken to confirm that the nose and mouth were 
within the nose cone to prevent any dilution of the inhaled gas due to gasping of 
room air. Data were acquired every 2.5 minutes for the duration of the challenge. 
All mice survived this challenge and were returned to their cage for recovery. 
 
In vivo Arterial Pressure and ECG Telemetry Implantable radio-telemetry 
probes (C-10 implants, DSI International, St. Paul, MN, USA) for measurement of 
real time systemic blood pressure and ECG in freely moving unanesthetized 
animals was accomplished as described previously445-447. One week after 
implantation of telemetry probe, mice were placed in a flow-through chamber 
initially flushed with room air (20.93% O2) allowing rodents time to equilibrate to 
the new environment. They were then exposed to a hypercapnic acidosis 
challenge (forty minutes exposure to 40% CO2 balanced with oxygen). Upon 
completion of the challenge, mice were removed from the chamber and returned 
to their cage for recovery. 
 
Blood Gas Analysis Mice were anesthetized with 1% isofluorane and exposed 
to a hypercapnic acidosis challenge (40% CO2 balanced with oxygen) for ten 
minutes without external ventilator support. During ventilation with CO2 efforts 
were taken to confirm that the nose and mouth were within the nose cone to 
prevent any dilution of the inhaled gas due to gasping of room air. At the end of 
the challenge the thoracic cavity was opened to expose the heart. Approximately 
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600 uL of oxygenated blood was drawn from the left ventricle and immediately 
analyzed using a Radiometer ABL505 blood gas analyzer (Radiometer, 
Westlake, Ohio, USA).  
 
Statistics All results are expressed as mean ± SEM. All single variable assays 
were assessed by two-tailed t-test. All multivariable assays were assessed using 
either one way analysis of variance (ANOVA) or two way repeated measures 
ANOVA with Tukey post-hoc test. Survival after the in vivo acute hypercapnic 





Echocardiography assessment during acute respiratory hypercapnic acidosis  
 
Using echocardiography to track in vivo LV function, Tg mice retained 
global cardiac performance and proper LV dimensions during exposure to 
acidosis.  By contrast, Ntg mice showed significant myocardial contractile 
dysfunction throughout the same challenge (e.g. EF(%) at ten minutes of 
acidosis [Tg] 68.1 ± 4.7 vs. [Ntg] 23.6 ± 4.9) (Figure 4-1). In addition to the 




Figure 4-1. Cardiac function assessed by echocardiography at baseline and 
during acidosis. (a, left) Representative m-mode echocardiographic images 
along the parasternal short axis view showing changes in contractility of 
nontransgenic and transgenic mice at baseline and after ten minutes of 
exposure to 40% CO2. White bars delineate systole and diastole. Time bar = 
100 ms, distance bar = 2 mm. (a, right) Representative conventional pulsed-
wave spectral Doppler analysis of mitral valve inflow and aortic valve outflow 
patterns at baseline and after ten minutes of exposure to 40% CO2  in 
nontransgenic and transgenic mice. Time bar = 100 ms, flow rate bar = 40 
cm/s. (b) Summarized mean data showing changes in cardiac functional 
parameters including ejection fraction, LV dimensions at systole and diastole, 
and stroke volume between Ntg (●) and Tg (○) mice during the time course of 
hypercapnic acidosis. (c) Mean data showing the difference in ejection 
fraction, LV dimensions at systole, and stroke volume after 10 minutes 
exposure to 40% CO2 (top) as well as the change (Δ) in function from baseline 
(bottom) in Ntg (■) and Tg (□) mice. Values are expressed as mean ± SEM. 2 
way repeated measures ANOVA main effects: time (‡) and genotype (†) P < 
0.05. 2 way repeated measures ANOVA interaction effects between time and 
genotype (§) P < 0.05. * P < 0.05 for Ntg vs. Tg. Ntg, nontransgenic (n=5); Tg, 






Table 4-1. Changes in Cardiac Function During Acidosis. Analysis of cardiac 
function during acidosis in Tg and Ntg mice showing changes between baseline, 
the nadir (worst value for a given parameter), and end of the challenge. 
Echocardiographic parameters: ejection fraction (EF), volume at systole (Vol s), 
TEI index, and inflow velocity of the Mitral valve E wave (MV E). Hemodynamic  
parameters: contractility index (CI), LV maximum volume (Max Vol), end diastolic 
pressure (EDp), and arterial elastance (Ea). Statistical analysis of points taken at 
baseline, the nadir, and end of the challenge were compared using a repeated 
measures 1 way analysis of variance: # P < 0.05 for baseline vs. nadir,  † P < 
0.05 for the nadir vs. end of the challenge, ‡  P < 0.05 for baseline vs. end of the 
challenge. Nadir to the end of the challenge (compared to a hypothetical zero), * 
P < 0.05 using a Dunnets one-sample t-test with Wilcoxon signed-rank post hoc. 
All values are expressed as mean ± s.e.m.  Echocardiography, Tg n = 7 and Ntg 
n = 5; Hemodynamics, Tg n = 7 and Ntg n = 6.   
190 
 
function at the end of the challenge compared to measurements taken at the 
beginning and at the nadir for each parameter. We found that the function of Tg 
hearts at the end of the challenge was not significantly different from baseline 
based on a repeated measures one way ANOVA.  In contrast, the lowest point of 
function for Ntg mice was at the end of the challenge in all cases or the nadir to 
the end of the challenge was not significant from zero based on a Dunnet’s test.  
In addition to being mildly hypercontractile at baseline, cumulative echo 
data show that measurements of contractility observed in Tg mice, such as 
ejection fraction (EF) and stroke volume (SV), all showed evidence of a modest 
decrease during the early stages of the acidosis challenge which reverted by the 
ten minute time point.  At the end of the challenge aspects of Tg heart 
performance were not significantly different than baseline  (e.g. Tg EF (%) at 
baseline 75.1 ± 4.7 vs. 68.1 ± 5.7 after 10 minutes of acidosis (NS)) (Figure 4-1b 
and c). By contrast Ntg mice showed a significant reduction in cardiac 
contractility throughout the challenge (e.g. EF at ten minutes of acidosis: [Ntg] 
23.6 ± 4.9% vs. [Tg] 67.8 ± 4.5%) (Figure 4-1b and c, Appendix: Figure 4-7). 
Furthermore, Tg mice retained ventricular geometry during the hypercapnic 
acidosis challenge compared to Ntg mice that underwent significant left 
ventricular cavitary dilation (e.g. LV dimensions at systole at ten minutes of 
acidosis: [Ntg] 17.3 ± 1.2 mm vs. [Tg] 9.3 ± 1.3 mm) (Figure 4-1b and c). As a 
measure of diastolic function, the mitral valve inflow velocity (MV E), measured 
by Doppler, recovered to baseline function after the nadir in Tg mice compared to 
Ntg mice in which compromised diastolic function persisted throughout the 
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acidosis challenge (MV E change from nadir to end in Tg mice: 262.5 ± 81.7 
mm/s) (Table 4-1). Lastly, as an assessment of overall diastolic and systolic 
function, the TEI index indicated that Tg mice underwent an initial phase of 
cardiac decompensation during the onset of acidosis but were able to recover 
function by the end of the challenge compared to Ntg mice that showed 
persistent cardiac dysfunction throughout the hypercapnic acidosis challenge 
(TEI index at ten minutes of acidosis: [Ntg] 0.61 ± 0.05 vs. [Tg] 0.5 ± 0.03) 
(Appendix: Figure 4-7). All mice recovered from this hypercapnic acidosis 
challenge. 
 
Blood gas analysis during acidosis 
 
To assess whether there were any differences in blood gas parameters during 
the acidosis challenge, arterial blood gases were analyzed during hypercapnic 
acidosis. These data indicate that, although significantly different from baseline 
values, blood gases taken at 10 minutes of exposure to 40% CO2 were not 
different between Tg and Ntg mice (Table 4-2). In both Tg and Ntg mice, blood 
pH decreased from 7.2 at baseline to below 6.63 during the hypercapnic 
challenge demonstrating the development of significant acidemia. This is 
consistent with changes in pCO2 which increased from baseline values at 55 to 
60 mmHg to greater than 250 mmHg during acidosis in both Tg and Ntg animals. 
This increase in carbon dioxide was also confirmed in measures of total plasma 








Table 4-2. Arterial blood gas analysis. Ntg measurements, *P < 0.05 based on t-
test comparing baseline vs. CO2 values. For Tg measurements statistics were 
performed using one way ANOVA where # P < 0.05 for baseline vs. CO2 (10 
min);  † P < 0.05 for CO2 (10 min) vs. CO2 (20 min); and .‡  P < 0.05 for CO2 (20 
min) vs. baseline. All values are expressed as mean ± s.e.m. Abbreviations: 
partial pressure of carbon dioxide (pCO2), partial pressure of oxygen (pO2), 
fraction of oxyhemoglobin in deoxy-plus oxyhemoglobin of blood (plasma oxygen 
saturation: sO2),  bicarbonate (HCO3-), total plasma carbon dioxide of whole 
blood (tCO2), and concentration of titratable base (standardized base excess: 
SBEc). Ntg Baseline n= 5, Tg Baseline n= 5, Ntg CO2 (10 min) n=5, Tg CO2 (10 










oxygen availability during acidosis was increased from room air values (60% 
compared to approximately 21%, respectively) oxygen saturation tended to 
decrease from baseline values of 102 % to below 88% during hypercapnia, 
although this trend did not reach statistical significance for either group. Lastly, 
plasma concentrations of titratable base (SBEc) were significantly reduced (P < 
0.05) during hypercapnia compared to baseline values, which is consistent with 
acidemia. There were no significant changes in plasma bicarbonate during 
ventilation with 40% CO2 indicating that these mice were not experiencing 
metabolic acidosis.   
 Blood gas analysis was also performed on Tg mice after twenty minutes of 
exposure to 40% CO2. Changes in pH indicate that the blood continued to acidify 
to a degree significantly lower than the pH reached after ten minutes of 
hypercapnic acidosis (serum pH [10 min] 6.62 ± 0.02 vs. [20 min] 6.55 ± 0.00). 
Furthermore, SBEc continued to decrease concomitant with the decrease in 
blood pH. These findings are consistent with the development of an increasingly 
severe respiratory hypercapnic acidemia. However, even at twenty minutes 
exposure to 40% CO2, plasma bicarbonate remained steady indicating the 
absence of any metabolic acidosis.     
 
Blood pressure and ECG telemetry in vivo during hypercapnic acidosis challenge 
 
In vivo continuous arterial pressure telemetry of freely moving unanesthetized 
animals was carried out between Ntg and Tg mice. Furthermore, this study 
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analyzed the extent to which cTnI A164H mice were able to maintain systemic 
perfusion pressures during a prolonged hypercapnic acidosis challenge (40 
minutes exposure to 40% CO2) compared to Ntg littermates (Figure 4-2). At 
baseline, circadian rhythms showing changes in blood pressure over 24 hours 
indicate that Ntg mice have increased systolic blood pressure compared to Tg 
mice (P < 0.05). However, diastolic arterial pressure was not different between 
groups. Furthermore, these telemetered data show that Ntg mice also have a 
higher baseline heart rate than Tg mice (HR [Tg] 472.2 ± 15.6 vs. [Ntg] 555.4 ± 
18.7, P < 0.05) (Figure 4-2a and b).  
After one week of baseline blood pressure measurements, mice were 
exposed to a forty minute hypercapnic acidosis challenge. The change in arterial 
systolic pressure between baseline (avg. daytime systolic pressure) and the 
initial exposure to high flow 40% CO2 indicated that both Ntg and Tg mice had a 
significant increase in blood pressure in response to this challenge (Figure 4-2c 
and d). This can be attributed as an indirect measure of whole animal adrenergic 
stimulation during this challenge in both groups. Furthermore, these data indicate 
that cTnI A164H mice had significantly higher systemic systolic and diastolic 
arterial pressures during the acidosis challenge compared to Ntg littermates (e.g. 
delta MAP [Ntg] -81.5 ± 18.4  vs. [Tg] -37.7 ±  6.3 mmHg) (Figure 4-2c, e, and f).  
To determine if Tg mice were able to maintain proper sinus rhythm during 
acidosis we performed continuous telemetered electrocardiographic 
measurements during a 40 minute hypercapnic acidosis challenge. These data 










Figure 4-2. Radio-telemetry based blood pressure recordings in vivo. (a) 
Representative raw arterial pressure and heart rate traces recording baseline 
circadian rhythms from Ntg and Tg mice over the course of five days. (b) Mean 
systolic arterial pressure (left), diastolic arterial pressure (middle) and heart rate 
(right) during a given 24 hours of baseline analysis for Ntg (■) and Tg (□) mice. 
(c) Representative raw pressure traces during forty minutes of exposure to 40% 
CO2 for Ntg and Tg mice. (d) The average change in systolic arterial blood 
pressure at baseline (■) and at the onset of acidosis (□) illustrating the stress 
response in both Ntg and Tg mice. (e) Mean data for systolic and diastolic 
arterial pressure measurements between nontransgenic (●) and transgenic (○) 
mice during the time course of hypercapnic acidosis. (f) The change in mean 
arterial pressure (MAP) from baseline to the completion of the hypercapnic 
acidosis challenge for Ntg (■) and Tg (□) mice. Values are expressed as mean ± 
SEM. 2 way repeated measures ANOVA main effects: time (‡) and genotype (†) 
P < 0.05. 2 way repeated measures ANOVA interaction effects between time 
and genotype (§) P < 0.05. * P < 0.05 for Ntg vs. Tg. Ntg, nontransgenic (n=4); 













associated with sinus pause or sinus dysfunction throughout the time course of 
hypercapnic acidosis (Appendix: Figure 4-8). Overall, there was no difference in 
the frequency or duration of this episodic sinus dysfunction between Ntg and Tg 
mice during acidosis (Appendix Figure 4-8b and c). Furthermore, core body 
temperature and heart rate decreased similarly between Ntg and Ttg mice during 
prolonged acidosis (Appendix: Figure 4-8d, e). All mice recovered from this forty 
minute hypercapnic acidosis challenge. 
 
Assessment of cardiac function during β-blockade  
 
To directly assess cardiac hemodymanics, mice were surgically 
instrumented by implantation of a conductance micromanometry catheter into the 
LV. After stabilization of cardiac function, baseline measurements were acquired 
followed by an infusion of esmolol (250 ug/kg/min) to suppress adrenergic 
involvement in the cardiac response to acidosis. Inferior vena cava occlusions 
(IVCO) were performed just prior to the start and after five minutes of esmolol 
infusion to acquire load independent measures of contractility. These data show 
that during the initial five minutes of esmolol infusion Ntg and Tg mice 
experienced a slowing of the heart rate, left ventricular cavitary dilation (e.g. 
increased LV max volume), a slight diminution in measures of contractility (e.g. 
systolic pressure, + dP/dt, contractility index, ejection fraction, and stroke work) 
and evidence of marked slowing in diastolic function (increased LVEDP and Tau) 







Figure 4-3. Raw data traces of real-time conductance micromanometry during 
hypercapnic acidosis. (a) Representative raw pressure-volume loops 
(pressure bar = 60 mmHg, volume bar = 20 uL) of a Ntg (gray) and Tg (black) 
mouse during the time course of an esmolol plus hypercapnic acidosis 
challenge (dotted line used as reference point for minimum volume at 
baseline, * indicates time of death for Ntg mouse). (b) Representative raw 
traces of pressure (bar = 60 mmHg), volume (bar = 30 uL), and pressure 
derivatives (bar = 10,000 mmHg/sec) for Ntg and Tg mice at baseline, during 
infusion of esmolol (5 minutes), at 8 minutes into the acidosis challenge, and 
at the end of the assay (25 minutes) illustrating changes in cardiac contractility 




significantly better in cTnIA164H Tg than Ntg mice after five minutes of esmolol 
infusion based on higher ejection fraction, stroke work, and +dP/dt (e.g. +dP/dt, 
[Ntg] 4603.7 ± 612 vs. [Tg] 7094.1 ± 545 mmHg/sec, P < 0.05) (Figure 4-5a). 
Intrinsic inotropic function measured from the slope of the end systolic pressure-
volume relationship (ESPVR; end systolic pressure: end systolic volume) and 
preload recruitable stroke work (PRSW; stroke work: end diastolic volume) 
assessed load independent measures of contractility (acquired by PV loop 
analysis during IVCO) (Figure 4-5b). This analysis showed a higher pre-load-
independent inotropic capacity in Tg mice compared to Ntg mice at baseline and 
during esmolol infusion. The negative derivative of pressure development (-dP/dt, 
data not shown), end diastolic pressure (EDp), and tau were not different 
between Ntg and Tg mice during esmolol infusion, indicating comparable 
diastolic function between these groups (Figure 4-4a). 
  
Cardiac function and survival during hypercapnic acidosis with β-blockade   
 
We next tested the hypothesis that catecholaminergic stimulation played a 
significant role in the survival capacity of mice during the acute hypercapnic 
acidosis challenge.  To address this, cardiac function was assessed during acute 
acidosis without β-adrenergic responsiveness. Mice were instrumented with a 
conductance micromanometry catheter and infused with esmolol for five minutes 











Figure 4-4.  Summary of real-time in vivo hemodynamic data.  (a) Summarized 
mean data showing changes in cardiac functional and geometric parameters 
including systolic pressure, end diastolic pressure, the positive derivative of 
pressure development (+dP/dt), contractility index, ejection fraction, max volume, 
tau, heart rate, and stroke work between Ntg (●) and Tg (○) mice during the time 
course of esmolol infusion and acute hypercapnic acidosis. (b) Representative 
raw data (derived from 5 sec. averages) of ESp, EF, maximum volume, and tau 
during 20 minutes of esmolol plus acidosis showing transgene enhancement 
(light gray) of cTnI A164H. Values are expressed as mean ± SEM. Ntg, 





















Figure 4-5.   Hemodynamic analysis of inotropic function during esmolol 
and acidosis. (a) Mean data extracted at baseline, at five minutes after 
esmolol infusion, at 8 minutes into the acidosis challenge, and at the end 
of the protocol (25 minutes) showing a significant difference between Ntg 
(■) and Tg (□) mice based on contractile properties including systolic 
pressure, +dP/dt, ejection fraction, and contractile index. (b) Load 
independent measures of contractility acquired by inferior vena cava 
occlusions (ICVO) including end systolic pressure volume relationship 
(ESPVR) and preload recruitable stroke work (PRSW) showing the 
difference between Ntg (■) and Tg (□) mice at baseline and during 
infusion of esmolol. Inset boxes show representative slopes for Ntg and 
Tg mice. Values are expressed as mean ± SEM. 2 way repeated 
measures ANOVA main effects: time (‡) and genotype (†) P < 0.05. 2 
way repeated measures ANOVA interaction effects between time and 
genotype (§) P < 0.05.  * P < 0.05 for Ntg vs. Tg. Ntg, nontransgenic 




esmolol infusion continuing to the completion of the challenge.  By pressure-
volume analysis, at the onset of respiratory hypercapnic acidosis Ntg mice 
underwent precipitous cardiac decompensation within the first five minutes of 
acidosis (Figures 4-3a and b). In terms of inotropic function, this decline in 
cardiac performance was characterized by a sudden decrease in systolic 
pressure, ejection fraction, contractility index, and stroke work (Figure 4-4 and 
Figure 4-5a). Furthermore, diastolic dysfunction emerged during the onset of 
acidosis (increased LVEDP and tau) together with further dilation of LV chamber 
geometry (Figure 4-4).  
In marked contrast, Tg mice, showed sustained cardiac function during 
this respiratory hypercapnic acidosis challenge even in the absence of β-
adrenergic support (Figure 4-3a and b). These data represent a transgene 
enhancement effect on the part cTnI A164H mice which contributes to their 
survival capacity compared to Ntg mice (Figure 4-4b). More specifically, Tg mice 
actually increased their developed pressure, made evident by an immediate 
increase in end systolic pressure and, more modestly, the positive derivative of 
pressure development (+dP/dt) and stroke work (Figure 4-4a,b and Figure 4-5a). 
This was sustained until the latter phases of acidosis when LV ESp decreased to 
slightly below baseline values together with a drop in the +dP/dt and stroke work 
(Figure 4-4a, b and Figure 4-5a).  
Other hemodynamic parameters of cardiac function for Tg mice in this 
group showed an initial decrease during the onset of acidosis followed 
unexpectedly by a recovery toward baseline values during the latter stages of 
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acidosis (Figure 4-4, and Table 4-1). Similar to the echo data, Table 4-1 shows 
the restoration in function at the end of the challenge compared to 
measurements taken at the beginning and at the nadir for parameters derived by 
hemodynamic analysis. These measurements reveal that function at the end of 
the challenge was not significantly different than baseline in Tg mice. During the 
onset of acidosis, measures of contractility decreased initially but returned toward 
baseline during the latter phases of acidosis (e.g. from the nadir contractility 
index increased by 21.1 ± 26.5 U) (Figure 4-4a, Figure 4-5a, and Table 4-1). The 
contractility index (CI) is defined as the positive pressure derivative (+dP/dt) 
normalized to the ventricular pressure at that point. Taking this into 
consideration, this change in CI is understood as the maintenance of the positive 
pressure derivative despite decreases in the ESp during acidosis suggestive of 
an overall increase in contractility during this challenge. Diastolic function also 
increased initially but returned to baseline values by the end of the challenge 
(e.g. from the nadir LVEDp decreased in Tg mice 4.4 ± 0.8 mmHg) (Figure 4-4 
and Table 4-1). Similarly, ventricular dilation occurred at the onset of acidosis 
followed by a restoration of the ventricular chamber geometry during the latter 
phases of hypercapnia (e.g. max volume decreased from the nadir in Tg mice 3.8 
± 1.2 uL) (Figure 4-4a and Table 4-1). In all cases, the absolute change between 
the nadir and the end of the challenge for parameters given in Table 1 were 
different from zero based on a Dunnet’s analysis showing a recovery of 
hemodynamic function during acidosis in Tg mice. However, in stark contrast to 









Figure 4-6. Survival data during respiratory hypercapnic acidosis. (a) 
Representative raw data (derived from 5 sec. averages) for ESp over the full 
time course of the experimental protocol including esmolol infusion followed 
by CO2 ventilation for Ntg and Tg mice. (b) Survival curve showing the time 
of death for Ntg mice which occurred after the onset of ventilation with 40% 
CO2 compared to the 100% survival of Tg mice after 25 minutes of exposure 




mice was at the time of death (Table 4-1). When assessed for survival, cTnI 
A164H mice show a significant transgene-mediated enhancement of cardiac 
function while Ntg mice develop severe cardiac dysfunction and death in 
response to hypercapnic acidosis induced with β-adrenergic blockade. The 100% 
survival of Tg mice compared to 100% mortality in Ntg mice within 5 min of the 
onset of CO2 is a striking indicator of the improved inotropy caused by this amino 




Cardiomyopathies associated with myocardial acidosis can result in 
profound systolic and diastolic dysfunction. Understanding mechanisms 
associated with protecting cardiac pump performance during acidosis are 
important in developing therapies. This study reveals whole animal responses in 
transgenic mice expressing a single histidine modified cardiac TnI during acute 
respiratory hypercapnic acidosis. During hypercapnia cTnI A164H mice had a 
significantly greater capacity for maintaining cardiac geometry and function 
during acidosis compared to Ntg. Furthermore, in the absence of 
catecholaminergic support, Tg mice showed markedly improved survival versus 
Ntg mice.  This outcome resulted from the ability of Tg mice to maintain 
significantly higher intrinsic cardiac function without compromising diastolic 
performance compared to Ntg mice. Among studies seeking to preserve pump 
function in disease 246, 301, 318, results from the present study show a unique 
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response of improved systolic and diastolic performance during acidosis in vivo. 
Overall, the results of this study illustrate that molecular manipulation of 
myofilament performance by means of a histidine button engineered into the 
switch region of cTnI results in significant protection of cardiac geometry and 
function, and improved survival in the context of severe respiratory hypercapnic 
acidosis in vivo. 
 
Myofilament calcium sensitivity and acidosis 
 
Elevated plasma CO2 occurs in numerous pathophysiological contexts 
such as severe COPD448, conditions of hypercarbic respiratory failure449, 
respiratory infections450, or congenital central hypoventilation syndrome451. A 
fundamental consequence of even modest decreases in pH results in the 
uncoupling of excitation-contraction (E-C) events which are necessary for the 
tight regulation of beat to beat pump activity in the heart134, 237. At the sub-cellular 
level E-C uncoupling is made evident by an acidosis-induced reduction in force 
generating capacity by the sarcomere for any given [Ca2+]i. Acidosis decreases 
both maximal Ca2+-activated tension and the Ca2+ sensitivity of tension 236, 246, 249-
252. Acidosis also decreases myocyte maximal sarcomere length shortening 
amplitude and shortening velocity246, 253, 254. These experiments illustrate that 
myofilament Ca2+ desensitization at low pH is a fundamental molecular 
deficiency responsible for cardiac organ pathologies associated with myocardial 
acidosis242.  Importantly, results from this study demonstrate that cTnI A164H 
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works effectively to prevent this Ca2+ desensitization and provides a survival 
benefit to respiratory acidosis in an intact animal model.   
 
Adrenergic blockade and cTnI A164H performance 
 
  Sympathetic stimulation increases cardiac inotropy and lusitropy. It has 
been shown that rodent hearts are under high β-adrenergic tone under baseline 
conditions246, 318.  This may mask cardiomyopathies associated with alterations in 
myofilament calcium handling442. Consequently, we addressed the role played by 
β-adrenergic signaling using a beta blocker, esmolol, during hemodynamic 
analysis to determine the intrinsic systolic and diastolic properties of the cTnI 
A164H heart. Importantly, we found load-independent measures of contractility 
were significantly higher in Tg versus Ntg mice under β-blockade, suggesting a 
higher intrinsic capacity for contractile function at baseline on the part of cTnI 
A164H Tg mice. Importantly, hemodynamic measurements obtained in this study 
demonstrate the first evidence that cTnI A164H mice can maintain cardiac 
function during acidosis in vivo. 
Although enhanced systolic function is expected with this model, diastolic 
function (e.g Tau, EDp) can be problematic for Tg mouse models expressing 
altered myofilament proteins. For example, calcium sensitizing models show 
diastolic dysfunction such as cTnI R193H333, cTnT R92Q371, and ssTnI mice in 
vivo 213. Importantly, this study shows that, in the absence of sympathetic activity, 
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baseline diastolic function of cTnI A164H Tg mice is not different from the Ntg 
cohort.  
 
cTnI A164H: a titratable myofilament inotrope 
 
 Multiple investigators have proposed that targeting myofilament calcium 
responsiveness via manipulation of TnC and TnI interactions is desirable for 
protecting cardiac function during acidosis246, 249, 297, 301, 318, 435, 452. However, 
previous approaches have found that enhancement of systolic function often 
concomitantly results in diastolic dysfunction, as discussed above. For example, 
Tg mice expressing ssTnI show improved cardiac function during acidosis318. 
However, they also show significant diastolic dysfunction during this challenge213, 
318, and more generally, these hearts lack the ability to modulate TnI function via 
PKA activation by β-adrenergic signaling. Pharmacologic alterations of the 
myofilament using TnC Ca2+ sensitizers such as levosimendan also improve 
inotropy289, 299-301 but have significant non-TnC actions. In contrast, the present 
study now shows that cTnIA164H is capable of improving myofilament function in 
response to acidosis, without concomitant diastolic dysfunction, alterations in β-
adrenergic signaling, or non-specific effects on myocyte function.   
 The underlying biochemistry of a histidine button engineered into TnI 
provides insights into potential mechanisms supporting this concept. Specifically, 
histidine ionizes near physiological pH with a pKR around 6.0. Consequently, 
under mildly acidic conditions the increasing propensity for the ionization of 
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histidine changes the biochemical function of surrounding residues and any 
interactions mediated by this region of the protein. In cardiac troponin I, this 
histidine substitution (A164H) is positioned in the regulatory domain between the 
amphiphilic switch region (helix 3) and the C-terminal actin binding domain (helix 
4). Previous studies have shown that this region is critically involved in the 
interaction between TnI and TnC during systole through the electrostatic binding 
of the switch region of TnI with the calcium saturated N-terminal hydrophobic 
patch of TnC52, 96-98, 327. Although further studies are required to address the 
specific biophysical consequences of these potential interactions, the 
physiological implications of this histidine modification have been studied by this 
and other studies246 showing that cTnI A164H acts as a molecular rheostat 
maintaining systolic and diastolic pump function in models of severe acidosis and 
ischemic cardiomyopathy in vitro and in vivo.  
This study contributes new evidence showing a potential therapeutic role 
of cTnI A164H in the heart. Specifically, evidence from these experiments 
demonstrate a marked transgene enhancement effect that confers protection 
from acidosis-induced pump failure and death in living animals. We hypothesize 
that this response is mediated foremost by the underlying biochemistry of the 
histidine modified cTnI acting as a molecular rheostat of the intracellular milieu.  
This study contributes to the growing evidence that histidine-modified troponin I 
is an effective target protein for the protection of cardiac performance during 
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Figure 4-7. Mean data showing cardiac function by echocardiography at baseline 
and during hypercapnia. Summarized mean data showing changes in cardiac 
functional parameters including fractional shortening, cardiac output, LV ejection 
time, and TEI Index between Ntg (●) and Tg (○) mice during the time course of 
hypercapnic acidosis. Values are expressed as mean ± SEM. 2 way repeated 
measures ANOVA main effects: time (‡) and genotype (†) P < 0.05. 2 way 
repeated measures ANOVA interaction effects between time and genotype (§) P 





Figure 4-8. Continuous in vivo radio-telemetry ECG measurements during a 
prolonged hypercapnic acidosis challenge. (a) Representative raw ECG tracings 
extracted during the final five minutes of the acidosis challenge showing 
arrhythmias in both Ntg and Tg mice. (b) Representative graphs showing the R-R 
interval as a measure of time during the forty minute acidosis challenge for Ntg 
and Tg mice. (c) Distribution and average R-R interval (left) and number of R-R 
intervals greater than 0.3 sec (right) during the acidosis challenge for Ntg (■) and 
Tg (□) mice. (d and e) The change in body temperature (d) and heart rate (e) 
during the time course of hypercapnic acidosis. Values are expressed as mean ± 














pH responsive titratable inotropic performance of histidine-modified cardiac 




 Cardiac troponin I (cTnI) functions as the molecular switch of the thin 
filament. At the level of the sarcomere, cTnI regulates inotropic capacity during 
systole by engaging with the calcium saturated N-terminal lobe of cTnC and thus 
permitting actomyosin cross bridge formation. Acidosis significantly attenuates 
contractility causing severe cardiomyopathy at the whole organ level. However, 
studies have shown that a histidine button engineered into cTnI therapeutically 
protects ionotropic function in the context of numerous pathophysiological 
challenges. This study provides a molecular mechanism for this observation. 
Methods The role of ionization was analyzed by studying myofilament calcium 
sensitivity and sarcomere shortening kinetics of arginine substituted cTnI 
(A164R), a biochemical correlate to the protonated histidine. Atomic resolution 
molecular dynamics (MD) simulations of WT cTnI as well as cTnI A164H in 
different ionization states were also performed. Results Under physiological 
conditions, cTnI H164 is deprotonated (pKa = 6.14) and behaves functionally and 
structurally similar to WT cTnI. Newly observed intermolecular electrostatic 
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interactions (cTnI R163: cTnCE19/D25) as well as hydrophobic side chain 
contacts are involved in regulating cTnI function at baseline. Under acidic 
conditions, cTnI A164H has similar function compared to the constitutively 
protonated cTnI A164R variant. Consistent with this, MD simulations indicate that 
a single proton added to the imidazole side chain of cTnI H164 results in a 
translocation of cTnI H4 toward cTnC resulting in added intermolecular 
electrostatic (cTnI R163: cTnC D25 and cTnI H164: cTnC E19) and hydrophobic 
side chain interactions (cTnI L170: cTnC A22). Conclusion These data indicate 
that differential histidine ionization is required for cTnI A164H to act as a 
molecular rheostat capable of therapeutically modulating sarcomere performance 




 Cardiac contraction and relaxation occur through the rhythmic interactions 
of the thin and thick filaments of the sarcomere. The key allosteric regulatory 
complex that mediates the transition between the systolic and diastolic phases of 
the cardiac cycle is troponin. Troponin is a heterotrimeric protein complex 
comprised of three subunits. These include the tropomyosin binding subunit, 
troponin T (TnT), the calcium binding subunit, troponin C (TnC), and the 
actomyosin ATPase inhibitory subunit, troponin I (TnI)49, 50.  As originally 
proposed by Herzberg and colleagues63, 153, calcium binding fundamentally 
changes the structure of TnC from the apo “closed” conformation, its 
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thermodynamic nadir, to the calcium saturated “open” conformation. With the 
change in the structure and biochemistry of the calcium-bound N-terminal region 
of TnC, the switch arm of TnI develops an affinity for TnC measured as an 
increase of two orders of magnitude158. This increased affinity causes a 
translocation of the entire regulatory arm of TnI and binds with TnC by multiple 
van der Waals contacts52, 161. During diastole, calcium is re-sequestered into the 
sarcoplasmic reticulum causing its dissociation from the TnC EF hand. TnI 
subsequently releases TnC and binds actin both at the inhibitory region (IR) and 
the C-terminal region. This initiates diastole by inhibition of actin-myosin cross 
bridge formation. With this important role in differentially toggling between actin 
and TnC and thus regulating cross-bridge cycling events, TnI has come to be 
known as the molecular switch of the myofilament9. 
Studies using acutely isolated adult rat myocytes have shown that 
myofilament sensitivity to activating calcium is markedly diminished during 
acidosis133. These reports show that the pCa (-log[Ca2+]) required for 50% 
activation of myofilaments in acutely isolated adult cardiac myocytes drops 
during acidification of pH (from pH 7.0 to 6.2)133. Decreases in myocyte maximal 
sarcomere length shortening amplitude and shortening velocity are also found to 
occur during acidosis246, 253, 254. These experiments illustrate that myofilament 
Ca2+ desensitization at low pH is a fundamental molecular maladaptation 
responsible for myocyte and cardiac organ pathologies associated with 
myocardial acidosis242.  
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Importantly, numerous studies have shown that a unique histidine moiety 
in the regulatory arm of TnI (ssTnI H132 and cTnI A164H) acts as a pH-
dependent titratable inotrope capable of ameliorating contractile deficiencies 
caused by acidosis in vitro133, 246 and in vivo203, 246, 290. These reports show that a 
histidine button in cardiac TnI functions as a molecular rheostat with no 
significant contractile effects at baseline but marked enhancement of inotropic 
performance under various pathophysiological stresses including acute and 
chronic myocardial ischemia and acidosis203, 246, 290.  
The switch mechanism of histidine buttons play a critical role in mediating 
key functions in numerous molecules by altering intramolecular and 
intermolecular structures and interactions. This property has been well studied in 
hemoglobin, for example, where H146β appears to mediate the Bohr affect by 
altering its pH dependent intramolecular interaction with D94β303, 326. Numerous 
other histidine buttons have been identified in molecules including HLA-DR 
molecules306, GABA ρ1 receptors364, the pacemaker channel HCN2 (H321)309, 
the acid sensitive potassium channel TASK-3 (H98)310, the inward rectifying 
potassium channel HIR (H117)308, and the G-protein-coupled inward rectifying 
potassium channel (GIRK1/GIRK4)( H64, H228, and H352)307.  
The chemical nature of histidine and its pH responsive binary ionization 
states make it unique among all of the amino acids as capable of mediating the 
so-called “switch function” of these pH responsive buttons. The differential 
ionization of histidine within the physiologic range is principally due to its unique 
imidazole side chain which has a pKa around 6.0. The non-protonated histidine is 
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hydrophobic and aromatic in character whereas the protonated histidine is 
hydrophilic and positively charged.  
The implications of histidine ionization on cardiac troponin I structure and 
function have not been investigated. Numerous strategies involving site directed 
protein mutagenesis have been employed in previous studies analyzing the 
molecular mechanism of histidine buttons in other molecules303, 306, 308, 310, 326. 
Here, we studied the functional implications of arginine (cTnI A164R) as a 
biochemical mimic of the protonated histidine compared to contractile dynamics 
of WT cTnI (A164) and cTnI A164H.  Atomic resolution in silico molecular 
dynamics (MD) simulations were also used to analyze the implications of the 
ionization state of histidine’s imidazole side chain on structural engagement with 
cTnC in the calcium saturated state. This study provides evidence that structural 
changes caused by differential imidizole side chain ionization are a necessary 
and sufficient molecular basis for titratable inotropic performance of histidine-




TnI mutagenesis and viral vector construction. We used a pDC315 vector 
containing cTnI and the QuikChange mutagenesis kit (Stratagene) to generate 
site directed mutagenesis. As previously described246, the primers used for 
mutagenesis of cTnI to cTnIA164H FLAG removed an Xma1 site and were 5’- 
ggcactactggggacccggcacaaggaatccttggacctg-3’ (sense) and 5’-
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caggtccaaggattccttgtgccgggtccccagtagtgcc-3’ (antisense). Mutagenesis of cTnI 
A164R FLAG and cTnI A164Y FLAG were generated from the cTnI A164H FLAG 
cDNA. Primers used for mutagenesis from cTnI A164H FLAG to cTnI A164R 
FLAG were 5’- GCACTACTGGGGACCCGGCGCAAGGAATCCTTGG-3’ (sense) 
and 5’- CCAAGGATTCCTTGCGCCGGGTCCCCAGTAGTGC -3’ (antisense). 
Primers used to mutagenesis from cTnI A164H FLAG to cTnI A164Y FLAG were 
5’-GCACTACTGGGGACCCGGTACAAGGAATCCTTGG-3’ (sense) and 5-
CCAAGGATTCCTTGTACCGGGTCCCCAGTAGTGC-3’ (antisense).  In all 
cases, primers were extended using Pfu DNA polymerase and methylated 
parental DNA was subsequently digested with Dpn I. DNA was transformed into 
competent bacterial cells. Mutated DNA with appropriate restriction enzyme sites 
was sequenced prior to ligation of mutant cTnI cDNA into Ad5 viral shuttle 
vectors. All DNA sequences were verified by overlapping sequence runs. The 
cTnI FLAG vector was produced and used as previously described453 and used 
here as control for viral transduction and the FLAG epitope. Recombinant vectors 
were produced and purified as described previously454. The cTnI A164Y mutant 
did not provide any additive insight into the current data set and so results are 
not shown.  
 
Ventricular myocyte isolation, gene transfer, and primary culture Rat 
ventricular myocytes isolation was performed as previously described24, 290, 333. 
Briefly, rats were anaesthetized by inhalation of isoflurane followed by i.p. 
injection of heparin (1500 U/kg) and Nembutal (162.5 U/kg). Following enzymatic 
220 
 
digestion by retro-grade perfusion with collagenase and hyaluronidase and 
gentle mincing of the cardiac ventricles, cardiac myocytes were plated on 
laminin-coated glass coverslips (2x104 myocytes/coverslip) and cultured in M199 
media (Sigma, supplemented with 10 mmol/L glutathione, 26.2 mmol/L sodium 
bicarbonate, 0.02% bovine serum albumin, and 50 U/ml penicillin-streptomycin, 
with pH adjusted to 7.4, as described previously426). Recombinant adenovirus 
was applied to the cells immediately after plating as previously described24. Cells 
were subsequently cultured for four days to provide sufficient time for 
stoichiometric replacement of troponin I proteins delivered by adenoviral gene 
transfer (Figure 2).  
 
Immunoblot detection Myocytes were removed from cover slips using Laemmli 
sample buffer. Proteins were separated by SDS-PAGE and transferred to a 
nitrocellulose membrane for immunodetection. After blocking in 5% milk (in Tris-
buffered saline), membranes were probed with a pan troponin I antibody 
(MAB1691, Chemicon). Indirect immunodetection was carried out using a 
fluorescently labeled secondary antibody (Rockland, IRDye 680 conjugated 
affinity purified; 1:5000). Western blot analysis was accomplished using the 
infrared imaging system, Odyssey (Li-Cor, Inc.) and images analyzed using 
Odyssey software v. 1.2.  
 
Indirect expression and incorporation by immunofluorescence and 
confocal microscopy Dual labeling immunofluorescence was performed as 
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previously described9. Briefly, cultured cardiac myocytes were fixed in 3% 
paraformaldehyde/PBS and blocked in 20% normal goat serum (NGS). Myocytes 
were incubated in the first primary antibody directed against the Flag epitope 
(M2, 1:500, Sigma) and detected with an Alexa 488-conjugated secondary 
antibody directed against mouse IgG (1:100, Molecular Probes). Myocytes were 
incubated in the second primary antibody directed against α-actinin (EA53, 
1:500, Sigma) and detected with Texas Red-conjugated secondary antibody 
directed against mouse IgG. All antibodies were diluted in 2% NGS + 0.5%Triton 
X-100/PBS. Immunofluorescence was visualized on a Zeiss Axioskop LSM 510 
laser scanning confocal microscope. 
 
Contractility measurements in single myocytes Sarcomere length shortening 
and relaxation kinetics were performed as previously described24, 290. Briefly, 
cover slips containing single isolated myocytes were placed on an inverted 
microscope (Nikon, Eclipse TE2000) and stimulated at 0.2 Hz. The chamber’s 
temperature was maintained at 37°C. Myocyte images were collected (240Hz) 
using a CCD camera (MyoCam, IonOptix). Myocytes that did not follow the 
pacing protocol (0.2Hz) were excluded, as were myocytes with a resting 
sarcomere length less than 1.70 μm. Sarcomere length shortening and relaxation 
kineitics were calculated using IonOptix software. Myocytes were initially 
analyzed under baseline conditions in M199 (pH 7.4). To understand the 
changes in myocyte performance during exposure to acidosis, myocytes were 
subsequently incubated with acidic M199 (pH 6.2). Since control (non-
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transduced) and cTnIFLAG transduced myocytes had no functional difference in 
sarcomere contractile kinetics the data were combined into the control dataset. 
The summary data for myocyte kinetics are outlined in Supplemental Table 1.  
 
Skinned myocyte tension pCa measurements Single rod-shaped cardiac 
myocytes were attached to micropipettes coated in silicone adhesive and 
permeabilized in 0.2% Triton X-100 for one minute. All measurements were 
made at 15°C in relaxation (RS) or activating solutions (AS). Both RS and AS 
contained 1mM/L free Mg2+, 4 mM/L MgATP, 14.5 mM/L creatine phosphate, 20 
mM/L imidazole, and KCL to yield an ionic strength of 180 mM/L. Solution pH 
was adjusted to 7.00 (or 6.20 for acidic pH experiments) with KOH/HCl. The pCa 
(-log[Ca2+]) of the RS was 9.0 and the pCa of maximal AS was 4.0. Sarcomere 
length was set to 2.1 um and the isometric tension-pCa relation was constructed 
by measuring the calcium activated isometric tension at basal (pCa=9.0), 
maximal (pCa=4.0), and various submaximal calcium levels as previously 
described246. Every third contraction was taken at maximal activating calcium 
concentrations in order to normalize tension values. A non-linear least squares 
fitting algorithm was used to determine Hill coefficient (n) and pCa50, the calcium 
concentration at which 50% of maximal tension was produced. Since control 
(non-transduced) and cTnIFLAG genetically engineered myocytes had no 
functional difference in steady state isometric tension-Ca2+ relationship the data 
were combined into the control dataset. The summary data for myocyte tension 




Molecular Dynamics Simulation Molecular Dynamics (MD) simulations were 
performed for the solved X-ray structures of the cardiac troponin complex 
(PDB:1J1E ) using NAMD 353 version 2.6 with CHARMM27 forcefield 354. The cTn 
regulatory complex between cTnC and cTnI was isolated by exclusion of all other 
residues in the crystal structure except cTnI R148 – L173 and cTnC M1 – K90. 
Residue mutagenesis was performed to substitute cTnI alanine 164 for histidine 
(cTnI A164H). This histidine was analyzed in the deprotonated state with the 
hydrogen atom present (cTnI A164H protonated) or removed (cTnI A164H 
deprotonated) at position NE2 of the imidazole side chain. All the X-ray 
structures were prepared by CHARMM version c35b1. Each of the complex was 
solvated with explicit TIP3P water model 355 using a simulation solvent box with a 
15 Å buffer region around the protein. Sodium counter ions were placed at 5 Å 
from the box boundary to neutralize the system. The solvated system was 
initialized with 5000 steps of conjugate gradient energy minimization with protein 
heavy atoms restrained at 50kcal/(mol•Å2). The system was then gradually 
heated with the same restraint from 25K to 300K at 25 K increment at 10 ps 
interval for 100 ps followed by a 100 ps equilibration with gradual removal of the 
heavy atoms restraint at 10 ps interval under NVT condition. The final 
unrestrained equilibration was carried out for 100 ps followed by 20 ns of 
production simulation at 1 atm and 300K NPT condition. All simulations were 
carried with periodic boundary condition using Particle Mesh Ewald (PME) 356 
with SHAKE 357 method employed to constrain bond lengths involving hydrogen 
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atoms. The time step in the simulations was 2 fs with coordinates saved at 1-ps 
time intervals, resulting in a total of 20,000 configurations for analysis. 
 
Interatomic distance calculations All distances were measured in angstroms 
over the 40 ns simulations for each of the simulated trajectories. For the 
simulations of the cTnI-cTnC complex involving wild type as well as protonated 
and deprotonated cTnI A164H, the following distances were evaluated: (1) cTnI 
R163 HH22:cTnC D25 OD1, (2) cTnI R163 HH22:cTnC E19 OE1, (3) cTnI H164 
HD1:cTnC E19 OE2, and (4) cTnI L170 CD2:cTnC A22 CB.   
 
Theoretical pKa calculations of cTn molecular dynamics structures The 
starting structures (frame 1) of the simulated cTnI A164H (protonated and 
deprotonated):cTnC complex were analyzed for determination of the theoretical 
residue ionization titration curve. Analysis was accomplished as previously 
described and implemented on the Virginia tech H++ server347-352.  Calculation 
was derived using the following inputs: salinity = 0.15; internal dielectric = 10; 
external dielectric = 80; structure protonation assuming pH = 7.2. Calculated by 
the Poisson Boltzmann method.  
 
Statistics All results are expressed as mean ± SEM. Multi-group comparisons 
were assessed using two way analysis of variance (ANOVA) with Newman Keuls 






Stoichiometric incorporation of TnI into myocytes after adenoviral gene transfer 
 
 Acute genetic manipulation of adult cardiac myocytes can be 
accomplished by adenoviral gene transfer. Recombinant adenoviruses were 
generated containing various troponin I genes to achieve synchronous and 
efficient genetic modification of adult cardiac myocytes. Over-expression of 
exogenously delivered myofilament proteins causes dose dependent competitive 
replacement of endogenous proteins as shown previously24, 133, 246, 290. In this 
study, adenoviral gene transfer of specific TnI genes (WT cTnI, cTnI A164H, and 
cTnI A164R) was performed in order to assess the functional implications of 
specific TnI proteins in the context of the adult rat cardiac myocyte. Beginning at 
day one, stoichiometric replacement of endogenous cTnI by AdTnI could be 
detected by western blot (Figure 5-1a). AdTnI expression increased 
progressively until day four after gene transfer at which point genetically modified 
myocytes showed, in all cases, approximately 80-90% replacement of 
endogenous cTnI (Figure 5-1a). Laser scanning confocal microscopy using 
indirect immunoflourescence against the FLAG epitope showed ubiquitous and 
precise localization of exogenous TnI proteins in the thin filament of the 



















Figure 5-1. Adenoviral gene transfer of TnI into adult rat cardiac myocytes. (a) 
Protein expression by western blot showing precise stoichiometric replacement 
of endogenous TnI by cTnI FLAG, cTnI A164H, or cTnI A164R over the time 
course of four days of in vitro cell culture. (b) Immunofluorescence images 
showing proper incorporation of cTnI FLAG, cTnI A164H, or cTnI A164R in the 







Myocyte sarcomere function at baseline and acidosis 
 
Dynamic sarcomere length shortening and relaxation kinetics as well as 
the steady state isometric tension-pCa relationship were analyzed four days after 
acute adenoviral-mediated gene transfer into isolated single adult rat cardiac 
myocytes (Figure 5-2a). Measurements were taken under baseline and acidic 
conditions. As a measure of contractility, calcium activated isometric tension 
(pCa50) and normalized sarcomere length shortening were used as markers of 
inotropic performance in the context of WT and TnI modified thin filaments. 
Baseline analysis of SL shortening and pCa50 showed that WT and cTnI A164H 
modified myofilaments  were not different compared to heightened inotropy 
observed in myocytes expressing cTnI A164R (P < 0.05 vs. WT and cTnI A164H) 
(Figure 5-2b). When myocytes were exposed to acidosis, contractile function of 
cTnI A164H and cTnI A164R was not statistically different compared to a 
significantly compromised inotropic capacity observed in WT myocytes (P < 0.05 
vs. cTnI A164H and cTnI A164R) (Figure 5-2c). The delta change from baseline 
to acidosis was calculated to determine the net change in inotropy attributable to 
reduced pH (Figure 5-2d). This data showed that only cTnI A164H had pH-
dependent titratable inotropy indicated by the maintenance of contractile function 
during the pH shift. In contrast, WT cTnI and cTnI A164R were equally affected 
by the acidosis as seen by a similar decrease in normalized sarcomere length 










Figure 5-2. Sarcomere length shortening and tension pCa measurements under 
physiologic and acidic conditions. (a) Raw traces illustrating the change in 
sarcomere shortening kinetics between 7.4 and 6.2 for each group (horizontal 
bar (time) = 0.1 seconds; vertical bar (SL) = 0.1 umeter) (top). Normalized 
tension-pCa50 curves illustrating the change in myofilament calcium sensitivity 
between 7.0 and 6.2 for each group (horizontal bar (pCa50) = 1 unit) (bottom). 
(b) Mean values of percent sarcomere length peak height and myofilament 
calcium sensitivity (pCa50) at baseline. (c) Mean values of percent sarcomere 
length peak height and myofilament calcium sensitivity (pCa50) during exposure 
to acidosis. (d) Mean values showing the delta change from baseline to acidosis 
in terms of sarcomere length shortening as a percent of peak height and (left) 
myofilament calcium sensitivity (pCa50) (right).  For all groups n > 50 myocytes 
from greater than 3 independent myocyte preparations. * P < 0.05 compared to 







Atomic resolution molecular dynamics simulations 
 
 To correlate with the in vitro inotropic functional analysis the calcium 
saturated state of the cTn complex52 was used to provide atomistic insight into 
the implications of differential ionization of histidine’s imidazole side chain on the 
structural engagement of cTnI:cTnC during systole. This was accomplished by in 
silico protein mutagenesis followed by forty nanosecond molecular dynamics 
simulations (Figure 5-3a,b and Supplemental movie 4 (WTcTnI:cTnC), movie 5 
(cTnI A164H deprotonated: cTnC), and movie 6 (cTnI A164H protonated:cTnC).  
In addition to the well defined hydrophobic contacts52, 420, this analysis revealed 
novel electrostatic interactions at the intramolecular interface of the calcium 
saturated WT cTn complex (Figure 5-3c, 5- 4a, Supplemental movie 4). 
Specifically, interatomic distance measurements showed cTnI R163 transiently 
engaging highly conserved acidic residues decorating the hydrophobic patch in 
the N-terminal cTnC helix A including E19 and D25 (Figure 5-3c, 5-4a).  
 Histidine substitution at cTnI residue 164 (cTnI A164H) was subsequently 
simulated in different protonation states at position NE2 of the imidazole side 
chain. Theoretical side chain ionization pH titration analysis showed that H164 
(protonated or deprotonated) was not affected by close structural electrostatic 







Figure 5-3. Structural analysis of cTn molecular simulations. Simulated structures 
shown here were extracted at 20 and 40 nanoseconds with reference to the 
starting cTn structure 1 (yellow). Structural alignments of cTnC (a) and cTnI (b). 
Helix N-D of cTnC denoted as HN-HD; Helix 3 and 4 of cTnI denoted as H3 and 
H4. (c) Residue focus on electrostatic interactions during cTn simulations, 
specifically cTnI R163 interacting with cTnC E19:D25. (d) Residue focus on 
hydrophobic contacts with emphasis on the interaction between cTnC A22 and 
L170 in the final structure of the cTnI A164H protonated simulation (inset). 
Hydrophobic residues shown for cTnC include A22, A23, I26, F27, L41, V44, 
M47, and L48; for cTnI include A154, M155, A158, L159, and L170. For 
reference, A164 and H164 are also shown. Interface between cTnC and cTnI is 
















Figure 5-4. Interatomic distance measurements 
during cTn simulations. Interatomic distances were 
calculated during the 40 nanosecond simulations 
including: (a) WT cTnI R163: cTnC E19 and cTnC 
D25; (b) cTnI A164H deprotonated R163: cTnC E19 
and cTnC D25 (top) as well as H164: cTnC E19 
(bottom); (c) cTnI A164H protonated R163: cTnC E19 
and cTnC D25 (top), H164: cTnC E19 (middle), and 















effects contribute to the H164 imidazole ionization state in the calcium saturated 
cTn complex and that histidine protonation is increasingly likely under acidic 
conditions. MD simulations of the deprotonated cTnI A164H showed interatomic 
distance measurements and structural dynamics similar to WT cTn including 
transient engagements between cTnI R163 and cTnC E19:D25 (Figure 5-3c, 5-
4a, Supplemental movie 5). The deprotonated H164 primarily remained 
disengaged from residue contacts at the intramolecular interface (Figure 5-4b). In 
marked contrast, a single proton added to the imidazole side chain of cTnI 
A164H markedly affected the intermolecular structural characteristics of the 
calcium saturated cTn regulatory complex (Figure 5-3b, Supplemental movie 6). 
Histidine ionization resulted in a complete translocation of cTnI helix 4 toward the 
N-terminal hydrophobic patch of cTnC. Structural analysis indicated that helix 4 
engagement with cTnC was associated with numerous intermolecular 
electrostatic contacts (cTnI R163: cTnC D25 and cTnI H164: cTnC E19) (Figure 
5-3c, 5-4c) and increased hydrophobic interactions (cTnI L170:cTnC A22) 




 This study assessed the molecular mechanism for pH responsive titratable 
inotropy observed with cTnI A164H. Prior reports have revealed that a histidine 
button engineered into the regulatory domain of cTnI provides a substrate for 
therapeutically modulating cardiac performance in response to various 
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pathophysiological stresses203, 246, 290. However, the molecular mechanism for 
this phenotype has not been analyzed. This study used in vitro functional 
analysis and in silico molecular dynamics simulations to elucidate the basis for 
differential imidizole ionization in regulating the unique function of histidine 
modified cardiac TnI. These data support the hypothesis that differential 
protonation of histidine enables cTnI A164H to act as a molecular rheostat 
capable of regulating sarcomere function in response to acute and chronic 
changes to the intracellular biochemical milieu.  
 Early studies by Rarick et al assessed calcium sensitivity of myofibrillar 
ATPase activity after extraction and exchange with cTnI peptide fragments to 
show the requirement for the C-terminal region of cTnI (residues 152-199) in 
regulating cardiac contractility120, 266, 319. Furthermore, Förster resonance energy 
transfer (FRET) experiments have shown that the movements of the regulatory 
arm of TnI during systole and diastole are essential for the transmission of the 
calcium signal to the rest of the myofilament proteins159, 160. As a basis for this 
observation, Li et al used multinuclear, multidimensional NMR spectroscopy to 
show that side chain contacts between the switch peptide of cTnI (residues 147-
163) engaged the calcium saturated N-terminal region of cTnC through multiple 
hydrophobic interactions327. This observation was supported more recently by 
crystal structure analysis of the calcium saturated cTn core complex52. These 
hydrophobic side chain contacts are similarly observed in the regulatory 
interaction between slow skeletal TnI (ssTnI) and cTnC51. In the current study, in 
silico modeling during unrestrained molecular dynamics simulations revealed 
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novel electrostatic side chain contacts involving cTnI R163 toggling between 
cTnC E19 and D25 contribute to the binding interaction at the engaged interface 
between cTnI and cTnC.  
 Gene transfer and transgenic studies have shown that alterations in the 
peptide composition of the TnI switch arm can markedly alter myofilament 
performance246, 249, 252, 325. Importantly, a histidine residue in the switch arm has 
emerged as a key moiety responsible for modulating performance in ssTnI133 
and, more recently, cTnI246, 249. Site directed mutagenesis studies have shown 
that a single histidine to alanine substitution in the switch arm of slow skeletal TnI 
(ssTnI H132A) causes increased pH sensitivity, reduced inotropy, and a 
significant enhancement of relaxation analogous to WT cTnI252. Crystal structure 
analysis of a closely related TnI, fast skeletal TnI (fsTnI), would suggest that 
H132 engages closely with cTnC E19 in the calcium saturated state51. As such, 
alanine substitution would break this close intermolecular electrostatic interaction 
required for heightened inotropy as well as eliminate the substrate for pH 
responsive histidine ionization necessary for titratable contractile performance 
observed with ssTnI. The reciprocal substitution in cTnI (cTnI A164H) has been 
shown to provide a means for pH responsive contractile performance without 
markedly enhanced inotropy at baseline203, 246. Taken together, these functional 
studies indicate that sarcomere function of cTnI A164H does not completely 
recapitulate ssTnI. Fundamental differences in the structural position of histidine 
in the switch arm of ssTnI H132 (engaged with cTnC E19) compared to cTnI 
A164H (solvent exposed) in the calcium saturated Tn complex would suggest 
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different mechanisms of influence. The molecular basis for histidine ionization in 
ssTnI function has not been elucidated. 
This study provides evidence that histidine imidazole ionization as the 
primary mechanism for pH responsive titratable inotropy observed with cTnI 
A164H. Under baseline conditions (pH 7.2), WT cTnI and cTnI A164H have 
similar inotropic function based on myofilament sensitivity to activating calcium 
(pCa) and SL shortening kinetics. Given that pK analysis showed increased 
propensity for H164 imidazole protonation only by acidic solvent, we hypothesize 
that under physiologic conditions the H164 side chain remains deprotonated. 
Compared to A164H, hypercontractility observed with constitutive protonation at 
residue 164 (cTnI A164R) at baseline supports this conclusion. Consistent with 
this, MD simulations showed similar helical behavior of WT cTnI and the 
deprotonated cTnI A164H. Thus, at physiological pH, WT cTnI and cTnI A164H 
have similar inotropic function mediated by structural dynamics involving 
electrostatic interactions between cTnI R163: cTnC E19/D25 and hydrophobic 
side chain contacts52, 327.  
 In contrast, under acidic conditions measures of myofilament sensitivity to 
activating calcium and sarcomere length shortening dynamics indicate that WT 
cTnI had significantly compromised inotropic function compared to cTnI A164H 
and the cTnI A164R variant. Titration analysis of side chain ionization indicates 
that solvent effects on H164 would support imidazole protonation under acidic 
conditions. As such, the functional implications of histidine ionization are 
corroborated by structural modeling of the protonated cTnI A164H. A single 
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proton added to the imidizole side chain of histidine modified cTnI resulted in a 
marked structural change that enabled cTnI to engage more extensively with 
cTnC. Interestingly, this simulation analysis suggests that protonation of histidine 
is not solely responsible for mediating the enhanced interface engagement. 
Rather, these data show that H164 ionization supports more intricate structural 
alterations that involve both electrostatic (cTnI R163:cTnC D25 and cTnI 
H164:cTnC E19) and hydrophobic (cTnI L170:cTnC A22) intermolecular side 
chain contacts that alter engagement of the cTnI switch arm to the calcium 
saturated N-terminal hydrophobic patch of cTnC during acidosis. Taken together, 
these data indicate that solvent-mediated differential ionization of histidine 
enables cTnI A164H to remain deprotonated at baseline resulting in inotropy 
similar to WT cTnI. As pH becomes increasingly acidic, protonation of histidine’s 
imidazole group enables the maintenance of baseline myofilament contractile 
performance.  
This analysis does not exclude the possibility that pH dependent effects of 
histidine modified cTnI might occur in structural positions other than the calcium 
saturated state. For example, differential histidine ionization may also decrease 
TnI:actin interactions during diastole or alter TnI structural dynamics during 
translocation of the TnI regulatory arm thoughout systole. As such, MD 
simulations in this study focused on the implications of histidine ionization in the 
calcium saturated state with a particular emphasis on the regulatory interaction 
between the switch arm of cTnI and the N-terminal domain of cTnC. 
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Understanding the basis for the therapeutic implications of a histidine 
button in cTnI provides important insights into mechanisms of modulating cardiac 
performance in response to ischemia or acidosis. Use of cTnI A164H as a gene 
therapy vector or identification of small molecules that mimic the pH responsive 
features of histidine-modified cTnI may be a valuable approach for treatment of 
numerous cardiomyopathies. Specifically, this molecule has mild to no side 
effects on contractile function at baseline but protects inotropic performance in 
response to acute or chronic stresses such as myocardial ischemia. This study 
provides evidence to show that imidazole ionization is required for pH responsive 
titratable inotropy observed with myofilaments containing histidine modified 
cardiac TnI.  
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Supplemental movies 4-6. Forty nanosecond molecular dynamics simulations of 
WT cTnI (movie 4), cTnI A164H deprotonated (movie 5), and cTnI A164H 





Table 5-1. Sarcomere dynamics at baseline and acidosis 
Parameter pH WT cTnI cTnI A164H cTnI A164R 
Baseline SL  (um)  7.4 1.820 ± 0.006* 1.773 ± 0.005  1.776 ± 0.005 
Baseline SL  (um)  6.2 1.808 ± 0.004* 1.755 ± 0.005   1.746 ± 0.005 
Time to peak (s) 7.4 0.108 ± 0.002  0.110 ± 0.002  0.117 ± 0.002*
Time to peak (s) 6.2 0.094 ± 0.002* 0.110 ± 0.003  0.104 ± 0.002 
Normalized peak height 
(%) 7.4 10.18 ± 0.379  11.11 ± 0.498  13.40 ± 0.383*
Normalized peak height 
(%) 6.2 5.219 ± 0.382* 10.96 ± 0.596  9.619 ± 0.451 
Time to baseline 50% 
(s) 7.4 0.0405 ± 0.001* 0.0466 ± 0.001  0.0504 ± 0.001 
Time to baseline 50% 
(s) 6.2 0.0364 ± 0.001* 0.0464 ± 0.002  0.0470 ± 0.002 
Time to baseline 75% 
(s) 7.4 0.0627 ± 0.002* 0.0750 ± 0.002  0.0781 ± 0.002 
Time to baseline 75% 
(s) 6.2 0.0634 ± 0.003* 0.0741 ± 0.003  0.0768 ± 0.003 
 
All values are expressed as mean ± SEM. n > 50 myocytes from > 3 myocyte 
isolations. P < 0.05 vs. all other groups. 
 
Table 5-2. Myofilament calcium sensitivity and coorperativity analysis at baseline 
and acidosis 






Coefficient 7.0 3.14 ± 0.46 1.83 ± 0.25 2.30 ± 0.28 
Hill 
Coefficient 6.2 5.62 ± 1.94 2.74 ± 0.50 4.35 ± 1.11 
pCa50 7.0 6.00 ± 0.03 6.09 ±0.07 
6.29 ± 0.02 
* 
pCa50 6.2 4.66 ± 0.03* 4.92 ± 0.07  5.02 ± 0.02  
 
All values are expressed as mean ± SEM. n > 50 myocytes from > 3 myocyte 











 Troponin I is a critical mediator of myofilament function. As a 
consequence, significant effort has been vested in understanding the structure 
and function of this protein in physiology and pathophysiology. The studies 
outlined here provide a significant step forward in elucidating our knowledge of 
this protein within the context of its related troponin proteins (TnC and TnT) and 
its functional regulation of other members of the myofilament. These studies 
provide a new level of knowledge encompassing in silico molecular modeling, in 
vitro analysis using genetically engineered isolated cardiac myocytes, and whole 
organ hemodynamic analysis in vivo. Brought into the context of other important 
studies of troponin I, these studies collectively provide an emerging knowledge of 
how troponin I (its various isoforms and targeted modifications) influences both 
the inotropic and lusitropic aspects of heart muscle function. This conclusion will 
outline the current state of knowledge of how TnI histidine buttons affect systolic 
function (part I) and diastolic function (part II). The second part will also draw on 




Part I: Systolic function 
 
 Classic studies in the field of troponin function have rigorously assessed 
the role of a histidine button in the regulatory domain as a pH responsive 
moiety133, 246, 252. Evolutionary studies show that this histidine is found in all 
isoforms of TnI in all species across chordate evolution with the exception of a 
proline in the platypus cTnI sequence followed by an alanine in all other 
mammalian cTnI sequences. Histidine has been shown to act as an effective pH-
dependent titratable moiety within the ssTnI complex133, 317, 318.  
The working model to explain the functional implications of a histidine in 
the switch arm of TnI focuses on the differential ionization of the histidine residue 
(Figure 6-1). The model relies on the presumed biophysical effects of histidine 
ionization on the performance of the regulatory arm of cTnI interacting with the N-
terminal hydrophobic patch of cTnC. Under baseline physiological conditions, we 
hypothesize that histidine is deprotonated resulting in a switch arm somewhat 
analogous to function to the WT cTnI. Under these conditions, myofilament 
activation at the myocyte level and hemodynamic function at the whole organ 
level are not markedly different. However, during acidosis, pH falls precipitously 
resulting in ionization of histidine. A positively charged moiety is hypothesized to 
enhance the binding affinity of the cTnI switch arm to cTnC such that contractility 
is maintained during acidosis. As such, a histidine residue in the TnI switch arm 
is thought to act as a molecular rheostat that modulates myofilament 






Figure 6-1. Funcutional implications of different switch arm motifs in TnI. 
Histidine-modified cardiac troponin I acts as a molecular rheostat of intracellular 
pH. a) The heterotrimeric troponin complex is part of the thin filament and 
functions as the molecular switch of the sarcomere. b) Differences in the primary 
amino acid sequence of troponin I led to the discovery of a critical histidine 
residue in ssTnI (and ancestral cTnI) which conferrs pH dependent activation of 
the myofilament. This histidine was substituted for an alanine to confer this 
biochemical advantage to the adult mammalian cTnI isoform (cTnI A164H). c) 
Under baseline conditions cTnI A164H has similar functional characteristics as 
WT cTnI in vitro and in vivo. However, under conditions of ischemia, protonation 
of the histidine in cTnI A164H protects myofilament calcium responsiveness thus 







Numerous studies at the whole organ, single cell, and atomic level have 
provided evidence to assert this model133, 203, 246, 249, 252, 290, 318, 405-408. To begin, 
evolutionary studies have shown that ancestral species such as fish and 
amphibians require heightened calcium sensitivity of the myofilaments and pH 
responsive regulation of inotropy due to normal physiological conditions of cold 
temperatures and periods of chronic hypoxia experienced by these ectothermic 
species4, 5, 331, 334, 405-408. In vitro analysis of genetically modified cardiac myocytes 
showed that changes in the N-terminal domain of cTnC were at least partly 
responsible for increasing myofilament sensitivity to calcium in pre-mammalian 
species4, 331, 334, 395. Studies of perfused frog hearts have also shown that 
amphibians can maintain normal cardiac function during severe hypoxia or 
ischemia408.  
New phylogenetic analysis of TnI has shown that ancestral cardiac 
troponin I homologues have high sequence similarity to the ssTnI isoform found 
in all chordate species. There are a plethora of studies showing heightened 
calcium sensitivity attributable to ssTnI in large part because of the key histidine 
residue in the switch domain246, 249, 252. These studies provide strong evidence 
that the heightened calcium sensitivity as well as resistance to pH alterations of 
ancenstral myofilaments is the result of key residues in cTnC as well as a 
histidine moiety in the cTnI switch arm.  
 Interestingly, these and other studies have also shown that heightened 
calcium sensitivity of the myofilaments and pH insensitivity are critical for 
development of every species across chordate evolution. Studies have shown 
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that a single TnI isoform (cardiac) is expressed in all phases of amphibian 
development from the larva to the adult. However, in avian and mammalian 
species the developmental isoform changes to ssTnI which is stoichiometrically 
replaced with cTnI in the adult heart. The evolutionary pressure for this 
phenotype is likely the preserved nature of heart development in all species. 
Specifically, studies have shown that the fetal heart has high lactate levels and 
relies on glucose metabolism384. Second, there is evidence that the critical 
cardiac developmental transcription factor Nkx2.5 is regulated by hypoxia-
inducible factor (HIF-1α)385. Together these would require contractile function that 
is not affected by changes in pH. Third, immature sarcoplasmic reticulum and 
calcium cycling in the developing heart require heightened sensitization of the 
myofilaments to establish sufficient inotropy387. These data would suggest that 
mutations that eliminate this key feature of pH responsiveness and heightened 
calcium sensitivity (e.g. ssTnI H132A) would be embryonic lethal if expressed 
during the developmental stages of any species. This hypothesis is yet to be 
tested.  
Atomic level molecular dynamics simulations and modeling have provided 
an immense amount of knowledge regarding the mechanism by which this 
histidine button affects intramolecular and intermolecular structural 
characteristics of TnI within the calcium saturated troponin complex. To begin, 20 
nanosecond simulations of ssTnI:cTnC structure showed a tight and nearly 
inflexible interaction at the interface between these proteins. Structural analysis 
was performed to calculate theoretical residue ionization titration (pK) and 
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electrostatic atomic energy binding interaction between all ionizable groups. This 
showed that sTnI histidine132 and cTnC glutamate19 develop a salt bridge and 
generate an electrostatic interaction strength of 5.24 kcal/mol. This level of 
interatomic bonding far exceeds the interaction strength between any other two 
ionizable groups within the entire regulatory complex of either sTnI:cTnC or 
cTnI:cTnC structures. The reciprocal effect of these residues on each others’ pK 
shift further confirms the importance of this interaction in mediating the 
intermolecular stability of the sTnI:cTnC regulatory complex. Functionally, these 
atomic resolution structural modeling data are consistent with heightened 
myofilament calcium sensitivity and pH responsive inotropy as observed with 
hearts containing ssTnI or ancestral cTnI molecules4, 133, 252, 331. 
Given this abundance of data supporting the important role of histidine in 
TnI, the hypothesis was tested that a histidine button in cTnI (cTnI A164H) could 
act as a molecular rheostat capable of augmenting contractility in response to 
injury. Day and colleagues elegantly showed that cTnI A164H had a mild effect 
on contractility at baseline but therapeutically enhanced cardiac performance in 
the context of a variety of pathological models in vitro, ex vivo, and in vivo246. 
Similarly, recent studies have shown that cTnI A164H is able to protect cardiac 
function during aging290 and in the context of a severe hypercapnic acidosis 
challenge203. In the latter study, cardiac conductance micromanometry analysis 
during severe acidosis (pH 6.5) showed that cTnI A164H mice were able to 
sustain heart function without mortality in the absence of adrenergic support. 
Statistical analysis showed that systolic, diastolic, and geometric parameters 
247 
 
were not significantly different after 20 minutes of acidosis compared to baseline 
values. This was in marked contrast to Ntg mice that, in the absence of 
adrenergic support, experienced acute pump failure and 100% mortality within 
the first 5 minutes of acidosis. Taken together with the study by Day et al246, 
these observations provide strong evidence that cTnI A164H can act as a 
therapeutic molecule to augment cardiac performance in the context of various 
pathophysiological challenges. 
These in vivo studies are supported by in vitro analysis of myocytes 
genetically modified to express cTnI A164H and assessed for inotropic capacity. 
Under baseline conditions, measures of sarcomere length shortening kinetics 
and myofilament calcium sensitivity of cTnI A164H myocytes was not significantly 
different from myocytes expressing WT cTnI. Atomic resolution molecular 
dynamics simulations and pH titration analysis indicates that histidine (H164) 
remains deprotonated under baseline conditions causing structural dynamics 
similar to WT cTnI. However, when exposed to acidic media myocytes 
expressing WT cTnI have markedly diminished contractility compared to 
myofilaments expressing either cTnI A164H or arginine modified cTnI (A164R) 
which is a constitutively protonated correlate to the ionized histidine. Consistent 
with this, pK analysis indicates increased propensity for imidazole protonation 
under acidic conditions. Furthermore, molecular simulations where a single 
proton is added to histidine’s imidazole group show markedly different structural 
dynamics involving added intermolecular electrostatic and hydrophobic side 
chain contacts across the cTnI:cTnC interface in the calcium saturated state. 
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Taken together, these data provide evidence to show that imidazole ionization is 
required for pH responsive titratable inotropy observed with myofilaments 
containing histidine modified cardiac TnI. 
   
Part II: Diastolic function and physiological adaptations 
 
 Functional studies of chordate species indicate that myofilament calcium 
sensitivity has significantly decreased during evolution4, 332. As discussed above, 
studies of ancestral species indicate the requirement for heightened sensitivity to 
activating calcium and pH responsive inotropy in these organisms405-408. The 
earliest known sequence within the mammalian taxa is derived from the platypus. 
Alignment data show that a proline residue in the switch domain likely acted as a 
key molecular intermediate that broke the high energy histidine-glutamate 
interaction of ancestral cTnI isoforms. All other mammals have an alanine at this 
position.  
To understand the structural implications of breaking this His-Glu 
interaction, molecular dynamics simulation and in silico alanine scanning was 
performed. In this analysis the change in the binding free energy (ΔΔG) was 
calculated for alanine substitutions of all residues involved in the interface 
bonding of the sTnI:cTnC calcium saturated crystal structure. Of the cTnC 
residues, these data show that E19A had the greatest impact on ΔΔG (ΔΔG 
E19A = 0.91kcal/mol). However, the greatest impact on the binding free energy 
among all residues engaged at the cTnC:sTnI interface was observed with the 
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sTnI H132A substitution (ΔΔG H132 = 2.46 kcal/mol). Structural comparison of 
sTnI:cTnC and cTnI:cTnC indicate that breaking this His-Glu interaction resulted 
in a molecularly untethered TnI helix 4. Importantly, this decreased the binding 
free energy of the TnI:TnC interface resulting in enhanced relaxation of the 
troponin complex. Twenty nanosecond molecular dynamics simulations of the 
alanine substituted sTnI H132A:cTnC structure support this hypothesis.  
Furthermore, functional studies of genetically engineered adult cardiac 
myocytes have shown that a single amino acid substitution in the TnI switch 
domain (ssTnI H132A) is able to fully recapitulate the phenotype of the 
mammalian cTnI isoform252. Compared to ssTnI, the functionality of cTnI/ssTnI 
H132A includes reduced myofilament calcium sensitivity, reduced inotropic 
function, enhanced relaxation, and increased pH sensitivity252. These data 
support the conclusion that evolutionary pressures were aimed at enhancing the 
relaxation efficiency of the troponin complex in order to meet changing lusitropic 
requirements during evolution of the mammalian cardiovascular system.  
 In support of this hypothesis, studies of human disease causing mutations 
within the cTn complex can result in an evolutionary revertant phenotype; that is, 
heightened calcium sensitivity of the myofilaments333, 335, 337, 358. Patients with 
these SNPs have shown symptoms of heart failure including diastolic 
dysfunction, increased propensity for arrhythmias, and susceptibility to sudden 
cardiac death329, 333, 335, 337, 358. Animal models of these diseases together with the 
well studied ssTnI transgenic mouse all recapitulate aspects of these heart failure 
phenotypes213, 333, 374, 455. The observation of significant cardiomyopathy and 
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heart failure when mammalian cardiac myofilaments have heightened calcium 
sensitivity supports the hypothesis that evolutionary pressures required a 
troponin complex with enhanced relaxation in order to meet the lusitropic 
requirements of mammalian heart. Phylogenetic analysis, molecular modeling, 
and functional data suggest that this occurred by means of a critical histidine to 
alanine substitution in the switch arm of cTnI. 
 These observations are in marked contrast to the finding that a histidine 
engineered back into cTnI (cTnI A164H) does not cause diastolic dysfunction in 
vivo. In fact, numerous assays using cTnI A164H Tg mice have shown that 
diastolic performance is markedly protected by the cTnI A164H molecule203, 246, 
290. The study by Day et al was the first to reveal the protective nature of cTnI 
A164H on diastolic function246. During ischemia/reperfusion injury ex vivo, Tg 
hearts on the Langendorff apparatus recovered baseline diastolic performance 
immediately upon reperfusion compared to Ntg mice which never recovered 
baseline diastolic function (EDp). Furthermore, diastolic function during aging, as 
measured by the ratio of the mitral valve E wave to the lateral annular E wave 
(E/Ela), was significantly lower in Tg than Ntg mice at the 2 year time point290. 
Lastly, during an extended acidosis challenge with beta blockade, cTnI A164H 
Tg mice were able to protect diastolic function during the entire time course of 
the challenge203. Surprisingly, diastolic performance in Tg mice was not 
statistically different at the end of the challenge (20 min of acidosis) compared to 
the beginning (e.g. EDp). In contrast, severe diastolic dysfunction occurred in Ntg 
mice resulting on whole organ cardiac decompensation within 5 minutes after the 
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onset of acidosis. Taken together, data from cTnI A164H Tg mice provide strong 
evidence for the advantage conferred by a histidine-modified cTnI on diastolic 
performance.  
The proposed model for the biophysical implications of cTnI A164H 
(Figure 6-1) are not sufficient to explain the observed advantage on diastolic 
performance. Adaptive modifications to the cTnI A164H heart have been 
described in detail elsewhere246, 290 and must be considered. Specifically, studies 
have shown that myocytes isolated from Tg hearts have reduced calcium 
transients and SR calcium load246, 290. In terms of regulating calcium cycling, Tg 
hearts have increased levels of SERCA2a and phospholamban290. Energetically, 
Tg mice have been shown to be more economical compared to Ntg 
littermates246. Morphometric measurements showed that Tg mice have small 
hearts and myocytes than Ntg hearts246. For various reasons, it has been 
hypothesized that all of these adaptations contribute to the protective nature of 
cTnI A164H during various cardiac challenges242, 246, 290.  
On the basis of diastolic function, it could be argued that adaptations 
associated with calcium regulation are required to protect baseline diastolic 
parameters in the presence of a molecule that, in vitro, is shown to cause 
diastolic dysfunction. Reduced calcium load and enhanced reuptake by higher 
levels of SERCA2a would enhance relaxation through calcium cycling 
mechanisms. These changes also contribute to the advantage conferred to cTnI 
A164H mice during injury such as I/R where reduced calcium may attenuate the 
post-ischemic calcium overload246. Differing observations in terms of cTnI 
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phosphorylation246, 290 make potential differences in PKA signaling unclear. If 
PKA signaling is increased in cTnI A164H hearts246 this may also enhance 
diastolic performance to compensate for a heightened myofilament 
responsiveness.  
Elasticity of the myocardium may also be enhanced in cTnI A164H mice 
which would augment LV relaxation capacity. Reduced E/Ela during 2 years of 
aging290 showed improvement in the ratio of the inflow velocity to the tissue 
velocity providing insight into the elastic properties of the ventricle290. In essence, 
the E wave velocity controls for cardiac output, heart rate, and filling so that the 
ratio (E/Ela) correlates with left atrial pressure. The link between cTnI A164H and 
increased ventricular elasticity is currently unclear. Based on our current 
knowledge, there is no direct evidence that cTnI A164H itself confers any 
advantage to diastolic performance outside of significant contributions associated 
with myocardial remodeling. In the absence of these adaptive changes as seen 
with genetically engineered rat myocytes, diastolic dysfunction is observed when 
cTnIA164H is incorporated into the myofilament at high stoichiometric levels.  
 Experiments are underway to determine the molecular mechanism for 
calcium modulation in the cTnI A164H Tg hearts. I outline novel methodologies to 
determining the mechanism for this observation in the future directions. Whether 
the purpose for modulation of calcium handling in this model is aimed at 
regulating systolic and/or diastolic function (or neither) is not known. Taking 
these data together, the physiological phenotype of hearts containing cTnI 
A164H is inextricably tied to the adaptive effects it elicits. As discussed in future 
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directions, defining the physiological phenotype of cTnI A164H without 
developmental adaptations will be critical for further understanding the 




 Given the expanded knowledge provided by these studies, an interesting 
model has emerged regarding the role of the cardiac troponin complex in 
mammalian cardiovascular function (Figure 6-2). To begin, ancestral cTnI 
molecules together with TnI isoforms expressed during development in all 
chordates indicate that the physiological demands of these hearts require 
heightened calcium sensitivity of the myofilaments and resilience to changes in 
pH. This characteristic is, at least in part, attributed to a key histidine residue in 
TnI and its interatomic bonding with a highly conserved glutamate moiety in helix 
A of cTnC. During evolution of the mammalian cardiovascular system, the 
histidine residue of the cTnI switch domain was modified to a proline initially  
(platypus) and subsequently changed to an alanine in all other mammals. This 
alteration was required to achieve appropriate relaxation of the cTn complex to 
meet lusitropic demands of the mammalian heart. This modified cTnI molecule 
has increased mobility of helix 4 involving interactions with cTnC that are largely 




Figure 6-2. Model for structural, functional, and evolutionary implications of a 




primarily observed between cTnI R163 and cTnC E19/D25. Cardiomyopathies 
that cause evolutionary revertant phenotypes (e.g. cTn SNPs that cause 
heightened myofilament calcium sensitivity) result in symptoms of heart failure 
including arrhythmias, diastolic dysfunction, and increase susceptibility to sudden 
cardiac death. The emergence of heart disease phenotypes in patients with 
revertant phenotypes supports the conclusion that enhanced relaxation by cTn 
was required to meet lusitropic demands of the mammalian heart.  
Other heart diseases such as ischemic cardiomyopathy, primarily 
observed in the modern aging population suggest potential therapeutic value of 
pH-dependent titration of inotropy in response to cardiac challenges. A histidine 
placed back into its original position in the switch domain of cTnI provides this 
sort of cardiovascular advantage in response to numerous pathophysiological 
insults203, 246, 290. At the molecular level, the capacity for cTnI A164H to act as a 
molecular rheostat is based on the differential ionization of histidine’s imidizole 


















 The studies outlined in this dissertation provide a strong basis for a 
number of additional studies to help elucidate the role of troponin in regulating 
myofilament function. The first part will outline an extensive array of proposed 
experiments related to the translational research potential of the cTnI A164H 
protein as a therapeutic tool. The second section will outline some basic science 
questions designed to understand the fundamental nature of the critical 
interaction between TnI and TnC in the intact myofilament. The third section will 
outline experiments designed to understand the correlation between myofilament 
calcium sensitivity and calcium handling using Tg mouse models of Tn mutants. 
 
Part I: Structural and Functional Protection of the Acute and Chronically Ischemic 
Heart Using Gene Transfer of Cardiac TnIA164H 
 
We have found in our initial studies that cTnIA164H enables differential 
changes in myofilament calcium sensitivity based on alterations in the 
biochemical milieu of the cell during myocardial ischemia/acidosis203, 246, 290. 
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Under these conditions, histidine-modified cTnI provides a substrate for 
increased myofilament responsiveness to intracellular calcium transients which 
translate functionally to improve sarcomere-based force production and, 
subsequently, ventricular contractility. These conclusions from studies using the 
cTnIA164H transgenic mouse are encouraging and informative. This proposal is 
significant because it invokes the use of rAAV technology for temporal regulation 
of gene delivery to the heart together with an array of powerful methodologies 
which will enable observation of effects specifically attributable to cTnIA164H 
within the context of clinically relevant models of ischemic heart disease. This is 
opposed to potential limitations of the transgenesis study wherein expression of 
the cTnIA164H transgene early during developmental growth may have been 
causal to compensatory changes in structure and function of the heart. These 
compensatory changes raise some questions as to what is and what is not a true 
effect of histidine-engineered cTnI. As a consequence, several major questions 
remain which this proposal is uniquely designed to address. First, does rAAV 
mediated transduction of cTnIA164H into the adult heart protect contractility 
during acute ischemia? Second, does cardiac transduction of cTnIA164H prevent 
myocardial remodeling in a model of chronic ischemic cardiomyopathy? Third, is 
the therapeutic effect of cTnIA164H restricted to protecting contractility during the 
initial ischemic injury or can it also therapeutically improve cardiac structure and 
function when delivered after an ischemic insult? The nature of these questions 
emphasizes the need to temporally regulate gene transfer and subsequent 
expression of cTnIA164H. The methodologies outlined here will improve the 
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specificity of truly defining the consequent impact of cTnIA164H on the normal 
and pathologic heart in vivo.  
To begin, it will be necessary to determine the transduction efficiency of in 
vivo viral-mediated systemic gene transfer of rAAV-cTnIA164H to the hearts of 
adult mice and assess whether subsequent incorporation into the sarcomere 
protects global cardiac contractility in the acutely ischemic heart. As a part of this, 
it will be important to determine the transduction efficiency of rAAV-cTnIA164H 
and the extent of replacement of endogenous cTnI to cTnIA164H in transduced 
hearts. 
Based on preliminary results using control vectors transduction efficiency 
of rAAV is expected to be nearly 90% of the heart (Figure 7-1). Consequently, 
initial assays showing the rate and extent of cTnIA164H incorporation into the 
myofilament will provide supportive evidence for functional effects observed. 
Correspondingly, the control virus, cTnIFLAG, will similarly be assayed for rate 
and duration of incorporation to show efficacy of this as a control virus in acute 
and chronic models employed in this proposal. This will be the first study to use 
AAV-mediated delivery of a modified myofilament protein to the heart in vivo to 
show competitive stoichiometric replacement of the endogenous protein.  
 
To accomplish this it will be necessary to assess the rate and extent of 
competitive stoichiometric replacement of endogenous cTnI by cTnIFLAG and 
cTnIA164HFLAG. To accomplish this rAAV-cTnIFLAG or rAAV-cTnIA164HFLAG 









Figure 7-1. Evidence of global in vivo transduction of cardiac tissue after 







analysis of whole heart lysate every four days until day twenty post-injection. 
Consistent with previous reports456, 457, we will confirm long term transcriptional 
activity by isolating lysate from transduced hearts once every month for six 
months. Expression of endogenous cTnI and cTnIFLAG or TnIA164HFLAG will 
be immunodetected by Western blot analysis using a cTnI specific antibody 
(Chemicon, AB1627) and a fluorescence tagged secondary (Alexa Fluor 680, 
Molecular Probes). Incorporation into the intact myofilament will be determined 
by indirect dual immunofluorescence detection for flag-tagged cTnIA164H and 
actin in isolated myocytes from transduced hearts. Mouse myocyte isolation will 
be as previously described by our lab24. For dual immunofluorescence, 
antibodies used will include anti-flag antibody (mouse monoclonal, M2 Flag, 
Sigma) conjugated to Alexa Flour 488 (Molecular Probes) and anti-actin N-
terminal antibody (rabbit polyclonal, A2103, Sigma) conjugated to Texas Red 
(Molecular Probes). Analysis will be performed with a laser scanning confocal 
microscope.  
Based on preliminary data using rAAV, global myocardial expression of 
control protein is noted at ten to twelve days post gene transfer (Figure 7-1). 
However, in the case of gene transfer using a sarcomeric protein, the rate of 
incorporation into the myofilament is dependent on the half life of the 
endogenous protein. Adenoviral mediated gene transfer of cTnIA164H into 
isolated adult rat myocytes in vitro has shown greater than fifty percent 
replacement of native cTnI occuring at day four post gene transfer (Figure 5B). 
Furthermore, this data indicates that native cTnI can be separated from 
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cTnIFLAG or cTnIA164HFLAG by SDS-PAGE in order to determine the 
stoichiometric ratio of each protein in the myofilament. In this study, incorporation 
of cTnIA164HFLAG or cTnIFLAG into the myofilament is expected to begin ten to 
twelve days post AAV-mediated gene transfer with complete replacement 
between fourteen and sixteen days. Proper incorporation into the sarcomere is 
expected as shown by dual immunofluorescence. 
Studies using mice injected with a reporter construct (rAAV CMV 
Luciferase) have provided strong evidence for global gene transfer to striated 
muscle after a single tail vein injection (Figure 7-2). Vector production has been 
accomplished in a similar fashion with rAAV cTnI A164H. After a single  
tail vein injection of extremely high vector genomes results show that the 
maximum extent of stoichiometric replacement occurring in cardiac tissues is 
perhaps 5-10% of endogenous cTnI levels (Figure 7-2a). This is in marked 
contrast to the transgenic mouse and isolated rat myocytes trandsuced with Ad 
cTnI A164H which show 80-90% replacement. This is a surprising result given 
that lower doses of vector containing micro dystrophin have been sufficient to 
transducer the entire heart and replace dystrophin deficient heart muscle to a 
therapeutic level458.  
 We hypothesize that differences in regulation of protein expression 





Figure 7-2. Analysis of mRNA and protein expression of hearts transduced 
with AAV cTnI A164H. (a) Western blot analysis showing protein expression 
level after AAV injection of cTnI A164H. Tail vein injection of 250-300 uL 
virus containing 3-4x1013 vector genomes. Western blot was performed 3 
months after injection (antibodies: MAB 1691 (top) and M2 FLAG (bottom)). 
Lanes 4 and 5 show approximately 5% replacement of endogenous cTnI. 
(b, c) mRNA analysis of hearts expressing cTnI A164H by transgenesis (b) 
or AAV injection (3 months post injection) (c). Transgenic expression of cTnI 
A164H achieved 70 fold higher expression level compared to endogenous 
and resulted in ~ 80% stoichiometric replacement. AAV gene transfer of 




dystrophin is not a stoichiometrically regulated protein. As such, over-expression 
of this protein is possible in both dystrophin deficient and normal skeletal muscle. 
However, cTnI is a component of the myofilament where stringent stoichiometric 
replacement is absolutely necessary in order to protect the integrity and thus 
proper functionality of the sarcomere. As such “over-expression” of myofilament 
proteins is only manifest in the way of stoichiometric replacement of endogenous 
proteins via a competitive mechanism. Recent studies have shown that although 
the cTnI knockout is lethal, haploid under-expression of cTnI is sufficient to attain 
proper stoichiometric incorporation into the myofilaments, an indication that 
endogenous levels of TnI are naturally higher than is required for minimal 
incorporation and function of the myofilaments459.  
Studies of transgene mRNA levels of the cTnI A164H transgenic mouse 
show a remarkable degree of overexpression of exogenous cTnI A164H 
compared to endogenous levels (Figure 7-2b). This indicates that a significant 
level of overexpression is required to achieve stoichiometric replacement to 
levels sufficient for a therapeutic effect (80-90% replacement). We hypothesize 
that rAAV cTnI A164H is not achieving the level of vector genome copy number 
per cell relative to what is achieved either by transgenesis in vivo or adenoviral 
mediated gene transfer into isolated myocytes in vitro. Preliminary data support 
this conclusion (Figure 7-2c). However, further experiments are required to 
substantiate this assertion. If sufficient levels of replacement can be achieved 





Standard neonatal cardiac-specific overexpression studies are useful for 
defining candidate genes that have a pathophysiologic or, conversely, 
therapeutic impact on the heart. Transgene mediated manipulation of the 
physiologic norm during early cardiac developmental stages will, however, 
induce compensatory alterations in various components of the underlying 
structure and function of the heart. In other words, during development the 
immature heart is able to undergo a global phenotypic adjustment in response to 
specific genotypic alterations. The fully differentiated adult heart, however, 
responds exclusively to transgene-mediated effects460. In light of this, 
subsequent conditional and temporally defined gene manipulation studies 
provide clarity for the relevance of that gene within the context of various 
physiologic or pathologic states461.  
Our previous studies have shown that cTnIA164H is a candidate gene 
useful for therapeutic treatment of ischemic heart disease246, 290. However, it is 
likely that compensation occurred in the cTnIA164H transgenic mouse where 
transgene expression was driven by the alpha myosin heavy chain promoter 
which is active during the early post-natal stages of cardiac growth and 
differentiation. This may have influenced the development of structural and 
functional differences (e.g. calcium homeostasis, global cardiac morphology, and 
energetics) observed at baseline and under various cardiomyopathic stresses. 
This raises a significant question: what aspects of myocardial protection during 
acute and chronic ischemia can really be directly attributed to cTnIA164H? 
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Taking this rationale into consideration provides background for the importance 
of the experimental model employed in this aim. It is important to note that 
compensatory changes will also likely occur in the adult heart in response to 
cTnIA164H. The crux of this aim, however, is based on the fact that AAV gene 
transfer into the mature adult heart will provide a means of understanding the 
extent to which cTnIA164H protects contractility during an acute ischemic 
challenge devoid of developmentally induced cardiac compensatory changes.  
Preliminary data show that critical functional aspects of myofilament calcium 
sensitivity are similar between the cTnIA164H transgenic heart and acutely 
isolated adult rat myocytes transduced with cTnIA164H. Comparable to 
transgenic hearts, adenoviral transduction of cTnIA164H into adult rat cardiac 
myocytes replaces greater than 80% of native cTnI. Based on this level of 
replacement, preliminary data indicate that the calcium sensitivity of isometric 
force (pCa50) at baseline (pH 7.0) and under acidic conditions (pH 6.2) is higher 
in acutely isolated adult rat myocytes transduced with cTnIA164H compared to 
controls. Furthermore, the pCa50 observed in cTnIA164H adenovirally transduced 
myocytes at neutral and acidic pH is analogous to that observed in myocytes 
isolated from cTnIA164H transgenic hearts. These data indicate that under acidic 
conditions contractile performance can be significantly improved in adult 
myocytes transduced with cTnIA164H. This conclusion supports my hypothesis 
that cTnIA164H transduced hearts in vivo will correspondingly show protection of 
myocardial contractility during an acute ischemic challenge.  
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Similar methodological approaches will be employed first to assess 
changes in baseline cardiac function and second to assess whether cTnIA164H 
acutely protects inotropic function in the ischemic adult heart. To begin, rAAV 
cTnIA164H will be delivered systemically by a single tail vein injection. All 
experiments will be performed four weeks after injection to allow sufficient time 
for viral transduction of the heart, transgene expression and protein incorporation 
into the myofilament. Assays will involve echocardiography, Millar 
catheterization, and the Langendorff isolated heart preparation as described 
previously in detail by our lab246 with some modifications. Echo will be used to 
assess cardiac structure as measured in M-mode in the parasternal short axis 
view at the level of the papillary muscle. Furthermore, systolic function will be 
analyzed in M-mode and diastolic function by pulsed-wave spectral Doppler 
analysis and Doppler tissue imaging of the mitral valve annulus. For millar 
catheterization, mice will be anesthetized and ventilated via a tracheal 
cannulation. A Millar pressure-volume catheter (Millar Instruments Inc.) will be 
inserted into the right carotid artery and advanced into the left ventricle.  Inferior 
vena cava occlusions will also be performed to obtain the end systolic and end 
diastolic pressure-volume relationships. In each assay (Millar, Langendorff, 
Echo) baseline data will be acquired with hearts exposed to normal physiologic 
conditions. In assays involving millar catheterization and Langendorff isolated 
hearts, physiologic conditions will subsequently be altered to determine if 
transduced hearts retain improved inotropic function in the context of an acute 
ischemic stress. The Langendorff perfused hearts will be exposed to one of the 
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following two different ischemic challenges. Isolated hearts in Cohort 1 will be 
exposed to twenty minutes of acidic perfusate (pH 6.8) followed by thirty minutes 
of exposure to neutral perfusate (pH 7.4). Cohort 2 will be exposed to twenty 
minutes of no-flow ischemia followed by thirty minutes of reperfusion. Hearts that 
have undergone condunctance catheterization will also be exposed to one of two 
different ischemic challenges. In cohort 1, baseline data will be acquired during 
ventilation with 100% oxygen. A hypoxic challenge will then be introduced by 
altering the composition of ventilated air to include 7% oxygen and 93% 
nitrogenIn cohort 2 during cardiac catheterization the left coronary artery (LCA) 
will be permanently ligated to induce a 30-40% infarction of the LV free wall. 
At baseline, hearts transduced with cTnIA164H are expected to have an 
improvement in systolic performance while diastolic function will remain 
unaltered. Concerning the ischemic challenges, previous reports have made 
strong arguments for the fact that myocardium in the peri-infarct zone is 
inadequately perfused, and consequently hypoxic, which supports the hypothesis 
that cTnIA164H will increase contractility in this critical region of the injured 
myocardium462. Furthermore, the cTnIA164H transgenic study showed whole 
heart improvements in contractility at baseline compared to non-transgenics. 
Based on these data, it is expected, in general, that cTnIA164H transduced 
hearts stressed by an acute ischemic challenge will have improved contractility 
compared to controls. In the Langendorff isolated heart method these 
observations will be mild in hearts that are exposed to acidosis with reperfusion 
(cohort 1) and accentuated in hearts that undergo no-flow ischemia with 
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reperfusion (cohort 2). In assays involving conductance micromanometry global 
cardiac hypoxia as well as an induced myocardial infarction of 40-50% of the LV 
will significantly challenge contractile function. Specifically, hearts transduced 
with cTnIA164H are expected to have improved contractility during an acute 
ischemic challenge as characterized in part by increased left ventricular 
developed pressure (LVDP) compared to controls. Furthermore, consistent with 
data derived from the transgenic mouse, cTnIA164H transduced hearts are 
expected to show an attenuation of diastolic dysfunction based on maintenance 
of LV end diastolic pressure (LVEDP) in contrast to severe diastolic dysfunction 
expected in control hearts. In summary, the experimental model used in this aim 
is significant because it eliminates the variable of developmental compensation 
which likely influenced these assays in the transgenic mouse study. Together, 
these data would support the hypothesis that rAAV-mediated cardiac 
transduction of histidine-modified cTnI into an adult heart improves inotropy and 
decreases diastolic chamber stiffness during an acute ischemic stress. 
Data at baseline and during ischemic challenges will be compared to 
control hearts transduced with cTnIFLAG to account for any effects attributable to 
the flag epitope. We have previously shown no effect of the FLAG epitope on 
cTnI function246, 251.  
Despite evidence showing improved inotropy in isolated adult rat 
myocytes transduced with cTnIA164H (Figure 4D), in vivo differences in 
contractile function may not be observed between rAAV-cTnIA164H transduced 
hearts and controls. Assuming that sufficient gene transfer can be accomplished, 
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the most probable alternative explanation includes the observed changes in 
calcium handling in transgenic hearts. To account for this possibility, experiments 
are already underway to understand how compensatory changes in calcium 
homeostasis could account for the phenotype observed in the cTnIA164H 
transgenic mouse. If differences are not significant between groups, a beta 
adrenergic receptor agonist (e.g. dobutamine) infusion protocol during acute 
ischemic challenges could be used to exacerbate these differences. Despite 
these considerations, previous reports support the alternative argument that 
developmental compensatory changes in the transgenic mouse may blunt the 
potent effects of cTnIA164H461.  
 
It is established that compensatory LV dilation and eccentric myocardial 
hypertrophy are signs of cardiac remodeling which significantly contribute to the 
pathology of chronic ischemic cardiomyopathy463-465. Over time this leads to 
severe systolic and diastolic dysfunction antecedent to cardiac decompensation 
and death466, 467. LV volume in particular is a powerful prognostic indicator of 
survival in patients with coronary heart disease468. Cavitary dilation of the LV is in 
part the result of asymmetric aneurismal expansion of necrotic tissue.  However, 
compensatory stretch of the non-infarcted myocardium also increases 
contractility and subsequently cardiac output468, 469. Furthermore, contractile 
dysfunction after an MI is associated with regional hypertrophy of the non-
infarcted myocardium. This response enables the heart to compensate for the 
loss of myocytes in the infarct zone in order to improve contractility and retain 
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cardiac output. These mechanisms of increasing wall tension must be generated 
by the ventricle due to the law of LaPlace. However, this need for increased 
tension development ultimately results in the negative spiral of events leading to 
decompensation and heart failure. Based on this, reports have suggested that 
therapeutically increasing myofilament-based inotropy may provide a mechanism 
for maintaining cardiac output and consequently attenuate LV dilation and 
myocardial hypertrophy associated with cardiac remodeling after an MI435. To 
address this, our lab has engineered cTnIA164H which is specifically designed to 
increase calcium sensitivity of the myofilament. The physiologic result of this 
biochemical alteration in cTnI leads to a shift wherein the same cardiac output 
can be generated with reduced end diastolic volume. To support this, our data 
indicate that cTnIA164H attenuates LV remodeling while maintaining inotropy in 
a model of chronic ischemic cardiomyopathy246. Additionally, adenoviral-
mediated delivery of cTnIA164H to failing human myocytes was found to partially 
restore contractility246. Recognizing the merits of this data, however, several 
important questions remain. First, to what extent can cTnIA164H therapeutically 
improve contractility and alter the progression of remodeling in the mature adult 
heart in vivo using temporally different treatment modalities for chronic ischemic 
cardiomyopathy? Furthermore, emergency intervention for ischemic heart 
disease often does not occur until significant myocardial damage has already 
taken place post MI. Taking this intervention model into consideration, the 
question remains whether the therapeutic effect of cTnIA164H is related to its 
presence only during the initial acute ischemic injury or whether cTnIA164H has 
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a more global affect on the heart which is capable of preventing or even 
reversing myocardial remodeling when delivered after the initial ischemic injury? 
These questions take engineered cTnIA164H out of the context of initial 
transgenic studies and into the applicable realm of clinical medicine and the 
diverse mechanisms of delivering therapeutics relative to disease onset.  
Clinical approaches for therapeutic treatment of ischemic cardiomyopathy 
are variable based on the temporal separation of injury from intervention. 
Specifically, for high risk patients therapies are often prescribed preemptively. In 
other cases interventions occur at the time of ischemic injury or, as in chronic 
ischemic cardiomyopathy, may occur long after the injury. To determine if 
cTnIA164H is effective for treatment of ischemic heart disease, these time points 
will be incorporated into the experimental design as separate clinical models. 
Permanent ligation of the LCA as previously described246, 470 will be used to 
model chronic ischemic cardiomyopathy with an expected infarct size of thirty to 
forty percent of the left ventricle. The general experimental approach for Specific 
Aim 2 will be as follows: relative to the time of LCA ligation, rAAV cTnIA164H will 
be delivered systemically by a single tail vein injection four weeks prior to injury 
(cohort 1), at the time of injury (cohort 2), two weeks after the injury (cohort 3), 
and two months after the injury (cohort 4).  
To assess the efficacy of this treatment in these models, several 
methodological assays will be used to measure changes in cardiac structure and 
function. To begin, after acquiring baseline echo data on mice from all groups, 
serial echo measurements will continue to be performed at specific time points to 
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observe changes in disease progression. As a terminal experiment at six months 
post LCA ligation all mice will undergo conductance micromanometry for 
acquisition of hemodynamic function. Heart weight to body weight ratios will be 
measured in addition to analysis of infarct size and area at risk. Lastly, histology 
of frozen whole heart sections will be performed using H&E as well as trichrome 
staining to show any post-MI morphological changes as well as the extent of 
necrosis. 
Results from all assays performed in Specific Aim 2 are expected to show 
that preemptive gene therapy of cTnIA164H (cohort 1) will be the most 
efficacious at improving inotropy and attenuating myocardial remodeling during 
the disease progression of chronic ischemic cardiomyopathy. In this model, 
improved calcium sensitivity and the subsequent shift in the Frank-Starling curve 
at baseline and increasingly during post-infarction ischemia will enable the heart 
to retain contractility, and consequently cardiac output, while protecting global left 
ventricular geometry. Over six months of serial echo, this will be characterized by 
improved systolic function, decreased LV diastolic dimensions and volumes, and 
reduced heart-weight to body weight ratio in cTnIA164H transduced mice 
compared to controls. At the six month endpoint, analysis by conductance 
micromanometry is expected to corroborate echo data showing that improved 
myocardial structure and function correlate with cTnIA164H treatment. 
Consistent with previous data, an abrogated hypertrophic response in 
cTnIA164H transduced hearts is expected to yield an increase in relative infarct 
size and area at risk compared to controls. However, histological analysis of 
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heart sections is expected to show that cTnIA164H treated hearts have reduced 
necrosis and less myofibrillar disarray in the peri-infarct zone and non infarcted 
myocardium relative to controls. In cohorts two, three, and four gradations of 
improved inotropy and attenuated remodeling are expected to show a correlation 
between time of injury and delivery of cTnIA164H. Despite the delay in treatment, 
these clinically relevant treatment modalities are expected to show that in all 
cases therapeutic intervention using cTnIA164H will improve contractility and 
alter the course of myocardial remodeling. Furthermore, experimental designs for 
cohorts three and four will provide models to determine whether AAV-mediated 
delivery of cTnIA164H results in reverse myocardial remodeling. Improved 
inotropy as well as changes in myocyte morphology and calcium homeostasis 
associated with long term cTnIA164H expression may provide a basis for reverse 
remodeling246. It is arguable that these structural and functional improvements 
would result in a reduction of both eccentric hypertrophy and LV dilation. 
Previous studies have shown reverse remodeling after mechanical interventions 
using left ventricular assist devices (LVAD)471. LVADs are specifically designed 
to attenuate LV wall stress by reducing end diastolic volume while still retaining 
sufficient cardiac output. Based on the Frank-Starling law, reverse remodeling is 
an achievable outcome of this therapy. Similarly, it follows that the biochemistry 
of cTnIA164H provides a mechanism for improving contractility such that, again, 
the same cardiac output can be achieved with reduced LV end diastolic volume. 
This would be the first study to show reverse myocardial remodeling by means of 
a simple biochemical alteration of a myofilament protein.  
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Mice transduced with cTnIA164H will be compared to controls including 
sham operated mice transduced with cTnIA164H as well as mice with LCA 
ligation transduced with wild type cTnIFLAG.  
Evidence to support the null hypothesis would suggest that certain 
developmentally acquired compensatory traits in the cTnIA164H transgenic 
mouse likely account for maintenance of contractility and attenuation of 
myocardial remodeling observed in a model of chronic myocardial ischemia. In 
addition to changes in calcium homeostasis that may contribute to abrogating the 
pathophysiology of chronic ischemia, acquired morphologic changes including a 
reduced myocyte size in transgenic hearts could also account for attenuated 
remodeling in the case of chronic myocardial infarction. In this way, the null 
hypothesis is informative, providing the basis for further analysis of morphologic 
changes and alterations in calcium homeostasis in protecting the heart from 
chronic ischemic injury. However, the argument remains that developmentally 
acquired compensatory changes in the transgenic mouse may blunt the potent 
effects of cTnIA164H461. AAV mediated gene transfer into the adult heart would 
consequently enhance the functional and structural effects of cTnIA164H. Other 
potentially informative non-hemodynamic assays to study the efficacy of 
cTnIA164H to protect cardiovascular function include analysis of metabolic 
oxygen consumption or expression of heart failure markers such as β-MyHC, 




Part II: Site directed mutagenesis to determine the mechanism of the regulatory 
interaction between TnI and TnC 
 
The studies outlined in this dissertation provide some progress in the way of 
understanding troponin function in the context of the myofilaments. However, our 
basic understanding of troponin performance as a critical regulatory complex 
requires further investigation. A powerful methodology to further delineate the 
role of single amino acids in this regulatory interaction of troponin can be 
accomplished by site-directed mutagenesis followed by adenoviral-mediated 
gene transfer into adult cardiac myocytes (as described previously104, 202, 246, 314, 
319, 333, 392). Genetically modified cardiac myocytes can then be used to 
understand the effect of specific protein modifications on contractile performance 
of intact myocytes and calcium sensitivity of the myofilaments in permeabilized 
myocytes.  
  
Overall, the goal of these assays would be to determine the role of amino acids 
at the interface of the calcium saturated cTnI:cTnC structure in regulating 
contractility. 
To begin, it would be interesting to determine whether cTnC E19, as 
opposed to any other acidic residue in the N-terminal hydrophobic patch, has a 
dominant effect in regulating contact with cTnI in the calcium saturated state. The 
studies outlined in this dissertation provide a basis with which to generate 
additional troponin mutants to further understand this regulatory interaction 
276 
 
between TnI and TnC. Specifically, I have generated cTnC mutants containing 
alanine mutants of some of the key acidic residues known to decorate the rim of 
the hydrophobic patch (E19A and D25A). The molecular modeling studies 
(chapters 2 and 5) provide strong evidence for the role of E19A as a key residue 
involved in the electrostatic binding between cTnC and TnI (slow skeletal and 
cardiac) in the calcium saturated state. If this is true, I would hypothesize that the 
E19A mutant will markedly diminish the contractile performance of myocytes 
compared to D25A. Furthermore, given the very close and stabile interaction 
between H132 and E19 in the slow skeletal complex compared to the transient 
interaction between R163 and E19 in the cardiac complex I would hypothesize 
that the E19A mutant would have a greater effect on the contractile performance 
of the skeletal complex. Using permeabilized myocytes and assessing calcium 
activated isometric tension, I would hypothesize that the E19A mutant would 
decrease the calcium sensitivity of the myofilaments, again, with the greater 
effect being seen in the skeletal complex compared to the cardiac complex. 
Furthermore, I would hypothesize that the D25A mutant would have very minimal 
effects on calcium sensitivity of the myofilaments, at least based on structural 
modeling of the TnI interaction with this residue. Together, these studies would 
provide key insights into the role of acidic residues of the hydrophobic patch of 
cTnC on troponin regulatory function.  
  
In additional experiments, it would be interesting to determine whether a proline 
in the cTnI switch arm functions as a biochemical correlate to alanine. 
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Phylogenetic data provide evidence that a proline residue may have acted as an 
intermediate moiety between the cTnI histidine of ancestral species and the 
alanine observed in mammals. To test the hypothesis that proline acts to break 
the key high energy intermolecular contact with cTnC E19, mutagenesis 
experiments could be performed by generating an ssTnI H132P molecule. I 
would hypothesize that very similar results would be obtained compared to the 
ssTnI H132A mutant. Alternatively, one could generate a cTnI A164P molecule. I 
would hypothesize that this protein would not have marked differences in 
contractility compared to WT cTnI.  
 
In other mutagenesis experiments, it would be informative to determine 
whether a single amino acid modification, ssTnI L122 to cTnI M156 markedly 
alters contractility and provides insight into the functional difference between the 
cTnI and ssTnI isoforms. Molecular dynamic simulations using alanine scanning 
to calculate the binding free energy at the interface of sTnI and cTnC showed 
that ssTnI leucine 122 contributes significantly to the free energy of binding 
between TnC and TnI (0.84 kcal/mol). This is compared to the >0.99 kcal/mol 
contribution generated by histidine. Structural analysis of sTnI-cTnC show that 
Leu122 interacts with cTnC Phe20 (2.3 angstroms) providing a substrate for 
intermolecular hydrophobic contacts. In all species ssTnI L122 is converted to 
methionine (M156) in cardiac TnI. This would indicate that there is a unique 
function for these hydrophobic residues in mediating the functional difference 
between ssTnI and cTnI. In the simulated cTnI structure, M156 has an 
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intermolecular distance from Phe20 of 2.4 angstroms which likely is a significant 
contributor to the hydrophobic strength of the cTnI-cTnC interaction (Figure 7-
3a). If mutagenesis was performed on cTnC Phe20 (F20A) I would hypothesize a 
similar reduction in contractile performance when cTnC F20A is complexed with 
ssTnI and cTnI.  
  
Furthermore, it would be interesting to determine the role of basic residues 
in mediating the electrostatic contacts between cTnI and cTnC in the calcium 
saturated state. The molecular simulations show that cTnI R163 is critical for 
generating electrostatic interactions with cTnC E19 (distance = 2.0 angstroms) 
(Figure 7-3b). In contrast, K 165 which flanks the opposite side of the alanine, 
does not appear to have any role in electrostatically mediating the interaction 
between cTnI and cTnC. One could test this hypothesis by mutating both 
residues (R163A and K165A) to determine which of these is most important for 
electrastic binding to TnC. Molecular modeling supports R163 in this role 
suggesting that K165 would not have any (or mild) effect on contractility of cTnI. 
Alignment data show that R163 and K165 are basic residues in all TnI isoforms 
of all species across chordate evolution (with the exception of a threonine in 
place of R163 in xenopus). Assuming that K165 does not effect cTnI binding to 
cTnC in the calcium saturated state, it is possible (given the high conservation of 
this residue) that it is a key mediator for the binding of this domain to actin during 





Figure 7-3. Testable hypotheses for residues important in cTn function. (a) cTnI 
M156 interaction with cTnC F20. (b) cTnI R163 interaction with cTnC E19 is the 
key electrostatic interaction of cTn. (c) cTnI H172 – D168 interaction potentially 
important in helix stabilization. (d, e) Residues important for the hydrophobic 
contacts between cTnC and cTnI with an emphasis on L159. (d) Residues within 
the ribbon structure and (e) clearer representation of the position of hydrophobic 
residues between cTnC (green) and cTnI (Methionine residues: yellow; Leucine 









To study the importance of structural features, it would be interesting to 
determine if cTnI switch domain helix stability is important for mediating 
contractility. In contrast to ssTnI which has an extended, unstructured domain 
interacting with cTnC, the cTnI switch domain is helical. Based on molecular 
simulation structures, the substitutions that would theoretically disrupt the helical 
stability of cTnI H4 include: H172A and D168A (these residues form a salt bridge 
in the simulated structure; distance = 1.9 angstroms) (Figure 7-3c). Mutagenesis 
experiments that disrupt this salt bridge would like extend the helix. Given that 
this helical stabilization is beyond the key cTnC E19- cTnI R163 interaction, it is 
difficult to determine exactly what effect this might have on contractile 
performance. 
  
Lastly, it would be interesting to determine whether cTnI L159 is the most 
important residue involved in the hydrophobic contact with cTnC in the calcium 
saturated state. It has long been established that hydrophobic interactions 
mediate a large part of the contact of the cTnI switch domain to the N-terminus of 
cTnC. Molecular simulations of the calcium saturated cTn structure indicate that 
L159 is likely the most important hydrophobic moiety in cTnI that interacts with a 
number of hydrophobic residues on numerous helices of cTnC (Figure 7-3d,e). In 
the original 1j1e crystal structure, L160 is shown to make hydrophobic contacts 
with cTnC. However, molecular simulation structures indicate that L160 is solvent 
exposed and thus has no interactions with cTnC. Furthermore, cTnI M155 and 
M156 interact with Phe moieties on cTnC but have markedly reduced 
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hydrophobic contacts compared to L159. These data would suggest that, more 
than any other hydrophobic residue on cTnI, mutation of L156 would significantly 
decrease the binding affinity of the switch domain and thus diminish contractility 
because of the loss of a key hydrophobic interaction between these molecules. 
Molecular dynamics simulations with alanine scanning (as performed in chapter 
2) could be used to in silico prove this point followed by functional assessments 
in vitro.  
  
Part III: Calcium cycling and myofilament calcium sensitivity 
 
I would like to propose a hypothesis that ties together regulation of 
calcium sensitivity of the myofilaments and dynamic modulation of calcium 
activation. The current data indicate that cTnI A164H alone is able to modulate 
calcium cycling in single and double (cross with PLN KO) Tg mice. Several 
studies of Tg mice containing amino acid mutations in the Tn complex indicate a 
correlation between heightened myofilament calcium sensitivity and differential 
remodeling of calcium handling. First, in a study by Du et al. a knock-in model of 
dilated cardiomyopathy caused by a deletion in TnT (TnT Δ210-219) showed 
decreased calcium sensitivity with a correlative increase in calcium transient 
amplitude compaired to control472. A report by Baudenbacher et al showed that 
the TnT F110I mutant has a mild increase in calcium sensitivity compared to 
controls. However, calcium cycling and SR storage have not been reported on 
this model. In terms of the cTnI A164H Tg mouse, there is a marked increase in 
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calcium sensitivity of the myofilaments compared to controls with a correlative 
decrease in SR calcium storage compared to controls246, 290. Studies by 
Knollmann and colleagues have shown that the TnT I79N mutation has 
increased myofilament calcium sensitivity with reduced calcium transients473. As 
mentioned previously, the ssTnI Tg mouse has heightend calcium sensitivity of 
the myofilaments with no changes in calcium transient amplitude213. Lastly, 
unpublished data of the cTnI R193H transgenic mouse also indicate that 
myofilaments containing this mutant protein have heightened calcium sensitivity 
without changes in calcium transients compared to WT mice. Reported measures 
of myofilament calcium sensitivity place these mice in the following order: 
TnTΔ210-219 < WT < TnT F110I < cTnI A164H = TnT I79N = ssTnI = cTnI 
R193H. With the exception of unreported data on the TnT F110I mutant, calcium 
appears to increase with decreased myofilament calcium sensitivity (TnT Δ210-
219) and subsequently decrease with progressive increases in calcium sensitivity 
(WT through TnT I79N). In the last 2 cases (ssTnI and cTnI R193H) calcium is 
not different from WT levels. Functionally, reports have shown that compared to 
WT mice, cTnI A164H and TnT I79N do not have reproducible diastolic 
dysfunction in every assay246, 474. In contrast, ssTnI and cTnI R193H show 
profound diastolic dysfunction compared to WT mice in every measure of 
lusitropy213(R193H data not reported).  
These data indicate that there may be a correlation between calcium 
cycling and myofilament calcium sensitivity within a certain working range. In 
other words, remodeling of calcium cycling may be allowable within a range 
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where decreases in activating calcium are advantageous to maintain diastolic 
performance as much as possible. To test this hypothesis, we could cross the 
PLN KO mouse with all or some of these lines with a specific focus on models 
that provide a range of calcium sensitization. If the hypothesis is true then the 
TnT Δ210-219 would perhaps increase calcium cycling compared to WT mice. In 
contrast, TnT F110I and TnT I79N would decrease activating calcium similar to 
observations with cTnI A164H. Lastly, similar with the ssTnI PLN KO double Tg 
mouse, cTnI R193H crossed with PLN KO would not decrease calcium cycling 
because it is outside of the domain in which modulation of calcium cycling would 
benefit cardiac performance. At the very least, these observed differences at the 
level of single Tg mice are consistant with the hypothesis and as such lead to the 
potential of testing whether similar modulation occurs in a model of heightened 
calcium cycling such as the PLN KO mouse. 
These assays simply address whether calcium sensitivity actually 
influences calcium cycling. However it provides no insight into the mechanism by 
which this occurs. Additionally, important questions to assess include whether 
this modulation of calcium cycling occurs exclusively during heart development in 
vivo. It would also be important to determine if calcium cycling is modulated in 
vitro after genetic modification of myocytes and if there is a dose dependent 








1. Bishopric NH. Evolution of the heart from bacteria to man. Ann N Y Acad 
Sci. 2005;1047:13-29. 
2. Schiaffino S, Reggiani C. Molecular diversity of myofibrillar proteins: Gene 
regulation and functional significance. Physiological Reviews. 
1996;76(2):371-423. 
3. Willis MS, Schisler JC, Portbury AL, Patterson C. Build it up-Tear it down: 
protein quality control in the cardiac sarcomere. Cardiovasc Res. 
2009;81(3):439-448. 
4. Shiels HA, White E. The Frank-Starling mechanism in vertebrate cardiac 
myocytes. J Exp Biol. 2008;211(Pt 13):2005-2013. 
5. Lillywhite HB, Zippel KC, Farrell AP. Resting and maximal heart rates in 
ectothermic vertebrates. Comp Biochem Physiol A Mol Integr Physiol. 
1999;124(4):369-382. 
6. Mendonca PC, Genge AG, Deitch EJ, Gamperl AK. Mechanisms 
responsible for the enhanced pumping capacity of the in situ winter 
flounder heart (Pseudopleuronectes americanus). Am J Physiol Regul 
Integr Comp Physiol. 2007;293(5):R2112-2119. 
7. Jurgens KD, Fons R, Peters T, Sender S. Heart and respiratory rates and 
their significance for convective oxygen transport rates in the smallest 
mammal, the Etruscan shrew Suncus etruscus. J Exp Biol. 1996;199(Pt 
12):2579-2584. 
8. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial Substrate 
Metabolism in the Normal and Failing Heart. Physiol. Rev. 
2005;85(3):1093-1129. 
9. Metzger JM, Westfall MV. Covalent and Noncovalent Modification of Thin 
Filament Action: The Essential Role of Troponin in Cardiac Muscle 
Regulation. Circulation Research. 2004;94(2):146-158. 
10. Brodde OE. Beta-adrenoceptor blocker treatment and the cardiac beta-
adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart 
failure. Naunyn Schmiedebergs Arch Pharmacol. 2007;374(5-6):361-372. 
11. Brutsaert DL, Sys SU. Relaxation and diastole of the heart. Physiol Rev. 
1989;69(4):1228-1315. 
12. Swynghedauw B. Molecular mechanisms of myocardial remodeling. 
Physiol Rev. 1999;79(1):215-262. 
13. Taylor EW, Jordan D, Coote JH. Central control of the cardiovascular and 
respiratory systems and their interactions in vertebrates. Physiol Rev. 
1999;79(3):855-916. 
14. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, 
Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC, Jr., 
Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, 
Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller 
285 
 
S, Wilson M, Wolf P. Heart disease and stroke statistics--2006 update: a 
report from the American Heart Association Statistics Committee and 
Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85-151. 
15. Huxley HE. Fifty years of muscle and the sliding filament hypothesis. Eur J 
Biochem. 2004;271(8):1403-1415. 
16. Maughan DW. Kinetics and energetics of the crossbridge cycle. Heart Fail 
Rev. 2005;10(3):175-185. 
17. Gordon AM, ter Keurs HE. Molecular and cellular aspects of muscle 
contraction. General discussion part II. Adv Exp Med Biol. 2003;538:661-
669, 687-668. 
18. Gordon AM, Homsher E, Regnier M. Regulation of Contraction in Striated 
Muscle. Physiol. Rev. 2000;80(2):853-924. 
19. Moss RL, Razumova M, Fitzsimons DP. Myosin Crossbridge Activation of 
Cardiac Thin Filaments: Implications for Myocardial Function in Health and 
Disease. Circ Res. 2004;94(10):1290-1300. 
20. Moss RL, Fitzsimons DP. Myosin Light Chain 2 Into the Mainstream of 
Cardiac Development and Contractility. Circulation Research. 
2006;99(3):225-227. 
21. Herron TJ, Devaney EJ, Metzger JM. Modulation of cardiac performance 
by motor protein gene transfer. Ann N Y Acad Sci. 2008;1123:96-104. 
22. Hinken AC, Solaro RJ. A Dominant Role of Cardiac Molecular Motors in 
the Intrinsic Regulation of Ventricular Ejection and Relaxation. Physiology. 
2007;22(2):73-80. 
23. Haselgrove JC, Huxley HE. X-ray evidence for radial cross-bridge 
movement and for the sliding filament model in actively contracting 
skeletal muscle. J Mol Biol. 1973;77(4):549-568. 
24. Herron TJ, Vandenboom R, Fomicheva E, Mundada L, Edwards T, 
Metzger JM. Calcium-independent negative inotropy by beta-myosin 
heavy chain gene transfer in cardiac myocytes. Circ Res. 
2007;100(8):1182-1190. 
25. Harris DE, Work SS, Wright RK, Alpert NR, Warshaw DM. Smooth, 
cardiac and skeletal muscle myosin force and motion generation assessed 
by cross-bridge mechanical interactions in vitro. J Muscle Res Cell Motil. 
1994;15(1):11-19. 
26. Malmqvist UP, Aronshtam A, Lowey S. Cardiac myosin isoforms from 
different species have unique enzymatic and mechanical properties. 
Biochemistry. 2004;43(47):15058-15065. 
27. Palmiter KA, Tyska MJ, Dupuis DE, Alpert NR, Warshaw DM. Kinetic 
differences at the single molecule level account for the functional diversity 
of rabbit cardiac myosin isoforms. J Physiol. 1999;519 Pt 3:669-678. 
28. Cooke R. Actomyosin interaction in striated muscle. Physiol. Rev. 
1997;77(3):671-697. 
29. Kobayashi T, Solaro RJ. CALCIUM, THIN FILAMENTS, AND THE 
INTEGRATIVE BIOLOGY OF CARDIAC CONTRACTILITY. Annual 
Review of Physiology. 2005;67(1):39-67. 
286 
 
30. Guan JQ, Takamoto K, Almo SC, Reisler E, Chance MR. Structure and 
dynamics of the actin filament. Biochemistry. 2005;44(9):3166-3175. 
31. Holmes KC, Popp D, Gebhard W, Kabsch W. Atomic model of the actin 
filament. Nature. 1990;347(6288):44-49. 
32. Lorenz M, Poole KJ, Popp D, Rosenbaum G, Holmes KC. An atomic 
model of the unregulated thin filament obtained by X-ray fiber diffraction 
on oriented actin-tropomyosin gels. J Mol Biol. 1995;246(1):108-119. 
33. Farah CS, Reinach FC. The troponin complex and regulation of muscle 
contraction. The FASEB Journal. 1995;9(9):755-767. 
34. Phillips GN, Jr., Cohen C, Stewart M. A new crystal form of tropomyosin. 
Preliminary X-ray diffraction analysis. J Mol Biol. 1987;195(1):219-223. 
35. Whitby FG, Phillips GN, Jr. Crystal structure of tropomyosin at 7 
Angstroms resolution. Proteins. 2000;38(1):49-59. 
36. Phillips GN, Jr., Fillers JP, Cohen C. Tropomyosin crystal structure and 
muscle regulation. J Mol Biol. 1986;192(1):111-131. 
37. Brown JH, Kim KH, Jun G, Greenfield NJ, Dominguez R, Volkmann N, 
Hitchcock-DeGregori SE, Cohen C. Deciphering the design of the 
tropomyosin molecule. Proc Natl Acad Sci U S A. 2001;98(15):8496-8501. 
38. Murakami K, Stewart M, Nozawa K, Tomii K, Kudou N, Igarashi N, 
Shirakihara Y, Wakatsuki S, Yasunaga T, Wakabayashi T. Structural basis 
for tropomyosin overlap in thin (actin) filaments and the generation of a 
molecular swivel by troponin-T. Proceedings of the National Academy of 
Sciences. 2008;105(20):7200-7205. 
39. Potter JD. The content of troponin, tropomyosin, actin, and myosin in 
rabbit skeletal muscle myofibrils. Arch Biochem Biophys. 1974;162(2):436-
441. 
40. Yates LD, Greaser ML. Troponin subunit stoichiometry and content in 
rabbit skeletal muscle and myofibrils. J Biol Chem. 1983;258(9):5770-
5774. 
41. Shiner JS, Solaro RJ. Activation of thin-filament-regulated muscle by 
calcium ion: considerations based on nearest-neighbor lattice statistics. 
Proc Natl Acad Sci U S A. 1982;79(15):4637-4641. 
42. Solaro RJ, Van Eyk J. Altered interactions among thin filament proteins 
modulate cardiac function. J Mol Cell Cardiol. 1996;28(2):217-230. 
43. Parry DA, Squire JM. Structural role of tropomyosin in muscle regulation: 
analysis of the x-ray diffraction patterns from relaxed and contracting 
muscles. J Mol Biol. 1973;75(1):33-55. 
44. Chalovich JM, Eisenberg E. Inhibition of actomyosin ATPase activity by 
troponin-tropomyosin without blocking the binding of myosin to actin. J. 
Biol. Chem. 1982;257(5):2432-2437. 
45. Lehrer SS, Morris EP. Comparison of the effects of smooth and skeletal 




46. Valerie B. Patchell CEGMAHAFSVPBAL. The inhibitory region of troponin-
I alters the ability of F-actin to interact with different segments of myosin. 
European Journal of Biochemistry. 2002;269(20):5088-5100. 
47. Patchell VB, Gallon CE, Evans JS, Gao Y, Perry SV, Levine BA. The 
Regulatory Effects of Tropomyosin and Troponin-I on the Interaction of 
Myosin Loop Regions with F-actin. J. Biol. Chem. 2005;280(15):14469-
14475. 
48. Ebashi S, Kodama A. A new protein factor promoting aggregation of 
tropomyosin. J Biochem. 1965;58(1):107-108. 
49. Greaser ML, Gergely J. Reconstitution of troponin activity from three 
protein components. J Biol Chem. 1971;246(13):4226-4233. 
50. Filatov VL, Katrukha AG, Bulargina TV, Gusev NB. Troponin: structure, 
properties, and mechanism of functioning. Biochemistry (Mosc). 
1999;64(9):969-985. 
51. Vinogradova MV, Stone DB, Malanina GG, Karatzaferi C, Cooke R, 
Mendelson RA, Fletterick RJ. Ca(2+)-regulated structural changes in 
troponin. Proc Natl Acad Sci U S A. 2005;102(14):5038-5043. 
52. Takeda S, Yamashita A, Maeda K, Maeda Y. Structure of the core domain 
of human cardiac troponin in the Ca2+-saturated form. Nature. 
2003;424(6944):35-41. 
53. Nassar R, Malouf NN, Kelly MB, Oakeley AE, Anderson PA. Force-pCa 
relation and troponin T isoforms of rabbit myocardium. Circ Res. 
1991;69(6):1470-1475. 
54. Schachat FH, Diamond MS, Brandt PW. Effect of different troponin T-
tropomyosin combinations on thin filament activation. J Mol Biol. 
1987;198(3):551-554. 
55. Farah CS, Miyamoto CA, Ramos CH, da Silva AC, Quaggio RB, Fujimori 
K, Smillie LB, Reinach FC. Structural and regulatory functions of the NH2- 
and COOH-terminal regions of skeletal muscle troponin I. Journal of 
Biological Chemistry. 1994;269(7):5230-5240. 
56. Potter JD, Sheng Z, Pan BS, Zhao J. A direct regulatory role for troponin T 
and a dual role for troponin C in the Ca2+ regulation of muscle 
contraction. J Biol Chem. 1995;270(6):2557-2562. 
57. Mak AS, Smillie LB. Non-polymerizable tropomyosin: preparation, some 
properties and F-actin binding. Biochem Biophys Res Commun. 
1981;101(1):208-214. 
58. Blumenschein TM, Tripet BP, Hodges RS, Sykes BD. Mapping the 
interacting regions between troponins T and C. Binding of TnT and TnI 
peptides to TnC and NMR mapping of the TnT-binding site on TnC. J Biol 
Chem. 2001;276(39):36606-36612. 
59. Maytum R, Geeves MA, Lehrer SS. A modulatory role for the troponin T 
tail domain in thin filament regulation. J Biol Chem. 2002;277(33):29774-
29780. 
60. Tobacman LS, Nihli M, Butters C, Heller M, Hatch V, Craig R, Lehman W, 
Homsher E. The troponin tail domain promotes a conformational state of 
288 
 
the thin filament that suppresses myosin activity. J Biol Chem. 
2002;277(31):27636-27642. 
61. van Eerd JP, Takahashi K. The amino acid sequence of bovine cardiac 
tamponin-C. Comparison with rabbit skeletal troponin-C. Biochem Biophys 
Res Commun. 1975;64(1):122-127. 
62. Zot HG, Potter JD. A structural role for the Ca2+-Mg2+ sites on troponin C 
in the regulation of muscle contraction. Preparation and properties of 
troponin C depleted myofibrils. J Biol Chem. 1982;257(13):7678-7683. 
63. Herzberg O, James MN. Structure of the calcium regulatory muscle 
protein troponin-C at 2.8 A resolution. Nature. 1985;313(6004):653-659. 
64. Sia SK, Li MX, Spyracopoulos L, Gagne SM, Liu W, Putkey JA, Sykes BD. 
Structure of cardiac muscle troponin C unexpectedly reveals a closed 
regulatory domain. J Biol Chem. 1997;272(29):18216-18221. 
65. Slupsky CM, Sykes BD. NMR solution structure of calcium-saturated 
skeletal muscle troponin C. Biochemistry. 1995;34(49):15953-15964. 
66. Sun YB, Brandmeier B, Irving M. Structural changes in troponin in 
response to Ca2+ and myosin binding to thin filaments during activation of 
skeletal muscle. Proc Natl Acad Sci U S A. 2006;103(47):17771-17776. 
67. Babu A, Rao VG, Su H, Gulati J. Critical minimum length of the central 
helix in troponin C for the Ca2+ switch in muscular contraction. J Biol 
Chem. 1993;268(26):19232-19238. 
68. Sheng ZL, Francois JM, Hitchcock-DeGregori SE, Potter JD. Effects of 
mutations in the central helix of troponin C on its biological activity. J Biol 
Chem. 1991;266(9):5711-5715. 
69. Babu A, Scordilis SP, Sonnenblick EH, Gulati J. The control of myocardial 
contraction with skeletal fast muscle troponin C. J Biol Chem. 
1987;262(12):5815-5822. 
70. Gulati J, Scordilis S, Babu A. Effect of troponin C on the cooperativity in 
Ca2+ activation of cardiac muscle. FEBS Lett. 1988;236(2):441-444. 
71. Holroyde MJ, Robertson SP, Johnson JD, Solaro RJ, Potter JD. The 
calcium and magnesium binding sites on cardiac troponin and their role in 
the regulation of myofibrillar adenosine triphosphatase. J Biol Chem. 
1980;255(24):11688-11693. 
72. Kretsinger RH, Nockolds CE. Carp muscle calcium-binding protein. II. 
Structure determination and general description. J Biol Chem. 
1973;248(9):3313-3326. 
73. Sweeney HL, Brito RM, Rosevear PR, Putkey JA. The low-affinity Ca2(+)-
binding sites in cardiac/slow skeletal muscle troponin C perform distinct 
functions: site I alone cannot trigger contraction. Proc Natl Acad Sci U S 
A. 1990;87(24):9538-9542. 
74. Putkey JA, Sweeney HL, Campbell ST. Site-directed mutation of the 




75. Robertson SP, Johnson JD, Potter JD. The time-course of Ca2+ exchange 
with calmodulin, troponin, parvalbumin, and myosin in response to 
transient increases in Ca2+. Biophys J. 1981;34(3):559-569. 
76. Johnson JD, Charlton SC, Potter JD. A fluorescence stopped flow analysis 
of Ca2+ exchange with troponin C. J Biol Chem. 1979;254(9):3497-3502. 
77. Gagne SM, Tsuda S, Li MX, Smillie LB, Sykes BD. Structures of the 
troponin C regulatory domains in the apo and calcium-saturated states. 
Nat Struct Biol. 1995;2(9):784-789. 
78. Li MX, Gagne SM, Spyracopoulos L, Kloks CP, Audette G, Chandra M, 
Solaro RJ, Smillie LB, Sykes BD. NMR studies of Ca2+ binding to the 
regulatory domains of cardiac and E41A skeletal muscle troponin C reveal 
the importance of site I to energetics of the induced structural changes. 
Biochemistry. 1997;36(41):12519-12525. 
79. McKay RT, Saltibus LF, Li MX, Sykes BD. Energetics of the induced 
structural change in a Ca2+ regulatory protein: Ca2+ and troponin I 
peptide binding to the E41A mutant of the N-domain of skeletal troponin C. 
Biochemistry. 2000;39(41):12731-12738. 
80. Brito RM, Putkey JA, Strynadka NC, James MN, Rosevear PR. 
Comparative NMR studies on cardiac troponin C and a mutant incapable 
of binding calcium at site II. Biochemistry. 1991;30(42):10236-10245. 
81. Kobayashi T, Zhao X, Wade R, Collins JH. Involvement of conserved, 
acidic residues in the N-terminal domain of troponin C in calcium-
dependent regulation. Biochemistry. 1999;38(17):5386-5391. 
82. Brito RM, Krudy GA, Negele JC, Putkey JA, Rosevear PR. Calcium plays 
distinctive structural roles in the N- and C-terminal domains of cardiac 
troponin C. J Biol Chem. 1993;268(28):20966-20973. 
83. Pan BS, Solaro RJ. Calcium-binding properties of troponin C in detergent-
skinned heart muscle fibers. J Biol Chem. 1987;262(16):7839-7849. 
84. Hazard AL, Kohout SC, Stricker NL, Putkey JA, Falke JJ. The kinetic cycle 
of cardiac troponin C: calcium binding and dissociation at site II trigger 
slow conformational rearrangements. Protein Sci. 1998;7(11):2451-2459. 
85. Johnson JD, Collins JH, Robertson SP, Potter JD. A fluorescent probe 
study of Ca2+ binding to the Ca2+-specific sites of cardiac troponin and 
troponin C. J Biol Chem. 1980;255(20):9635-9640. 
86. Dong WJ, Cheung HC. Calcium-induced conformational change in cardiac 
troponin C studied by fluorescence probes attached to Cys-84. Biochim 
Biophys Acta. 1996;1295(2):139-146. 
87. Putkey JA, Liu W, Lin X, Ahmed S, Zhang M, Potter JD, Kerrick WG. 
Fluorescent probes attached to Cys 35 or Cys 84 in cardiac troponin C are 
differentially sensitive to Ca(2+)-dependent events in vitro and in situ. 
Biochemistry. 1997;36(4):970-978. 
88. Perry SV. Troponin I: inhibitor or facilitator. Mol Cell Biochem. 1999;190(1-
2):9-32. 
89. Siedner S, Kruger M, Schroeter M, Metzler D, Roell W, Fleischmann BK, 
Hescheler J, Pfitzer G, Stehle R. Developmental changes in contractility 
290 
 
and sarcomeric proteins from the early embryonic to the adult stage in the 
mouse heart. Journal of Physiology-London. 2003;548(2):493-505. 
90. Hunkeler NM, Kullman J, Murphy AM. Troponin I isoform expression in 
human heart. Circ Res. 1991;69(5):1409-1414. 
91. Van Eyk JE, Thomas LT, Tripet B, Wiesner RJ, Pearlstone JR, Farah CS, 
Reinach FC, Hodges RS. Distinct regions of troponin I regulate Ca2+-
dependent activation and Ca2+ sensitivity of the acto-S1-TM ATPase 
activity of the thin filament. J Biol Chem. 1997;272(16):10529-10537. 
92. Robinson JM, Dong W-J, Xing J, Cheung HC. Switching of Troponin I: 
Ca2+ and Myosin-induced Activation of Heart Muscle. Journal of 
Molecular Biology. 2004;340(2):295-305. 
93. Westfall MV, Albayya FP, Metzger JM. Functional Analysis of Troponin I 
Regulatory Domains in the Intact Myofilament of Adult Single Cardiac 
Myocytes. Journal of Biological Chemistry. 1999;274(32):22508-22516. 
94. Brown LJ, Sale KL, Hills R, Rouviere C, Song L, Zhang X, Fajer PG. 
Structure of the inhibitory region of troponin by site directed spin labeling 
electron paramagnetic resonance. Proceedings of the National Academy 
of Sciences. 2002;99(20):12765-12770. 
95. Vassylyev DG, Takeda S, Wakatsuki S, Maeda K, Maeda Y. Crystal 
structure of troponin C in complex with troponin I fragment at 2.3-A 
resolution. Proceedings of the National Academy of Sciences. 
1998;95(9):4847-4852. 
96. Blumenschein TMA, Tripet BP, Hodges RS, Sykes BD. Mapping the 
Interacting Regions between Troponins T and C. BINDING OF TnT AND 
TnI PEPTIDES TO TnC AND NMR MAPPING OF THE TnT-BINDING 
SITE ON TnC. J. Biol. Chem. 2001;276(39):36606-36612. 
97. Campbell AP, Sykes BD. Interaction of troponin I and troponin C : Use of 
the two-dimensional nuclear magnetic resonance transferred nuclear 
overhauser effect to determine the structure of the inhibitory troponin I 
peptide when bound to skeletal troponin C. Journal of Molecular Biology. 
1991;222(2):405-421. 
98. Lindhout DA, Sykes BD. Structure and Dynamics of the C-domain of 
Human Cardiac Troponin C in Complex with the Inhibitory Region of 
Human Cardiac Troponin I. J. Biol. Chem. 2003;278(29):27024-27034. 
99. Syska H, Wilkinson JM, Grand RJ, Perry SV. The relationship between 
biological activity and primary structure of troponin I from white skeletal 
muscle of the rabbit. Biochem J. 1976;153(2):375-387. 
100. Sheng Z, Pan BS, Miller TE, Potter JD. Isolation, expression, and mutation 
of a rabbit skeletal muscle cDNA clone for troponin I. The role of the NH2 
terminus of fast skeletal muscle troponin I in its biological activity. J Biol 
Chem. 1992;267(35):25407-25413. 
101. Abbott MB, Dong WJ, Dvoretsky A, DaGue B, Caprioli RM, Cheung HC, 
Rosevear PR. Modulation of Cardiac Troponin C-Cardiac Troponin I 




102. Baryshnikova OK, Li MX, Sykes BD. Modulation of Cardiac Troponin C 
Function by the Cardiac-Specific N-Terminus of Troponin I: Influence of 
PKA Phosphorylation and Involvement in Cardiomyopathies. Journal of 
Molecular Biology. 2008;375(3):735-751. 
103. Rarick HM, Tang H-p, Guo X-d, Martin AF, Solaro RJ. Interactions at the 
NH2-Terminal Interface of Cardiac Troponin I Modulate Myofilament 
Activation. Journal of Molecular and Cellular Cardiology. 1999;31(2):363-
375. 
104. Westfall MV, Turner I, Albayya FP, Metzger JM. Troponin I chimera 
analysis of the cardiac myofilament tension response to protein kinase A. 
Am J Physiol Cell Physiol. 2001;280(2):C324-332. 
105. Ward DG, Brewer SM, Calvert MJ, Gallon CE, Gao Y, Trayer IP. 
Characterization of the interaction between the N-terminal extension of 
human cardiac troponin I and troponin C. Biochemistry. 2004;43(13):4020-
4027. 
106. Ward DG, Brewer SM, Cornes MP, Trayer IP. A cross-linking study of the 
N-terminal extension of human cardiac troponin I. Biochemistry. 
2003;42(34):10324-10332. 
107. Sadayappan S, Finley N, Howarth JW, Osinska H, Klevitsky R, Lorenz JN, 
Rosevear PR, Robbins J. Role of the acidic N' region of cardiac troponin I 
in regulating myocardial function. FASEB J. 2008;22(4):1246-1257. 
108. Howarth JW, Meller J, Solaro RJ, Trewhella J, Rosevear PR. 
Phosphorylation-dependent Conformational Transition of the Cardiac 
Specific N-Extension of Troponin I in Cardiac Troponin. Journal of 
Molecular Biology. 2007;373(3):706-722. 
109. Jaquet K, Lohmann K, Czisch M, Holak T, Gulati J, Jaquet R. A model for 
the function of the bisphosphorylated heart-specific troponin-I N-terminus. 
J Muscle Res Cell Motil. 1998;19(6):647-659. 
110. Cachia PJ, Sykes BD, Hodges RS. Calcium-dependent inhibitory region of 
troponin: a proton nuclear magnetic resonance study on the interaction 
between troponin C and the synthetic peptide N alpha-
acetyl[FPhe106]TnI-(104-115) amide. Biochemistry. 1983;22(17):4145-
4152. 
111. Talbot JA, Hodges RS. Synthetic studies on the inhibitory region of rabbit 
skeletal troponin I. Relationship of amino acid sequence to biological 
activity. J Biol Chem. 1981;256(6):2798-2802. 
112. Talbot JA, Hodges RS. Comparative studies on the inhibitory region of 
selected species of troponin-I. The use of synthetic peptide analogs to 
probe structure-function relationships. J Biol Chem. 1981;256(23):12374-
12378. 
113. Van Eyk JE, Hodges RS. The biological importance of each amino acid 
residue of the troponin I inhibitory sequence 104-115 in the interaction 




114. Tung CS, Wall ME, Gallagher SC, Trewhella J. A model of troponin-I in 
complex with troponin-C using hybrid experimental data: the inhibitory 
region is a beta-hairpin. Protein Sci. 2000;9(7):1312-1326. 
115. Barry A. Levine AJGMSVP. The interaction of troponin-I with the N-
terminal region of actin. European Journal of Biochemistry. 
1988;172(2):389-397. 
116. Lehman W, Rosol M, Tobacman LS, Craig R. Troponin organization on 
relaxed and activated thin filaments revealed by electron microscopy and 
three-dimensional reconstruction. J Mol Biol. 2001;307(3):739-744. 
117. Kobayashi T, Patrick SE, Kobayashi M. Ala-scanning of the inhibitory 
region of cardiac troponin I. J. Biol. Chem. 2009:M109.001396. 
118. Aihara T, Ueki S, Nakamura M, Arata T. Calcium-dependent movement of 
troponin I between troponin C and actin as revealed by spin-labeling EPR. 
Biochem Biophys Res Commun. 2006;340(2):462-468. 
119. Tripet B, Van Eyk JE, Hodges RS. Mapping of a second actin-tropomyosin 
and a second troponin C binding site within the C terminus of troponin I, 
and their importance in the Ca2+-dependent regulation of muscle 
contraction. Journal of Molecular Biology. 1997;271(5):728-750. 
120. Rarick HM, Tu XH, Solaro RJ, Martin AF. The C terminus of cardiac 
troponin I is essential for full inhibitory activity and Ca2+ sensitivity of rat 
myofibrils. J Biol Chem. 1997;272(43):26887-26892. 
121. Foster DB, Huang R, Hatch V, Craig R, Graceffa P, Lehman W, Wang CL. 
Modes of caldesmon binding to actin: sites of caldesmon contact and 
modulation of interactions by phosphorylation. J Biol Chem. 
2004;279(51):53387-53394. 
122. Galinska-Rakoczy A, Engel P, Xu C, Jung H, Craig R, Tobacman LS, 
Lehman W. Structural Basis for the Regulation of Muscle Contraction by 
Troponin and Tropomyosin. Journal of Molecular Biology. 
2008;379(5):929-935. 
123. Tachampa K, Kobayashi T, Wang H, Martin AF, Biesiadecki BJ, Solaro 
RJ, de Tombe PP. Increased cross-bridge cycling kinetics after exchange 
of C-terminal truncated troponin I in skinned rat cardiac muscle. J Biol 
Chem. 2008;283(22):15114-15121. 
124. Murakami K, Yumoto F, Ohki S-y, Yasunaga T, Tanokura M, 
Wakabayashi T. Structural Basis for Ca2+-regulated Muscle Relaxation at 
Interaction Sites of Troponin with Actin and Tropomyosin. Journal of 
Molecular Biology. 2005;352(1):178-201. 
125. Hatch V, Zhi G, Smith L, Stull JT, Craig R, Lehman W. Myosin light chain 
kinase binding to a unique site on F-actin revealed by three-dimensional 
image reconstruction. J Cell Biol. 2001;154(3):611-617. 
126. Kobayashi T, Solaro RJ. Increased Ca2+ affinity of cardiac thin filaments 




127. Solaro RJ, Rosevear P, Kobayashi T. The unique functions of cardiac 
troponin I in the control of cardiac muscle contraction and relaxation. 
Biochem Biophys Res Commun. 2008;369(1):82-87. 
128. Greenberg MJ, Wang CL, Lehman W, Moore JR. Modulation of actin 
mechanics by caldesmon and tropomyosin. Cell Motil Cytoskeleton. 
2008;65(2):156-164. 
129. Isambert H, Venier P, Maggs AC, Fattoum A, Kassab R, Pantaloni D, 
Carlier MF. Flexibility of actin filaments derived from thermal fluctuations. 
Effect of bound nucleotide, phalloidin, and muscle regulatory proteins. J 
Biol Chem. 1995;270(19):11437-11444. 
130. Gordon AM, Huxley AF, Julian FJ. The variation in isometric tension with 
sarcomere length in vertebrate muscle fibres. J Physiol. 1966;184(1):170-
192. 
131. Davis J, Westfall MV, Townsend D, Blankinship M, Herron TJ, Guerrero-
Serna G, Wang W, Devaney E, Metzger JM. Designing heart performance 
by gene transfer. Physiol Rev. 2008;88(4):1567-1651. 
132. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM. 
Dystrophic heart failure blocked by membrane sealant poloxamer. Nature. 
2005;436(7053):1025-1029. 
133. Westfall MV, Rust EM, Metzger JM. Slow skeletal troponin I gene transfer, 
expression, and myofilament incorporation enhances adult cardiac 
myocyte contractile function. Proceedings of the National Academy of 
Sciences. 1997;94(10):5444-5449. 
134. Bers DM. Cardiac excitation-contraction coupling. Nature. 
2002;415(6868):198-205. 
135. Bers DM, Despa S. Cardiac myocytes Ca2+ and Na+ regulation in normal 
and failing hearts. J Pharmacol Sci. 2006;100(5):315-322. 
136. Bers DM. Calcium Cycling and Signaling in Cardiac Myocytes. Annual 
Review of Physiology. 2008;70(1):23-49. 
137. Kranias EG, Bers DM. Calcium and cardiomyopathies. Subcell Biochem. 
2007;45:523-537. 
138. Wolff MR, McDonald KS, Moss RL. Rate of tension development in 
cardiac muscle varies with level of activator calcium. Circ Res. 
1995;76(1):154-160. 
139. Fitzsimons DP, Patel JR, Moss RL. Role of myosin heavy chain 
composition in kinetics of force development and relaxation in rat 
myocardium. J Physiol. 1998;513 ( Pt 1):171-183. 
140. Kentish JC, McCloskey DT, Layland J, Palmer S, Leiden JM, Martin AF, 
Solaro RJ. Phosphorylation of troponin I by protein kinase A accelerates 
relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ 
Res. 2001;88(10):1059-1065. 
141. Palmer S, Kentish JC. Roles of Ca2+ and crossbridge kinetics in 
determining the maximum rates of Ca2+ activation and relaxation in rat 
and guinea pig skinned trabeculae. Circ Res. 1998;83(2):179-186. 
294 
 
142. Swartz DR, Yang Z, Sen A, Tikunova SB, Davis JP. Myofibrillar troponin 
exists in three states and there is signal transduction along skeletal 
myofibrillar thin filaments. J Mol Biol. 2006;361(3):420-435. 
143. Hill TL, Eisenberg E, Greene L. Theoretical model for the cooperative 
equilibrium binding of myosin subfragment 1 to the actin-troponin-
tropomyosin complex. Proc Natl Acad Sci U S A. 1980;77(6):3186-3190. 
144. McKillop DF, Geeves MA. Regulation of the interaction between actin and 
myosin subfragment 1: evidence for three states of the thin filament. 
Biophys J. 1993;65(2):693-701. 
145. Tobacman LS, Butters CA. A new model of cooperative myosin-thin 
filament binding. J Biol Chem. 2000;275(36):27587-27593. 
146. Galinska-Rakoczy A, Engel P, Xu C, Jung H, Craig R, Tobacman LS, 
Lehman W. Structural basis for the regulation of muscle contraction by 
troponin and tropomyosin. J Mol Biol. 2008;379(5):929-935. 
147. Lehman W, Galinska-Rakoczy A, Hatch V, Tobacman LS, Craig R. 
Structural basis for the activation of muscle contraction by troponin and 
tropomyosin. J Mol Biol. 2009;388(4):673-681. 
148. Maytum R, Westerdorf B, Jaquet K, Geeves MA. Differential regulation of 
the actomyosin interaction by skeletal and cardiac troponin isoforms. J 
Biol Chem. 2003;278(9):6696-6701. 
149. Homsher E, Lacktis J, Regnier M. Strain-dependent modulation of 
phosphate transients in rabbit skeletal muscle fibers. Biophys J. 
1997;72(4):1780-1791. 
150. Fitzsimons DP, Moss RL. Strong binding of myosin modulates length-
dependent Ca2+ activation of rat ventricular myocytes. Circ Res. 
1998;83(6):602-607. 
151. Fitzsimons DP, Patel JR, Moss RL. Cross-bridge interaction kinetics in rat 
myocardium are accelerated by strong binding of myosin to the thin 
filament. J Physiol. 2001;530(Pt 2):263-272. 
152. Stelzer JE, Moss RL. Contributions of stretch activation to length-
dependent contraction in murine myocardium. J Gen Physiol. 
2006;128(4):461-471. 
153. Herzberg O, Moult J, James MN. A model for the Ca2+-induced 
conformational transition of troponin C. A trigger for muscle contraction. J 
Biol Chem. 1986;261(6):2638-2644. 
154. Dong WJ, Robinson JM, Xing J, Cheung HC. Kinetics of conformational 
transitions in cardiac troponin induced by Ca2+ dissociation determined by 
Forster resonance energy transfer. J Biol Chem. 2003;278(43):42394-
42402. 
155. Gomes AV, Venkatraman G, Davis JP, Tikunova SB, Engel P, Solaro RJ, 
Potter JD. Cardiac troponin T isoforms affect the Ca(2+) sensitivity of force 
development in the presence of slow skeletal troponin I: insights into the 




156. Davis JP, Norman C, Kobayashi T, Solaro RJ, Swartz DR, Tikunova SB. 
Effects of thin and thick filament proteins on calcium binding and 
exchange with cardiac troponin C. Biophys J. 2007;92(9):3195-3206. 
157. Spyracopoulos L, Gagne SM, Li MX, Sykes BD. Dynamics and 
thermodynamics of the regulatory domain of human cardiac troponin C in 
the apo- and calcium-saturated states. Biochemistry. 1998;37(51):18032-
18044. 
158. Liao R, Wang CK, Cheung HC. Coupling of calcium to the interaction of 
troponin I with troponin C from cardiac muscle. Biochemistry. 
1994;33(42):12729-12734. 
159. Miki M, Kobayashi T, Kimura H, Hagiwara A, Hai H, Maeda Y. Ca2+-
induced distance change between points on actin and troponin in skeletal 
muscle thin filaments estimated by fluorescence energy transfer 
spectroscopy. J Biochem. 1998;123(2):324-331. 
160. Li Z, Gergely J, Tao T. Proximity relationships between residue 117 of 
rabbit skeletal troponin-I and residues in troponin-C and actin. Biophys J. 
2001;81(1):321-333. 
161. Dong WJ, Robinson JM, Stagg S, Xing J, Cheung HC. Ca2+-induced 
conformational transition in the inhibitory and regulatory regions of cardiac 
troponin I. J Biol Chem. 2003;278(10):8686-8692. 
162. Xing J, Chinnaraj M, Zhang Z, Cheung HC, Dong WJ. Structural studies of 
interactions between cardiac troponin I and actin in regulated thin filament 
using Forster resonance energy transfer. Biochemistry. 
2008;47(50):13383-13393. 
163. Li MX, Spyracopoulos L, Sykes BD. Binding of cardiac troponin-I147-163 
induces a structural opening in human cardiac troponin-C. Biochemistry. 
1999;38(26):8289-8298. 
164. Dong W-J, Xing J, Villain M, Hellinger M, Robinson JM, Chandra M, 
Solaro RJ, Umeda PK, Cheung HC. Conformation of the Regulatory 
Domain of Cardiac Muscle Troponin C in Its Complex with Cardiac 
Troponin I. J. Biol. Chem. 1999;274(44):31382-31390. 
165. Bell MG, Lankford EB, Gonye GE, Ellis-Davies GC, Martyn DA, Regnier 
M, Barsotti RJ. Kinetics of cardiac thin-filament activation probed by 
fluorescence polarization of rhodamine-labeled troponin C in skinned 
guinea pig trabeculae. Biophys J. 2006;90(2):531-543. 
166. de Tombe PP, Belus A, Piroddi N, Scellini B, Walker JS, Martin AF, Tesi 
C, Poggesi C. Myofilament calcium sensitivity does not affect cross-bridge 
activation-relaxation kinetics. Am J Physiol Regul Integr Comp Physiol. 
2007;292(3):R1129-1136. 
167. Solzin J, Iorga B, Sierakowski E, Gomez Alcazar DP, Ruess DF, Kubacki 
T, Zittrich S, Blaudeck N, Pfitzer G, Stehle R. Kinetic mechanism of the 
Ca2+-dependent switch-on and switch-off of cardiac troponin in myofibrils. 
Biophys J. 2007;93(11):3917-3931. 
296 
 
168. Regnier M, Martin H, Barsotti RJ, Rivera AJ, Martyn DA, Clemmens E. 
Cross-bridge versus thin filament contributions to the level and rate of 
force development in cardiac muscle. Biophys J. 2004;87(3):1815-1824. 
169. Hoffman RM, Sykes BD. Isoform-specific variation in the intrinsic disorder 
of troponin I. Proteins. 2008;73(2):338-350. 
170. Dong WJ, Xing J, Robinson JM, Cheung HC. Ca(2+) induces an extended 
conformation of the inhibitory region of troponin I in cardiac muscle 
troponin. J Mol Biol. 2001;314(1):51-61. 
171. McKay RT, Pearlstone JR, Corson DC, Gagne SM, Smillie LB, Sykes BD. 
Structure and interaction site of the regulatory domain of troponin-C when 
complexed with the 96-148 region of troponin-I. Biochemistry. 
1998;37(36):12419-12430. 
172. McKay RT, Tripet BP, Hodges RS, Sykes BD. Interaction of the second 
binding region of troponin I with the regulatory domain of skeletal muscle 
troponin C as determined by NMR spectroscopy. J Biol Chem. 
1997;272(45):28494-28500. 
173. McKay RT, Tripet BP, Pearlstone JR, Smillie LB, Sykes BD. Defining the 
region of troponin-I that binds to troponin-C. Biochemistry. 
1999;38(17):5478-5489. 
174. Ramakrishnan S, Hitchcock-DeGregori SE. Investigation of the structural 
requirements of the troponin C central helix for function. Biochemistry. 
1995;34(51):16789-16796. 
175. Ramakrishnan S, Hitchcock-DeGregori SE. Structural and functional 
significance of aspartic acid 89 of the troponin C central helix in Ca2+ 
signaling. Biochemistry. 1996;35(48):15515-15521. 
176. Lehman W, Craig R, Vibert P. Ca(2+)-induced tropomyosin movement in 
Limulus thin filaments revealed by three-dimensional reconstruction. 
Nature. 1994;368(6466):65-67. 
177. Zhao Y, Kawai M. The effect of the lattice spacing change on cross-bridge 
kinetics in chemically skinned rabbit psoas muscle fibers. II. Elementary 
steps affected by the spacing change. Biophys J. 1993;64(1):197-210. 
178. Lidke DS, Thomas DD. Coordination of the two heads of myosin during 
muscle contraction. Proc Natl Acad Sci U S A. 2002;99(23):14801-14806. 
179. Thomas DD, Prochniewicz E, Roopnarine O. Changes in actin and myosin 
structural dynamics due to their weak and strong interactions. Results 
Probl Cell Differ. 2002;36:7-19. 
180. Stehle R, Iorga B, Pfitzer G. Calcium regulation of troponin and its role in 
the dynamics of contraction and relaxation. Am J Physiol Regul Integr 
Comp Physiol. 2007;292(3):R1125-1128. 
181. Hinken AC, McDonald KS. Inorganic phosphate speeds loaded shortening 
in rat skinned cardiac myocytes. Am J Physiol Cell Physiol. 
2004;287(2):C500-507. 
182. Solaro RJ, Rarick HM. Troponin and tropomyosin: proteins that switch on 




183. Heeley DH, Belknap B, White HD. Maximal activation of skeletal muscle 
thin filaments requires both rigor myosin S1 and calcium. J Biol Chem. 
2006;281(1):668-676. 
184. Pirani A, Vinogradova MV, Curmi PM, King WA, Fletterick RJ, Craig R, 
Tobacman LS, Xu C, Hatch V, Lehman W. An atomic model of the thin 
filament in the relaxed and Ca2+-activated states. J Mol Biol. 
2006;357(3):707-717. 
185. Tregear RT, Reedy MC, Goldman YE, Taylor KA, Winkler H, Franzini-
Armstrong C, Sasaki H, Lucaveche C, Reedy MK. Cross-bridge number, 
position, and angle in target zones of cryofixed isometrically active insect 
flight muscle. Biophys J. 2004;86(5):3009-3019. 
186. Poggesi C, Tesi C, Stehle R. Sarcomeric determinants of striated muscle 
relaxation kinetics. Pflugers Arch. 2005;449(6):505-517. 
187. Tesi C, Piroddi N, Colomo F, Poggesi C. Relaxation kinetics following 
sudden Ca(2+) reduction in single myofibrils from skeletal muscle. Biophys 
J. 2002;83(4):2142-2151. 
188. Hunter WC. Role of myofilaments and calcium handling in left ventricular 
relaxation. Cardiol Clin. 2000;18(3):443-457. 
189. Peterson JN, Hunter WC, Berman MR. Estimated time course of Ca2+ 
bound to troponin C during relaxation in isolated cardiac muscle. Am J 
Physiol. 1991;260(3 Pt 2):H1013-1024. 
190. Ishikawa T, J OU, Mochizuki S, Kurihara S. Evaluation of the cross-bridge-
dependent change in the Ca2+ affinity of troponin C in aequorin-injected 
ferret ventricular muscles. Cell Calcium. 2005;37(2):153-162. 
191. Tikunova SB, Davis JP. Designing calcium-sensitizing mutations in the 
regulatory domain of cardiac troponin C. J Biol Chem. 
2004;279(34):35341-35352. 
192. Davis JP, Tikunova SB. Ca(2+) exchange with troponin C and cardiac 
muscle dynamics. Cardiovasc Res. 2008;77(4):619-626. 
193. Dong W, Rosenfeld SS, Wang CK, Gordon AM, Cheung HC. Kinetic 
studies of calcium binding to the regulatory site of troponin C from cardiac 
muscle. J Biol Chem. 1996;271(2):688-694. 
194. Xing J, Jayasundar JJ, Ouyang Y, Dong WJ. Forster resonance energy 
transfer structural kinetic studies of cardiac thin filament deactivation. J 
Biol Chem. 2009;284(24):16432-16441. 
195. Janssen PM, Stull LB, Marban E. Myofilament properties comprise the 
rate-limiting step for cardiac relaxation at body temperature in the rat. Am 
J Physiol Heart Circ Physiol. 2002;282(2):H499-507. 
196. Bodem R, Sonnenblick EH. Deactivation of contraction by quick releases 
in the isolated papillary muscle of the cat. Effects of lever damping, 
caffeine, and tetanization. Circ Res. 1974;34(2):214-225. 
197. Brady AJ. Time and displacement dependence of cardiac contractility: 




198. Brutsaert DL, Housmans PR, Goethals MA. Dual control of relaxation. Its 
role in the ventricular function in the mammalian heart. Circ Res. 
1980;47(5):637-652. 
199. O'Rourke B, Kass DA, Tomaselli GF, Kaab S, Tunin R, Marban E. 
Mechanisms of altered excitation-contraction coupling in canine 
tachycardia-induced heart failure, I: experimental studies. Circ Res. 
1999;84(5):562-570. 
200. del Monte F, Hajjar RJ, Harding SE. Overwhelming evidence of the 
beneficial effects of SERCA gene transfer in heart failure. Circ Res. 
2001;88(11):E66-67. 
201. Xiang Y, Kobilka BK. Myocyte adrenoceptor signaling pathways. Science. 
2003;300(5625):1530-1532. 
202. Yasuda S, Coutu P, Sadayappan S, Robbins J, Metzger JM. Cardiac 
transgenic and gene transfer strategies converge to support an important 
role for troponin I in regulating relaxation in cardiac myocytes. Circ Res. 
2007;101(4):377-386. 
203. Palpant NJ, D'Alecy LG, Metzger JM. Single histidine button in cardiac 
troponin I sustains heart performance in response to severe hypercapnic 
respiratory acidosis in vivo. FASEB J. 2009. 
204. Xiao RP, Zhu W, Zheng M, Cao C, Zhang Y, Lakatta EG, Han Q. Subtype-
specific alpha1- and beta-adrenoceptor signaling in the heart. Trends 
Pharmacol Sci. 2006;27(6):330-337. 
205. Layland J, Solaro RJ, Shah AM. Regulation of cardiac contractile function 
by troponin I phosphorylation. Cardiovascular Research. 2005;66(1):12-
21. 
206. Solaro RJ, Moir AJG, Perry SV. Phosphorylation of Troponin-I and 
Inotropic Effect of Adrenaline in Perfused Rabbit Heart. Nature. 
1976;262(5569):615-617. 
207. Jweied EE, McKinney RD, Walker LA, Brodsky I, Geha AS, Massad MG, 
Buttrick PM, de Tombe PP. Depressed cardiac myofilament function in 
human diabetes mellitus. Am J Physiol Heart Circ Physiol. 
2005;289(6):H2478-2483. 
208. McConnell BK, Moravec CS, Bond M. Troponin I phosphorylation and 
myofilament calcium sensitivity during decompensated cardiac 
hypertrophy. Am J Physiol. 1998;274(2 Pt 2):H385-396. 
209. van der Velden J, Papp Z, Zaremba R, Boontje NM, de Jong JW, Owen 
VJ, Burton PB, Goldmann P, Jaquet K, Stienen GJ. Increased Ca2+-
sensitivity of the contractile apparatus in end-stage human heart failure 
results from altered phosphorylation of contractile proteins. Cardiovasc 
Res. 2003;57(1):37-47. 
210. Hamdani N, Kooij V, van Dijk S, Merkus D, Paulus WJ, Remedios Cd, 
Duncker DJ, Stienen GJM, van der Velden J. Sarcomeric dysfunction in 
heart failure. Cardiovasc Res. 2008;77(4):649-658. 
211. Heller WT, Finley NL, Dong WJ, Timmins P, Cheung HC, Rosevear PR, 
Trewhella J. Small-angle neutron scattering with contrast variation reveals 
299 
 
spatial relationships between the three subunits in the ternary cardiac 
troponin complex and the effects of troponin I phosphorylation. 
Biochemistry. 2003;42(25):7790-7800. 
212. Layland J, Grieve DJ, Cave AC, Sparks E, Solaro RJ, Shah AM. Essential 
role of troponin I in the positive inotropic response to isoprenaline in 
mouse hearts contracting auxotonically. J Physiol. 2004;556(Pt 3):835-
847. 
213. Fentzke RC, Buck SH, Patel JR, Lin H, Wolska BM, Stojanovic MO, Martin 
AF, Solaro RJ, Moss RL, Leiden JM. Impaired cardiomyocyte relaxation 
and diastolic function in transgenic mice expressing slow skeletal troponin 
I in the heart. J Physiol. 1999;517 ( Pt 1):143-157. 
214. Herron TJ, Korte FS, McDonald KS. Power output is increased after 
phosphorylation of myofibrillar proteins in rat skinned cardiac myocytes. 
Circ Res. 2001;89(12):1184-1190. 
215. Takimoto E, Soergel DG, Janssen PM, Stull LB, Kass DA, Murphy AM. 
Frequency- and afterload-dependent cardiac modulation in vivo by 
troponin I with constitutively active protein kinase A phosphorylation sites. 
Circ Res. 2004;94(4):496-504. 
216. Hanft LM, McDonald KS. Sarcomere length dependence of power output 
is increased after PKA treatment in rat cardiac myocytes. Am J Physiol 
Heart Circ Physiol. 2009;296(5):H1524-1531. 
217. Gwathmey JK, Hajjar RJ. Effect of protein kinase C activation on 
sarcoplasmic reticulum function and apparent myofibrillar Ca2+ sensitivity 
in intact and skinned muscles from normal and diseased human 
myocardium. Circ Res. 1990;67(3):744-752. 
218. Puceat M, Clement O, Lechene P, Pelosin JM, Ventura-Clapier R, Vassort 
G. Neurohormonal control of calcium sensitivity of myofilaments in rat 
single heart cells. Circ Res. 1990;67(2):517-524. 
219. Westfall MV, Borton AR. Role of troponin I phosphorylation in protein 
kinase C-mediated enhanced contractile performance of rat myocytes. J 
Biol Chem. 2003;278(36):33694-33700. 
220. Alden KJ, Goldspink PH, Ruch SW, Buttrick PM, Garcia J. Enhancement 
of L-type Ca(2+) current from neonatal mouse ventricular myocytes by 
constitutively active PKC-betaII. Am J Physiol Cell Physiol. 
2002;282(4):C768-774. 
221. Westfall MV, Lee AM, Robinson DA. Differential contribution of troponin I 
phosphorylation sites to the endothelin-modulated contractile response. J 
Biol Chem. 2005;280(50):41324-41331. 
222. Noland TA, Jr., Raynor RL, Kuo JF. Identification of sites phosphorylated 
in bovine cardiac troponin I and troponin T by protein kinase C and 
comparative substrate activity of synthetic peptides containing the 
phosphorylation sites. J Biol Chem. 1989;264(34):20778-20785. 
223. Damron DS, Darvish A, Murphy L, Sweet W, Moravec CS, Bond M. 
Arachidonic acid-dependent phosphorylation of troponin I and myosin light 
chain 2 in cardiac myocytes. Circ Res. 1995;76(6):1011-1019. 
300 
 
224. Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, 
Mintze K, Pickard T, Roden R, Bristow MR, Sabbah HN, Mizrahi JL, 
Gromo G, King GL, Vlahos CJ. Increased protein kinase C activity and 
expression of Ca2+-sensitive isoforms in the failing human heart. 
Circulation. 1999;99(3):384-391. 
225. Molnar A, Borbely A, Czuriga D, Ivetta SM, Szilagyi S, Hertelendi Z, 
Pasztor ET, Balogh A, Galajda Z, Szerafin T, Jaquet K, Papp Z, Edes I, 
Toth A. Protein kinase C contributes to the maintenance of contractile 
force in human ventricular cardiomyocytes. J Biol Chem. 
2009;284(2):1031-1039. 
226. Burkart EM, Sumandea MP, Kobayashi T, Nili M, Martin AF, Homsher E, 
Solaro RJ. Phosphorylation or glutamic acid substitution at protein kinase 
C sites on cardiac troponin I differentially depress myofilament tension and 
shortening velocity. J Biol Chem. 2003;278(13):11265-11272. 
227. Pyle WG, Sumandea MP, Solaro RJ, De Tombe PP. Troponin I serines 
43/45 and regulation of cardiac myofilament function. Am J Physiol Heart 
Circ Physiol. 2002;283(3):H1215-1224. 
228. Noland TA, Jr., Guo X, Raynor RL, Jideama NM, Averyhart-Fullard V, 
Solaro RJ, Kuo JF. Cardiac troponin I mutants. Phosphorylation by protein 
kinases C and A and regulation of Ca(2+)-stimulated MgATPase of 
reconstituted actomyosin S-1. J Biol Chem. 1995;270(43):25445-25454. 
229. MacKay J, Mensah G. The Atlas of Heart Disease and Stroke. World 
Health Organization. 2006. 
230. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, Lopez-
Sendon J, Budaj A, Goldberg RJ, Klein W, Anderson FA, Jr., for the 
Global Registry of Acute Coronary Events I. Determinants and Prognostic 
Impact of Heart Failure Complicating Acute Coronary Syndromes: 
Observations From the Global Registry of Acute Coronary Events 
(GRACE). Circulation. 2004;109(4):494-499. 
231. Atar D, Gao WD, Marban E. Alterations of excitation--contraction coupling 
in stunned myocardium and in failing myocardium. Journal of Molecular 
and Cellular Cardiology. 1995;27(2):783-791. 
232. Michaud CM, Murray CJL, Bloom BR. Burden of Disease--Implications for 
Future Research. JAMA: The Journal of the American Medical 
Association. 2001;285(5):535-539. 
233. Deedwania PC. The key to unraveling the mystery of mortality in heart 
failure - An integrated approach. Circulation. 2003;107(13):1719-1721. 
234. Dubin A, Estenssoro E. Mechanisms of tissue hypercarbia in sepsis. Front 
Biosci. 2008;13:1340-1351. 
235. Windisch W, Kostic S, Dreher M, Virchow JC, Jr., Sorichter S. Outcome of 
patients with stable COPD receiving controlled noninvasive positive 




236. Godt RE, Nosek TM. Changes of intracellular milieu with fatigue or 
hypoxia depress contraction of skinned rabbit skeletal and cardiac muscle. 
J Physiol. 1989;412:155-180. 
237. Orchard CH, Kentish JC. Effects of changes of pH on the contractile 
function of cardiac muscle. Am J Physiol. 1990;258(6 Pt 1):C967-981. 
238. Parsons B, Szczesna D, Zhao J, Van Slooten G, Kerrick WG, Putkey JA, 
Potter JD. The effect of pH on the Ca2+ affinity of the Ca2+ regulatory 
sites of skeletal and cardiac troponin C in skinned muscle fibres. J Muscle 
Res Cell Motil. 1997;18(5):599-609. 
239. Solaro RJ, Lee JA, Kentish JC, Allen DG. Effects of acidosis on ventricular 
muscle from adult and neonatal rats. Circulation Research. 
1988;63(4):779-787. 
240. Allen DG, Orchard CH. The effects of changes of pH on intracellular 
calcium transients in mammalian cardiac muscle. J Physiol. 
1983;335:555-567. 
241. Crampin EJ, Smith NP. A dynamic model of excitation-contraction 
coupling during acidosis in cardiac ventricular myocytes. Biophys J. 
2006;90(9):3074-3090. 
242. Day SM, Westfall MV, Metzger JM. Tuning cardiac performance in 
ischemic heart disease and failure by modulating myofilament function. J 
Mol Med. 2007;85(9):911-921. 
243. Murphy AM. Heart failure, myocardial stunning, and troponin: a key 
regulator of the cardiac myofilament. Congest Heart Fail. 2006;12(1):32-
38; quiz 39-40. 
244. Day S, Davis J, Westfall M, Metzger J. Genetic engineering and therapy 
for inherited and acquired cardiomyopathies. Ann N Y Acad Sci. 
2006;1080:437-450. 
245. Ball KL, Johnson MD, Solaro RJ. Isoform specific interactions of troponin I 
and troponin C determine pH sensitivity of myofibrillar Ca2+ activation. 
Biochemistry. 1994;33(28):8464-8471. 
246. Day SM, Westfall MV, Fomicheva EV, Hoyer K, Yasuda S, La Cross NC, 
D'Alecy LG, Ingwall JS, Metzger JM. Histidine button engineered into 
cardiac troponin I protects the ischemic and failing heart. Nat.Med. 
2006;12(2):181-189. 
247. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial 
stunning. Physiol Rev. 1999;79(2):609-634. 
248. Van Eyk JE, Powers F, Law W, Larue C, Hodges RS, Solaro RJ. 
Breakdown and release of myofilament proteins during ischemia and 
ischemia/reperfusion in rat hearts: identification of degradation products 
and effects on the pCa-force relation. Circ Res. 1998;82(2):261-271. 
249. Dargis R, Pearlstone JR, Barrette-Ng I, Edwards H, Smillie LB. Single 
mutation (A162H) in human cardiac troponin I corrects acid pH sensitivity 




250. Westfall MV, Borton AR, Albayya FP, Metzger JM. Specific charge 
differences in troponin I isoforms influence myofilament Ca2+ sensitivity of 
tension in adult cardiac myocytes. Biophysical Journal. 2001;80(1):356A-
356A. 
251. Westfall MV, Borton AR, Albayya FP, Metzger JM. Myofilament Calcium 
Sensitivity and Cardiac Disease: Insights From Troponin I Isoforms and 
Mutants. Circulation Research. 2002;91(6):525-531. 
252. Westfall MV, Metzger JM. Single amino acid substitutions define isoform-
specific effects of troponin I on myofilament Ca2+ and pH sensitivity. J Mol 
Cell Cardiol. 2007;43(2):107-118. 
253. Ricciardi L, Bottinelli R, Canepari M, Reggiani C. Effects of acidosis on 
maximum shortening velocity and force-velocity relation of skinned rat 
cardiac muscle. J Mol Cell Cardiol. 1994;26(5):601-607. 
254. Ricciardi L, Bucx JJ, ter Keurs HE. Effects of acidosis on force-sarcomere 
length and force-velocity relations of rat cardiac muscle. Cardiovasc Res. 
1986;20(2):117-123. 
255. Robertson SP, Kerrick WG. The effects of pH on Ca2+-activated force in 
frog skeletal muscle fibers. Pflugers Arch. 1979;380(1):41-45. 
256. el-Saleh SC, Solaro RJ. Troponin I enhances acidic pH-induced 
depression of Ca2+ binding to the regulatory sites in skeletal troponin C. J 
Biol Chem. 1988;263(7):3274-3278. 
257. Linse S, Forsen S. Determinants that govern high-affinity calcium binding. 
Adv Second Messenger Phosphoprotein Res. 1995;30:89-151. 
258. Metzger JM. Effects of troponin C isoforms on pH sensitivity of contraction 
in mammalian fast and slow skeletal muscle fibres. J Physiol. 1996;492 ( 
Pt 1):163-172. 
259. Metzger JM, Parmacek MS, Barr E, Pasyk K, Lin WI, Cochrane KL, Field 
LJ, Leiden JM. Skeletal troponin C reduces contractile sensitivity to 
acidosis in cardiac myocytes from transgenic mice. Proc Natl Acad Sci U 
S A. 1993;90(19):9036-9040. 
260. Metzger JM, Moss RL. Kinetics of a Ca(2+)-sensitive cross-bridge state 
transition in skeletal muscle fibers. Effects due to variations in thin filament 
activation by extraction of troponin C. J Gen Physiol. 1991;98(2):233-248. 
261. Ebus JP, Stienen GJ, Elzinga G. Influence of phosphate and pH on 
myofibrillar ATPase activity and force in skinned cardiac trabeculae from 
rat. J Physiol. 1994;476(3):501-516. 
262. Higuchi H, Takemori S, Umazume Y. Suppressing effect of 2,3-
butanedione monoxime on contraction and ATPase activity of rabbit 
skeletal muscle. Prog Clin Biol Res. 1989;315:225-226. 
263. Wattanapermpool J, Reiser PJ, Solaro RJ. Troponin I isoforms and 
differential effects of acidic pH on soleus and cardiac myofilaments. Am J 
Physiol. 1995;268(2 Pt 1):C323-330. 
264. Liou YM, Chang JC. Differential pH effect on calcium-induced 
conformational changes of cardiac troponin C complexed with cardiac and 
303 
 
fast skeletal isoforms of troponin I and troponin T. J Biochem. 
2004;136(5):683-692. 
265. Guo X, Wattanapermpool J, Palmiter KA, Murphy AM, Solaro RJ. 
Mutagenesis of cardiac troponin I. Role of the unique NH2-terminal 
peptide in myofilament activation. J Biol Chem. 1994;269(21):15210-
15216. 
266. Westfall MV, Albayya FP, Turner II, Metzger JM. Chimera Analysis of 
Troponin I Domains That Influence Ca2+-Activated Myofilament Tension 
in Adult Cardiac Myocytes. Circulation Research. 2000;86(4):470-477. 
267. Li G, Martin AF, Solaro JR. Localization of regions of troponin I important 
in deactivation of cardiac myofilaments by acidic pH. J Mol Cell Cardiol. 
2001;33(7):1309-1320. 
268. Lyn D, Liu X, Bennett NA, Emmett NL. Gene expression profile in mouse 
myocardium after ischemia. Physiol Genomics. 2000;2(3):93-100. 
269. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene 
program protects the stressed heart: a strong hypothesis. Heart Fail Rev. 
2007;12(3-4):331-343. 
270. Lompre AM, Schwartz K, d'Albis A, Lacombe G, Van Thiem N, 
Swynghedauw B. Myosin isoenzyme redistribution in chronic heart 
overload. Nature. 1979;282(5734):105-107. 
271. Mercadier JJ, Samuel JL, Michel JB, Zongazo MA, de la Bastie D, Lompre 
AM, Wisnewsky C, Rappaport L, Levy B, Schwartz K. Atrial natriuretic 
factor gene expression in rat ventricle during experimental hypertension. 
Am J Physiol. 1989;257(3 Pt 2):H979-987. 
272. Mercadier JJ, Zongazo MA, Wisnewsky C, Butler-Brown G, Gros D, 
Carayon A, Schwartz K. Atrial natriuretic factor messenger ribonucleic 
acid and peptide in the human heart during ontogenic development. 
Biochem Biophys Res Commun. 1989;159(2):777-782. 
273. Nagai R, Zarain-Herzberg A, Brandl CJ, Fujii J, Tada M, MacLennan DH, 
Alpert NR, Periasamy M. Regulation of myocardial Ca2+-ATPase and 
phospholamban mRNA expression in response to pressure overload and 
thyroid hormone. Proc Natl Acad Sci U S A. 1989;86(8):2966-2970. 
274. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M. Alterations in 
sarcoplasmic reticulum gene expression in human heart failure. A possible 
mechanism for alterations in systolic and diastolic properties of the failing 
myocardium. Circ Res. 1993;72(2):463-469. 
275. Arai M, Matsui H, Periasamy M. Sarcoplasmic reticulum gene expression 
in cardiac hypertrophy and heart failure. Circ Res. 1994;74(4):555-564. 
276. Otsu K, Fujii J, Periasamy M, Difilippantonio M, Uppender M, Ward DC, 
MacLennan DH. Chromosome mapping of five human cardiac and 
skeletal muscle sarcoplasmic reticulum protein genes. Genomics. 
1993;17(2):507-509. 
277. Mondry A, Bourgeois F, Carre F, Swynghedauw B, Moalic JM. Decrease 
in beta 1-adrenergic and M2-muscarinic receptor mRNA levels and 
unchanged accumulation of mRNAs coding for G alpha i-2 and G alpha s 
304 
 
proteins in rat cardiac hypertrophy. J Mol Cell Cardiol. 1995;27(10):2287-
2294. 
278. Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, Just H. 
Calcium handling proteins in the failing human heart. Basic Res Cardiol. 
1997;92 Suppl 1:87-93. 
279. Hasenfuss G, Pieske B. Calcium Cycling in Congestive Heart Failure. 
Journal of Molecular and Cellular Cardiology. 2002;34(8):951-969. 
280. Baartscheer A, Schumacher CA, Belterman CN, Coronel R, Fiolet JW. SR 
calcium handling and calcium after-transients in a rabbit model of heart 
failure. Cardiovasc Res. 2003;58(1):99-108. 
281. Hobai IA, O'Rourke B. Decreased sarcoplasmic reticulum calcium content 
is responsible for defective excitation-contraction coupling in canine heart 
failure. Circulation. 2001;103(11):1577-1584. 
282. Allard MF, Henning SL, Wambolt RB, Granleese SR, English DR, 
Lopaschuk GD. Glycogen metabolism in the aerobic hypertrophied rat 
heart. Circulation. 1997;96(2):676-682. 
283. Apstein CS, Opie LH. A challenge to the metabolic approach to 
myocardial ischaemia. Eur Heart J. 2005;26(10):956-959. 
284. Bye A, Langaas M, Hoydal MA, Kemi OJ, Heinrich G, Koch LG, Britton SL, 
Najjar SM, Ellingsen O, Wisloff U. Aerobic capacity-dependent differences 
in cardiac gene expression. Physiol Genomics. 2008;33(1):100-109. 
285. Gerdes AM, Capasso JM. Structural remodeling and mechanical 
dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol. 
1995;27(3):849-856. 
286. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological 
and pathophysiological relevance. J Pharmacol Sci. 2006;100(5):323-337. 
287. Zhu WZ, Wang SQ, Chakir K, Yang D, Zhang T, Brown JH, Devic E, 
Kobilka BK, Cheng H, Xiao RP. Linkage of beta1-adrenergic stimulation to 
apoptotic heart cell death through protein kinase A-independent activation 
of Ca2+/calmodulin kinase II. J Clin Invest. 2003;111(5):617-625. 
288. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie 
K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine 
sensitivity and beta-adrenergic-receptor density in failing human hearts. N 
Engl J Med. 1982;307(4):205-211. 
289. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for 
drugs against heart failure: interaction of levosimendan, a calcium 
sensitiser, with cardiac troponin c. Mol Cell Biochem. 2004;266(1-2):87-
107. 
290. Palpant NJ, Day SM, Herron TJ, Converso KL, Metzger JM. Single 
histidine-substituted cardiac troponin I confers protection from age-related 
systolic and diastolic dysfunction. Cardiovasc Res. 2008:cvn198. 
291. Kass DA, Solaro RJ. Mechanisms and Use of Calcium-Sensitizing Agents 
in the Failing Heart. Circulation. 2006;113(2):305-315. 
292. Bers DM. Excitation Contraction Coupling and Cardiac Contractile Force. 
Dordecht, Netherlands: Kluwer Academic Publishers; 2001. 
305 
 
293. Endoh M, Hori M. Acute heart failure: inotropic agents and their clinical 
uses. Expert Opin Pharmacother. 2006;7(16):2179-2202. 
294. Teerlink JR. Overview of randomized clinical trials in acute heart failure 
syndromes. Am J Cardiol. 2005;96(6A):59G-67G. 
295. Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of 
dobutamine, dopamine, and milrinone in the management of acute heart 
failure syndromes. Am J Cardiol. 2005;96(6A):47G-58G. 
296. Li Y, Love ML, Putkey JA, Cohen C. Bepridil opens the regulatory N-
terminal lobe of cardiac troponin C. Proc Natl Acad Sci U S A. 
2000;97(10):5140-5145. 
297. Arteaga GM, Warren CM, Milutinovic S, Martin AF, Solaro RJ. Specific 
enhancement of sarcomeric response to Ca2+ protects murine 
myocardium against ischemia-reperfusion dysfunction. American Journal 
of Physiology-Heart and Circulatory Physiology. 2005;289(5):H2183-
H2192. 
298. Cunha-Goncalves D, Perez-de-Sa V, Dahm P, Grins E, Thorne J, 
Blomquist S. Cardiovascular effects of levosimendan in the early stages of 
endotoxemia. Shock. 2007;28(1):71-77. 
299. Givertz MM, Andreou C, Conrad CH, Colucci WS. Direct myocardial 
effects of levosimendan in humans with left ventricular dysfunction: 
alteration of force-frequency and relaxation-frequency relationships. 
Circulation. 2007;115(10):1218-1224. 
300. Jorgensen K, Bech-Hanssen O, Houltz E, Ricksten SE. Effects of 
levosimendan on left ventricular relaxation and early filling at maintained 
preload and afterload conditions after aortic valve replacement for aortic 
stenosis. Circulation. 2008;117(8):1075-1081. 
301. Oldner A, Konrad D, Weitzberg E, Rudehill A, Rossi P, Wanecek M. 
Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in 
experimental septic shock. Crit Care Med. 2001;29(11):2185-2193. 
302. Segreti JA, Marsh KC, Polakowski JS, Fryer RM. Evoked Changes in 
Cardiovascular Function in Rats by Infusion of Levosimendan, OR-1896 
[(R)-N-(4-(4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-
yl)phenyl)acetamide], OR-1855 [(R)-6-(4-Aminophenyl)-5-methyl-4,5-
dihydropyridazin-3(2H)-one], Dobutamine, and Milrinone: Comparative 
Effects on Peripheral Resistance, Cardiac Output, dP/dt, Pulse Rate, and 
Blood Pressure. J Pharmacol Exp Ther. 2008;325(1):331-340. 
303. Perutz MF, Gronenborn AM, Clore GM, Fogg JH, Shih DTb. The pKa 
values of two histidine residues in human haemoglobin, the Bohr effect, 
and the dipole moments of [alpha]-helices. Journal of Molecular Biology. 
1985;183(3):491-498. 
304. T.b.-Shih D, Luisi BF, Miyazaki G, Perutz MF, Nagai K. A Mutagenic Study 
of the Allosteric Linkage of His(HC3)146[beta] in Haemoglobin. Journal of 
Molecular Biology. 1993;230(4):1291-1296. 
306 
 
305. Perutz MF, Kilmartin JV, Nishikura K, Fogg JH, Butler PJG, Rollema HS. 
Identification of residues contributing to the Bohr effect of human 
haemoglobin. Journal of Molecular Biology. 1980;138(3):649-668. 
306. RÃ¶tzschke O, Lau JM, HofstÃ¤tter M, Falk K, Strominger JL. A pH-
sensitive histidine residue as control element for ligand release from HLA-
DR molecules. Proceedings of the National Academy of Sciences of the 
United States of America. 2002;99(26):16946-16950. 
307. Mao J, Wu J, Chen F, Wang X, Jiang C. Inhibition of G-protein-coupled 
Inward Rectifying K+ Channels by Intracellular Acidosis. J. Biol. Chem. 
2003;278(9):7091-7098. 
308. Coulter KL, Pe´rier F, Redeke CM, Vanderberg CA. Identification and 
molecular localization of a pH-sensing domain for the inward rectifier 
potassium channel HIR. Neuron. 1995;15(5):1157-1168. 
309. Zong X, Stieber J, Ludwig A, Hofmann F, Biel M. A Single Histidine 
Residue Determines the pH Sensitivity of the Pacemaker Channel HCN2. 
J. Biol. Chem. 2001;276(9):6313-6319. 
310. Rajan S, Wischmeyer E, Xin Liu G, Preisig-Muller R, Daut J, Karschin A, 
Derst C. TASK-3, a Novel Tandem Pore Domain Acid-sensitive K+ 
Channel. AN EXTRACELLULAR HISTIDINE AS pH SENSOR. J. Biol. 
Chem. 2000;275(22):16650-16657. 
311. Sabry MA, Dhoot GK. Identification and pattern of expression of a 
developmental isoform of troponin I in chicken and rat cardiac muscle. J 
Muscle Res Cell Motil. 1989;10(1):85-91. 
312. Saggin L, Gorza L, Ausoni S, Schiaffino S. Troponin I switching in the 
developing heart. J Biol Chem. 1989;264(27):16299-16302. 
313. Kruger M, Kohl T, Linke WA. Developmental changes in passive stiffness 
and myofilament Ca2+ sensitivity due to titin and troponin-I isoform 
switching are not critically triggered by birth. Am J Physiol Heart Circ 
Physiol. 2006;291(2):H496-506. 
314. Westfall MV, Metzger JM. Gene transfer of troponin I isoforms, mutants, 
and chimeras. Adv Exp Med Biol. 2003;538:169-174; discussion 174. 
315. Westfall MV, Albayya FP, Turner, II, Metzger JM. Chimera analysis of 
troponin I domains that influence Ca(2+)-activated myofilament tension in 
adult cardiac myocytes. Circ Res. 2000;86(4):470-477. 
316. Wolska BM, Arteaga GM, Pena JR, Nowak G, Phillips RM, Sahai S, de 
Tombe PP, Martin AF, Kranias EG, Solaro RJ. Expression of slow skeletal 
troponin I in hearts of phospholamban knockout mice alters the relaxant 
effect of beta-adrenergic stimulation. Circ Res. 2002;90(8):882-888. 
317. Wolska BM, Vijayan K, Arteaga GM, Konhilas JP, Phillips RM, Kim R, 
Naya T, Leiden JM, Martin AF, de Tombe PP, Solaro RJ. Expression of 
slow skeletal troponin I in adult transgenic mouse heart muscle reduces 
the force decline observed during acidic conditions. J Physiol. 2001;536(Pt 
3):863-870. 
318. Urboniene D, Dias FAL, Pena JR, Walker LA, Solaro RJ, Wolska BM. 
Expression of slow skeletal troponin I in adult mouse heart helps to 
307 
 
maintain the left ventricular systolic function during respiratory 
hypercapnia. Circulation Research. 2005;97(1):70-77. 
319. Westfall MV, Metzger JM. Troponin I Isoforms and Chimeras: Tuning the 
Molecular Switch of Cardiac Contraction. News in Physiological Sciences. 
2001;16(6):278-281. 
320. Frank K, Kranias EG. Phospholamban and cardiac contractility. Ann Med. 
2000;32(8):572-578. 
321. MacLennan DH, Kranias EG. Phospholamban: A crucial regulator of 
cardiac contractility. Nature Reviews Molecular Cell Biology. 
2003;4(7):566-577. 
322. Li L, Desantiago J, Chu G, Kranias EG, Bers DM. Phosphorylation of 
phospholamban and troponin I in beta-adrenergic-induced acceleration of 
cardiac relaxation. Am J Physiol Heart Circ Physiol. 2000;278(3):H769-
779. 
323. Chu G, Lester JW, Young KB, Luo W, Zhai J, Kranias EG. A single site 
(Ser16) phosphorylation in phospholamban is sufficient in mediating its 
maximal cardiac responses to beta -agonists. J Biol Chem. 
2000;275(49):38938-38943. 
324. Metzger JM, Michele DE, Rust EM, Borton AR, Westfall MV. Sarcomere 
Thin Filament Regulatory Isoforms. EVIDENCE OF A DOMINANT 
EFFECT OF SLOW SKELETAL TROPONIN I ON CARDIAC 
CONTRACTION. Journal of Biological Chemistry. 2003;278(15):13118-
13123. 
325. Pearlstone JR, Sykes BD, Smillie LB. Interactions of structural C and 
regulatory N domains of troponin C with repeated sequence motifs in 
troponin I. Biochemistry. 1997;36(24):7601-7606. 
326. Berenbrink M. Evolution of vertebrate haemoglobins: Histidine side chains, 
specific buffer value and Bohr effect. Respiratory Physiology & 
Neurobiology. 2006;154(1-2):165-184. 
327. Li MX, Spyracopoulos L, Sykes BD. Binding of Cardiac Troponin-I147-163 
Induces a Structural Opening in Human Cardiac Troponin-C. 
Biochemistry. 1999;38(26):8289-8298. 
328. Ebashi S, Kodama A. A New Protein Factor Promoting Aggregation of 
Tropomyosin. Biochemical and Biophysical Research Communications. 
2008;369(1):13-14. 
329. Carballo S, Robinson P, Otway R, Fatkin D, Jongbloed JD, de Jonge N, 
Blair E, van Tintelen JP, Redwood C, Watkins H. Identification and 
Functional Characterization of Cardiac Troponin I As a Novel Disease 
Gene in Autosomal Dominant Dilated Cardiomyopathy. Circ Res. 2009. 
330. Dong WJ, An J, Xing J, Cheung HC. Structural transition of the inhibitory 
region of troponin I within the regulated cardiac thin filament. Arch 
Biochem Biophys. 2006;456(2):135-142. 
331. Stecyk JA, Galli GL, Shiels HA, Farrell AP. Cardiac survival in anoxia-
tolerant vertebrates: An electrophysiological perspective. Comp Biochem 
Physiol C Toxicol Pharmacol. 2008;148(4):339-354. 
308 
 
332. Gillis TE, Marshall CR, Tibbits GF. Functional and evolutionary 
relationships of troponin C. Physiol Genomics. 2007;32(1):16-27. 
333. Davis J, Wen H, Edwards T, Metzger JM. Thin filament disinhibition by 
restrictive cardiomyopathy mutant R193H troponin I induces Ca2+-
independent mechanical tone and acute myocyte remodeling. Circ Res. 
2007;100(10):1494-1502. 
334. Shiels HA, Calaghan SC, White E. The cellular basis for enhanced 
volume-modulated cardiac output in fish hearts. J Gen Physiol. 
2006;128(1):37-44. 
335. Baudenbacher F. Myofilament Ca2+ sensitization causes susceptibility to 
cardiac arrhythmia in mice. The Journal of Clinical Investigation. 
2008;118(12):3893-3903. 
336. Moolman JC, Corfield VA, Posen B, Ngumbela K, Seidman C, Brink PA, 
Watkins H. Sudden death due to troponin T mutations. J Am Coll Cardiol. 
1997;29(3):549-555. 
337. Tsoutsman T, Kelly M, Ng DC, Tan JE, Tu E, Lam L, Bogoyevitch MA, 
Seidman CE, Seidman JG, Semsarian C. Severe heart failure and early 
mortality in a double-mutation mouse model of familial hypertrophic 
cardiomyopathy. Circulation. 2008;117(14):1820-1831. 
338. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the 
sensitivity of progressive multiple sequence alignment through sequence 
weighting, position-specific gap penalties and weight matrix choice. 
Nucleic Acids Res. 1994;22(22):4673-4680. 
339. Anisimova M, Kosiol C. Investigating protein-coding sequence evolution 
with probabilistic codon substitution models. Mol Biol Evol. 
2009;26(2):255-271. 
340. Delport W, Scheffler K, Seoighe C. Models of coding sequence evolution. 
Brief Bioinform. 2009;10(1):97-109. 
341. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate 
large phylogenies by maximum likelihood. Syst Biol. 2003;52(5):696-704. 
342. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SD. 
GARD: a genetic algorithm for recombination detection. Bioinformatics. 
2006;22(24):3096-3098. 
343. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SD. 
Automated phylogenetic detection of recombination using a genetic 
algorithm. Mol Biol Evol. 2006;23(10):1891-1901. 
344. Sugiura N. Further analysis of the data by {Akaike's} information criterion 
and the finite corrections. Communications in Statistics - Theory and 
Methods. 1978;A7. 
345. Pond SL, Frost SD. Datamonkey: rapid detection of selective pressure on 
individual sites of codon alignments. Bioinformatics. 2005;21(10):2531-
2533. 
346. Bjellqvist B, Hughes GJ, Pasquali C, Paquet N, Ravier F, Sanchez JC, 
Frutiger S, Hochstrasser D. The focusing positions of polypeptides in 
309 
 
immobilized pH gradients can be predicted from their amino acid 
sequences. Electrophoresis. 1993;14(10):1023-1031. 
347. Case DA, Cheatham TE, 3rd, Darden T, Gohlke H, Luo R, Merz KM, Jr., 
Onufriev A, Simmerling C, Wang B, Woods RJ. The Amber biomolecular 
simulation programs. J Comput Chem. 2005;26(16):1668-1688. 
348. Anandakrishnan R, Onufriev A. Analysis of basic clustering algorithms for 
numerical estimation of statistical averages in biomolecules. J Comput 
Biol. 2008;15(2):165-184. 
349. Fenley AT, Gordon JC, Onufriev A. An analytical approach to computing 
biomolecular electrostatic potential. I. Derivation and analysis. J Chem 
Phys. 2008;129(7):075101. 
350. Gordon JC, Fenley AT, Onufriev A. An analytical approach to computing 
biomolecular electrostatic potential. II. Validation and applications. J Chem 
Phys. 2008;129(7):075102. 
351. Sigalov G, Fenley A, Onufriev A. Analytical electrostatics for biomolecules: 
beyond the generalized Born approximation. J Chem Phys. 
2006;124(12):124902. 
352. Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A. H++: a 
server for estimating pKas and adding missing hydrogens to 
macromolecules. Nucleic Acids Res. 2005;33(Web Server issue):W368-
371. 
353. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot 
C, Skeel RD, Kale L, Schulten K. Scalable molecular dynamics with 
NAMD. J Comput Chem. 2005;26(16):1781-1802. 
354. MacKerell AD, Jr., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. 
D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., Joseph-McCarthy, 
D., Kuchnir, L., Kuczera, K., Lau, F. T. K., Mattos, C., Michnick, S., Ngo, 
T., Nguyen, D. T., Prodhom, B., Reiher, W. E., III, Roux, B., Schlenkrich, 
M., Smith, J. C., Stote, R., Straub, J., Watanabe, M., Wiorkiewicz-
Kuczera, J., Yin, D., and Karplus, M. J. Phys. Chem. 1998;102(18):3586-
3616. 
355. Jorgensen W, Chandrasekar, J., Madura, J., Impey, R., and Klein, M. . J. 
Chem. Phys. 1983;79:926-935. 
356. Essmann U, Perera, L., Berkowitz, M., Darden, T., Lee, H., and Pedersen, 
L. G. . J. Chem. Phys. 1995;103:8577-8593. 
357. Ryckaert JP, Ciccotti, G., and Berendsen, H. J. C. . J. Comput. Phys. 
1977;23:327-341. 
358. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, 
Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet J-P, Millaire A, 
Desnos M, Schwartz K, Hainque B, Komajda M, for the EUROGENE 
Heart Failure Project. Hypertrophic Cardiomyopathy: Distribution of 
Disease Genes, Spectrum of Mutations, and Implications for a Molecular 
Diagnosis Strategy. Circulation. 2003;107(17):2227-2232. 
310 
 
359. Warkman AS, Atkinson BG. Amphibian cardiac troponin I gene's 
organization, developmental expression, and regulatory properties are 
different from its mammalian homologue. Dev Dyn. 2004;229(2):275-288. 
360. Warkman AS, Atkinson BG. The slow isoform of Xenopus troponin I is 
expressed in developing skeletal muscle but not in the heart. Mech Dev. 
2002;115(1-2):143-146. 
361. Drysdale TA, Tonissen KF, Patterson KD, Crawford MJ, Krieg PA. Cardiac 
troponin I is a heart-specific marker in the Xenopus embryo: expression 
during abnormal heart morphogenesis. Dev Biol. 1994;165(2):432-441. 
362. Palpant NJ, Yasuda S-i, MacDougald O, Metzger JM. Non-canonical Wnt 
signaling enhances differentiation of Sca1+/c-kit+ adipose-derived murine 
stromal vascular cells into spontaneously beating cardiac myocytes. 
Journal of Molecular and Cellular Cardiology. 2007;43(3):362-370. 
363. Metzger JM, Michele DE, Rust EM, Borton AR, Westfall MV. Sarcomere 
Thin Filament Regulatory Isoforms. EVIDENCE OF A DOMINANT 
EFFECT OF SLOW SKELETAL TROPONIN I ON CARDIAC 
CONTRACTION. J. Biol. Chem. 2003;278(15):13118-13123. 
364. Wang T, Hackam A, Guggino W, Cutting G. A single histidine residue is 
essential for zinc inhibition of GABA rho 1 receptors. J. Neurosci. 
1995;15(11):7684-7691. 
365. Liang B, Chung F, Qu Y, Pavlov D, Gillis TE, Tikunova SB, Davis JP, 
Tibbits GF. Familial hypertrophic cardiomyopathy-related cardiac troponin 
C mutation L29Q affects Ca2+ binding and myofilament contractility. 
Physiol Genomics. 2008;33(2):257-266. 
366. Hoffmann B, Schmidt-Traub H, Perrot A, Osterziel KJ, Gessner R. First 
mutation in cardiac troponin C, L29Q, in a patient with hypertrophic 
cardiomyopathy. Hum Mutat. 2001;17(6):524. 
367. Landstrom AP, Parvatiyar MS, Pinto JR, Marquardt ML, Bos JM, Tester 
DJ, Ommen SR, Potter JD, Ackerman MJ. Molecular and functional 
characterization of novel hypertrophic cardiomyopathy susceptibility 
mutations in TNNC1-encoded troponin C. J Mol Cell Cardiol. 
2008;45(2):281-288. 
368. Pinto JR, Parvatiyar MS, Jones MA, Liang J, Ackerman MJ, Potter JD. A 
functional and structural study of troponin C mutations related to 
hypertrophic cardiomyopathy. J Biol Chem. 2009;284(28):19090-19100. 
369. Baudenbacher F, Schober T, Pinto JR, Sidorov VY, Hilliard F, Solaro RJ, 
Potter JD, Knollmann BC. Myofilament Ca2+ sensitization causes 
susceptibility to cardiac arrhythmia in mice. J Clin Invest. 
2008;118(12):3893-3903. 
370. Xu C, Wei M, Su B, Hua XW, Zhang GW, Xue XP, Pan CM, Liu R, Sheng 
Y, Lu ZG, Jin LR, Song HD. Ile90Met, a novel mutation in the cardiac 
troponin T gene for familial hypertrophic cardiomyopathy in a Chinese 
pedigree. Genet Res. 2008;90(5):445-450. 
371. Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, 
Robbins J, Leinwand LA. Cardiac troponin T mutations result in allele-
311 
 
specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J 
Clin Invest. 1999;104(4):469-481. 
372. Mukherjea P, Tong L, Seidman JG, Seidman CE, Hitchcock-DeGregori 
SE. Altered regulatory function of two familial hypertrophic 
cardiomyopathy troponin T mutants. Biochemistry. 1999;38(40):13296-
13301. 
373. Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, 
Seidman JG, Seidman CE. Alpha-tropomyosin and cardiac troponin T 
mutations cause familial hypertrophic cardiomyopathy: a disease of the 
sarcomere. Cell. 1994;77(5):701-712. 
374. Fiset C, Giles WR. Cardiac troponin T mutations promote life-threatening 
arrhythmias. J Clin Invest. 2008;118(12):3845-3847. 
375. Victor S, Nayak VM. Evolutionary anticipation of the human heart. Ann R 
Coll Surg Engl. 2000;82(5):297-302. 
376. Victor S, Nayak VM, Rajasingh R. Evolution of the ventricles. Tex Heart 
Inst J. 1999;26(3):168-175; discussion 175-166. 
377. Taylor EW. The evolution of efferent vagal control of the heart in 
vertebrates. Cardioscience. 1994;5(3):173-182. 
378. Kubler W. The sympathetic system in evolution and in ischaemic heart 
disease--a controversy? Eur Heart J. 1992;13(10):1301-1303. 
379. MacLean DW, Meedel TH, Hastings KE. Tissue-specific alternative 
splicing of ascidian troponin I isoforms. Redesign of a protein isoform-
generating mechanism during chordate evolution. J Biol Chem. 
1997;272(51):32115-32120. 
380. Hastings KE. Strong evolutionary conservation of broadly expressed 
protein isoforms in the troponin I gene family and other vertebrate gene 
families. J Mol Evol. 1996;42(6):631-640. 
381. Hastings KE. Molecular evolution of the vertebrate troponin I gene family. 
Cell Struct Funct. 1997;22(1):205-211. 
382. Maisonpierre PC, Hastings KE, Emerson CP, Jr. The cloning and the 
codon and amino acid sequence of the quail slow/cardiac troponin C 
cDNA. Methods Enzymol. 1987;139:326-337. 
383. Cleto CL, Vandenberghe AE, MacLean DW, Pannunzio P, Tortorelli C, 
Meedel TH, Satou Y, Satoh N, Hastings KE. Ascidian larva reveals 
ancient origin of vertebrate-skeletal-muscle troponin I characteristics in 
chordate locomotory muscle. Mol Biol Evol. 2003;20(12):2113-2122. 
384. Makinde AO, Kantor PF, Lopaschuk GD. Maturation of fatty acid and 
carbohydrate metabolism in the newborn heart. Mol Cell Biochem. 
1998;188(1-2):49-56. 
385. Nagao K, Taniyama Y, Kietzmann T, Doi T, Komuro I, Morishita R. HIF-
1{alpha} Signaling Upstream of NKX2.5 Is Required for Cardiac 
Development in Xenopus. J. Biol. Chem. 2008;283(17):11841-11849. 
386. Seki S, Nagashima M, Yamada Y, Tsutsuura M, Kobayashi T, Namiki A, 
Tohse N. Fetal and postnatal development of Ca2+ transients and Ca2+ 
sparks in rat cardiomyocytes. Cardiovasc Res. 2003;58(3):535-548. 
312 
 
387. Fu JD, Yang HT. Developmental regulation of intracellular calcium 
homeostasis in early cardiac myocytes. Sheng Li Xue.Bao. 2006;58(2):95-
103. 
388. Redfield MM. Understanding "diastolic" heart failure. N Engl J Med. 
2004;350(19):1930-1931. 
389. James J, Zhang Y, Osinska H, Sanbe A, Klevitsky R, Hewett TE, Robbins 
J. Transgenic modeling of a cardiac troponin I mutation linked to familial 
hypertrophic cardiomyopathy. Circulation Research. 2000;87(9):805-811. 
390. Sheng HZ, Shan QJ, Wu X, Cao KJ. [Cardiac troponin I gene mutation 
(Asp127Tyr) in a Chinese patient with hypertrophic cardiomyopathy]. 
Zhonghua Xin Xue Guan Bing Za Zhi. 2008;36(12):1063-1065. 
391. Wen Y, Pinto JR, Gomes AV, Xu Y, Wang Y, Potter JD, Kerrick WG. 
Functional consequences of the human cardiac troponin I hypertrophic 
cardiomyopathy mutation R145G in transgenic mice. J Biol Chem. 
2008;283(29):20484-20494. 
392. Davis J, Wen H, Edwards T, Metzger JM. Allele and species dependent 
contractile defects by restrictive and hypertrophic cardiomyopathy-linked 
troponin I mutants. J Mol Cell Cardiol. 2008;44(5):891-904. 
393. Du J, Liu J, Feng H-Z, Hossain MM, Gobara N, Zhang C, Li Y, Jean-
Charles P-Y, Jin J-P, Huang X-P. Impaired relaxation is the main 
manifestation in transgenic mice expressing a restrictive cardiomyopathy 
mutation, R193H, in cardiac TnI. Am J Physiol Heart Circ Physiol. 
2008;294(6):H2604-2613. 
394. Iorga B, Blaudeck N, Solzin J, Neulen A, Stehle I, Davila AJL, Pfitzer G, 
Stehle R. Lys184 deletion in troponin I impairs relaxation kinetics and 
induces hypercontractility in murine cardiac myofibrils. Cardiovasc Res. 
2008;77(4):676-686. 
395. Shiels HA, White E. Temporal and spatial properties of cellular Ca2+ flux 
in trout ventricular myocytes. Am J Physiol Regul Integr Comp Physiol. 
2005;288(6):R1756-1766. 
396. Bonaventura C, Crumbliss AL, Weber RE. New insights into the proton-
dependent oxygen affinity of Root effect haemoglobins. Acta Physiol 
Scand. 2004;182(3):245-258. 
397. Root RW. The respiratory function of the blood of marine fishes. Biol Bull. 
1931.;61:427–456. 
398. Franklin CE, Davie PS. Dimensional analysis of the ventricle of an in situ 
perfused trout heart using echocardiography. J Exp Biol. 1992;166:47-60. 
399. Hedrick MS, Palioca WB, Hillman SS. Effects of temperature and physical 
activity on blood flow shunts and intracardiac mixing in the toad Bufo 
marinus. Physiol Biochem Zool. 1999;72(5):509-519. 
400. Farrell TG, Bashir Y, Cripps T, Malik M, Poloniecki J, Bennett ED, Ward 
DE, Camm AJ. Risk stratification for arrhythmic events in postinfarction 
patients based on heart rate variability, ambulatory electrocardiographic 




401. Syme DA, Josephson RK. Influence of muscle length on work from 
trabecular muscle of frog atrium and ventricle. J Exp Biol. 1995;198(Pt 
10):2221-2227. 
402. Fabiato A, Fabiato F. Myofilament-generated tension oscillations during 
partial calcium activation and activation dependence of the sarcomere 
length-tension relation of skinned cardiac cells. J Gen Physiol. 
1978;72(5):667-699. 
403. Axelsson M, Davison W, Forster ME, Farrell AP. Cardiovascular 
responses of the red-blooded antarctic fishes Pagothenia bernacchii and 
P. borchgrevinki. J Exp Biol. 1992;167:179-201. 
404. Franklin C, Axelsson M. The Intrinsic Properties of an in Situ Perfused 
Crocodile Heart. J Exp Biol. 1994;186(1):269-288. 
405. Pelster B. Environmental influences on the development of the cardiac 
system in fish and amphibians. Comp Biochem Physiol A Mol Integr 
Physiol. 1999;124(4):407-412. 
406. Currie S, Boutilier RG. Strategies of hypoxia and anoxia tolerance in 
cardiomyocytes from the overwintering common frog, Rana temporaria. 
Physiol Biochem Zool. 2001;74(3):420-428. 
407. Joseph T, Coirault C, Lecarpentier Y. Species-dependent changes in 
mechano-energetics of isolated cardiac muscle during hypoxia. Basic Res 
Cardiol. 2000;95(5):378-384. 
408. McKean T, Scherzer A, Park H. Hypoxia and ischaemia in buffer-perfused 
toad hearts. J Exp Biol. 1997;200(Pt 19):2575-2581. 
409. Park IS, Michael LH, Driscoll DJ. Comparative response of the developing 
canine myocardium to inotropic agents. Am J Physiol. 1982;242(1):H13-
18. 
410. Swiderek K, Jaquet K, Meyer HE, Heilmeyer LM, Jr. Cardiac troponin I, 
isolated from bovine heart, contains two adjacent phosphoserines. A first 
example of phosphoserine determination by derivatization to S-
ethylcysteine. Eur J Biochem. 1988;176(2):335-342. 
411. Robertson SP, Johnson JD, Holroyde MJ, Kranias EG, Potter JD, Solaro 
RJ. The effect of troponin I phosphorylation on the Ca2+-binding 
properties of the Ca2+-regulatory site of bovine cardiac troponin. J Biol 
Chem. 1982;257(1):260-263. 
412. Solaro RJ, Moir AJ, Perry SV. Phosphorylation of troponin I and the 
inotropic effect of adrenaline in the perfused rabbit heart. Nature. 
1976;262(5569):615-617. 
413. Tong CW, Gaffin RD, Zawieja DC, Muthuchamy M. Roles of 
phosphorylation of myosin binding protein-C and troponin I in mouse 
cardiac muscle twitch dynamics. J Physiol. 2004;558(Pt 3):927-941. 
414. McClellan G, Kulikovskaya I, Winegrad S. Changes in cardiac contractility 
related to calcium-mediated changes in phosphorylation of myosin-binding 
protein C. Biophys J. 2001;81(2):1083-1092. 
314 
 
415. Flashman E, Redwood C, Moolman-Smook J, Watkins H. Cardiac Myosin 
Binding Protein C: Its Role in Physiology and Disease. Circ Res. 
2004;94(10):1279-1289. 
416. Gautel M, Zuffardi O, Freiburg A, Labeit S. Phosphorylation switches 
specific for the cardiac isoform of myosin binding protein-C: a modulator of 
cardiac contraction? EMBO J. 1995;14(9):1952-1960. 
417. Mattiazzi A, Mundina-Weilenmann C, Guoxiang C, Vittone L, Kranias E. 
Role of phospholamban phosphorylation on Thr17 in cardiac physiological 
and pathological conditions. Cardiovasc Res. 2005;68(3):366-375. 
418. Luo W, Chu G, Sato Y, Zhou Z, Kadambi VJ, Kranias EG. Transgenic 
approaches to define the functional role of dual site phospholamban 
phosphorylation. J Biol Chem. 1998;273(8):4734-4739. 
419. Pond SLK, Frost SDW. A Genetic Algorithm Approach to Detecting 
Lineage-Specific Variation in Selection Pressure. Mol Biol Evol. 
2005;22(3):478-485. 
420. Mercier P, Ferguson RE, Irving M, Corrie JE, Trentham DR, Sykes BD. 
NMR structure of a bifunctional rhodamine labeled N-domain of troponin C 
complexed with the regulatory "switch" peptide from troponin I: 
implications for in situ fluorescence studies in muscle fibers. Biochemistry. 
2003;42(15):4333-4348. 
421. Jahangir A, Sagar S, Terzic A. Aging and cardioprotection. J Appl Physiol. 
2007;103(6):2120-2128. 
422. Lakatta EG. Arterial and cardiac aging: major shareholders in 
cardiovascular disease enterprises: Part III: cellular and molecular clues to 
heart and arterial aging. Circulation. 2003;107(3):490-497. 
423. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in 
cardiovascular disease enterprises: Part II: the aging heart in health: links 
to heart disease. Circulation. 2003;107(2):346-354. 
424. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in 
cardiovascular disease enterprises: Part I: aging arteries: a "set up" for 
vascular disease. Circulation. 2003;107(1):139-146. 
425. Coutu P, Bennett CN, Favre EG, Day SM, Metzger JM. Parvalbumin 
corrects slowed relaxation in adult cardiac myocytes expressing 
hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations. Circ 
Res. 2004;94(9):1235-1241. 
426. Coutu P, Metzger JM. Optimal range for parvalbumin as relaxing agent in 
adult cardiac myocytes: gene transfer and mathematical modeling. 
Biophys J. 2002;82(5):2565-2579. 
427. Koretsune Y, Marban E. Cell Calcium in the Patho-Physiology of 
Ventricular-Fibrillation and in the Pathogenesis of Postarrhythmic 
Contractile Dysfunction. Circulation. 1989;80(2):369-379. 
428. Lakatta EG, Sollott SJ. Perspectives on mammalian cardiovascular aging: 
humans to molecules. Comparative Biochemistry and Physiology - Part A: 
Molecular & Integrative Physiology. 2002;132(4):699-721. 
315 
 
429. Lee JA, Allen DG. Mechanisms of acute ischemic contractile failure of the 
heart. Role of intracellular calcium. J Clin.Invest. 1991;88(2):361-367. 
430. Wehrens XHT, Lehnart SE, Marks AR. INTRACELLULAR CALCIUM 
RELEASE AND CARDIAC DISEASE. Annual Review of Physiology. 
2005;67(1):69-98. 
431. Solaro RJ, el Saleh SC, Kentish JC. Ca2+, pH and the regulation of 
cardiac myofilament force and ATPase activity. Mol.Cell Biochem. 
1989;89(2):163-167. 
432. Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR, 
Rodeheffer RJ. Burden of Systolic and Diastolic Ventricular Dysfunction in 
the Community: Appreciating the Scope of the Heart Failure Epidemic. 
JAMA. 2003;289(2):194-202. 
433. Ataka K, Chen D, Levitsky S, Jimenez E, Feinberg H. Effect of aging on 
intracellular Ca2+, pHi, and contractility during ischemia and reperfusion. 
Circulation. 1992;86(5 Suppl):II371-376. 
434. Frolkis VV, Frolkis RA, Mkhitarian LS, Shevchuk VG, Fraifeld VE, 
Vakulenko LG, Syrovy I. Contractile function and Ca2+ transport system of 
myocardium in ageing. Gerontology. 1988;34(1-2):64-74. 
435. Mann DL, Bristow MR. Mechanisms and Models in Heart Failure: The 
Biomechanical Model and Beyond. Circulation. 2005;111(21):2837-2849. 
436. Tsunezuka Y, Sato H, Tsubota M, Seki M. Significance of percutaneous 
cardiopulmonary bypass support for volume reduction surgery with severe 
hypercapnia. Artif Organs. 2000;24(1):70-73. 
437. Lutgens E, Daemen MJAP, de Muinck ED, Debets J, Leenders P, Smits 
JFM. Chronic myocardial infarction in the mouse: cardiac structural and 
functional change. Cardiovascular Research. 1999;41(3):586-593. 
438. del Monte F, Lebeche D, Guerrero JL, Tsuji T, Doye AA, Gwathmey JK, 
Hajjar RJ. From the Cover: Abrogation of ventricular arrhythmias in a 
model of ischemia and reperfusion by targeting myocardial calcium 
cycling. Proceedings of the National Academy of Sciences. 
2004;101(15):5622-5627. 
439. Fukuda N, J OU, Sasaki D, Kajiwara H, Ishiwata S, Kurihara S. Acidosis 
or inorganic phosphate enhances the length dependence of tension in rat 
skinned cardiac muscle. J Physiol. 2001;536(Pt 1):153-160. 
440. Ding XL, Akella AB, Gulati J. Contributions of troponin I and troponin C to 
the acidic pH-induced depression of contractile Ca2+ sensitivity in 
cardiotrabeculae. Biochemistry. 1995;34(7):2309-2316. 
441. Ding XL, Akella AB, Sonnenblick EH, Rao VG, Gulati J. Molecular basis of 
depression of Ca2+ sensitivity of tension by acid pH in cardiac muscles of 
the mouse and the rat. J Card Fail. 1996;2(4):319-326. 
442. Cho MC, Rapacciuolo A, Koch WJ, Kobayashi Y, Jones LR, Rockman HA. 
Defective beta-adrenergic receptor signaling precedes the development of 
dilated cardiomyopathy in transgenic mice with calsequestrin 
overexpression. J Biol Chem. 1999;274(32):22251-22256. 
316 
 
443. Szatkowski ML, Westfall MV, Gomez CA, Wahr PA, Michele DE, 
DelloRusso C, Turner II, Hong KE, Albayya FP, Metzger JM. In vivo 
acceleration of heart relaxation performance by parvalbumin gene 
delivery. Journal of Clinical Investigation. 2001;107(2):191-197. 
444. Michele DE, Gomez CA, Hong KE, Westfall MV, Metzger JM. Cardiac 
dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is 
transgene-dependent, hypertrophy-independent, and improved by beta-
blockade. Circulation Research. 2002;91(3):255-262. 
445. Whitesall SE, Hoff JB, Vollmer AP, D'Alecy LG. Comparison of 
simultaneous measurement of mouse systolic arterial blood pressure by 
radiotelemetry and tail-cuff methods. Am J Physiol Heart Circ Physiol. 
2004;286(6):H2408-2415. 
446. Fu Y, Huang X, Zhong H, Mortensen RM, D'Alecy LG, Neubig RR. 
Endogenous RGS proteins and Galpha subtypes differentially control 
muscarinic and adenosine-mediated chronotropic effects. Circ Res. 
2006;98(5):659-666. 
447. Linder AE, Weber DS, Whitesall SE, D'Alecy LG, Webb RC. Altered 
vascular reactivity in mice made hypertensive by nitric oxide synthase 
inhibition. J Cardiovasc Pharmacol. 2005;46(4):438-444. 
448. Ucgun I, Oztuna F, Dagli CE, Yildirim H, Bal C. Relationship of Metabolic 
Alkalosis, Azotemia and Morbidity in Patients with Chronic Obstructive 
Pulmonary Disease and Hypercapnia. Respiration. 2008. 
449. Rocker GM, Mackenzie M-G, Williams B, Logan PM. Noninvasive Positive 
Pressure Ventilation: Successful Outcome in Patients With Acute Lung 
Injury/ARDS. Chest. 1999;115(1):173-177. 
450. O'Croinin DF, Nichol AD, Hopkins N, Boylan J, O'Brien S, O'Connor C, 
Laffey JG, McLoughlin P. Sustained hypercapnic acidosis during 
pulmonary infection increases bacterial load and worsens lung injury. Crit 
Care Med. 2008;36(7):2128-2135. 
451. Harper RM, Macey PM, Woo MA, Macey KE, Keens TG, Gozal D, Alger 
JR. Hypercapnic Exposure in Congenital Central Hypoventilation 
Syndrome Reveals CNS Respiratory Control Mechanisms. J 
Neurophysiol. 2005;93(3):1647-1658. 
452. Liou YM, Kuo SC, Hsieh SR. Differential effects of a green tea-derived 
polyphenol (-)-epigallocatechin-3-gallate on the acidosis-induced decrease 
in the Ca(2+) sensitivity of cardiac and skeletal muscle. Pflugers Arch. 
2008. 
453. Michele DE, Albayya FP, Metzger JM. Thin Filament Protein Dynamics in 
Fully Differentiated Adult Cardiac Myocytes: Toward A Model of 
Sarcomere Maintenance. J. Cell Biol. 1999;145(7):1483-1495. 
454. Westfall MV, Rust EM, Albayya F, Metzger JM. Adenovirus-mediated 




455. Baudenbacher F, Schober T, Pinto JR, Sidorov VY, Hilliard F, Solaro RJ, 
Potter JD, Knollmann BC. Myofilament Ca sensitization causes 
susceptibility to cardiac arrhythmia in mice. J Clin Invest. 2008. 
456. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene 
therapy vectors: influence on vector function and effector mechanisms. 
Gene Therapy. 2004;11:S10-S17. 
457. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VP, 
Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DGB, 
Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, 
High KA, Glader B. AAV-mediated factor IX gene transfer to skeletal 
muscle in patients with severe hemophilia B. Blood. 2003;101(8):2963-
2972. 
458. Townsend D, Blankinship MJ, Allen JM, Gregorevic P, Chamberlain JS, 
Metzger JM. Systemic administration of micro-dystrophin restores cardiac 
geometry and prevents dobutamine-induced cardiac pump failure. Mol 
Ther. 2007;15(6):1086-1092. 
459. Feng HZ, Hossain MM, Huang XP, Jin JP. Myofilament incorporation 
determines the stoichiometry of troponin I in transgenic expression and 
the rescue of a null mutation. Arch Biochem Biophys. 2009;487(1):36-41. 
460. Syed F, Odley A, Hahn HS, Brunskill EW, Lynch RA, Marreez Y, Sanbe A, 
Robbins J, Dorn GW, II. Physiological Growth Synergizes With 
Pathological Genes in Experimental Cardiomyopathy. Circulation 
Research. 2004;95(12):1200-1206. 
461. Dorn Ii GW. Physiologic Growth and Pathologic Genes in Cardiac 
Development and Cardiomyopathy. Trends in Cardiovascular Medicine. 
2005;15(5):185-189. 
462. Kido M, Du LL, Sullivan CC, Li XD, Deutsch R, Jamieson SW, 
Thistlethwaite PA. Hypoxia-inducible factor 1-alpha reduces infarction and 
attenuates progression of cardiac dysfunction after myocardial infarction in 
the mouse. Journal of the American College of Cardiology. 
2005;46(11):2116-2124. 
463. Kumar D, Hacker TA, Buck J, Whitesell LF, Kaji EH, Douglas PS, Kamp 
TJ. Distinct mouse coronary anatomy and myocardial infarction 
consequent to ligation. Coron.Artery Dis. 2005;16(1):41-44. 
464. Yang F, Liu YH, Yang XP, Xu J, Kapke A, Carretero OA. Myocardial 
infarction and cardiac remodelling in mice. Experimental Physiology. 
2002;87(5):547-555. 
465. Hunter JJ, Chien KR. Signaling Pathways for Cardiac Hypertrophy and 
Failure. The New England Journal of Medicine. 1999;341(17):1276-1283. 
466. Kenchaiah S, Pfeffer MA, John Sutton M, Plappert T, Rouleau JL, Lamas 
GA, Sasson Z, Parker JO, Geltman EM, Solomon SD. Effect of 
antecedent systemic hypertension on subsequent left ventricular dilation 
after acute myocardial infarction (from the Survival and Ventricular 
Enlargement trial). The American Journal of Cardiology. 2004;94(1):1-8. 
318 
 
467. Poulsen SH. Clinical aspects of left ventricular diastolic function assessed 
by Doppler echocardiography following acute myocardial infarction. 
Dan.Med Bull. 2001;48(4):199-210. 
468. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive Left-Ventricular 
Dysfunction and Remodeling After Myocardial-Infarction - Potential 
Mechanisms and Early Predictors. Circulation. 1993;87(3):755-763. 
469. Hubka M, McDonald JA, Wong S, Bolson EL, Sheehan FH. Monitoring 
change in the three-dimensional shape of the human left ventricle. Journal 
of the American Society of Echocardiography. 2004;17(5):404-410. 
470. Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, Izumo S. Mouse 
cardiac surgery: comprehensive techniques for the generation of mouse 
models of human diseases and their application for genomic studies. 
Physiological Genomics. 2004;16(3):349-360. 
471. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, Banner 
NR, Khaghani A, Yacoub MH. Left Ventricular Assist Device and Drug 
Therapy for the Reversal of Heart Failure. The New England Journal of 
Medicine. 2006;355(18):1873-1884. 
472. Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, Lu QW, 
Wang YY, Zhan DY, Mochizuki M, Kita S, Miwa Y, Takahashi-Yanaga F, 
Iwamoto T, Ohtsuki I, Sasaguri T. Knock-in mouse model of dilated 
cardiomyopathy caused by troponin mutation. Circ Res. 2007;101(2):185-
194. 
473. Knollmann BC, Kirchhof P, Sirenko SG, Degen H, Greene AE, Schober T, 
Mackow JC, Fabritz L, Potter JD, Morad M. Familial Hypertrophic 
Cardiomyopathy-Linked Mutant Troponin T Causes Stress-Induced 
Ventricular Tachycardia and Ca2+-Dependent Action Potential 
Remodeling. Circ Res. 2003;92(4):428-436. 
474. Knollmann BC, Blatt SA, Horton K, de Freitas F, Miller T, Bell M, 
Housmans PR, Weissman NJ, Morad M, Potter JD. Inotropic stimulation 
induces cardiac dysfunction in transgenic mice expressing a troponin T 
(I79N) mutation linked to familial hypertrophic cardiomyopathy. J Biol 
Chem. 2001;276(13):10039-10048. 
 
 
